AU710672B2 - Inhibitors of farnesyl-protein transferase - Google Patents
Inhibitors of farnesyl-protein transferase Download PDFInfo
- Publication number
- AU710672B2 AU710672B2 AU53223/96A AU5322396A AU710672B2 AU 710672 B2 AU710672 B2 AU 710672B2 AU 53223/96 A AU53223/96 A AU 53223/96A AU 5322396 A AU5322396 A AU 5322396A AU 710672 B2 AU710672 B2 AU 710672B2
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- unsubstituted
- aryl
- alkyl
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
1 Inhibitors of Farnesyl-Protein Transferase Background of the Invention The Ras proteins (Ha-Ras, Ki4a-Ras, Ki4b-Ras and N-Ras) are part of a signalling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation. Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein. In the inactive state, Ras is bound to GDP. Upon growth factor receptor activation Ras is induced to exchange GDP for GTP and undergoes a conformational change. The GTP-bound form of Ras propagates the grown stimulatory signal until the signal is terminated by the intrinsic GTPase activity of Ras, which returns the protein to its inactive GDP bound form Lowy and D.M. Willumsen, Ann. Rev.
Biochem. 62:851-891 (1993)). Mutated ras genes (Ha-ras, Ki4a-ras, Ki4b-ras and N-ras) are found in many human cancers, including colorectal carcinoma. exocrine pancreatic carcinoma, and myeloid leukemias. The protein products of these genes are defective in their GTPase activity and constitutively transmit a growth stimulatory signal.
15 Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras. The Ras C-terminus .contains a sequence motif termed a "'CAAX" or "Cys-Aaa -Aaa 2 -Xaa" box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen et al., Nature 20 310:583-586 (1984)). Depending on the specific sequence, this motif serves as a signal sequence for the
S
[I :\DAYLIB\iba]393945d.doc:SSD WO 96/30343 PCTIUS96/04019 -2enzymes farnesyl-protein transferase or geranylgeranyl-protein transferase, which catalyze the alkylation of the cysteine residue of the CAAX motif with a C15 or C20 isoprenoid, respectively. Clarke., Ann. Rev. Biochem. 61:355-386 (1992); W.R. Schafer and J. Rine, Ann. Rev. Genetics 30:209-237 (1992)). The Ras protein is one of several proteins that are known to undergo post-translational farnesylation. Other famesylated proteins include the Ras-related GTPbinding proteins such as Rho, fungal mating factors, the nuclear lamins, and the gamma subunit of transducin. James, et al., J. Biol. Chem. 269, 14182 (1994) have identified a peroxisome associated protein Pxf which is also farnesylated. James, et al., have also suggested that there are farnesylated proteins of unknown structure and function in addition to those listed above.
Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar and to modify other aspects of their transformed phenotype. It has also been demonstrated that certain inhibitors of farnesyl-protein transferase selectively block the processing of the Ras oncoprotein intracellularly Kohl et al., Science, 260:1934-1937 (1993) and G.L. James et al., Science, 260:1937-1942 (1993). Recently, it has been shown that an inhibitor of farnesyl-protein transferase blocks the growth of rasdependent tumors in nude mice Kohl et al., Proc. Natl. Acad. Sci 91:9141-9145 (1994) and induces regression of mammary and salivary carcinomas in ras transgenic mice Kohl et al., Nature Medicine, 1:792-797 (1995).
Indirect inhibition of farnesyl-protein transferase in vivo has been demonstrated with lovastatin (Merck Co., Rahway, NJ) and compactin (Hancock et al., ibid; Casey et al., ibid; Schafer et al., Science 245:379 (1989)). These drugs inhibit HMG-CoA reductase, the rate limiting enzyme for the production of polyisoprenoids including farnesyl pyrophosphate. Farnesyl-protein transferase utilizes farnesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a famesyl group (Reiss et al., Cell, 62:81-88 (1990); Schaber et al., J. Biol. Chem., 265:14701-14704 (1990); Schafer et al., WO 96/30343 PCT/US96/04019 -3- Science, 249:1133-1139 (1990); Manne et al., Proc. Natl. Acad. Sci USA, 87:7541-7545 (1990)). Inhibition of farnesyl pyrophosphate biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells. However, direct inhibition of farnesylprotein transferase would be more specific and attended by fewer side effects than would occur with the required dose of a general inhibitor of isoprene biosynthesis.
Inhibitors of farnesyl-protein transferase (FPTase) have been described in two general classes. The first are analogs of famesyl diphosphate (FPP), while the second class of inhibitors is related to the protein substrates Ras) for the enzyme. The peptide derived inhibitors that have been described are generally cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation. (Schaber et al., ibid; Reiss et. al., ibid; Reiss et al., PNAS, 88:732-736 (1991)). Such inhibitors may inhibit protein prenylation while serving as alternate substrates for the farnesyl-protein transferase enzyme, or may be purely competitive inhibitors (U.S.
Patent 5,141,851, University of Texas; N.E. Kohl et al., Science, 260:1934-1937 (1993); Graham, et al., J. Med. Chem., 37, 725 (1994)).
In general, deletion of the thiol from a CAAX derivative has been shown to dramatically reduce the inhibitory potency of the compound.
However, the thiol group potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable.
It has recently been reported that farnesyl-protein transferase inhibitors are inhibitors of proliferation of vascular smooth muscle cells and are therefore useful in the prevention and therapy of arteriosclerosis and diabetic disturbance of blood vessels (JP H7- 112930).
It has recently been disclosed that certain tricyclic compounds which optionally incorporate a piperidine moiety are inhibitors of FPTase (WO 95/10514, WO 95/10515 and WO 95/10516).
I WO 96/30343 PCTIUS96/04019 -4- Imidazole-containing inhibitors of farnesyl protein transferase have also been disclosed (WO 95/09001 and EP 0 675 112 Al).
It is, therefore, an object of this invention to develop peptidomimetic compounds that do not have a thiol moiety, and that will inhibit farnesyl-protein transferase and thus, the post-translational farnesylation of proteins. It is a further object of this invention to develop chemotherapeutic compositions containing the compounds of this invention and methods for producing the compounds of this invention.
SUMMARY OF THE INVENTION The present invention comprises peptidomimetic piperazine-containing compounds which inhibit the farnesyl-protein transferase. The instant compounds lack a thiol moiety and thus offer unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.
The compounds of this invention are illustrated by the formulae A, B and C: WO 96/30343 WO 9630343PCTIUS96104019
(R
8 )r (R9)qR2 R3 V Al(CRla 2 )nA 2 (CRla) On W (CR lb 2 )pKN /N x \j y R 4 R
A
(R 8 )r (R 9 )q
R
2
G
V Al(CR a 2 )nA 2 (CRlbOnP 7 N N x R 3 R 4
B
8/ (R9)q R R V Al(CRla 2 )nA 2 (CRla 2 On\W t- (CR lb 2 N\ N-Z mmwmm A first aspect of the present invention provides a compound which which inhibits farnesyt-protein transferase of the formula A: (R 8 )r (R 9 )qR2 R3 V Al(C Rl 2 (C Rl 2 WA (CR b 2 )P''ZI N R 4 R
A
wherein: Ra andR lbare independently selected from: hydrogen, -N(R R C(O)NR -or unsubstituted or substituted C 1
-C
6 alkyl wherein the substituent on the substituted C-C 6 alkvi is selected from unsubstituted or substituted phenyl, -N(R R 0- and 10 R C(O')NR
R
6
R
7 R 6 is selected from: H, 0 0 and an unsubstituted or 1 substituted group, the group selected from C 18 2lyC 8 aknlad 9 lyy hri the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with:
C
14 alkyl, uJ 'H2)POR *6 7 cd) (CH 2 )PNRR d)halogen, 2) C 3 6 cycloalkyl, 6 3) OR 6a 6 a 6a 4) SR S(O)R a, S 2
R
[IA:DAYLI B\Iiba]393945d .doc: SSD -NR 6
R'
1 7 6) -N
R
0 7) 1N.h R 7
R
7 a 0 8) -0O NR 6 R 7 0 9) -O OR 6 0 NR 6 R 7 RI 6 12) -N S2 R6 13 6* 4 44 0 4* .41) F;0 2 or 6
R
4 5* R4n. aehdrgn 12 3 4SO 2 R an n 13) rR ,RRadRaeotoal tahdt h aecro tm 6 7 7 R 4 n r neednl eetdfo :hdoeusbtttdo susiue .IC 0lyusbtttdo usiue rladusbtttdo usiue cycoalyl [I :DAYLIB\Iiba393945d.doc:SSD R 0ais selected from: unsubstituted or substituted C 1
-C
6 alkyl, unsubstituted or Substituted aryl and unsubstituted or substituted cyc loalkyl; R 8is independently selected from: a) hydrogen.
b) aryl, heterocycle, C 3
-C
10 ccoakl C 2
I-C
6 aleyC 2
-C
6 aknl 11 to perfluoroalkvl. F, Cl, Br, R 0,RSOm R C(O)NR 2 R, IN-C(NR CN, NO,, R 10C(O)-, R OOC(O)-, N 3 -N(R 10, or R IIOC(O)NR 10. and C) C 1 -C 6 alkvl unsubstituted or substituted by aryl. cyanophenyl, heterocycle.
(2 -C 1 cyc loalkyl, C,-C 6 alkenyl. C,-C 6 alkynyl, perfinoroalkyl, F. Cl. Br. RIOO-.
R. R 0CON- (R I R 10N-C(NR CN. R 10C(O)-. R 10OC(O)-. N3.2 I I() -N(R or R OC(O)NH-: PR is selected from: hydrogen and methyl: 00 P is independently selected from hydrogeni. CI-C(, alkvl. ben/Ni and arvi: R P is independently selected from C 1 -C6 alkyl and aryl, 14 2 A and A are independently selected from: a bond. -CH=CH-. -C'(Ol)Ni -NR 0, -N(R -N(R )S(O) 2 or S(O)m; V is phenyl:- N is a heterocycle selected from imidazolinyl, imidazolyl, oxazolyl, pyrazolyl.
pyrrolidinvl. thiazolyl and pyridyl: X is Y is unsubstituted or substituted phenyl or unsubstituted or substituted naphthyl.
*wherein the substituted phenyl or substituted naphthyl is substituted with one or more of: 6 7 c) C3-6 cycloalkyl.
d) aryl or heterocycle.
e) HO, 6a f) R or g) -C(O)NRR 2) aryl or heterocycle, [i:\DAYLiB\Iiba]393945ddoc:SSD 3) halogen, 6 4) OR, 6 7 NR R 6) CN, 7) NO 2 8) CE7 3 6a 9) -S(O)mR 6 7 -C(O)NR R, or I1) C-_C 6 cycloalkyl; mnis 0, 1 or 2; n is 0,1, 2,3or 4: p is 0. 1, 2 3or4; q is I or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0 or 1: t~ is 0Gor 1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof.
A second aspect of the present invention provides a compound which inhibits farnesyl -protein transferase of the formula B:
(R
8 )r2
G
()q 06*009 V Al(CRla )A 2 (CRla 2 I (GRlb 2 )PK, N N Z
B
wherein: R laand R' are independently selected from: hydrogen, -N(R 10)2, RI C(O)NRI or unsubstituted or substituted C 1
-C
6 alkyl wherein the substituent on the substituted C 1
-C
6 alkyl is selected from unsubstituted or substituted phenyl, 1 10 10 -N(R 2
R
10 0- and R C(O)NR [I :DAYLIB\Iiba]393945d.doc:SSD R is selected from: H, 0 0 and an unsubstituted or substituted group, the group selected from Cj- 8 alkyl, C 2 alkenyl and C 2 8 alkynyl; wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C- 4 alkyl, 6 b) (CH2)POR 6 7 c) (CH 2 )NR R d) halogen, 2) C 3 6 cycloalkyl, 6 1) OR 6a 6a 6a SR S(O)R S02R 6* R 6 7) 1 N:N6)7-N 7a 0 [I:\DAYLIB\flba]393945d.doc:SSD 8) -0O' NR 6 R 7 0 9) -0O OR 6 0 "YNR 6 R 7 0 I 0.
*0 0 11) -S 2 NR 6 R 7 12) -N-SO 2 -Ra 13)R6 0 14) OR 6 0
N
3 or 16) F o r *3is selected from: hydrogen and C C alkyl, 4 and R are hydrogen; 2 3 4 and any two of R R R and R are optionally attached to the same carbon atom; R 6,R 7and R 7aare independently selected from: hydrogen, unsubstituted or substituted C 1
-C
6 alkyl, unsubstituted or substituted aryl and unsubstituted or substituted cycloalkyl; R 6ais selected from: unsubstituted or substituted C 1
-C
6 alkyl, unsubstituted or substituted aryl and unsubstituted or substituted cycloalkyl; R 8is independently selected from: a) hydrogen, b) aryl, heterocycle, C 3
-C
1 0 cycloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, 11 I10 10 perfluoroalkyl, F, Cl, Br, R R S(O)mn-, R'OC(O)NR (RI 2
NC(O)-,
R 10 2 N-C(NR CN, N0 2 R 10C(O)-, RI N 3 -N(R 10)21 or R 11OC(O)NR 10-, and [I:\DAYLIB\iba393945ddoc:SSD c) C 1 -C6 alkyl unsubstituted or substituted by aryl, cyanophenyl, hieterocycle. C 3
-C,
0 c ycloalkyl, C 2
-C
6 alkenyl, C,-C 6 alkynyl, perfluoroalkyt, F, Cl, Br, R 100-, R I S(O)in-, R toC(O)NH-, (R R to N-C(NRO)-, CN, RI)C(O)-, IZ 1 N 3 -N(R 10)21 or R toOC(O)NH-;
R
9 is selected from: hydrogen and methyl: R Iis independently selected from hydrogen. CI-C6~ alkyl. benzvl and aryl; P. is independently selected from CFC alkyl and aryl: A and A 2are independently selected from: a bond, -CH=CH-, tto 10 1 o -C(O)NR -NR 0, -N(R -N(R or S(O)m; G isO0: \V is phenvl: is; a heterocycle selected Crom imidazolinyl. imidazolyl. oxazolyl. pyrazolyl.
p\ ~rroliclinyl. thiazolyl aind pyridyl.
~Z is aClbUlnsubstjtuted or substituted group selected fromn aryl, heteroaryl, Lrll3ethl hecteroarvlmethyl. arylsulfonvyl. heteroaryl sul I-bnyl. wherein the substituted g)roup is substituted with one or more of the 1 bllowing: S1) C 1 -4 alkl, unsubstituted or substituted with: a) C 4 alkoxy.
b) NR R, C) C 36 cycloalkyl, d) aryl or heterocycle.
e) HO0, 6a f) 1 IR or 6 7 2 g) -C(O)NR R 2) aryl or heterocycle, 3) halogen, 6 4) OR' 6 7 NR R 6) CN, 7) NO 2 8) CF 3 [I:\DAYLIB\iba393945d.doc:SSD 6a 9) -S(O)mR 67 -C(O)NR R, or 11) C 3
-C
6 cycloalkyl; m is 0, 1 or 2; nis 0, 1,2, 3 or 4; pis 0,1,2,3 or4; q is 1 or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0 or 1; t is 1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof.
A third aspect of the present invention provides a compound which inhibits farnesyl-protein transferase of the formula C:
(R
8 )r 9 )R2
R
3 9 R 2 V- CR-lanA2/' CR-la 2 Nr -Z 0 a R V-A R)a inden 2)n W f h)p N N-Z wherein: R a n lb 10 10 R and R are independently selected from: hydrogen, -N(R 2 R C(O)NR or unsubstituted or substituted C 1
-C
6 alkyl wherein the substituent on the substituted Ci-C 6 alkyl is selected from unsubstituted or substituted phenyl, -N(R R 0- and R C(0)NR
R
6
R
7
R
6 R2 is selected from: H, 0O and an unsubstituted or substituted group, the group selected from C- 8 alkyl, C2- 8 alkenyl and C2- 8 alkynyl; wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C, 4 alkyl, 6 b) (CH 2 pOR, 6 7 c) (CH 2 )pNR R [l:\DAYLIB\liba]393945d.doc:SSD d) halogen, 2) C 3 6 cycloalkyl, 6 3
OR,
4) SR 6a, S(O)R, S02R 6 -NR 6 R 7 6) -N
R
7 0 7) -N N 7
R
7 a 0 8) -0 NR R 7 a 0 RI 6 9) OR 6 1) N3 R or 1) F; 2
NRR
R Isslce rom yrgnadC 6 6akl [1A:DAYLIB\Iiba]393945d.doc:SSD R and R are hydrogen; and any two of R2, R 3, R 4and R are optionally attached to the same carbon atom; R 6,R 7and R 7aare independently selected from: hydrogen, unsubstituted or subsitued C-C 0 alky t, unsubstituted or substituted aryl and unsubstituted or substituted cN cloalkyl: R is selected from: unsubstituted or substituted C _C 6 alkyl. usbtttdo .Substituted aryl and unsubstituted or substituted cycloalky1: Ris independently selected from: a) h\'droaen, Ib) arvl. heterocycle. C,-C 10 cyctoalkyl, C,-C 6 alkenl., C,-C6 alkynyi.
pcriluoroalkyl. F. Cl1. Br. R I R IIS(0)rj-_ R IC(0)NRI'-, (R 10 )NC(0l)-.
1) R CN. 0.RC0 R -N(R y.or R OC(0)NR and at L CI-6 alkvI unisubstituted orsubstituted by aryl. cvanopbenvl. heterocycle.
a. UC) cvcloalkyl, C,-C 6 alkenvI. C>-C 6 alkynyl. perfluoroalkyl. F. Cl. Br. R 0-.
1 (0 6 1 1 0 Veo R: IF RI C(0)NH-. (R 10 R I N-C(NR I- CN. R I( R IO)0C N, -N(P.B or R OC(0)NH-: R is selected from: hydrogen and methyl; a0 R is independently selected from hydrogen. ClI-C6 alkyl. benz-vl and aryl: R is independently selected from CF 1 6 atkvl and aryl-, and A are independently selected from: a bond, -CH=CLI-, at a. 10 10 10 10 1I -C(0)NR -NRs 0, -N(K ~u 2 N(R -N(R or SO,, GisO V is phenyl, WV is a heterocycle selected From imidazolinyF, imidazolxl. oxazolvi, pyrazolyl.
2§pyrrolidfiyl, thiazolyl and pyridyl: X is Z is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, heteroary imethyl. arylsulfonyl, heteroarylsulfonyl. wherein the substituted group is Substituted with one or more of the following: 1 C ~alkyl, unsubstituted or- substituted with: a) C, 4 alkoxy, tI:\DAYLIB\iba393945d.doc:SSD 67 b) NR R, c) C 3 cycloalkyl, d) aryl or heterocycle, e) HO, 6a f) -S(O)mR or 67 g) -C(O)NR R, aryl or heterocycle, halogen, 6
OR,
6 7 NR R
CN.
NO,.
CF;
6a -S(O)mR 67 -C(O)NR R or
C
3 cycloalkyl; t 9* 9 a 9 a a a a **a a a a.
9) 10) 11) m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; pis 0, 1, 2, 3 or 4; 20 q is I or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 1: t is 0 or 1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof.
A fourth aspect of the present invention provides a pharmaceutical composition comprising a pharmaceutical carrier and dispersed therein, a therapectucially effective amount of a compound of any of the first, second or third aspects of the invention as described above.
A fifth aspect of the present invention provides a method of inhibiting farnesyl-protein transferase which comprises administering a therapeutically effective amount of a compound of the first, second or third aspects of the present invention described above to a mammal in need thereof.
[1:\DAYLIB\Iiba]393945d.doc:SSD A sixth aspect of the present invention provides a method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula A: (R )r (R 9 )qR2 R3 V -Al(CR a 2 2 (CRla 2 W )t-(CR I)
A
wherein: R I a and R ib are independently selected from: a) hydrogen. b) aryl. heterocycle, C 3
-CIO
cx'cloalkyl. C 2
C
6 alkenyl, C 2
C
6 alkynvi. R' 0
R
1 0
'C(O)NR
10
(R
1 0 2 CN. NO,, (R' 0 2
N-C(NR'
0
R'
0
R'
0
N
3
-N(R
1 0 2 or R''OC(O)NR 1 c) to: unsubstituted or substituted CI-C 6 alkyl wherein the substitutent on the substituted CI-C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3
-CI
0 cycloalkyl, C 2 Cc, alkenyl, C 2
-C
6 alkynyl, R 10 R''S(O)mn, R 1 0
C(O)NR'
0
(R
1 0 2 CN, (R' 0 2
N-
C(NR R' 0
R'
0
N
3
-N(R
10 2 and R 1 1 0C(O)-NR' 0 R R 2 and R 3 are independently selected from: H; unsubstituted or substituted Cl-g alkyl, 15 unsubstituted or substituted C 2 -g alkenyl. unsubstitutcd or substituted C 2 8 alkynyl, Lnsubstituted or substituted aryl, unsubstituted or substituted heterocycle, .R R 6
R
7
R
6 R or 0 0 wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) Cv-4 alkyl, b) (CH 2 0 0R c)
(CH,),NR
6 d) halogen, e) CN, 2) C 3 6 cycloalkyl,
OR
6 6a 6a 6 4) SR S(O)R S0 2
R~
[I:\DAYLiB\iba393945d.doc:SSD
-NR
6
R
7 6)6 0 7)N...NR 7
R
7 a 0 8) -0
NR
6
R
7 0 9) -O0 R 6
NR
6
R
7 0 S11) -S0 2
-NR
6
R
7
R
6 a.6a 12) NS 2 Ra 13)R6 14) OR 6 0
N
3 or 16) F; or R 2 and R 3 are attached to the same C atom and are combined to form (CH 2 wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S(0)m, and -N(C0R 1 0 R 4 and R" are independently selected from H and CH- 3 and any two of R R W 4 and R 5 are optionally attached to the same carbon atom; R R 7 and Rh are independently selected from: H; C 1 4 alkyl, C3- 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: [I:\DAYLI B\iba]393945d. doc: SSD a) C 14 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) y
R
-S0 2
R
1 1 or g)N(R 1 0 or R 6 and R 7 may be joined in a ring;
R
7 and R'a may be joined in a ring; R6, I S selected from: C 1 4 alkyl. C 3 6 cycloalkyl. heterocycle. aryl. unsubstituted or I I)substituted with: a) C 14 alkoxy.
b) aryl or heterocycle, c) halogen.
d) HO,
R
11 0 15 or g) N(R")2;
R
8 is independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -CIO cycloalkyl, C 2
C
6 alkenyl, C 2
-C
6 alkynyl, perfluoroalkyl, F, Cl, Br, R' 0
R
1 0
C(O)NR'
0 (R '0) 2 R 2 CN, NO,, R 0
R'
0
N
3
-N(R
10 2 or 20 R' 'OC(O)NR and c) C 1
-C
6 alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C 3 -CIO cycloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, perfluoroalkyl, F, Cl, Br,
R'
0
R'
0 C(O)NH-, (R 10 2
R'
0 2
N-C(NR'
0 CN, R' 0
R'
0 0C(O)-,
N,-N(R
1 0 ),or R' 0
OC(O)NH-
R" is selected from: a) hydrogen, b) C 2
-C
6 alkenyl, C 2
-C
6 alkyniyl, perfluoroalkyl, F, Cl, Br,
R'
0 0- R" 1
R
1 0
C(O)NR
1 0
(R
10 2
R
10
NC(NR"
0 CN, NO 2
R
10
R'
0
N
3
-N(R
10 2 or R 11 0C(O)NR' 0 and c) CI-C 6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R 10 R"(U)m,-RI t{L(U)NI-, (R 0) 2
R
2
N
C(NR
10 CN, R 1 0
R'
0 N3, 2 or R' 1
OC(O)NR
1
O-;
R 10 is independently selected from hydrogen, C I-C 6 alkyl, benzyl and aryl; is independently selected from C 1
-C
6 alkyl and aryl; [h:DAY LI B\Iiba]393945d.doc:SSD A and A 2 are independently selected from: a bond, -CH=CIIl-, -C(O)NR 1 \p~jO)0, -N(R 10
-S(O)
2
-N(R'
0 orS(), V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) CI-C 20 alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatomn selected from 0, S, and N, and e) C2)-C 2 0 §alkenyl.
provided that V is not hydrogen if A' is and V is not hydrogen if A' is a bond, n is 0 and A- is W is a heterocvcle, X is (1 Y is unsubstituted or substituted aryl or unsubstituted or substituted heterocycle. wherein the substituted aryl or substituted heterocycle is substituted with one or more of: I 1-4 alkNI. uinsubstituted or substituted with: a) C 1 4 alkoxy. b) NR0R'. C) cvcloalkyl.
aryi or heterocycle. e) HO. f) 6 or g) -C(O)NR 6 R 7, )arvi or heterocvcle.
)haloaen.
0.
0* 4) ORi 7- 6) C N.
7) N'O,, -C(O)NR R 7or I I C- 3 cycloalkyl:.
m is 0. 1 or 2: n isO0, 1,2.3 or 4; p isO0, 1.2,3 or 4; q is 1 or 2; r is 0 to 5, provided that r is -i~Owen Vis hydrogen; sis 0or; tis 0or1; and uis 4or or an optical isomer or pharmaceutically acceptable salt thereof A seventh aspect of the present invention provides a method for inhibiting farnesylprotein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a 3~plarmnaceutical carrier. and dispersed therein, a therapeutically effective amount of a cornpotind of the formula B: [I;\DAYLI B\Iiba]393945d. doc: S, (R 8 )r 2
G
V -A A(CRla 2 )nA (CRla 2 )n W -(CR 1 2) P\ N-Z
B
wherein: R" and Rh are independently selected from: a) hydrogen, b) aryl, heterocycle, C 3
-CIO
eveloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, R 10
R
1 1
R'
0
C(O)NR
10 CN(R 0 2
R'
0 2
N-C(NR'
0 CN, N02, R' 0
R"'
0
N
3
-N(R'
0 2 or R' '0C(0)NR 1 c) unsubstituted or substituted C 1
-C
6 alkyl wherein the substitutent on the substituted C 1
-C
6 alkvl is selected from unsubstituted or substituted aryl, heterocyclic, C 3
CI
11 cvcloalkyl. C 2
C
6 alkenyl, C 2
-C
6 alky~nyl, R' 0
R'
1 S(0)ITI-- R 1 0 C(0)NR m 2 R'%,N-CcNR 1 0 CN, R 1 0
R'
0
N
3
-N(R
1 0)2, and R' 1 0C(0)io R R 2 and R 3 are independently selected from: H: unsubstituted or substituted C -8 alkyl, unsubstituted or substituted C 2 -8 alkenyl, unsubstituted or substituted C,- 8 alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle.
R 6 R 7 R 6 o r 0 0 15 wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkyl, b) (CH 2 )p0R 6 c) (CI-I)pNR 6 d) halogen, e) CN, 2) C 3 6 cycloalkyl, 4) SR S(0)R a, S0 2 Ra -NR 6 R 7 R6) 0 R 6 7) N R7 0 [I :\DAYLIB\Iiba]393945d.doc:SSD 8) -0 NR 6 R 7 0 9) -O R 6 0 N<IyNR 6 R 7 0 11) -S0 2 -NR 6 R 7 12) -N-SO 2 -Ra 13) R 6
O
6 0
N
3 or 16) F; o r P 2
R
2 and R' are attached to the same C atom and are combined to form (CH 2 )u wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S(O)m, and -N(COR' 0 *4 i
R
4 i selected from HI and CH 3 *and any two of R 2 R 3 and R 4 are optionally attached to the same carbon atom; R 6 R 7 and R 7 are independently selected from: H; C 1 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) C 14 alkoxy, b) aryl or heterocycle, c) halogen.
d) HO, e)
R
0 f) S0R or [F:\DAYLIB\Iiba]393945d.doc:SSEJ N(R or R" and R 7 may be joined in a ring; R' and R 7 may be joined in a ring;
R"
8 is selected from: C 1 4 alkyl, C 3 -6 CVCloalkyl, heterocycle, aryl, unsubstituted or Substituted with: a) C 4 alkoxy.
h) ar\iI or heterocycle, C) halouil.
d) 110.
e)
Y
0 f) -S0,R 1 1 or R is independently selected from: a) hydrogen. b) aryl, heteroecce. C3-CIO cycloalkyl. C 2 alkenvi1. C 2 I-C6 alkvnvl. perfluoroalkyl. F, Cl. Br, R w0-. R' R'"C(0)NR")10 kR")hNC(0)-. R 2
,,N-CC-NR
15 CN. NO,. -N(R 10 or EC(0)NPIK)- and C) C,-C 6 alkVl Lnsubstituted or substituted by aryi. cyanlophenyl.
IlterOCNI Cle. C' 3 -CI cycloalkvl. C,-C 6 alkenyi. CI-C6 alkvnyl. perfluoroalkyl, F. Cl, Br.
P, In 0 R R (R 0)2NC(0)-. R"'2N-C(NR CN, R' 0 NV. or R OC(0)NH-; :P is selected from: a) hydrogen, b) alkenvi. alkynyl, perfluoroalkyl. F, Cl. Br. R' t1 0-, S m P. R 1 (R ")2NC R'NCNR)- CNNI ''C0-,RIOC(0)-, or and c) CI-C 6 alkyl unsubstituted or substituted by *peliLloroalkyl. F, Cl. Br, R R' R' 0 2 NC(0) CN. RIuC(0)-. R N 3 or R''0C(0)NR is independently selected from hydrogen, C I-C 6 alkyl, benzvl and aryl; is independently selected from CI-C 6 alkyl and aryl; A Iand A 2are independently selected from: a bond, -CH=CH-. -C(0)NR 0. -N(R -S(0) 2
-N(R'
0 )S(0) 2 or SO,, GI is H)b or 0: V/ is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C,-C 20 alkyl wherein from 0 to 4 ih carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C 2
-C
2 0 alkenyl.
[I:\DAYLIB\Iiba]393945d.doc:SSD pp provided that V is not hydrogen if A' is S(O)m and V is not hydrogen if A is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; X is -CH 2 or Z is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, heteroarylmethyl, arylsulfonyl, heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: 1) Ci- 4 alkyl, unsubstituted or substituted with: a) C1- 4 alkoxy, b) NR 6
R
7 c) C 3 -6 cycloalkyl, d) aryl or heterocycle, e) HO, f) -S(O)mR 6a or g) -C(O)NR 6
R
7 2) aryl or heterocycle, 3) halogen, 4) OR 5) NR6R 7 6) CN.
to" 15 7)NO-.
8) CF 3
-C(O)NR
6
R
7 or 11) C 3
-C
6 cycloalkyl; 20 m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q is I or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0 or 1; t is 0 or 1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof.
An eighth aspect of the present invention provides a method for inhibiting farnesylprotein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula C:
(R
8 (R9) (R(R9)q
R
2 R3 I a 2-a V Al(CRa2)nA 2 (CRa 2 )n W (CRb2)p, N Z C
R
4 wherein: [1:\DAYLIB\iba393945d.doc:SSD R" and Rib are independently selected from: a) hydrogen, b) aryl, heterocycle, C 3
-C
10 cycloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, R' 0 R' R I C(O)NR' 0 R 1 0 2
N-C(NR'
0 CN, N0 2
R'
0
R'
0
-N(R'
0 2 or R' OC(O)NR' 0 c) unsubstituted or substituted C 1
-C
6 alkyl wherein the substitutent on the substituted CI-C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 -CIO cycloalkyl, C 2
C
6 alkenyl, C 2
-C
6 alkynyl, R' 0
R
11
R'
0
C(O)NR'
0
(R'
0 2
R
1 0 2 N-C(NR' 0 ICN, R' 0
R'
0
N
3
-N(R'
0 2 and R" 1
OC(O)-NR
1
O-;
R 2and R 3are independently selected from: H; unsubstituted or substituted C 1-8 alkyl, unsubstituted or substituted C 2 8 alkenyl. unsubstituted or substituted C?_ 8 alkynyl, I0 unsubstituted or substituted aryl, unsubstituted or substituted heterocycle.
Re or R 6 0 0 wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkyl, b) (CH 2 )OR 6 c) to (CH 2 )pNR d) halogen, e) CN, 2) C 3 -6 cycloalkyl, 6a la 6a SR ,S(O)R S0 2
R
-NR 6 R 7 *R 6 1* R 6) 0 R 6* 7) 1N.. R 7
R
7 a 0 [I:\DAYLIB\iba1393945d .doc: SSD 8) -ONR 6 R 7 9) 0 O6 0 rNR 6 R 7 0 11) -S0 2 -NR 6 R 7 12) -N-S0 2 -Ra 13)R6 OR 6
N
3 o r ft ftft16) F; or PR and R. are attached to the same C atom and are combined to form (CH 2 wherein one ft of the carbon atoms is optionally replaced by a moiety selected from: 0, S(0)m, S 5 and -N(COR R is selected from H and CH 3 and any two of R 2 R 3 and R 4 are optionally attached to the same carbon atom; R 6 R 7 and R 7 are independently selected from: H; CI- 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) CI- 4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e)
R
11 f) -SO 2
R'
1 or [1A:DAYLI B\Iiba]393945d. .doc: SSD N~ N(R' or R" and R 7 may be Joined in a ring; \i and R may be joined in a ring; R is selected fromn: C 1 4 alkyl. C 3 -6 cycloalkyh. heterocycle, aryl. unsubstituted or SSubstituted with: a) C 1 4 alkoxv, h2) arvl or heterocycle.
c) halogen.
di) H-O.
e)
R
11 0 f) -S0 2
R
1 or is indepcndentlv selected frorn: a) hydrogen. b) arvL heterocycle. C--C 10 cycloalkvl. C,- Calkenvi. C -C 6 alkynyh, perfluoroalkyh, F. Br. R I00- R' 0
(PR')
2 CN. N 3
-N(R
1 or P. OC(O)NR and c) C- 6 alkyl unsubstituteci or substituted by aryl. cyanophenyi.
*heteroevcle. C3-CI 1 cyeloalkyl. C&-C 6 alkenyi. C-1-C6, alkynyl, perfluoroalkyl, F. Cl. Br.
R'1 R I S((y, 1 R"C(O)NH-, R' 1 1 2 CN. R"OC(O)-, or R")OC(O)NH-: Rf is selected from: a) hydrogen. b) C 2
-C
6 alkenyl, C 2
-C
6 alkynyl. perfluoroalkyl. F. Cl, Br.
N
3
-N(R
1 0 2 or R' I0C(O)NR 10 and e) C 1
-C
6 alkyl unsubstituted or substituted by perfi Loroalkyl, F, Cl, Br. R 10 R' R' 0 C(O)NR O- (R' 0 2
R
1 0
'N-
CN. R N 3
-N(R
1 2 or R' 'OC(O)NR' 0 P. is independently selected from hydrogen, C I -C 6 alkyl, benzyl and aryl; R' is independently selected from C I -C 6 alkyl and aryl; A and A 2 are independently selected from: a bond, -CH=CH-, -C(O)NR' 0 0, -N(R' 0
-S(O)
2
N(R
10
-N(R'
0
)S(O)
2 or SO,, G isO0: V is selected from: a) hydrogen, b) heterocycle, c) aryl, di) C 1
-C
2 0 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatomn selected from 0, S, and N. and e) C?-C 20 alkeriyl, [I:\DAYLB\iba]393945ddoc:SSD
MMMEN
provided that V is not hydrogen if A' is S(O)m and V is not hydrogen if A' is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; X is -CH 2 or Z is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, heteroarylmethyl, arylsulfonyl, heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: 1) C 14 alkyl, unsubstituted or substituted with: a) C1- 4 alkoxy, b) NR 6
R
7 c) C 3 -6 cycloalkyl, d) aryl or heterocycle, e) HO, f) -S(O)mR 6 a or g) -C(O)NR6R 7 2) aryl or heterocycle, 3) halogen, 4) OR' 5) NR R 7 6) CN.
5 7)N02, 8) CF 3 S* 9) -S(O)mR 6 a, -C(O)NRR 7 ,or 11) C 3
-C
6 cycloalkyl; 20 m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q is I or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 1; t is 0 or 1; and u is 4 or S or an optical isomer or pharmaceutically acceptable salt thereof.
:A ninth aspect of the present invention provides a method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula A:
(R
8 )r 9 R2q R 3 R 0 V Al(CRa 2
),A
2 (CRa 2 )n W (CR1b 2 )P KN JN4 t X U Y
R
4
R
A
wherein:
R"
a and R b are independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -Clo cycloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, R'0O-, R 1 "S(O)m RioC(O)NRi 0
(R"I)
2 [l:\DAYLIB\liba]393945d.doc:SSD CN, NO,, (RlO),N-C(NR 10)-1 R I 0
R'
0
N
3
-N(R'
0 or c) unsubstituted or substituted C 1
-C
6 alkyl wherein the substitutent on the substituted C 1
-C
6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 -CIO cycloalkyl, C 2 alkenyl, C 2
-C
6 alkynyl, R 10
R
11
R
10
C(O)NR
10
(R'
0 2 CN, (R' 0 2
N-
C(NR'
0
R
1 0
R'
0
N
3
-N(R
1 0 2 and R' R 2 and R 3 are independently selected from: H; unsubstituted or substituted CI-g alkyl, unsubstituted or substituted C 2 8 alkenyl, unsubstituted or substituted C2-g alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, R 6
R
7 R 6 1--e ~or 1- 0 0 1 ewherein the substituted group is substituted with one or more of: 9*1) arvl or heterocycle. unsubstituted or substituted with: a) C 1 4 alkyl. b) c) (CH7))NR 6 R d) halogen, e) CN, 2) C3- 6 cycloalkyl, 6a a 6a 15 4) SR ,S(O)R a, S0 2
R
-NR 6 R 7 6) -N R 7 0 R 6 7) 7 7 0 [I:\DAYLI B\iba]393945d. doc: SD 8) -O NR 6 R 7 0 9) -0 Y R 6 0 "YNR 6 R 7 0 11) -S 2 -NR 6 R 7 R 6 12) ~NS0 2 R 6 a *13)R6 9. 9 0 N3 o 16 F;.o R n r tahdt h aeCao ndaecmie ofr CA hri n of th carbo -tm-6 otoalyrpae yamieyslce rm 0 1) N 3 akx, o b 1) F;y orhteoyce c) 3aogn RrOtahdthesm tmadae obndt om-(C 2 1 hri n e)
R"
0 -S 2 1 or [I:\DAYLIBIiba]393945d.doc:SSD g)N(R LU or R" and R7 may be Joined in a ring, Rand R 7 may be joined in a ring-, is selected from: C 1 4 alkyl. C3-6 cycloalkyl. heterocycle. aryl. unsubstituted or §substituted with: a) C i alkoxy.
b) aryl or heterocycle, c) halogen.
ci) HO.
e)
R
0 f) -SOR" or R is independently selected from: a) hydrogen. b) aryl. heterocycle, C 3
-CI
0 eveloalkyl. C-- ),alken\vl. C 2 I-C6, alkynyl. perflUoroalkvl. F, Cl, Br. R R"C(O)NR O-, Rl' 0 CN. N0O% R' t1
N
3 or P. O(?(O)NR -,and c) C 1
-C
6 alkyl unsubstituted or substituted by ary'l. cyanophenvi.
hieterocycie. C 3 -CIO cycloalkyl, C 2 -C6 alkenyl. C-)-C6 alkynyl, perfIloroalkyl., F. Cl.Br P. R'C(O)NH-, R", 3 N-C(NR" CN, R 1
R'
0 0C(O)-.
-N(R >.or R"OC(O)NH-; P. is selected from: a) hydrogen, b) C2--C 6 alkenyl, C 2
C
6 alkynyl. perfluoroalkyl. F. Cl. Br, P. R' 0
C(O)NR'
0
(R'
0
R'
0 2 N-C(NR CN, NO 2
R'
0
N
3
-N(R'
0 2 or R''OC(O)NR' 0 and c) C 1 alkyl unsubstituted or substituted b\ perflUoroalkyl, F, Cl, Br. R' R' 1
(R'
0 2 CN, R' 0
R'
0
N
3 or OC(O)NR('-, R" is independently selected from hydrogen, CI-C 6 alkyl, benzyl and aryl; 23R' is independently selected from C,-C 6 alkyl and aryl; A and A are independently selected from: a bond, -CH=CH-. -C(O)NR 0 NR 0 0, -N(R 10
-S(O)
2 N(R -N(R 2 or SO,, V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C,-C'o alkyl wherein from 0 to 4 carbon atomns are replaced with a heteroatom selected from 0. S. and N, and e) C 2
)-C
2 0 provided that V is not hydrogen if A' is and V is not hydrogen if A Iis a bond, n is 0 and A 2 is [I :\DAYLIB\iba393945ddoc:SSD W is a heterocycle; X is -CH 2 or Y is unsubstituted or substituted aryl or unsubstituted or substituted heterocycle, wherein the substituted aryl or substituted heterocycle is substituted with one or more of: 1) Ci- 4 alkyl, unsubstituted or substituted with: a) CI- 4 alkoxy, b) NR'R 7 c) C 3 -6 cycloalkyl, d) aryl or heterocycle, e) HO, f) -S(O)mR 6 a, or g) -C(O)NR 6
R
7 2) aryl or heterocycle, 3) halogen, 4) OR 6 1 5) NR'R 7 6) CN.
7) NO2, 8) CF 3 15 10) -C(O)NR 6
R
7 or 11) C3-C6 cycloalkyl; Sm is 0, 1 or 2; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q is I or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0 or 1; t is 0 or 1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof 20 A tenth aspect of the present invention provides a method for treating cancer which i comprises administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula B: 0 -S
(R
8 )r
(R
9 )q
R
2
G
V Al(CRa 2
),A
2 (CRa 2 W (CR 1 b2) p N N-Z
R
3
R
4
B
wherein: Ria and Rlb are independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -Clo cycloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, R'0O-, RI 0
C(O)NR
1 0
CN(R'
0 2 RI2N-C(NRo)-, CN, NO 2 RioOC(O)-, N 3
-N(R'
0 2 or
R"OC(O)NR'
0 c) unsubstituted or substituted CI-C 6 alkyl wherein the substitutent on the substituted Ci-C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, [:\DAYLIB\Iiba393945d.doc:SSD
C
3 -CIO cycloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, R 111
R'
0
C(O)NR
1
(R'
0 2 R"2N-C(NR' 0 CN, R 1
R'
0
N
3 -N(R'0) 2 and R''OC(O)- R 2 and R3 are independently selected from: unsubstituted or substituted CI-8 alkyl, unsubstituted or substituted C 2 8 alkenyl, unsubstituted or substituted C 2 8 alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, -e or 0 0 wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) CI- 4 alkyl, b) 6
C)
(C1-L)pNR 6 d) halogen, e) CN, 2) C3-6 cycloalkyh.
S 6 3) OR SR la, S(O)R la, SOR la, 6* 7 5) -NR R 7 *R 6 5?6) 1 0
R
6 N N R 7
R
7 a
S
0 [I:\DAYLIB\iba]393945d.doc:SSD 8) -0o NR 6 R 7 0 9) OR 6 0 "Y NR 6 R 7 0 11) -S0 2 -NR 6 R 7 R 6 12) 1 1 O 2 R 6 a *13)6 0 14)6
N
3 or 16) F; or 2 3whrion RRand Rare attached to the same C atom and are combined to form (CH)A weri n of the carbon atoms is optionally replaced by a moiety selected from: 0, 5 and -N(COR'j-;
R
4 is selected from H and CH 3 2 3 4 and any two of R R and R4 are optionally attached to the same carbon atom; R 6 R' and R 7 a are independently selected from: H; C 1 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) C 1 4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e)
R'
f) -S0 2
R
1 or [1ADAYLIB\[ba393945d.doc:SSD
C)N(R
1 or R" and R'7 may be joined in a ring; R' and R 7 a may be joined in a ring,; IS iSselected from: C 1 4 alkyl, C3- 6 cycloalkyl, heterocycle, aryl, unsubstituted or 3suibstituted with: a) (i1-4 alkoxy, b) aryl or heterocycle, c) lialolgen.
d) HO.
e)
R
11 0 T) -S0 2
R
1 1 or QL\(R b R' P is independently selected from: a) hydrogen. b) aryl, heterocycle. C 1 U ccloalkvl. C 1U 0- C, alkenmi. alkynvi. perfinoroalkyl. F. Cl. Br. R R' R (C(O)NR' 1 (R R CN. NO,. R R 1
N
3 -N(Rl 1 or I R 11
OC(O)NR
1 and c) C 1
-C
6 alkyl unsubstituted or substituted by aryl. cyanophenyl, heterocycle. C 3 -CIO cycloalkyl. C 2
-C
6 alkenyl, C 2 1-C 6 alkynyl. perfluoroalkyl, F, Cl. Br, -N(R >?.orR' 0 0C(O)NH-; RUis selected from: a) hydrogen, b) alkenyk. alkynvi, perfinoroalkyl, F. Cl. Br, R' 0 perfinoroalkyl. F, Cl, Br, R'0 1
R
11 RIOC(O)NRIU,
(R
1 0 R1 0 ,N-C(NR I CN, R R 11 OOC(O)-, N 3 -N(R 0)2, or R' 'OC(O)NR 1 0 1 R I is independently selected from hydrogen, C 1
-C
6 alkyl, benzyl and aryl; is indepenidently selected from C 1
-C
6 alkyl and aryl; A and A? are independently selected from: a bond. -CH=CH-,
-C(O)NR
1 0, -N(R -SCO) 2
N(R
10
-N(R
10
)S(O)
2 orS(),- G is IH, or 0: V 'is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C 1
-C
2 0 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C 2
-C
2 0 alkenyl, [I i\DAYLIB\Iiba1393945d.doc:SSD provided that V is not hydrogen if A' is S(O)m and V is not hydrogen if A' is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; X is -CH 2 or Z is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, heteroarylmethyl, arylsulfonyl, heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: 1) C -4 alkyl, unsubstituted or substituted with: a) C1.4 alkoxy, b) NR 6
R
7 c) C 3 6 cycloalkyl, d) aryl or heterocycle, e) HO, f) -S(O)mR 6 a, or g) -C(O)NR 6
R
7 2) aryl or heterocycle, 3) halogen.
4) OR 6 5) NR 6
R'
6) CN.
1 5 7) NO,.
8) CF 3 9) -S(O)mR 6 -C(O)NR6R 7 or 11) C 3
-C
6 cycloalkyl; m is 0. 1 or 2; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q is I or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0 or 1; t is 0 or 1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof.
An eleventh aspect of the present invention provides a method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula C:
(R
8 )r
(R
9 )q R2 R 3 V A l(CRla2)nA 2 (CRla2) n W CR 1
/N-Z
t x kG C
R
4 wherein: Ria and R l b are independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 cycloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, RoO- Ri°C(O)NR 1 0
(RI°)
2
NC(O)-,
[l:\DAYLIB\liba]393945d.doc:SSD R CN, NO 2
N
3
-N(R'
0 2 or R" OC(O)NR c) unsubstituted or substituted CI-C 6 alkyl wherein the substitutent on the substituted CI-C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3
-CI
0 cycloalkyl, C 2
C
6 alkenyl, C 2
-C
6 alkynyl, R1 0
R'
1
R'
0
C(O)NR
1 0
(R'
0 2
R'
0 2
N-C(NR'
0 CN, R 10
R'
0
-N(R
1 0 2 and R''0C(O)-NR' 0 R2 and R 3are independently selected from: H; unsubstituted or substituted C 1-8 alkyl, unsubstituted or substituted C 2 -8 alkenyl, unsubstituted or substituted C 2 -8 alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, R 6 R 7 R 6 1--e or 0 0 I 0 wherein the substituted groupo is substituted with one or more of: Iaryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkvl. b) (CH 2 )pOR 6
C)
(CT-1)pNRR 7 d) halogen. e) CN.
2) C 3 6 cycloalkyl,
OR',
4) SR~a S(O)Roa, SO2Ro *6 7 -NR R 7 R 6 7 6) q R 6 7) -N N NR 7 R 7 a 0 [I:\DAYLIB\Iiba]393945d .doc: SSD 8) -0O NR 6 R 7 0 9) -0 OR 6 0 NR 6 R 7 0 11) -S0 2 -NR 6 R 7 12) -N-SO 2 -Ra 13) rR 6 0 14 6 *00 R 0* 0
N
3 or 16) F; or R 2 and R' are attached to the same C atom and are combined to form (CH 2 wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S(O)m, and -N(COR
R
4 is selected from H and CH 3 and any two of R 2 R 3 and R 4 are optionally attached to the same carbon atom; R 6, R 7 and R 7 are independently selected from: H; C 1 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) C 14 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) R1 f) -S0 2
R"
1 or [I:\DAYLI B\Iiba]393945d. doc: SS D P.an P' aybejone i0arig
R"
7 and R 7 may be joined in a ring; R" is selected from: C 1 4 alkyl, C 3 -6 cycloalkyl, heterocycle. aryl, unsubstituted or Ssubstituted with: a) CI- 4 alkoxy.
b) aryl or heterocycle.
C haloen.
d) HO.
e) Y
R
0 f) S 2 R or :RN Is independently selected from: a) hydrogen. b) arvl. heterocxcle. C3-C10 cycloalkyl., C,- C,,alkenyi. Cr'-C6 alkynvi. perfluoroalkyl, F. Cl, Br. R' R' R'O'C(O)NR' CN, NO% Rl N 3
-N(R
1 0 o r 3 P.''OC(O)NR and C ,C alkyi unsubstituted or substituted by arvi rpeyl. a :heterocycle. C 3 -CIO cycloalkyl, Cr-1C 6 alkenyl. C 2
)-C
6 alkynyl. perfluoroalkyl, F. Cl. Br.
R 0O-. R' 1
R
10 C(O)NH-, (R" 1 2
R
10 7N-C(NR")I CN. -N(R or R")OC(O)NH-; R"K is selected from: a) hydrogen, b) C:1-C6 alkenyl. C 2 C6 alkynyl. perfluoroalkyl. F. Cl. Br.
:0 20 R"C(0)NR 2 2 CN, NO- R
N
3 -N(R Ju)2, or R 1 'OC(0)NR and c) C,-C 6 alkyl unsubstituted or substituted by perfluoroalkvl, F. Cl, Br, R 1 R' R 11
(R'
1 b 2 3
N-
C(NR CN. R' 0
N
3 or R 1 RIis independently selected from hydrogen, C I -C6 alkyl, benzyl and aryl; is independently selected from CI-C 6 alkyl and aryl; A. anid A'arc independently selected from: a bond. -CI I=CH-. -C -C(O)NR 10 0, -S(O) 2
-N(R
10 or G isO0: V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C 1 -Co alkyl wherein fromn 0 to 4 M0 carbon atoms are replaced with a a heteroatom selected from 0, S. and N, and e) C 2
-C
2 0 alkenyl.
[I:\DAYL1 B\Ii ba]393945d .doc: SS D provided that V is not hydrogen if A' is S(O)m and V is not hydrogen if A' is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; X is -CH 2 or Z is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, heteroarylmethyl, arylsulfonyl, heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: 1) C 14 alkyl, unsubstituted or substituted with: a) C 14 alkoxy, b) NR 6
R
7 c) C3- 6 cycloalkyl, d) aryl or heterocycle, e) HO, f) -S(O)mRa, or g) -C(O)NR 6
R
7 2) aryl or heterocycle, 3) halogen, 4) OR 6 NR
R
7 6) CN, 15 7) NO2, 8) CF 3 9) -S(O)R 6 a,
-C(O)NR'R
7 or 11) C 3
-C
6 cycloalkyl; 20 m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q is 1 or 2; r is 0 to 5, provided that r is *0 when V is hydrogen; s is 1; t is 0 or 1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof.
A twelfth aspect of the present invention provides a method for treating or preventing a disease selected from neurofibromin benign proliferative disorder, blindness related to retinal vascularization, infections from hepatitis delta and related viruses, restenosis and polycystic kidney disease, which comprises administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula B:
(R
8 )r
(R
9
R
2 G V A(CRa2)nA 2 (CR la2n W (CR1 b 2 p N N-Z t
X
R
3
R
4
B
[I :DAYLI8MIiba]393945d.doc:SSD wherein: I a lb R and R1 are independently selected from: a) hydrogen, b) aryl, heterocycle, C 3
-C
10 cycloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, R' 0 R" R' 0
C(O)NR
10
CN(R'
0 2
R'
0 2
N-C(NR'
0 CN, NO 2
R'
0
R'
0
N
3
-N(R
1 0 2 or R''OC(O)NR c) unsubstituted or substituted CI-C 6 alkyl wherein the substitutent on the substituted CI-C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 CIO cycloalkyl, C 2
-C
6 alkenyl, C 2
-C
6 alkynyl, WOO0-, R 11
R'
0
C(O)NR
1 0
(R
10 2 R1 0 2 N-CENR")-, CN, R' 0
R'
0
N
3
-N(R"
0 and R' 1 0C(O)-
NR
1 o0 R 2 and R 3 are independently selected from: H; unsubstituted or substituted CI-8 alkyl, unsubstituted or substituted C?-g alkenil, unsubstituted or substituted alkynyl, unsubstituted or substituted aryl, unsubstituLted or substituted heterocycle, or 0 0 wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle. unsubstituted or substituted with: a) C 14 alkyl, b) (CH 2 ),OR 6
C)
*(CH,),NR
6 d) halogen, e) CN, 2) C3-6 cycloalkyl, *3)OR 4) SR 6,S('jyi 6, S0 2 Ra, -NR R 7
R
6 -NY R 7 0
R
6 7) 1 N 7 7 a 0 EI:\DAYLB\Iiba393945d.doc:SSD 8) O0 YNR 6
R
7 0 9) -0OOR 6 0 NR 6 R 7 0 11) -S0 2 -NR 6 R 7 12) -NS0- 13)6 0 14)OR 0 R6
N
3 or 16) F) o r
R
2 and R 3 are attached to the same C atom and are combined to form (CHA), wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S(O)m, and -N(C0R 1 R4 is selected from H and CH 3 and any two of R2, R 3and RWare optionally attached to the same carbon atom; R 6 R 7 and R 7 are independently selected from: H4; C 1 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) C 14 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) Y R 1 1 -S0 2
R
1 1 or [I:\DAYLIB\iba]393945d.doc:SSD e)N(R' 0 or R 0 and R 7 may be joined in a ring;
R
7 and R 7 may be Joined in a ring; is selected from: CI- 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, unsubstituted or §substituted with: a) C 14 atkoxv.
b) aryt or heterocycle, c) halogen.
di) HO.
e) Y
R
0 f) -S0 2
R
1 or R' is independently selected from: a) hydrogen. b) aryl. heterocycle. C 3 -CIO cycloalkyl. C,- C6, alkenvi. CI-Cc, alkynyl. perfluoroalkyl, F, Cl. Br, R 10
R
10
R
1 CN. NO-, N3. Or 1' 'OC(O)NR 1 and c) C -C 6 alkyt umsubstituted or substituted by aryl. cyanophenyl.
p heterocv cle. C 3 -Ci 10 cycloalkyl, C 2
-C
6 alkenyl. C 2
C
6 alkynyl, perfinoroalkyl. F. Cl. Br, to 0 or R'()OC(O)NH-; PC~ is selected from: a) hydrogen, b) alkenyl, alkynyl, perfluoroalkvl. F. Cl. Br, R 13 0-, R"C(O)NR (R R 0 2
R"OC(O)-,
-N(R
1 2 or R 1
'OC(O)NR'
0 and c) C 1
-C
6 alkyl unsubstituted or substituted by perfluoroalkyl. F, Cl, Br. R'10-, R' 1
R'
1 )C(O)NR tO..
R'
0 N-C(NR CN, R 1 0 R' 0
N
3 3 2 or R 11 0C(O)NR 10 R is independently selected from hydrogen, C 1 -C6 alkyl, benzyl and aryl; 2§R' is independently selected from C 1
-C
6 alkyl and aryl; A I and A2 are independently selected from: a bond, -CH=CiI- -C(O)NR" 1
NR
1 0, -N(R 1
-S(O)
2
N(R
1
-N(R'
0
)S(O)
2 or SO,, G is 112or 0;, V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C I-C') 0 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatrm selected from 0, S, and N, and e) C 2
-C
20 alkenyt, [I:\DAYLIB\Iiba]393945d.doc:SSD provided that V is not hydrogen if A' is and V is not hydrogen if A' is a bond, n isO0 and A 2 is W is a heterocycle; X is -CH 2 or Z is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, heteroarylmethyl, arylsulfonyl, heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: 1) C 1 4 alkyl, unsubstituted or substituted with: a) C 1 4 alkoxy, b) NR R 7 C) C3-6 cycloalkyl, d) aryl or heterocycle, e) HO, f) or g) -C(O)NR R.
t0 2) aryl or heterocycle.
halogen, 4) OR 6, NR 6R 6 6) CN.
CF
3 9) S),Ra foe 10) 6 7o 11) C 3
-C
6 cycloalkyl; mis 0, 1 or 2; n is 0, 1, 2.3 or 4; p is 0, 1,2, 3 or 4; q is 1 or 2: r isO0 to 5, provided that r is 0 when Vis hydrogen; sis 0or; t is 0or1; and uis 4or or an optical isomer or pharmaceutically acceptable salt thereof.
[I:\DAYLIB\fiba1393945d.doc:SSD WO 96/30343 PCT/US96/04019 -6- DETAILED DESCRIPTION OF THE INVENTION The compounds of this invention are useful in the inhibition of farnesyl-protein transferase and the farnesylation of the oncogene protein Ras. In a first embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula A:
(R
8 )r (R9) R R3 V AI(CRla 2 )nA 2 (CR1a 2 W t-(CR 1 b 2 )p N' N n O n x N xJ
R
4
R
A
wherein: Ria and Rib are independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, R 10
R
1 1 R10C(O)NR 10 (RO1)2N-C(O)-, CN, N02, (R10)2N-C(NR 1 RO1C(O)-, N3, -N(R 10 or R 1 1O
C(O)NR
10 c) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R 10 0-, R11S(O)m-, R10C(O)NRO 10 (R10)2N-C(0)-, CN, (R10)2N-C(NR 10 R10C(O)-, R10OC(O)-, N3,
-N(R
10 and R 1 1
OC(O)-NR
10
R
2 and R 3 are independently selected from: H; unsubstituted or substituted Cl-8 alkyl, unsubstituted or substituted C2-8 alkenyl, unsubstituted or substituted C2-8 alkynyl, unsubstituted or substituted aryl, R 6or R6 orunsubstituted or substituted heterocycle, unsubstituted or substituted heterocycle, 0 0 WO 96/30343 WO 9630343PCT/US96/04019 -7wherein the substituted group is substituted with one or more of: 1) aryl. or heterocycle, unsubstituted or substituted with: a) C 1-4 alkyl, b) (CH2)pOR 6 c) (CH2)pNR 6
R
7 d) halogen, e) CN, 2) C3-6 cycloalkyl, 3) OR 6 4) SR 6
S(O)R
6 a, SO2R 6 a, -NR 6 R 7 6) -N R 7 0 7) 7N~ NR 7 a 0 8) -0o"
NR
6 R 7 0 9) -O OR 6 0 '-rNR 6 R 7 0 11) -S0 2 -NR 6 R 7 WO 96/30343 PCT/US96/04019 -8- 13) R 6 0 14) OR 6 0
N
3 or 16) F; or
R
2 and R 3 are attached to the same C atom and are combined to form (CH2)u wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S(O)m, and
R
4 and R 5 are independently selected from H and CH3; and any two of R 2
R
3
R
4 and R 5 are optionally attached to the same carbon atom;
R
6
R
7 and R 7 a are independently selected from: H; C1-4 alkyl, C3-6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) Cl-4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) Rll 0 f)
-SO
2 R11 or g) N(R 10 or
R
6 and R 7 may be joined in a ring; WO 96130343 WO 9630343PCT/US96/04019 -9-
R
7 and R 7 a may be joined in a ring;
R
6 a is selected from: C1-4 alkyl, C3-6 cycloalkyl, heterocycle, aryl, unsubstituted or substituted with: a) C1-4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e)
YR
0 f) S0 2
R
1 g) N(R 1 0 )2; ,or R8 is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C1O cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, peffluoroalkyl, F, Cl, Br, R 10
R
1 1 S(O)m-,
RIOC(O)NR
10 (RIO)2NC(O)-, R102N-C(NR 10
CN,
N02, RIOC(O)-, R 10 N3, -N(R 1 0 or
R
1 lOC(O)NR 10 and c) C 1-C6 alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C3-C1O cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, perfiuoroalkyl, F, Cl, Br, R100-,
R
1 1 Rl 0 C(O)NH-, (R 1 Q)2NC(O)-, R 10 2N- CN, RlOC(O)-, R10OC(O)-, N3, -N(RIO)2, or RIO0C(O)NH-;
R
9 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, perfluoroalkyl, F, Cl, Br, RIO0-, R 11 Rl 0
C(O)NRIO
0
(R
1 0 )2NC(O)-, R102N-C(NRIO)-, CN, N02, RlOC(O)-, R10OC(O)-, N3, 102,or R I IOC(O)NR 10 and WO 96/30343 PCTIUS96/04019 c) C1-C6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R 10
R
1 1 R10C(O)NR 10 (R10)2NC(O)-, R 10 2N-C(NR 1 CN, N3, -N(R 10 or R 1 1
OC(O)NR
10 R1 0 is independently selected from hydrogen, C1-C6 alkyl, benzyl and aryl;
R
1 1 is independently selected from C1-C6 alkyl and aryl;
A
1 and A 2 are independently selected from: a bond, -CH=CH-, -C(O)NR10-, -NRO1C(O)-, 0, -N(R 10 -S(0)2N(R10)-, -N(R 10 or S(O)m; V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; X is -CH2-, or Y is unsubstituted or substituted aryl or unsubstituted or substituted heterocycle, wherein the substituted aryl or substituted heterocycle is substituted with one or more of: 1) C1-4 alkyl, unsubstituted or substituted with: a) C1-4 alkoxy, WO 96/30343 PCTIUS96/04019 2) 3) 4) 6) 7) 8) 9) 11) 11 b) NR 6
R
7 c) C3-6 cycloalkyl, d) aryl or heterocycle, e) HO, f) -S(O)mR 6 a, or g) -C(O)NR 6
R
7 aryl or heterocycle, halogen,
OR
6
NR
6
R
7
CN,
N02, CF3; -S(O)mR 6 a,
-C(O)NR
6
R
7 or C3-C6 cycloalkyl; m is nis pis q is r is s is t is u is 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1, 2, 3 or 4; 1 or 2; 0 to 5, provided that r is 0 when V is hydrogen; 0 or 1; 0 or 1; and 4 or or the pharmaceutically acceptable salts thereof.
In a second embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula B: WO 96130343 WO 9630343PCTIUS96104019 12
(R
9 )q R 2
G
V Al(CRla 2 )nA 2 l 2 )n wO Cl 2 p", 7 N
R
3 R 4
B
wherein: Ri1a and R Ib are independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C 10 cycloalkyl., C2-C6 alkenyl, C2- C6 alkynyl, R 1 0
R
1 1 Rl 0
C(O)NR
1 0 CN(Rl 0
R
1 02N-C(NR' 0 CN, N02, RIOC(O)-, R10OC(O)-, N3, -N(RIO)2, or R1 1
OC(O)NRIO-,
c) unsubstituted or substituted C 1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C1O cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, RIO0-, R1 1 R I C(O)NR 10 (R 10 R 10 2N- CN, RlOC(O)-, RIOOC(O)-, N3, -N(RIO)2, and R 1
OC(O)-NR
10
R
2 and R 3 are independently selected from: H; unsubstituted or substituted C1-8 alkyl, unsubstituted or substituted C2-8 alkenyl, unsubstituted or substituted C2-8 alkynyl, unsubstituted or substituted aryl, 6
R
7 or -e R6 unsubstituted or substituted heterocycle, 0 0 wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C 1-4 alkyl, b) (CH2)pOR 6 WO 96/30343 WO 9630343PCTJUS96O4019 13 c) (CH2)pNR 6
R
7 d) halogen, e) CN, 2) C3-6 cycloalkyl, 3) OR 6 4) SR 6 a, S(O)R 6 a, SO2R 6 a, -NR 6 R 7 6) -NY R 7 0 7) -N y NR Ra 0 8) -0O NR 6 R 7 0 9) -0O OR 6 0 NR 6 R 7 0 11) -S0 2 -NR 6 R 7 12) S0 2 -Ra WO 96/30343 PCTIUS96/04019 14- 13) R 6 0 14) Or OR 6 0
N
3 or 16) F; or
R
2 and R 3 are attached to the same C atom and are combined to form (CH2)u wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S(0)m, and -N(COR 10
R
4 is selected from H and CH3; and any two of R 2
R
3 and R 4 are optionally attached to the same carbon atom;
R
6
R
7 and R7a are independently selected from: H; Cl-4 alkyl, C3-6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) Cl-4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) "Y 0 f) -SO 2 R or g) N(R 10 or
R
6 and R 7 may be joined in a ring;
R
7 and R7a may be joined in a ring; WO 96/30343 WO 9630343PCTIUS96/04019 15 R6a is selected from: Cl-4 alkyl, C3-6 cycloalkyl, heterocycle, aryl, unsubstituted or substituted with: a) C1-4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e)
YR
0 f) -S0 2
R
1 I or g) N(R 1 0 )2;
R
8 is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C1O cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, peffluoroalkyl, F, Cl, Br, R 1 0 R1 1 S(O)m-,
R
1
OC(O)NR
1 (RI 0
R
1 0 2N-C(NR 1
CN,
N02, RlOC(O)-, R10OC(O)-, N3, -N(R 1 0 or R1 1OC(O)NR 10 and c) C I -C6 alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C3-ClO cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, perfluoroalkyl, F, Cl, Br, R100-,
R
1 1 RIOC(O)NH-, (R 1 Q)2NC(O>-, R 10 2N-
C(NR
1 0 CN, RlOC(O)-, RIOOC(O)-, N3, -N(Rlo)2, or
R
1
OOC(O)NH-;
R
9 is selected from: a) hydrogen, b) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, RIO0-,
R
11
RIOC(O)NRIO
0
(R
1
R
1 0 2N-
C(NR
10 CN, N02, RIOC(O)-, R10OC(O)-, N3, -N(R 1 0 or R 1 1OC(O)NR 1 0 and WO 96/30343 PCT/US96/04019 16c) C1-C6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R 10
R
1 1
R
10
C(O)NR
10 (R10)2NC(O)-,
R
10 2N-C(NR10)-, CN, R1OOC(O)-, N3, -N(R 10 or R11OC(0)NR 10
R
10 is independently selected from hydrogen, C1-C6 alkyl, benzyl and aryl;
R
1 1 is independently selected from C1-C6 alkyl and aryl; Al and A 2 are independently selected from: a bond, -CH=CH-,
-C(O)NR
1 0 -NR10C(O)-, 0, -S(0)2N(R 10 -N(R10)S(0)2-, or S(O)m; G is H2 or O; V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; X is -CH2-, or Z is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, heteroarylmethyl, arylsulfonyl, WO 96/30343 PCT/US96/04019 17heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: 1) C1-4 alkyl, unsubstituted or substituted with: a) C1-4 alkoxy, b) NR 6
R
7 c) C3-6 cycloalkyl, d) aryl or heterocycle, e) HO, f) -S(O)mR 6 a, or g) -C(O)NR 6
R
7 2) aryl or heterocycle, 3) halogen, 4) OR 6
NR
6
R
7 6) CN, 7) N02, 8) CF3; 9) -S(O)mR 6 a,
-C(O)NR
6
R
7 or 11) C3-C6 cycloalkyl; 0, 1 or 2; 0, 1, 2, 3 or 4; 0, 1, 2, 3 or 4; 1 or 2; 0 to 5, provided that r is 0 when V is hydrogen; 0 or 1; 0 or 1; and 4 or m is n is p is q is r is S is t is u is or the pharmaceutically acceptable salts thereof.
In a third embodiment of this invention, the inhibitors of farnesyl-protein transferase are illustrated by the formula C: WO 96/30343 WO 9630343PCT[US96104019 18 (R )r jR9)qR2 R3 V Al(CRla 2 )nA 2 (CRla 2 OnW) (CRIb 2
N--Z
wherein: Ri1a and R Ib are independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C1O cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, R 1 0 RI 1 S(O)mn-, RlQC(O)NR 10 (Ri 0
R
1 O2N-C(NRi CN, N02, Ri OC(O)-,
R
1 0 N3, -N(Rl 0 or R1IOC(O)NRO-, c) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C3-C1O cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R 10 0-, R 1 1 S Ri1OC(O)NRi10-, (R I 0 RI 02Nand R 1 iOC(O)-NRIO-;
R
2 and R 3 are independently selected from: H; unsubstituted or substituted C1-8 alkyl, unsubstituted or substituted C2-8 alkenyl, unsubstituted or substituted C2-8 alkynyl, unsubstituted or substituted aryl, R< R 6 R 7 R6 or unsubstituted or substituted heterocycle, 0 0 wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) Ci1-4 alkyl, b) (CH2)pOR 6 c) (CH2)pNR 6
R
7 d) halogen, WO 96/30343 WO 9630343PCTIUS96104019 19 e) CN, 2) C3-6 cycloalkyl, 3) OR 6 4) SR 6 a, S(O)R 6 a, SO2R 6 a, -NR 6 R 7
R
6 6) -NY R 7 0 7) -N
R
7
R
7 a 0 8) -0O
NR
6 R 7 0 9) -0O OR 6 0 NR 6 R 7 0 11) -S0 2 -NR 6 R 7 -N-SO-R
R
6 a WO 96/30343 PCT/US96/04019 20 13) R 6 0 14) -rOR 6 0
N
3 or 16) F; or
R
2 and R 3 are attached to the same C atom and are combined to form (CH2)u wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, S(O)m, and
R
4 is selected from H and CH3; and any two of R 2
R
3 and R 4 are optionally attached to the same carbon atom;
R
6
R
7 and R 7 a are independently selected from: H; C1-4 alkyl, C3-6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) Cl-4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) Rll 0 f) -S0 2
R
1 or g) N(R 10 or
R
6 and R 7 may be joined in a ring;
R
7 and R 7 a may be joined in a ring; WO 96130343 WO 9630343PCTIUS96/04019 21
R
6 a is selected from: Cl-4 alkyl, C3-6 cycloalkyl, heterocycle, aryl, unsubstituted or substituted with: a) Ci -4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) -rR 0 f) S0 2
R
1 1 g) N(RlO)2; ,or
R
8 is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C1O cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, perfluoroalkyl, F, Cl, Br, RIO0-, R 1 1 S(O)m-, RlOC(O)NR 10 (Rl 0 R102N-C(NR10%-, CN, N02, RlOC(O)-, R10OC(O)-, N3, -N(Rl 0 or
R
1
IOC(O)NR
1 0 and c) C I -C6 alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C3-C1O cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, perfluoroalkyl, F, Cl, Br, RIO0-,
R
1 1 RlGC(O)NH-, (Rl 1
R
10 2N- C(NRIO)-, CN, RlOC(O)-, R10OC(O)-, N3, -N(Rlo)2, or
R
1
OOC(O)NH-;
R
9 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, perfluoroalkyl, F, Cl, Br, RIO0-, R 1 1 Rl 0
C(O)NRIO
0 (Rlo)2NC(O)-, R102N-C(NR 1 0 CN, N02, RIOC(O)-, R10OC(O)-, N3, -N(Rl 0 or R11OC(O)NRIO-, and I WO 96/30343 PCTIUS96/04019 22 c) C1-C6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R 10
R
1 1
R
10
C(O)NR
10 (R10)2NC(O)-, R 10 2N-C(NR 10 CN, R1OOC(O)-, N3, -N(R 10 or R 1 1
OC(O)NR
10
R
10 is independently selected from hydrogen, C1-C6 alkyl, benzyl and aryl;
R
1 1 is independently selected from C1-C6 alkyl and aryl; Al and A 2 are independently selected from: a bond, -CH=CH-, -C(0)NR10-, -NRO10C(O)-, O, -S(0)2N(R 10
-N(R
10 or S(O)m; G is 0; V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C 1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; X is -CH2-, or Z is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, heteroarylmethyl, arylsulfonyl, WO 96/30343 PCTIUS96/04019 23 heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: 1) C1-4 alkyl, unsubstituted or substituted with: a) C1-4 alkoxy, b) NR 6
R
7 c) C3-6 cycloalkyl, d) aryl or heterocycle, e) HO, f) -S(O)mR 6 a, or g) -C(O)NR 6
R
7 2) aryl or heterocycle, 3) halogen, 4) OR 6
NR
6
R
7 6) CN, 7) N02, 8) CF3; 9) -S(O)mR 6 a,
-C(O)NR
6
R
7 or 11) C3-C6 cycloalkyl; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q is 1 or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 1; t is 0 or 1; and u is 4 or or the pharmaceutically acceptable salts thereof.
A preferred embodiment of the compounds of this invention is illustrated by the following formula: WO 96/30343 PCTIUS96/04019 24 (R)r R9 R2 R 3 V- A(CRa 2 )nA 2 (CRa 2 n W (CR 1 2)p t Y Y
R
4
R
A
wherein: Ria is independently selected from: hydrogen or C1-C6 alkyl; Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10
-N(R
10 )2 or C2-C6 [0 alkenyl, c) unsubstituted or substituted C1-C6 alkyl wherein the substitutent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted aryl, heterocycle, cycloalkyl, alkenyl, R 10 0- and -N(R 10 )2;
R
3
R
4 and R 5 are independently selected from H and CH3;
NR
6
R
7
R
2 is H; 0 or C1-5 alkyl, unbranched or branched, unsubstituted or substituted with one or more of: 1) aryl, 2) heterocycle, 3) OR 6 4) SR 6 a, SO2R 6 a, or
NR
6
R
7 y 0 and any two of R 2
R
3
R
4 and R 5 are optionally attached to the same carbon atom; WO 96130343 WO 9630343PCTIUS96104019 25
R
6
R
7 and R7a are independently selected from: H; Cl-4 alkyl, C3-6 cycloalkyl., aryl, heterocycle, unsubstituted or substituted with: a) C 1-4 alkoxy, b) halogen, or c) aryl or heterocycle;
R
6 a is selected from:k C1-4 alkyl or C3-6 cycloalkyl., unsubstituted or substituted with: a) C 1-4 alkoxy, b) halogen, or c) aryl or heterocycle;
R
8 is independently selected from: a) hydrogen, b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 1 0 RIOC(O)NR1 0 CN, N02, (RlO)2N-C(NRIO)-, RlOC(O)-, RIOOC(O)-, -N(Rl 0 or R11OC(O)NR 1 0 and C) C1-C6 alkyl substituted by Cl-C6 perfiuoroalkyl,
R
1 0 0-,
R
1
OC(O)NR
1 (RI O)2N-C(NR 1
R
1
OC(O)-,
RIOOC(O)-, -N(R 1 0 or RI 1
OC(O)NR
10
R
9 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfiuoroalkyl, F, Cl, R 1 0 R 1 1 R I C(O)NR 10 CN, N02, RlOC(O)-, RIOOC(O)-, -N(Rl 0 or R11OC(O)NRIO-, and c) C I-C6 alkyl unsubstituted or substituted by C1I-C6 peffluoroalkyl, F, Cl, R 1 0 R1 1 R I OC(O)NR CN, (RlO)2N-C(NR 10 RIOC(O)-, R 1
OOC(O)-,
-N(lO2,or R 1 1OC(O)NR 10 WO 96/30343 PCTIUS96/04019 26
R
10 is independently selected from hydrogen, C1-C6 alkyl, benzyl and aryl;
R
1 1 is independently selected from Cl-C6 alkyl and aryl; Al and A 2 are independently selected from: a bond, -CH=CH-,
-C(O)NR
10 O, or S(O)m; V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C 1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if Al is S(O)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; X is -CH2- or Y is mono- or bicyclic aryl, or mono- or bicyclic heterocycle, unsubstituted or substituted with one or more of: a) Cl-4 alkyl, b) C1-4 alkoxy, c) halogen, or d) NR 6
R
7 WO 96/30343 PCT/US96/04019 27 m is 0, 1 or 2; nis 0, 1, 2, 3 or 4; pis 0, 1, 2, 3 or 4; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0 or 1; and t is 0 or 1; or the pharmaceutically acceptable salts thereof.
In a second preferred embodiment of this invention, the inhibitors of famesyl-protein transferase are illustrated by the formula
B:
(R
8 )r R R 2
G
V-AI(CR
1 a2)n(CRCR 1a 2)n\ W (CR 1b 2
N-Z
R
3
R
4
B
wherein: Ria is independently selected from: hydrogen or C1-C6 alkyl; Rlb is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 10
-N(R
10 )2 or C2-C6 alkenyl, c) unsubstituted or substituted CI-C6 alkyl wherein the substitutent on the substituted Cl-C6 alkyl is selected from unsubstituted or substituted aryl, heterocycle, cycloalkyl, alkenyl, R 10 0- and -N(R 10 )2; WO 96/30343 PCT/US96/04019 28
R
3 and R 4 are independently selected from H and CH3;
NR
6
R
7
R
2 is H; 0 or C1-5 alkyl, unbranched or branched, unsubstituted or substituted with one or more of: 1) aryl, 2) heterocycle, 3) OR 6 4) SR 6 a, SO2R 6 a, or
NR
6
R
7 0 and any two of R 2
R
3
R
4 and R 5 are optionally attached to the same carbon atom;
R
6
R
7 and R7a are independently selected from: H; Cl-4 alkyl, C3-6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with: a) C1-4 alkoxy, b) halogen, or c) aryl or heterocycle;
R
6 a is selected from: C1-4 alkyl or C3-6 cycloalkyl, unsubstituted or substituted with: a) C1-4 alkoxy, b) halogen, or c) aryl or heterocycle;
R
8 is independently selected from: a) hydrogen, b) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, R 10 R10C(O)NR 10 CN, N02, (RO1)2N-C(NR10)-, RO1C(O)-, R 10 -N(Rl0)2, or
R
1 1
OC(O)NR
10 and WO 96/30343 WO 9630343PCT/US96/04019 29 C) C1I-C6 alkyl substituted by ClI-C6 peffluoroalkyl, R 100-,
R
1
OC(O)NR
1 (Ri 0 )2N-C(NR R 1
OC(O)-,
RIOOC(O)-, -N(RIO)2, or Rl 1
OC(O)NR
10
R
9 is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 perfluoroalkyl, F, Cl, RIO0-, R 1 1
RIOC(O)NR
10 CN, N02,
(R
10 )2N-C(NR 10 RlOC(O)-, RIOOC(O)-, -N(R 1 0 or
R
1 1
OC(O)NR
10 and C) Ci1 -C6 alkyl unsubstituted or substituted by C I -C6 peffluoroalkyl, F, Cl, RIO0-, RIIS(O)m-, RlOC(O)NRiO-, CN, (Ri O)2N-C(NRi Ri R 1
OOC(O)-,
-N(Ri10)2, or R 11OC(O)NR10-;
R
10 is independently selected from hydrogen, Ci-C6 alkyl, benzyl and aryl;
*R
1 1 is independently selected from Cl1-C6 alkyl and aryl;
A
1 l and A 2 are independently selected from: a bond, -CH=CH-, -C=EC-, -C(O)NR10-, 0, or S(O)m; is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) Ci-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C2-C20 alkenyl, and WO 96/30343 PCTIUS96/04019 provided that V is not hydrogen if A 1 is S(O)m and V is not hydrogen if A 1 is a bond, n is 0 and A 2 is S(O)m; G is H2 or O; W is a heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl; X is -CH2- Z is mono- or bicyclic aryl, mono- or bicyclic heteroaryl, mono- or bicyclic arylmethyl, mono- or bicyclic heteroarylmethyl, mono- or bicyclic arylsulfonyl, mono- or bicyclic heteroarylsulfonyl, unsubstituted or substituted with one or two of the following: 1) CI-4 alkyl, unsubstituted or substituted with: a) Cl-4 alkoxy, b) NR 6
R
7 c) C3-6 cycloalkyl, d) aryl or heterocycle, e) HO, f) -S(O)mR 6 or g) -C(O)NR 6
R
7 2) aryl or heterocycle, 3) halogen, 4) OR 6
NR
6
R
7 6) CN, 7) N02, 8) CF3; 9) -S(O)mR 6
-C(O)NR
6
R
7 or 11) C3-C6 cycloalkyl; WO 96/30343 WO 9630343PCTJUS96O4019 31 m is 0, 1 or 2; n is 0, 1, 2, 3or 4; p is 0, 1, 2,3or 4; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0Oorl1; t is 0Oor 1; and u is 4 or provided that when G is H2 and W is imidazolyl, then the substitutent
(R
8 V Al(CRla2)nA 2 (CRla2)n is not H and provided that when X is or then t is 1 and the substitutent (R 8 V Al(CRla2)nA 2 (CRla2)n is not H; or the pharmaceutically acceptable salts thereof.
The preferred compounds of this invention are as follows: 2(S)-Butyl- 1 -(2,3-diaminoprop- 1l-yl)-4-(l -naphthoyl)piperazine 1 -(3-Amino-2-(2-naphthylmethylamino)prop- 1 -yl)-2(S)-butyl- 1 -naphthoyl)piperazine 2(S )-Butyl- 1- 1 5- [1-(2-naphthylmethyl)] dihydroimidazol I methyl-4-( 1 -naphthoyl)piperazine 1- [5 enzylimidazol)methyl] -2(S )-butyl-4-( 1 -naphthoyl)piperazine 1- 5- [1 -(4-Nitrobenzyl)imidazolyl]methyl -2(S)-butyl-4-( 1naphthoyl)piperazine 1- (3-Acetamidomethylthio-2(R)-aminoprop- 1 -yl)-2(S)-butyl-4-l naphthoyl)piperazine WO 96/30343 WO 9630343PCTIUS96/04019 32 2(S)-Butyl- 1- [2-(l1 -imidazolyl)ethyl] sulfonyl-4- (1 -naphthoyl)piperazine 2(R)-Butyl- 1 -imidazolyl-4-methyl-4-( 1 -naphthoyl)piperazine 2(S)-Butyl-4-( 1-naplithoyl)- 1-(3-pyridylmethyl)piperazine 1 -2(S )-butyl- (2(R)-(4-nitrobenzyl)amino-3-hydroxypropyl)-4-( 1naphthoyl)piperazine 1- (2(R)-Amino-3 -hydroxyheptadecyl)-2(S)-butyl-4-( 1naphthoyl)piperazine 2(S)-Benzyl- 1 -imidazolyl-4-methyl-4-( 1 -naphthoyl)piperazine 1 -(2(R)-Amino-3- (3 -benzylthio)propyl)-2(S )-butyl-4-( 1-naphthoyl)piperazine 1 -(2(R)-Amino-3- (4-nitrobenzylthio)propyl] 1naphthoyl)piperazine 2(S )-Butyl- 1- [(4-imidazolyl)ethyl]-4-( 1 -naphthoyl)piperazine 2(S)-Butyl- 1 [(4-imidazolyl)methyl]-4- (1 -naphthoyl)piperazine 2(S)-Butyl- 1 -naphth-2-ylmethyl)- 1 H-imidazol-5 -yl)acetyl] 1naphthoyl)piperazine 2(S)-Butyl- 1 -naphth-2-ylmethyl)- 1 H-imidazol-5-yl)ethyl]-4-( 1naphthoyl)piperazine 1 -(2(R)-Amino-3-hydroypropyl)-2(S )-butyl-4-( 1naphthoyl)piperazine 1- (2(R)-Amino-4-hydroxybutyl)-2(S )-butyl-4- (1-naphthoyl)piperazine WO 96/30343 WO 9630343PCTJLJS96/04019 33 1 -(2-Amino- 3-(2-benzyloxyphenyl)propyl)-2(S )-butyl-4-( 1naphthoyl)piperazine 1 -(2-Amino-3- (2-hydroxyphenyl)propyl)-2(S)-butyl-4-( 1naphthoyl)piperazine 1- [3-(4-imidazolyl)propyl] -2(S )-butyl-4-( 1naphthoyl)piperazine 2(S)-n-Butyl-4-( 1 -naphthoyl)- ylmethyl] -piperazine 2(S)-n-Butyl-4-( 1 -naplithoyl)- 1 1 ylmethyl] -piperazine 2(S)-n-Butyl- 1- [1-(4-cyanobenzyl)imidazol-5 -ylmethyl] 1naphthoyl)piperazine 2(S)-n-Butyl- 1- [1-(4-methoxybenzyl)imidazol-5-ylmethyl]-4-( 1naphthoyl)piperazine 2(S )-n-Butyl- 1 -methyl-2-butenyl)imidazol-5 -ylmethyl]-4-( 1naphthoyl)piperazine 2(S)-n-Butyl- [1-(4-fiuorobenzyl)imidazol-5 -ylmethyl]-4-( 1naphthoyl)piperazine 2(S )-n-Butyl- 1 1- (4-chlorobenzyl)imidazol-5 -ylmethyl]-4-( 1naphthoyl)piperazine 1-[i1 -(4-Bromobenzyl)imidazol-5-ylmethyl] -2(S )-n-butyl-4-( 1naphthoyl)piperazine 1-[l1 -(4-Bromobenzyl)imidazol-5 -ylmethyl] -2(S )-n-butyl-4-( 1naphthoyl)piperazine -34- 2(S)-n-Butyl-4-( 1 -naphthoyl)- 1- [I ylmethyl] -piperazine 2(S)-n-Butyl- 1-[ri -(4-methylbenzyl)imidazol-5-ylmethyl]-4-( 1naphthoyl)-piperazine 2(S)-n-Butyl- 1 1-(3-methylbenzyl)imidazol-5-ylmethyl]-4-( 1naphthoyl)-piperazine 1-[i -(4-Phenylbenzyl)imidazol-5-ylmethyl]-2(S)-n-butyl-4-( 1naphthoyl)-piperazine 2(S)-n-Butyl-4-(l1-naplithoyl)- 1-[1 2(S)-n -B utyl-4-( 1-naphthoyl)-l1-[1 -(4-trifluoromethoxy)-imidazol-5 y~methyl]piperazine 1- -(4-cyanobenzyl)- 1H-imidazol-5-yl] acetyl butyl-4-( 1-naphthoyl)piperazine S) -n-B utyl- 1- -dimethylphenyl)-4- imidazol ylmethyl)- piperazin- 2-one 5 (S)-n-Butyl-4- [1-(4-cyanobenzyl)imidazol-5-ylmethyl]- 1 dimethylphenyl)piperazin-2-:one 4-Il-(4-Cyanobenzyl)imidazol-5-ylmethyl] (2,3 -dimethyiphenyl)- )-(2-methoxyethyl)piperazin-2-one -(3-Chlorophenyl)-4- [1-(4-cyanobenzyl)-5-irmdazolylmethyl]-5-[2- (methanesulfonyl)ethyl]-2-piperazinone 1 -(3-Chlorophenyl)-4- [1-(4-cyanobenzyl)-5-irnidazolylmethyl] [2- (ethanesulfonyl)ethyl] -2-piperazinone WO 96/30343 WO 9630343PCTIUS96/04019 35 (S 1 -(3-Chlorophenyl)-4- [1 -(4-cyanobenzyl)-5-imidazolylmethyl] [2- (ethanesulfonyl)methyl] -2-piperazinone 1-(3-Chlorophenyl)-4- [1 -(4-cyanobenzyl)-5 -imidazolylmethyl] [N-ethyl-2-acetamido] -2-piperazinone (±)-5-(2-Butynyl)- 1 -(3-chlorophenyl)-4- [1 imidazolylmethyl] -2-piperazinone 1 -(3-Chlorophenyl)-4- [1-(4-cyanobenzyl)-5-imidazolylmethyl]-2piperazinone (S)-Butyl-4- [1-(4-cyanobenzyl-2-methyl)-5-imidazolylmethYl]- dimethylphenyl)-piperazin-2-one 4- [1-(2-(4-Cyanophenyl)-2-propyl)-5-imidazolylmethYl]- 1-(3- (S)-(2-methylsulfonylethyl)piperazin-2-oflC (S)-n-Butyl-4- [1-(4-cyanobenzyl)-5-imidazolylmethyl- -1 methylphenyl)piperazin-2-one 4- [1-(4-Cyanobenzyl)-5-imidazolylmethyl]-5 (S)-(2-fluoroethyl)- 1- (3chlorophenyl)piperazin-2-one 4- [3 -(4-Cyanobenzyl)pyridin-4-yl]- -1-(3-chlorophenyl)-5 (S methylsulfonylethyl)-piperazin-2-ofle 4- [5-(4-Cyanobenzyl)- 1 -imidazolylethyl]- -1-(3-chlorophenyl)piperazin- 2-one.
or the pharmaceutically acceptable salts thereof.
Specific examples of the compounds of the invention are: 1- 15- [1-(4-Nitrobenzyl)imidazolyl] methyl )-butyl-4-I naphthoyl)piperazine WO 96/30343 WO 9630343PCTJUS96/04019 36 0 2 N
-O-N
1- 1-B enzylimidazol)methyl] -2(S)-butyl-4- (1-naphthoyl)piperazine
-N
1- (2(R)-Amino- 3- (3-benzylthio)propyl)-2(S )-butyl-4- (1naphthoyl)piperazine 1- (2(R)-Amino-3- (4-nitrobenzylthio)propyl] )-2(S)-butyl-4- (1naphthoyl)piperazine WO 96130343 WO 9630343PCTIUS96/04019 37 0 2
N
-I
2(S)-n-Butyl- 1 1 -(4-cyanobenzyl)imidazol-5-ylmethyl]-4-( 1naphthoyl)piperazine 2(S)-n-Butyl- 1- [1 -(4-cyanobenzyl)imidazol-5-ylmethyl]
NC
7 WO 96/30343 WO 9630343PCTIUS96/04019 38 2(S)-n-Butyl- [1 -(4-chlorobenzyl)imidazol-5-ylmethyl] 1naphthoyl)piperazine 0 CI 1- -(4-Cyanobenzyl)-l1H-imidazol-5-yl]acetyl }-2(S)-n-butyl-4-( 1naphthoyl)piperazine N C 1-[l -(4-Cyanobenzyl)imidazol-5-ylmethyl]-4-(2,3-dimethYlphelYl)- WO 96/30343 WO 9630343PCTIUS96/04019 39
CH
3
CH
3 (S )-n-Butyl-4- [1 -(4-cyanobenzyl)-5-imidazolylmethyl]- methylphenyl)piperazin-2-one -(3-Chlorophenyl)-4- [1-(4-cyanobenzyl)-5 -imidazolylmethyl] [2- (methanesulfonyl)ethyl] -2-piperazinone 40 R)-1 -(3-Chlorophenyl)-4- [1-(4-cyanobenzyl)-5-imidazolylmethyl] [2- (ethanesulfonyl)ethyl] -2-piperazinone OH 2
H
CH
CI
N
N-
0 4. 4.
4 4 4 44 4 44 .4 4 44 4 4* 44 4 .4 44 44 4 4 4 4* *4 4. 4 4 44..
4* 4.
4444 4* *4 44 .4.
4444 4 4 4.44 4 4 4444 44 4 *4 44 4 (S 1 -Chlorophenyl)-4- [1-(4-cyanobenzyl)-5-imidazolylmethyl] [2- (ethanesulfonyl)methyl] -2-piperazinone
OH
3 NN0 0
NC
1 -(3-Chlorophenyl)-4- [1-(4-cyanobenzyl)-5-imidazolyl-methyl]-2piperazinone NC0-
N
CI
N0 0 WO 96/30343 PCT/US96/04019 -41 or the pharmaceutically acceptable salts thereof.
The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. When any variable aryl, heterocycle, R 1
R
2 etc.) occurs more than one time in any constituent, its definition on each occurence is independent at every other occurence. Also, combinations of substituents/or variables are permissible only if such combinations result in stable compounds.
As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge. "Halogen" or "halo" as used herein means fluoro, chloro, bromo and iodo.
As used herein, "aryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.
The term heterocycle or heterocyclic, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, 0, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, WO 96/30343 PCTIUS96/04019 42 dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, 2-oxopiperazinyl, 2-oxopiperdinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thienofuryl, thienothienyl, and thienyl.
As used herein, "heteroaryl" is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic and wherein from one to four carbon atoms are replaced by heteroatoms selected from the group consisting of N, 0, and S. Examples of such heterocyclic elements include, but are not limited to, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, pyridyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thiazolyl, thienofuryl, thienothienyl, and thienyl.
As used herein in the definition of R 2 and R 3 the term "the substituted group" intended to mean a substituted C 1-8 alkyl, substituted C2-8 alkenyl, substituted C2-8 alkynyl, substituted aryl or substituted heterocycle from which the substitutent(s) R 2 and R 3 are selected.
As used herein in the definition of R 6
R
7 and R 7 a, the substituted Cl-8 alkyl, substituted C3-6 alkenyl, substituted aroyl, substituted aryl, substituted heteroaroyl, substituted arylsulfonyl, substituted heteroarylsulfonyl and substituted heterocycle include WO 96/30343 PCTIUS96/04019 43 moieties containing from 1 to 3 substitutents in addition to the point of attachment to the rest of the compound.
As used herein, the term "substituted aryl"is intended to include the aryl group which is substituted with I or 2 substitutents selected from the group which includes but is not limited to F, Cl, Br, CF3, NH2, N(C1-C6 alkyl)2, N02, CN, (Cl-C6 alkyl)O-, -OH, (Cl-C6 alkyl)S(O)m-, (Cl-C6 alkyl)C(O)NH-, H2N-C(NH)-, (C1-C6 alkyl)C(O)-, (Cl-C6 alkyl)OC(O)-, N3,(Cl-C6 alkyl)OC(O)NH- and Cl -C20 alkyl.
When R 2 and R 3 are combined to form (CH2)u cyclic moieties are formed. Examples of such cyclic moieties include, but are not limited to: In addition, such cyclic moieties may optionally include a heteroatom(s). Examples of such heteroatom-containing cyclic moieties include, but are not limited to: 0 S 0
S
H 1O
N
O HCORo 1 Lines drawn into the ring systems from substituents (such as from R 2
R
3
R
4 etc.) indicate that the indicated bond may be attached to any of the substitutable ring carbon atoms.
WO 96/30343 PCTIUS96/04019 44 Preferably, R a and Rib are independently selected from: hydrogen, -N(R10)2, R10OC(O)NR10- or unsubstituted or substituted C1-C6 alkyl wherein the substituent on the substituted C1-C6 alkyl is selected from unsubstituted or substituted phenyl, -N(R10)2, R 10 0- and R10C(O)NR10-.
Preferably, R 2 is selected from: H, R6R 7
R
6
R
6
R
7 0 0 and an unsubstituted or substituted group, the group selected from C1-8 alkyl, C2-8 alkenyl and C2-8 alkynyl; wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C1-4 alkyl, b) (CH2)pOR 6 c) (CH2)pNR 6
R
7 d) halogen, 2) C3-6 cycloalkyl, 3) OR 6 4) SR 6 a, S(O)R 6 a, SO2R 6 a,
-NR
6
R
7
R
6 6) -N
R
7 0
R
6 7) -N NR R 7 a 0 WO 96/30343 PCTIUS96/04019 45 8) -0
NR
6
R
7 0 9) O OR 6 0 Y NR 6
R
7 0 11) -SO 2
-NR
6
R
7
R
6 12) -N-SO--R 6 a 13) R 6 0 14)
OR
6 0
N
3 or 16) F.
Preferably, R 3 is selected from: hydrogen and C1-C6 alkyl.
Preferably, R 4 and R 5 are hydrogen.
Preferably, R6, R7 and R 7 a is selected from: hydrogen, unsubstituted or substituted CI-C6 alkyl, unsubstituted or substituted aryl and unsubstituted or substituted cycloalkyl.
Preferably, R6a is unsubstituted or substituted C1-C6 alkyl, unsubstituted or substituted aryl and unsubstituted or substituted cycloalkyl.
Preferably, R 9 is hydrogen or methyl. Most preferably, Ra is hydrogen.
WO 96/30343 PCT/US96/04019 46 Preferably, R10 is selected from H, C1-C6 alkyl and benzyl.
Preferably, A and A 2 are independently selected from: a bond, -C(O)NR 10-, -NR10C(O)-, 0, -S(0)2N(R 10 and-
N(RO
1 Preferably, V is selected from hydrogen, heterocycle and aryl. More preferably, V is phenyl.
Preferably, Y is selected from unsubstituted or substituted phenyl, unsubstituted or substituted naphthyl, unsubstituted or substituted pyridyl, unsubstituted or substituted furanyl and unsubstituted or substituted thienyl. More preferably, Y is unsubstituted or substituted phenyl.
Preferably, Z is selected from unsubstituted or substituted phenyl, unsubstituted or substituted naphthyl, unsubstituted or substituted pyridyl, unsubstituted or substituted furanyl and unsubstituted or substituted thienyl. More preferably, Z is unsubstituted or substituted phenyl.
Preferably, W is selected from imidazolinyl, imidazolyl, oxazolyl, pyrazolyl, pyyrolidinyl, thiazolyl and pyridyl. More preferably, W is selected from imidazolyl and pyridyl.
Preferably, n and r are independently 0, 1, or 2.
Preferably p is 1, 2 or 3.
Preferably s is 0.
Preferably t is 1.
Preferably, in compounds of the formula B, when G is H2 and W is imidazolyl, then the substitutent (R 8 V Al(CRIa2)nA 2 (CRIa2)n is not H.
Preferably, in compounds of the formula B, when X is or then t is I and the substitutent (RS)r- V A (CRla2)nA 2 (CR a2)n is not H; It is intended that the definition of any substituent or variable R a, R 9 n, etc.) at a particular location in a molecule be independent of its definitions elsewhere in that molecule. Thus, WO 96/30343 PCTIUS96/04019 47 -N(R10)2 represents -NHH, -NHCH3, -NHC2H5, etc. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials.
The pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.
The pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods.
Generally, the salts are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.
Reactions used to generate the compounds of this invention are prepared by employing reactions as shown in the Schemes 1-22, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures. Substituents R, Ra and Rb, as shown in the Schemes, represent the substituents R 2
R
3
R
4 and R 5 however their point of attachment to the ring is illustrative only and is not meant to be limiting.
These reactions may be employed in a linear sequence to provide the compounds of the invention or they may be used to WO 96/30343 PCTIUS96/04019 48 synthesize fragments which are subsequently joined by the alkylation reactions described in the Schemes.
Synopsis of Schemes 1-22: The requisite intermediates are in some cases commercially available, or can be prepared according to literature procedures, for the most part. In Scheme 1, for example, the synthesis of 2-alkyl substituted piperazines is outlined, and is essentially that described by J.
S. Kiely and S. R. Priebe in Organic Preparations and Proceedings Int., 1990, 22, 761-768. Boc-protected amino acids I, available commercially or by procedures known to those skilled in the art, can be coupled to N-benzyl amino acid esters using a variety of dehydrating agents such as DCC (dicyclohexycarbodiimide) or EDC-HCl (1-ethyl-3- (3-dimethylaminopropyl)carbodiimide hydrochloride) in a solvent such as methylene chloride chloroform, dichloroethane, or in dimethylformamide. The product II is then deprotected with acid, for example hydrogen chloride in chloroform or ethyl acetate, or trifluoroacetic acid in methylene chloride, and cyclized under weakly basic conditions to give the diketopiperazine III. Reduction of III with lithium aluminum hydride in refluxing ether gives the piperazine IV, which is protected as the Boc derivative V. The N-benzyl group can be cleaved under standard conditions of hydrogenation, palladium on carbon at 60 psi hydrogen on a Parr apparatus for 24-48 h. The product VI can be treated with an acid chloride, or a carboxylic acid under standard dehydrating conditions to furnish the carboxamides VII; a final acid deprotection as previously described gives the intermediate VIII (Scheme The intermediate VIII can be reductively alkylated with a variety of aldehydes, such as IX. The aldehydes can be prepared by standard procedures, such as that described by 0. P. Goel, U. Krolls, M. Stier and S. Kesten in Organic Syntheses, 1988, 67, 69-75, from the appropriate amino acid (Scheme The reductive alkylation can be accomplished at pH 5-7 with a variety of reducing agents, such as sodium triacetoxyborohydride or sodium cyanoborohydride in a solvent such as dichloroethane, methanol WO 96/30343 PCTIUS96/04019 49 or dimethylformamide. The product X can be deprotected to give the final compounds XI with trifluoroacetic acid in methylene chloride.
The final product XI is isolated in the salt form, for example, as a trifluoroacetate, hydrochloride or acetate salt, among others. The product diamine XI can further be selectively protected to obtain XII, which can subsequently be reductively alkylated with a second aldehyde to obtain XIII. Removal of the protecting group, and conversion to cyclized products such as the dihydroimidazole XV can be accomplished by literature procedures.
Alternatively, the protected piperazine intermediate VII can be reductively alkylated with other aldehydes such as 1-trityl-4imidazolyl-carboxaldehyde or 1-trityl-4-imidazolylacetaldehyde, to give products such as XVI (Scheme The trityl protecting group can be removed from XVI to give XVII, or alternatively, XVI can first be treated with an alkyl halide then subsequently deprotected to give the alkylated imidazole XVIII. Alternatively, the intermediate VIII can be acylated or sulfonylated by standard techniques. The imidazole acetic acid XIX can be converted to the acetate XXI by standard procedures, and XXI can be first reacted with an alkyl halide, then treated with refluxing methanol to provide the regiospecifically alkylated imidazole acetic acid ester XXII. Hydrolysis and reaction with piperazine VIII in the presence of condensing reagents such as 1-(3-dimethylaminopropyl)- 3-ethylcarbodiimide (EDC) leads to acylated products such as XXIV.
If the piperazine VIII is reductively alkylated with an aldehyde which also has a protected hydroxyl group, such as XXV in Scheme 6, the protecting groups can be subsequently removed to unmask the hydroxyl group (Schemes 6, The alcohol can be oxidized under standard conditions to e.g. an aldehyde, which can then be reacted with a variety of organometallic reagents such as Grignard reagents, to obtain secondary alcohols such as XXIX. In addition, the fully deprotected amino alcohol XXX can be reductively alkylated (under conditions described previously) with a variety of aldehydes to obtain secondary amines, such as XXXI (Scheme or tertiary amines.
WO 96/30343 PCT/US96/04019 50 The Boc protected amino alcohol XXVII can also be utilized to synthesize 2-aziridinylmethylpiperazines such as XXXII (Scheme Treating XXVII with 1,1'-sulfonyldiimidazole and sodium hydride in a solvent such as dimethylformamide led to the formation of aziridine XXXII. The aziridine reacted in the presence of a nucleophile, such as a thiol, in the presence of base to yield the ringopened product XXXIII.
In addition, the piperazine VIII can be reacted with aldehydes derived from amino acids such as 0-alkylated tyrosines, according to standard procedures, to obtain compounds such as XXXIX.
When R' is an aryl group, XXXIX can first be hydrogenated to unmask the phenol, and the amine group deprotected with acid to produce XL.
Alternatively, the amine protecting group in XXXIX can be removed, and 0-alkylated phenolic amines such as XLI produced.
Depending on the identity of the amino acid I, various side chains can be incorporated into the piperazine. For example when I is the Boc-protected 13-benzyl ester of aspartic acid, the intermediate diketopiperazine XLII where n=1 and R=benzyl is obtained, as shown in Scheme 10. Subsequent lithium aluminum hydride reduction reduces the ester to the alcohol XLIII, which can then be reacted with a variety of alkylating agents such as an alkyl iodide, under basic conditions, for example, sodium hydride in dimethylformamide or tetrahydrofuran.
The resulting ether XLIV can then be carried on to final products as described in Schemes 3-9.
N-Aryl piperazines can be prepared as described in Scheme 11. An aryl amine XLV is reacted with bis -chloroethyl amine hydrochloride (XLVI) in refluxing n -butanol to furnish compounds XLVII. The resulting piperazines XLVII can then be carried on to final products as described in Schemes 3-9.
Piperazin-5-ones can be prepared as shown in Scheme 12.
Reductive amination of Boc-protected amino aldehydes XLIX (prepared from I as described previously) gives rise to compound L.
This is then reacted with bromoacetyl bromide under Schotten-Baumann conditions; ring closure is effected with a base such as sodium hydride WO 96/30343 PCTIUS96/04019 -51 in a polar aprotic solvent such as dimethylformamide to give LI. The carbamate protecting group is removed under acidic conditions such as trifluoroacetic acid in methylene chloride, or hydrogen chloride gas in methanol or ethyl acetate, and the resulting piperazine can then be carried on to final products as described in Schemes 3-9.
The isomeric piperazin-3-ones can be prepared as described in Scheme 13. The imine formed from arylcarboxamides LII and 2aminoglycinal diethyl acetal (LIII) can be reduced under a variety of conditions, including sodium triacetoxyborohydride in dichloroethane, to give the amine LIV. Amino acids I can be coupled to amines LIV under standard conditions, and the resulting amide LV when treated with aqueous acid in tetrahydrofuran can cyclize to the unsaturated LVI. Catalytic hydrogenation under standard conditions gives the requisite intermediate LVII, which is elaborated to final products as described in Schemes 3-9.
Access to alternatively substituted piperazines is described in Scheme 14. Following deprotection with trifluoroacetic acid, the Nbenzyl piperazine V can be acylated with an aryl carboxylic acid. The resulting N-benzyl aryl carboxamide LIX can be hydrogenated in the presence of a catalyst to give the piperazine carboxamide LX which can then be carried on to final products as described in Schemes 3-9.
Reaction Scheme 15 provides an illustrative example the synthesis of compounds of the instant invention wherein the substituents
R
2 and R 3 are combined to form (CH2)u For example, 1aminocyclohexane-1-carboxylic acid LXI can be converted to the spiropiperazine LXVI essentially according to the procedures outlined in Schemes 1 and 2. The piperazine intermediate LXIX can be deprotected as before, and carried on to final products as described in Schemes 3-9. It is understood that reagents utilized to provide the substituent Y which is 2-(naphthyl) and the imidazolylalkyl substituent may be readily replaced by other reagents well known in the art and readily available to provide other N-substituents on the piperazine.
The aldehyde XLIX from Scheme 12 can also be reductively alkylated with an aniline as shown in Scheme 16. The WO 96/30343 PCTIUS96/04019 52 product LXXI can be converted to a piperazinone by acylation with chloroacetyl chloride to give LXXII, followed by base-induced cyclization to LXXIII. Deprotection, followed by reductive alkylation with a protected imidazole carboxaldehyde leads to LXXV, which can be alkylation with an arylmethylhalide to give the imidazolium salt LXXVI. Final removal of protecting groups by either solvolysis with a lower alkyl alcohol, such as methanol, or treatment with triethylsilane in methylene chloride in the presence of trifluoroacetic acid gives the final product LXXVII.
Scheme 17 illustrates the use of an optionally substituted homoserine lactone LXXIX to prepare a Boc-protected piperazinone LXXXII. Intermediate LXXXII may be deprotected and reductively alkylated or acylated as illustrated in the previous Schemes.
Alternatively, the hydroxyl moiety of intermediate LXXXII may be mesylated and displaced by a suitable nucleophile, such as the sodium salt of ethane thiol, to provide an intermediate LXXXIII. Intermediate LXXXII may also be oxidized to provide the carboxylic acid on intermediate LXXXIV, which can be utilized form an ester or amide moiety.
Amino acids of the general formula LXXXVI which have a sidechain not found in natural amino acids may be prepared by the reactions illustrated in Scheme 18 starting with the readily prepared imine LXXXV.
Schemes 19-22 illustrate syntheses of suitably substituted aldehydes useful in the syntheses of the instant compounds wherein the variable W is present as a pyridyl moiety. Similar synthetic strategies for preparing alkanols that incorporate other heterocyclic moieties for variable W are also well known in the art.
WO 96/30343 WO 9630343PCTfUS96/04019 53 SCHEME 1 o N
OH
H 0 Rb PhCH 2 N HCHCO; 2
C;
2
H
DCC, CH 2
CI
2 0 Ra 0 N Ty C0 2
C
2
H-
H 0 R b 11 1) HOI, CH 2
CI
2 2) NaHCO 3 Ra HN N i O R b
III
LAH
THF, reflux HN N Rb/ Boc 2
O.
CH
2
CI
2 10% Pd/C
H
2
CH
3 0H
NH
0 Rb *0 WO 96/30343 PCTIUS96/04019 54 SCHEME 2 Ra
EE
BocN NH Ra~ BocN
N
R b ViI HIN. N )C-HCI, HOBT
)MF
~C
2
H
HCt, EtOAc Vill WO 96/30343 PCTIUS9604019 55 SCI-EME 3 HCI -N N- Rb Vill Boc NH I x Boo NH CHO NaBH(OAc)3 Et 3 N ClCH 2
CH
2
CI
Ra Boc
CF
3 C0 2
H
CH
2
CI
2
NH-
2 N N- NH1 2 xi BcON
CH
2
CI
2 BocNH cN N-
NH-
2 R b caCHO NaBH(OAc)3
EI
3 N ClCH 2
CH
2
CI
WO 96/30343 PTU9/41 PCTIUS96/04019 56 SCHEME 3 (continued) BocNH N N NH
R
CF
3
CO
2 H, CH 2
CI
2 NaHC0 3 xiII
NH
2 N N NH Rb
XIV
NC
AgON
R\/
N N4 b0 N N Rb N.v I WO 96/30343 WO 9630343PCTIUS96/04019 57 SCHEME 4
HOI
NaBH(OAc) 3 Et 3 N CICH 2
CH
2
CION
(CH
2 )nCHO
N-
Vill xvi 1) Ar CH 2 X, CH 3
CN
2) CF 3 00 2 H, CH 2
CI
2 (0 2
H
5 3 SiH
CF
3 00 2 H, CH- 2
CI
2 (0 2
H
5 3 SiH
R\/
N N xviI xviII WO 96/30343 WO 9630343PCTIUS96/04019 58 SCHEME 0- H 2 00 2
H
N
H
XX
(C
6
H
5 3 CBr
I
(0 2
H
5 3
N
DMF
CH
3 0H
HOI
N- 0H 2 00 2 0H 3
N
H HOI 1) ArCH 2
X
CH
3
CN
ref lux 2) CH 3 OH, reflux
XXI
N-CH2 00 2
CH
3
N
XXII
2.5N HClaq
P
5500 N 0 H 2 00 2
H
N
N xl WO 96/30343 WO 9630343PCTIUS96/04019 59 SCHEME 5 (continued) N CH 2 00 2 H
R\
HCI-HN
N
Nc XXIII R b Vill EDO HOI HOBt
DMF
HCI
Ar Ra N N N o 0 '0 N~ R b xxiv WO 96/30343 WO 9630343PCTIUS96/04019 60 SCHEME 6 HI N N- R b NaBH(OAc) 3 Et 3 N CICH 2
CHC
BnOI BocNH CHO xxv BnO N N- NHBoc Rb 20% Pd(OH) 2
H
2
CH
3 0H
CH
3 00 2
H
xxvi NHBoc Rb xxvi"
CICOCOC'
DMSO CH 2
CI
2
(C
2
H
5 3
N
WO 96130343 PCT/US96/04019 61 SCHEME 6 (CONTINUED) 0 N N H NHIoc Rb xxviII 1. RiMgX
(C
2
H
5 2 0 2. TEA,
CH
2
CI
2 H O N\ _N R'
NH
2 Rb
XXIX
WO 96/30343 PCTIUS96104019 62 SCHEME 7 HO N N NH oc Rb HO N4 NH1 2 Rb
XXX
CF
3 00 2
H
CH
2
CI
2
ROHO
NaBH(OAc) 3
CICH
2
CH
2
CI
HO N N4 /NH R b
R'CH
2
XXXI
WO 96/30343 WO 9630343PCTIUS96/04019 63 SCHEME 8 xxviI H
H
N, N~N NaH, DMF OIC
R'SH
(0 2
H
5 3 N
A
CH
3 0H N N4 N R b
H
XXXII
R'Sa
NH
2 Rb
XXXIII
WO 96130343 PTU9/41 PCTfUS96/04019 64 SCHEME 9 1) Boc 2 O, K 2 C0 3
THF-H
2 0 2) CH 2
N
2 EtOAc BocNH
CO
2
CH
3 -C0 2
H
XXXIV
XXXV
LiAIH 4
THE
0-200C
HO
B oc NH CH 2 0H
R'CH
2
X
CS
2 00 3
DMF
XXXVI
R'CH
2 0,
R'CI
pyridine -S0 3
DMSO
(0 2
H
5 3
N
200C BocNH- 'CH 2 OH BocNH 'CHO xxxvil
XXXVIIXXXVIII
WO 96/30343 WO 9630343PCTIUS96/04019 65 SCHEME 9 (continued)
R-CH
2 0 BocNH CHO xxxv"'l
R\/
+HIN -<N4b Rb NaBH(OAC) 3
CICH
2
CH
2
CI
1) 20% Pd(OH) 2
CH
3 OH, CH 3 00 2
H
2) HOI, EtOAc xxxix
HOI
ETOAc
NH
2
HO
NH
2 WO 96/30343 WO 9630343PCTIUS96/04019 66 SCHEME C0 2
R
HN
N-
0
XLII
1) LAH, Et 2
O
2) BOC 2 0
HO
R 6 1 0n( NaH, DMF
-N
R 6 0 n() 0
XLIV
XLIII
WO 96/30343 WO 9630343PCTIUS96/04019 67 SCHEME 11 R b ),NH -HOI
XLVI
ArNH 2
XLV
n butanol ref lux ArN NH -HCI Ra Rb
XLVII
WO 96/30343 PCTfUS96/04019 68 SCHEME 12 >J Ra >O N) OH
CH
3
NHOCH
3
-HOI
EDO. HOI,HOBT DMF, EI 3 N, pH 7 0 N J,,N(CH 3
)OCH,
H 0 LAH, Et 2
O
XLVIII
0 Ra H 0
XLIX
ArCH 2 N H 2 NaBH (OAc) 3
CICH
2
CH
2
CI
pH 6 1) BrCH 2 00Br EtOAc, H 2 0, NaHCO 3 2) NaH, THE, DMF 0 '0 J
NHCH
2 Ar WO 96/30343 PTU9/41 PCT/US96/04019 69 SCHEME 12 (CONT'D) 0 0 1) TEA, CH 2
CI
2 Ar 0 WO 96/30343 WO 9630343PCTIUS96O04019 70 SCHEME 13 ArCHO NH 2
CH
2 CH(0C 2
H
5 2 NaBH(OAc) 3 0 N
OH
I H 0 Ar CH 2
NHCH
2 CH(0C 2
H
5 2 LIV
E
Ar 0 R
K
o N, O-H (00 2
H
5 2 DC.HOI, HOBT )MF, Et 3 N, pH 7 6N HOI
THE
Ra 0 >N
N-
O
H
2 1 O%Pd/C
CH
3 0H Ra 0
N-
-O Ar
LVII
WO 96/30343 WO 9630343PCTJUS96/04019 71 SCHEME 14 1) CF 3 00 2 H, CH 2 01 2 2) NaHCO 3 Rb ArCO 2
H
N NH EDO*- HCI /Ra HOBT, DMF
LVIII
R b Ar
LIX
1Q%Pd/C
H
2
CH
3 0H Rb HN N Ar WO 96/30343 PTU9I41 PCTIUS96/04019 72 SCHEME BocN H C0 2
H
LXI
PhCH 2
NHCH
2 00 2
C
2
H
DCC, CH 2
CI
2 u BocNH NCOCH 0 LXII a) TEA, CH 2
CI
2 b) NaHCO 3 N',C0 2
C
2
H
(CH
3 3
AI
CHC1 3 0
LXIII
HN N 0#J/
LXIV
BOC
2 O Boc
CH
2
CI
2 LiAIH 4
THF
HN Nb
LXV
H
2 Pd/C
CH
3 0H
LXVI
WO 96/30343 WO 9630343PCT/US96/04019 73 SCHEME 15 (continued) cool NaHCO 3 EtOAc BocN NH
LXVII
U
0 BocN N LX VIII a) TEA, OH 2
CI
2 b) NaBH(OAC) 3 C(=0)H
N
CPh 3 TEA CH 2
CI
2 (0 2
H
53 SiH
U
N
N-
CPh 3 0
LXIX
0 N N H .2 TFA
LXX
WO 96/30343 PTU9/41 PCTfUS96/04019 74 SCHEME 16 BcH),COArNH 2 HoN)-N'A BocNH CHO NaBH(OAc) 3 BcH N~A
CICH
2
CH
2
CI
XLIX
LXXI
0 CI,
C
EtOAc H 2 0 NaHCO 3
R
BocNH N-Ar
LXXII
NaH
DMF
R
BocN N-Ar
HOI
EtOAc
LXXIII
WO 96130343 WO 9630343PCTJUS96/04019 75 SCHEME 16 (continued)
R
HCI-HN N-Ar
LXXIV
CHO
N
C(Ph) 3 NaBH(OAC) 3
CICH
2
CH
2
CI
pH 5-6
R
N NA
N
N
(Ph) 3
C
LXXV
ArCH 2
X
CH
3
CN
R
N N-Ar (Ph) 3 06 x
LXXVI
MeOH or
R
Ar-\N N-Ar
N
TEA, 0H 2 01
(C
2
H
5 3 SiH
LXXVII
WO 96/30343 WO 9630343PCTIUS96/04019 76 SCHEME 17 sub
H
2
N*
HOI 0 1. BOC 2 O, i-Pr 2 EtN 2. DIBAL
OH
LXXIX
OH
sub ArNH 2 BocNH, l-lAr NaBH(OAC) 3
CICH
2
CH
2
CI
LXXX
0
CI-AC
EtOAc H 2 0 NaHCO 3 HO sub BocNi- IN-Ar cI 0
LXXXI
CS
2 00 3
DMF
HO sub BocN N-Ar
LXXXII
WO 96130343 WO 9630343PCTIUS96/04019 77 SCHEME 17 (continued) HO sub BocN N-Ar 0 1 1: 1. MsCI, iPr 2 NEt 2. NaSEt, DMF EtS sub BocN N-Ar 0
D~
LXXXII
001)2, Et 3
N
Viso 2. NaC1O 2 t-BuOH 2-Me-2-butene NaH 2
PO
4 HO sub BocN N-Ar 0
LXXXIV
LXXXIII
WO 96/30343 WO 9630343PCTIUS96/04019 78 SCHEME 18 /-CO 2 Et Phr 1. KOtBu, THE R 2
X
2. 5% aqueous HOI R 2
CO
2 Et
H
2
N
HCI
LXXXV
1. Boc 2 O, NaHCO 3 2. LiAIH 4 Et 2
O
C0 2
H
BocHN LXXX VI WO 96/30343 WO 9630343PCT[US96/04019 79 REACTION SCHEME 19 1) HNO 2 ,Br 2 2) KMnO 4 3) MeOH,H' N H 3 R 00 2
CH
3
N
ZnCI 2 NiCI 2 (Ph 3
P)
2 NaBH 4 (excess) SOTPy, Et 3 N R
DMSO
WO 96/30343 WO 9630343PCTJUS96/04019 80 REACTION SCHEMI 1. EtO(CO)CI 2.RV MgCI 3Zn, CuON S CO 2
CH
3
N
3. S, xylene, heat NaBH 4 (excess) SOTPy, Et 3
N
ZnCI 2 NiC1 2 (Ph 3
P)
2 NaBH 4 (excess)
SO
3 'Py, Et 3
N
DMSQ
WO 96/30343 WO 9630343PCTIUS96/04019 81 REACTION SCHEME 21 C0 2
CH
3
N
1. LDA, 002 2. MeOH, H+ MgCI i ZnCI 2 NiCI 2 (Ph 3
P)
2 NaBH 4 (excess) HS0 3 'Py, Et 3
N
DMSO
WO 96/30343 WO 9630343PCTIUS96/040 19 82 REACTION SC-HEME 22 a N Br 1. LDA, 002 2. (0H 3 3 SiCHN 2 00 2 0H 3 Br R 6 1N Br Zn, Ni01 2 (Ph 3
P)
2 excess NaBH 4 R 6 N 00 2 CH 3
SO
3 -Py, Et 3
N
DMSO
WO 96/30343 WO 9630343PCTIUS96/04019 83 The instant compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer. Examples of the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, myeloid leukemias and neurological tumors.
Such tumors may arise by mutations in the ras genes themselves, mutations in the proteins that can regulate Ras activity neurofibromin neu, scr, ab Ick, fyn) or by other mechanisms.
The compounds of the instant invention inhibit farnesylprotein transferase and the farnesylation of the oncogene protein Ras.
The instant compounds may also inhibit tumor angiogenesis, thereby affecting the growth of tumors Rak et al. Cancer Research, 55:4575- 4580 (1995)). Such anti-angiogenesis properties of the instant compounds may also be useful in the treatment of certain forms of blindness related to retinal vascularization.
The compounds of this invention are also useful for inhibiting other proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes the Ras gene itself is not activated by mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the compounds of the invention to a mammal in need of such treatment. For example, a component of NF-1 is a benign proliferative disorder.
The instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis delta and related viruses Glenn et al. Science, 256:1331-1333 (1992).
The compounds of the instant invention are also useful in the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation Indolfi et al. Nature medicine, 1:541-545(1995).
The instant compounds may also be useful in the treatment and prevention of polycystic kidney disease Schaffner et al.
WO 96/30343 PCTIUS96/04019 84 American Journal of Pathology, 142:1051-1060 (1993) and B. Cowley, Jr. et al.FASEB Journal, 2:A3160 (1988)).
The instant compounds may also be useful for the treatment of fungal infections.
The compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
For oral use of a chemotherapeutic compound according to this invention, the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added. For oral administration in capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents.
If desired, certain sweetening and/or flavoring agents may be added.
For intramuscular, intraperitoneal, subcutaneous and intravenous use, sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered. For intravenous use, the total concentration of solutes should be controlled in order to render the preparation isotonic.
The compounds of the instant invention may also be coadministered with other well known therapeutic agents that are selected for their particular usefulness against the condition that is being treated.
For example, the instant compounds may be useful in combination with known anti-cancer and cytotoxic agents. Similarly, the instant compounds may be useful in combination with agents that are effective in the treatment and prevention of NF-1, restinosis, polycystic kidney WO 96/30343 PCT/US96/04019 85 disease, infections of hepatitis delta and related viruses and fungal infections.
If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent(s) within its approved dosage range. Compounds of the instant invention may alternatively be used sequentially with known pharmaceutically acceptable agent(s) when a combination formulation is inappropriate.
The present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the administration of a therapeutically effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents. Suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacologically acceptable carriers, saline, at a pH level, 7.4. The solutions may be introduced into a patient's blood-stream by local bolus injection.
When a compound according to this invention is administered into a human subject, the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
In one exemplary application, a suitable amount of compound is administered to a mammal undergoing treatment for cancer. Administration occurs in an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.
The compounds of the instant invention are also useful as a component in an assay to rapidly determine the presence and quantity of farnesyl-protein transferase (FPTase) in a composition.
Thus the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine WO 96/30343 PCT/US96/04019 86 terminus) and farnesyl pyrophosphate and, in one of the mixtures, a compound of the instant invention. After the assay mixtures are incubated for an sufficient period of time, well known in the art, to allow the FPTase to farnesylate the substrate, the chemical content of the assay mixtures may be determined by well known immunological, radiochemical or chromatographic techniques.
Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the assay containing the instant compound is indicative of the presence of FPTase in the composition to be tested.
It would be readily apparent to one of ordinary skill in the art that such an assay as described above would be useful in identifying tissue samples which contain farnesyl-protein transferase and quantitating the enzyme. Thus, potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample. A series of samples composed of aliquots of a tissue extract containing an unknown amount of farnesyl-protein transferase, an excess amount of a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and farnesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention. The concentration of a sufficiently potent inhibitor one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel) required to inhibit the enzymatic activity of the sample by 50% is approximately equal to half of the concentration of the enzyme in that particular sample.
EXAMPLES
Examples provided are intended to assist in a further understanding of the invention. Particular materials employed, species WO 96/30343 PCT/US96/04019 87 and conditions are intended to be further illustrative of the invention and not limitative of the reasonable scope thereof. Purification by HPLC was accomplished with a 40 X 100 mm Waters PrepPak® reverse phase HPLC column (Delta-Pak T C18 15 ptm, 100 A).
Gradient elution employed 0.1% trifluoroacetic acid in water (Solvent A) and 0.1% trifluoroacetic acid in acetonitrile (Solvent Chloride salts were obtained by passing an aqueous solution of the trifluoroacetic acid salt through a Biorad AG® 3X4 ion exchange resin column (100- 200 mesh, Cl-form). Purification by HPLC was utilized for each of the Examples 1-23, 27, 48 and 49 as set forth below.
EXAMPLE 1 2(S)-Butyl-1-(2,3-diaminoprop-1-yl)-4-(1-naphthoyl)piperazine trihydrochloride Step A: 1-Benzyl-3(S)-n The title compound was prepared according to the procedure described by John S. Kiely and Stephen R. Priebe in Organic Preparations and Procedures Int., 22 761-768 (1990). Thus dicyclohexylcarbodiimide (9.33 g, 45.2 mmol) in methylene chloride M) was added to methylene chloride (250 mL). This solution was cooled to 0°C under nitrogen and Boc-L-norleucine (10.5 g, 45.2 mmol) was added. The resulting slurry was stirred for 5 min, and then ethyl N-benzylglycinate (8.72 g, 45.2 mmol) was added. The reaction was stirred for 2 h at 0°C, then at 20 0 C overnight. The precipitate was removed by filtration, and hydrogen chloride gas bubbled through the methylene chloride solution for 2-4 h, until the reaction was shown to be complete by t1c. The solvent was removed in vacuo, and the residue partitioned between ethyl acetate (150 mL) and saturated sodium bicarbonate solution (42 mL). The organic phase was washed with saturated sodium chloride, dryed over magnesium sulfate, filtered and evaporated. The crude diketopiperazine was triturated with hexane to give the title compound as a white powder. 1 HNMR (300 MHz, CDC13) WO 96/30343 PCTIUS96/04019 88 8 7.24-7.40 (5H, 6.22 (1H, br 4.07 (1H, dt, J=3, 6 Hz), 3.87 (1H, d, J=17 Hz), 3.80 (1H, d, J=17 Hz), 1.88 (2H, 1.35 (4H, 0.91 (3H, t, J=7 Hz).
Step B: 4-Benzyl- 1-tert -butoxycarbonyl-2(S)-n -butylpiperazine The product from Step A (4.95 g, 0.019 mol) was dissolved in THF (200 mL) and cooled under nitrogen to 0 0 C with mechanical stirring. Lithium aluminum hydride (2.60 g, 0.0685 mol) was added slowly. The reaction was refluxed for 18 h, cooled to 0°C, and quenched by the sequential slow addition of 5 mL H20, 5 mL sodium hydroxide solution and 5 mL H20. The reaction was stirred for min and filtered. The solvent was removed in vacuo, the crude product taken up in methylene chloride and dried over magnesium sulfate. The drying agent was removed by filtration, and the filtrate treated with di-tert -butyl dicarbonate ((4.35 g, 0.020 mol). After 2 h at 20 0 C, saturated sodium bicarbonate was added. The layers were separated, and the organic phase washed with saturated sodium chloride solution, then dried over magnesium sulfate. Filtration and evaporation gave the crude product which was purified by column chromatography on silica gel, eluting with 5% ethyl acetate in hexane. The title compound was obtained as a foam. 1 HNMR (300 MHz, DMSO-d6) 8 7.25 (5H, 3.90 (1H, br 3.73 (1H, d, J=13 Hz), 3.51 (1H, d, J=13 Hz), 3.34 (1H, d, J=13 Hz), 2.93 (1H, 2.75 (1H, d, J= 1l Hz), 2.62 (1H, d, J= 11 Hz), 1.90 (2H, 1.60 (2H, 1.38 1.26 (2H, 1.04 (2H, 0.84 (3H, t, J=7 Hz).
Step C: 1 -tert -Butoxvcarbonvl-2(S)-n -butylpiperazine The product from Step B (3.75 g, 11.3 mmol) was dissolved in methanol (75 mL) in a Parr bottle, and the vessel purged with argon. To this was added 10 palladium on carbon (0.80 g) and the reaction hydrogenated under 60 psi hydrogen for 24 h. The catalyst was removed by filtration through Celite, and the filtrate evaporated in vacuo to give the title compound as an oil. 1 HNMR (300 MHz, CDC13) WO 96/30343 PCT/US96/04019 89 8 4.08 (1H, br 3.90 (1H, d, J=12 Hz), 2.5-3.8 (6H, 1.80 (1H, 1.60 (1H, 1.46 (9H, 1.30 (4H, m),0.90 (3H, t, J=7 Hz).
Step D: 1-tert -Butoxycarbonyl-2(S)-n -butyl-4-(1-naphthoyl)piperazine 1-tert -butoxycarbonyl-2(S)-n -butylpiperazine (0.325 g, 1.34 mmol), 1-hydroxybenzotriazole (HOBT) (0.203 g, 1.34 mmol) and 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (EDC HC1) (0.254 g, 1.34 mmol) were added to dry, degassed dimethylformamide (7 mL). The pH of the reaction was adjusted to 7 with triethylamine, and the reaction stirred for 2 h. The dimethylformamide (DMF) was distilled in vacuo, and the residue partitioned between ethyl acetate and water. The organic phase was washed with 2% aqueous potassium hydrogen sulfate, saturated sodium bicarbonate solution, saturated sodium chloride solution, and dried over magnesium sulfate. The title compound was obtained as a thick oil.
Step E: 2(S)-n -Butvl-4-(1-naphthovl)piperazine hydrochloride The product from Step D was dissolved in ethyl acetate, cooled to -40 0 C under nitrogen, and the solution saturated with HCl(g).
The solution was warmed to 0°C for 30 min, and then purged with nitrogen. The solvent was removed in vacuo. The product was evaporated from ethyl acetate three times. The title compound was obtained as a white solid.
Step F: 2.3-(bis-tert-Butoxycarbonylamino)propanoic acid Diaminopropanoic acid monohydrochloride (2.86 g, 0.0204 mol) was suspended in 1:1 water-dioxane (100 mL) containing triethylamine (5.97 mL, 0.0204 mol). BOC-ON (11.0 g, 0.0448 mol) was added along with additional triethylamine to adjust the pH to The reaction was stirred under nitrogen overnight at 20 0 C. The clear solution was diluted with water and extracted with diethyl ether (5 x 100 mL). The aqueous solution was adjusted to pH 1 with cold aqueous hydrochloric acid and extracted with ethyl acetate. The organic WO 96/30343 PCTIUS96/04019 90 layer was washed with water, saturated sodium chloride, then dried over magnesium sulfate. The resulting foam (5.46 g) was crystallized from ethyl acetate to give the title compound as a white solid.
Step G: N-Methoxy-N-methyl-2,3-(bis-tert-butoxycarbonylamino)proprionamide 2,3-bis-(tert-Butoxycarbonylamino)propanoic acid (1.80 g, 5.92 mmol) in dimethylformamide (25 mL) was stirred overnight with N-methoxy-N-methylamine hydrochloride (0.635 g, 6.51 mmol), EDC HC1 (1.24 g, 6.51 mmol), N-hydroxybenzotriazole (0.80 g, 5.92 mmol) and triethylamine (0.825 mL, 5.92 mmol). The dimethylformamide was removed in vacuo and the residue partitioned between ethyl acetate and water. The organic phase was washed with 10% hydrochloric acid, saturated sodium bicarbonate solution, saturated brine, and dried over magnesium sulfate. The crude product was chromatographed on silica gel with 30% ethyl acetate in hexane. The title compound was obtained as a foam. 1 HNMR (CDC13, 300 MHz) d 5.51 (1H, br 4.87 (1H, br 4.72 (1H, br 3.77 (3H, 3.50 (1H, 3.40 (1H, dt, J=12, 6 Hz), 3.20 (3H, 1.44 (9H, 1.42 (9H, s).
Step H: 2,3-(bis-tert-Butoxvcarbonylamino)propanal Lithium aluminum hydride (0.384 g, 10.14 mmol) was suspended in diethyl ether (20 mL) and cooled to -45 0 C under nitrogen.
N-Methoxy-N-methyl-2,3-(bis-tert-butoxycarbonylamino)proprionamide (2.07 g, 5.96 mmol) in 1:1 ether-tetrahydrofuran mL) was added at such a rate so as to keep the reaction temperature less than -35 0 C. The reaction was allowed to warm to 5 0 C, then cooled to 0 C and quenched with a solution of potassium hydrogen sulfate (3.08 g, 22.6 mmol) in water (20 mL). The reaction was stirred at 20 0 C lh, then filtered through celite. The organic phase was washed with citric acid and saturated brine, then dried over magnesium sulfate. The title compound was obtained as a foam. NMR (CDC13, 300 MHz) d 9.61 (1H, 5.60 (1H, br 4.88 (1H, br 4.24 (1H, br d, J=6 Hz), 3.68 (1H, 3.50 (1H, 1.40 (9H, 1.39 (9H, s).
WO 96/30343 PCTIUS96/04019 -91 Step I: 1-[(2,3-bis-tert-Butoxycarbonylamino)prop-1-yl]-2(S)butyl-4-( 1 -naphthoyl)piperazine A solution of 3(S)-butyl-1-(1-naphthoyl)piperazine (1.83 g, 6.20 mmol) (free base of the product from Step acetic acid (0.17 mL, 2.9 mmol) in dichloroethane (20 mL) was adjusted to pH 5.5 with triethylamine. Sodium triacetoxyborohydride (1.87 g, 8.79 mmol) and crushed molecular sieves (1 g) were added, and the reaction cooled to 0°C under nitrogen. A solution of 2,3-(bis-tert-butoxycarbonylamino)propanal (1.69 g, 5.86 mmol) in dichloroethane (10 mL) was added dropwise, and the reaction stirred at 20 0 C overnight. The reaction was cooled to 0°C, quenched with saturated sodium bicarbonate and stirred for lh. The layers were separated and the organic layer washed with saturated brine, then dried over magnesium sulfate. The crude product was chromatographed on silica gel with 40-50% ethyl acetate in hexane, and the title compound was isolated as a foam (Rf 0.30, 50% ethyl acetate in hexane).
Step J: 1-(2,3-Diaminoprop- 1-yl)-2(S)-butyl-4-(1naphthovl)piperazine trihydrochloride Trifluoroacetic acid (25 mL) was added to a solution of 1- [(2,3-bis-tert-butoxycarbonylamino)prop-1-yl]-2(S)-butyl-4-(1naphthoyl)piperazine (2.13 g, 3.75 mmol) in dichloromethane (75 mL).
After 25 min at 20 0 C, the solvent was evaporated and the residue partitioned between chlorform and 20% aqueous sodium hydroxide.
The organic layer was washed with saturated brine and dried over magnesium sulfate. The free base of the title compound was obtained as a yellow gum (1.72 A portion of this material (52 mg) was purified by preparative HPLC using a 100 mm Waters PrepPak® reverse phase column (DeltaPak T M C18, 50 mM, 100 and pure product isolated by gradient elution using 100% 0.1% trifluoroacetic acid in water (Solvent A) to 50% Solvent A and 50% 0.1% trifluoracetic acid in acetonitrile (Solvent The pure fractions were combined and the solvent evaporated, and the crude product dissolved in water and passed WO 96/30343 PCT/US96/04019 92 through an ion exchange column (Biorad AG® 3X4 ion exchange resin, chloride form). After lyophilization, the title compound was obtained as a white solid. Anal. Calc. for C22H32N40 4.45 HCI C, 49.78; H, 6.92; N, 10.56. Found: C, 49.75; H, 6.72; N, 10.36.
EXAMPLE 2 1-(3-Amino-2-(2-naphthylmethylamino)prop-1-yl)-2(S)-butyl-4-(1naphthoyl)piperazine trihydrochloride Step A: 1-[(2-Amino-3-tert-butoxycarbonylaminoprop-1-yl]-2(S)butyl-4-( 1 -naphthovl)piperazine Di-tert-butyl dicarbonate (0.282 g, 1.29 mmol) was added to a solution of 4-(2,3-diaminoprop-1-yl)-2(S)-butyl-1-(1naphthoyl)piperazine (0.476 g, 1.29 mmol) in dichloromethane mL). The reaction was stirred a total of 2h at 20 0 C, then quenched and extracted with water. The organic phase was washed with saturated brine and dried over magnesium sulfate. The crude product was chromatographed on silica gel with 5% methanol in chloroform followed by 5% (9:1 methanol-ammonium hydroxide) in chloroform.
The title compound was isolated as the major product. FAB ms (m+1) 469.
Step B: 1-(3-tert-Butoxycarbonylamino-2-(2naphthylmethylamino)prop-1 -yl)-2(S)-butyl-4-(1naphthoyl)piperazine The title compound was prepared according to the procedure described in Example 1, Step D except using 1-[(2-amino-3tert-butoxycarbonylaminoprop- 1 -yl]-2(S)-butyl-4-( 1naphthoyl)piperazine (0.287 g, 0.613 mmol), naphthalene-2carboxaldehyde (0.95 g, 0.613 mmol), sodium triacetoxyborohydride (0.194 g, 0.919 mmol), in dichloroethane (15 mL) at pH 6. The crude product was chromatographed on silica gel with 5% methanol in WO 96/30343 PCTIUS96/04019 93 chloroform (Rf 0.30), and the title compound isolated as a foam. FAB ms 609.
Step C: 1-(3-Amino-2-(2-naphthylmethylamino)prop-1-yl)-2(S)butyl-4-(1-naphthoyl)piperazine trihvdrochloride A solution of 1-(3-tert-butoxycarbonylamino- 2 2 naphthylmethylamino)prop-l-yl)-2(S)-butyl-4-(1-naphthoyl)piperazine (0.313 g, 0.514 mmol) in methylene chloride (10 mL) was deprotected with trifluoroacetic acid (5 mL) and converted to the free base (255 mg) according to the procedure described in Example 1, Step E.
Purification of 40 mg by preparative HPLC used gradient elution with solvents A and B (from Example 1; 95% to 5% solvent Ion exchange and lyophilization as described furnished the title compound as a white solid. FAB ms 509. Anal. Calc. for C33H40N40 0.05 H20 4.45 HCl: C, 59.00; H, 6.68; N, 8.34. Found: C, 59.00; H, 6.51; N, 8.44.
EXAMPLE 3 2(S)-Butyl-1- 5- [1-(2-naphthylmethyl)]-4,5-dihydroimidazol methyl-4- (1-naphthovl)piperazine ditrifluoroacetate 1-(3-Amino-2-(2-naphthylmethylamino)prop-l-yl)-2(S)butyl-4-(1-naphthoyl)piperazine (0.105 g, 0.207 mmol), tertbutylisocyanate (1.5 mL) and silver cyanide (0.023 g, 0.207 mmol) were heated in a sealed tube under nitrogen at 90 0 C overnight. The volatiles were removed in vacuo, and the residue chromatographed on silica gel with 5-10% methanol in chloroform to give the free base (73 mg). This was purified by preparative HPLC as described in Example 1 by gradient elution with solvents A and B (from Example 1; 95% to solvent A Lyophilization furnished the title compound as a white solid. FAB ms 519. Anal. Calc. for C34H38N40 0.85 3.75 TFA: C, 51.84; H, 4.55; N, 5.83. Found: C, 51.83; H, 4.56; N, 6.32.
WO 96/30343 PCT/US96/04019 -94- EXAMPLE 4 1-[5-(1-Benzylimidazol)methyl]-2(S)-butyl-4-(1-naphthoyl)piperazine dihydrochloride Benzyl bromide (0.012 mL, 0.103 mmol) was added to a solution of 2(S)-butyl-1-[5-(3-triphenylmethylimidazol)]methyl- 4 naphthoyl)piperazine (63 mg, 0.103 mmol) in acetonitrile (0.5 mL) at under nitrogen. The reaction was stirred overnight, concentrated in vacuo, and taken up in dichlormethane (2 mL) containing triethylsilane (0.100 mL). Trifluoroacetic acid was added and the reaction stirred for lh at 20 0 C. The solvent was evaporated and the residue purified by HPLC (95% to 5% solvent Pure fractions were combined and converted to the HC1 salt as described in Example 1, Step E. After lyophilization, the title compound was isolated as a white solid. FAB ms 467. Anal. Calc. for C30H34N40 0.05 H20 3.70 HC1: C, 59.81; H, 6.32; N, 9.30. Found: C, 59.78; H, 6.33; N, 9.30.
EXAMPLE 1- 5- [1 -(4-nitrobenzyl)] imidazolylmethyl} -2(S)-butyl-4-( 1 naphthovl)piperazine ditrifluoroacetate The title compound was prepared according to the procedure described in Example 4, except using p-nitrobenzylbromide (0.043 g, 0.199 mmol) and 2(S)-butyl-l-[5-( 3 triphenylmethylimidazol)]methyl-4-(1-naphthoyl)piperazine (123 mg, 0.199 mmol) in acetonitrile (2 mL). The crude product was treated with triethylsilane (0.127 mL, 0.80 mmol) and trifluoroacetic acid (2 mL) in dichloroethane (4 mL). Preparative HPLC (95-5% solvent
A)
provided the title compound as a white solid. FAB ms 512.
Anal. Calc. for C30H33N503 2 CF2CO2H 0.03 H20: C, 41.42; H, 3.98; N, 10.18. Found: C, 41.43; H, 3.96; N, 10.51.
WO 96130343 WO 9630343PCT/US96/04019 95 EXAMPLE 6 1 -Acetamidomethylthio-2(R)-amifloprop-l -yl)-2(S )-butyl-4- (1naphthovl)p2iperazifle ditrifluoroacetate 1- (3-Acetamidomethylthio-2(R)-amifloprop-l butyl-4-( 1-naphthoyl)piperazifle dihydrochioride and Nhydroxymethylacetamide (0.0 10 g, 0.105 mmol) (prepared as described in M. Bodansky, A. Bodanskyr, "The Practice of Peptide Synthesis", Springer-Verlag, 1984, p.82) were dissolved in trifluoroacetic acid for 0.5h. The solvent was removed in vacuo and the residue purified by preparative HPLC (85-60% solvent After lyophilization, the title compound was isolated as a solid. FAB ms 457. Anal. Calc. for C25H36N402 S 2 CF2CO2H -1.9 H20.- C, 44.38 H, 5.12; N, 6.64.
Found: C, 44.35; H, 5.11; N, 6.97.
EXAMPL 7 2(S)-Butyl-1- 1-imidazolyl)ethyl] sulfonyl-4-(l1-naphthoyl)piperazine ditrifluoroacetate Step A: 2(S)-Butyl-4-(l1-naphthoyl)- 1 -vinylsulfonylpiperazifle Chloroethylsulfonylchloride (0.038 mL, 0.314 mmol) was added to a solution of 3(S)-butyl-1-(1-naphthoyl)piperazine (0.095 g, 0.285 mmol) and diisopropylethylamine 119 mE, 0.685 mmol) in dichloromethane (3 mL). The reaction was stirred overnight under nitrogen, quenched with saturated sodium bicarbonate and extracted into ethyl acetate. After drying with magnesium sulfate, the title compound was isolated.
Step B: 2(S)-Butyl-1- [2-(l1-imidazolyl)ethyl] sulfonyl-4-( 1naphthoyl)piperazine ditrifluoroacetate- Imidazole (0.043 g, 0.627 mmol) was added to sodium hydride (60% dispersion in oil, 0.024 g, 0.598 mmol) suspended in dimethylformamide (2 mL). The reaction was cooled to 0 0 C under WO 96/30343 PCT/US96/04019 96 nitrogen, and 2(S)-butyl-4-(1-naphthoyl)-1-vinylsulfonylpiperazine (0.011 g, 0.29 mmol) in dimethylformamide (5 mL) was added. The reaction was stirred at 20 0 C overnight. The dimethylformaide was removed in vacuo and the residue dissolved in ethyl acetate. This was extracted with saturated sodium bicarbonate solution, saturated brine and dried over magnesium sulfate. The crude product was first purified by silica gel chromatography using 8% methanol in chloroform, then by preparative HPLC (80 to 40% solvent The trifluoroacetate salt was dissolved in water and partitioned between saturated sodium bicarbonate and ethyl acetate. The organic phase was washed with saturated brine and dried over magnesium sulfate. The title compound was obtained as a foam. FAB ms 455. Anal. Calc. for C25H36N402 S .0.8 C, 61.46; H, 6.79; N, 11.95. Found: C, 61.44; H, 6.97; N, 10.72.
EXAMPLE 8 2(R)-Butyl-1-imidazolyl-4-methyl-4-(1 -naphthoyl)piperazine Step A: 2(R)-Butyl-4-(1-naphthoyl)- triphenylmethylimidazolyllmethyl-piperazine 3(R)-Butyl-1-(1-naphthoyl)piperazine (0.202 g, 0.607 mmol) (prepared as described for the enantiomer in Example 1) was reacted with 1-triphenylmethylimidazole-4-carboxaldehye (0.226 g, 0.667 mmol), sodium triacetoxyborohydride (0.321 g, 1.52 mmol), in dichloroethane (7 mL) in the presence of crushed molecular sieves. The pH was adjusted to 5-6 with triethylamine/acetic acid. The reaction was stirred overnight, then quenched with saturated sodium bicarbonate.
The organic layer was washed with saturated brine, and dried over magnesium sulfate. The crude product was purified by chromatography on silica gel with 30% ethyl acetate in hexane followed by 5% methanol in chloroform, to obtain the title compound.
Step B: 2(R)-Butyl-1 -imidazolyl-4-methyl-4-(1 naphthovD)piperazine ditrifluoroacetate WO 96/30343 PCT/US96/04019 97 Triethylsilane (1.0 mL, 11.80 mmol) was added to a solution of 2(R)-butyl-4-(1-naphthoyl)-1-[4-(1 -triphenylmethylimidazolyl]methyl-piperazine (0.381 g, 0.616 mmol) in dichloromethane, followed by trifluoroacetic acid (8 mL). After 1h, the solvents were evaporated and the residue partitioned between water and hexane. The aqueous phase was injected directly onto a preparative HPLC column (100-40% solvent A) and the title compound isolated after lyophilization. FAB ms 377. Anal. Calc. for C25H36N402 2.35 CF3CO2H .0.32 H20 C, 48.93; H, 4.52; N, 7.98.
Found: C, 48.93; H, 4.55; N, 8.26.
EXAMPLE 9 2(S)-Butyl-4-(1-naphthoyl)-1-(3-pyridylmethyl)piperazine dihydrochloride 3(S)-Butyl-l-(1-naphthoyl)piperazine hydrochloride (0.200 g, 0.601 mmol) was reacted with pyridine-3-carboxaldehyde (0.062 mL, 0.661 mmol), sodium triacetoxyborohydride (0.321 g, 1.52 mmol), in dichloroethane (7 mL) at pH 5-6 in the presence of crushed molecular sieves as described in Example 8, Step A. The crude product was purified by silica gel chromatography with 30% acetone in hexane, followed by preparative HPLC (80-75% solvent After ion exchange, the title compound was isolated. FAB ms 388. Anal.
Calc. for C25H29N30 2.3 HC1 -0.95 H20 C, 61.49; H, 6.85; N, 8.60. Found: C, 61.49; H, 7.01; N, 8.76.
EXAMPLE 1-2(S)-Butyl-(2(R)-(4-nitrobenzyl)amino-3-hydroxypropyl)-4-(1naphthovl)piperazine dihydrochloride 1-(2(R)-amino-3-hydroxypropyl)-2(S)-butyl-4-( 1naphthoyl)piperazine (120 mg, 0.326 mmol) was converted to the title compound according to the procedure described in Example 8, Step A using 4-nitrobenzaldehyde (0.493 g, 0.327 mmol), sodium WO 96/30343 PCTIUS96/04019 98 triacetoxyborohydride (0.173 g, 0.817 mmol), in dichloroethane. The crude product was purified by preparative HPLC (100-75% solvent A), and after ion exchange to the HC1 salt and lyophilization, the title compound was obtained. FAB ms 505. Anal. Calc. for C25H29N30 3.6 HC1 .0.10 H20 C, 54.69; H, 6.30; N, 8.80. Found: C, 54.66; H, 5.85; N, 8.31.
EXAMPLE 11 1-(2(R)-Amino-3-hydroxyheptadecyl)-2(S)-butyl-4-(1naphthoyl)vpiperazine ditrifluoroacetate Step A: 1 -(2(R)-t-Butyoxycarbonylamino-2-formylethyl)- 2 butyl-4-(1 -naphthoyl)piperazine A solution of oxalyl chloride (1.36 mL, 14.9 mmol) in dichloromethane (35 mL) was cooled to -65 0 C under nitrogen, and dimethylsulfoxide (2.30 mL, 32.4 mmol) in methylene chloride (7 mL) added, and the reaction stirred 2 min. A solution of 1-(2(R)-amino-3hydroxypropyl)-2(S)-butyl-4-(1-naphthoyl)piperazine (3.19 g, 6.79 mmol) was added to this solution at -10 0 C and the reaction stirred at this temperature for 15 min. The reaction was cooled to -55 0 C and triethylamine (4.76 mL, 34 mmol) added. The reaction was stirred for min then warmed to room temperature. Additional methylene chloride is added and the reaction is extracted with water. The organic phase was washed with 2% potassium hydrogen sulfate, water, dilute sodium bicarbonate solution, and saturated brine. After drying with magnesium sulfate, the title compound was obtained.
Step B: 1-(2(R)-Amino-3-hydroxyheptadecyl)-2(S)-butyl-4-(1naphthovl)piperazine ditrifluoroacetate A solution of 0.25 g, 0.53 mmol)l-(2(R)-tbutoxycarbonylamino-2-formylethyl)- 2 (S)-butyl-4-(1naphthoyl)piperazine in dry tetrahydrofuran (5 mL) was cooled to 0 C under nitrogen in a flame-dried three necked flask. A solution of WO 96/30343 PCTJUS96/04019 99 heptadecylmagnesium chloride (1.01 mL of a 1M solution in ether, 1.01 mmol) was added via syringe, and the reaction allowed to warm to room temperature. The reaction was quenched with saturated sodium bicarbonate solution, and then extracted with ethyl acetate. After drying over magnesium sulfate, the crude product was chromatographed on silica gel with 25% ethyl acetate in hexane followed by 5% methanol in chloroform. The purified product was dissolved in methylene chloride (7 mL) and treated with trifluoroacetic acid (3.5 mL). After 45 min, the solvents were removed in vacuo and the residue purified by preparative HPLC (95-40% solvent Two isomers were separated. After lyophilization, the title compound was isolated as diastereomer A (retention time 8.405 min, gradient 100-50% solvent A overl5 min), FAB ms 566, Anal. Calc. for C36H59N302 2.35 CF3CO2H 0.35 H20. C, 58.19; H, 7.44; N, 5.00. Found: C, 58.21; H, 7.46; N, 5.36. After lyophilization, the title compound was also isolated as diastereomer B (retention time 9.269 min, gradient 100-50% solvent A overl5 min), FAB ms 566, Anal. Calc. for C36H59N302 2.35 CF3CO2H 0.05 H20. C, 58.56; H, 7.42; N, 5.03. Found: C, 58.53; H, 7.41; N, 5.17.
EXAMPLE 12 2(S)-Benzvl-l-imidazolvl-4-methyl-4-(1-naphthoyl)piperazine Step A: 1.(3S)-Dibenzvlpiperazine-2.5-dione The title compound was prepared according to the procedure described in Example 1, Step A, except using Boc-Lphenylalanine (12.8 g, 48.2 mmol), ethyl N-benzylglycinate (9.32 g, 48.2 mmol) and dicyclohexylcarbodiimide (96.5 mL 0.5 M in dichloromethane, 48.2 mmol). The crude diketopiperazine was triturated with hexane to give the title compound as a white powder.
1 HNMR (300 MHz, CD30D) 8 7.0-7.4 (10H, 4.61 (1H, d, J=16 Hz), 4.37 (1H, t, J=5 Hz), 4.24 (1H, d, J=16 Hz), 3.42 (1H, d, J=18 Hz), WO 96/30343 PCT/US96/04019 100 3.28 (1H, dd, J=4, 16 Hz), 2.96 (1H, dd, J=6, 16 Hz), 2.55 (1H, d, J=18 Hz).
Step B: 1 -tert -Butoxycarbonvl-2(S)-,(S),4-dibenzylpiperazine The title compound was prepared according to the procedure described in Example 1, Step B, except using 1,3(S)- (5.01 g, 17.1 mmol) and lithium aluminum hydride (2.33 g, 61.4 mmol), followed by di-tert -butyl dicarbonate (4.02 g, 18.4 mmol). The crude product was purified by column chromatography on silica gel, eluting with 7.5% ethyl acetate in hexane. The title compound was obtained as a white solid. 1
HNMR
(300 MHz, CD30D) 8 7.2-7.4 (5H, 7.0-7.2 (5H, 4.15 (1H, m), 3.90 (1H, d, J=15 Hz), 3.60 (1H, d, J=15 Hz), 3.15 (1H, 2.95 (3H, 2.7 (1H, d, J=13 Hz), 2.02 (1H, dt, J=6, 13 Hz), 1.95 (1H, br d), 1.35 (9H, s).
Step C: 2(S)-Benzyl-1 -tert -butoxycarbonvlpiperazine The title compound was prepared according to the procedure described in Example 1, Step C, except using 1-tert butoxycarbonyl-2(S),4-dibenzylpiperazine (4.78 g, 11.3 mmol) and palladium on carbon (1.04 The title compound was obtained as an oil. 1 HNMR (300 MHz, CD30D) 8 7.25 (5H, 4.35 (1H, m), 4.00 (1H, d, J=12 Hz), 2.7-3.3 (7H, 1.25 (9H, s).
Step D: 2(S)-Benzyl-1-tert -butoxycarbonyl-4-(1naphthoyl)piperazine The title compound was prepared according to the procedure described for Example 1, Step A except using 2(S)-benzyl-1tert -butoxycarbonylpiperazine (0.292 g, 1.06 mmol), 2,3-dimethylbenzoic acid (0.159 g, 1.06 mmol), HOBT (0.157 g, 1.02 mmol), EDC-HCl (0.213 g, 1.11 mmol) and triethylamine to adjust the pH to 7.
The title compound was obtained as a thick oil. 1 HNMR (DMSO-d6, 300 MHz) 8 7.15 (2H, 6.06 4.42 3.6-4.2 (2H, m), WO 96/30343 WO 9630343PCTfUS96/04019 101 2.7-3.24 (411, in), 2.24 (311, 2.03-2.20 (3H, 4s), 1.10-1.6 (15H, in), 0.72-1.00 (3H, in).
Step E: 2(S)-Benzyl-4-(l1-naphthoyl)-1- 1triphenvimethylimidazolyl] methyl-p2iperazine 3(S)-B enzyll--(1 -naphthoyl)piperazine (0.173 g, 0.472 mmol) was reacted with 1 -triphenylmethylimidazole-4-carboxaldehyde (0.160 g, 0.472 mmol), sodium triacetoxyborohydride (0.300 g, 1.42 inmol), in dichioroethane (7 mL) in the presence of crushed molecular sieves as described in Example 8, Step A. The title compound was obtained as an oil.
Step F: 2(S )-Benzyl-l1-imidazolyl-4-methyl-4-( 1naphthoyl)p2iperazine ditrifluoroacetate Triethylsilane (0.300 inL, 1.89 inmol) was added to a solution of 2(S)-benzyl-4-( 1-naphthoyl)-1- 1triphenylmethyliinidazolyllinethyl-piperazine (0.310 g, 0.472 mmol) in dichloroinethane (5 inL), followed by trifluoroacetic acid (5 inL).
After lh, the solvents were evaporated and the residue partitioned between water and hexane. The aqueous phase was injected directly onto a preparative HPLC column (8 5-45% solvent A) and the title compound isolated after lyophilization. FAB ins 1) 411. Anal.
Calc. for C26H26N4O2~ 2.75 CF3CO2H .0.05 H20. C, 52.11; H, 4.14; N, 7.72. Found: C, 52.10; H, 4.03; N, 8.16.
EXAMPLE 13 1- (2(R)-Amino-3- (3 -benzylthio)propyl)-2(S )-butyl-4- (1-naphthoyl)p2iperazine ditrifluoroacetate Step A: 1- -Aziridinyl)inethyl]-2(S)-butyl-4-(l1-naphthoyl)piperazine A solution of 1 -(2(R)-butoxycarbonylamino-3 hydroxypropyl)-2(S)-butyl-4-( 1-naphthoyl)piperazine (1.67 g, 3.56 WO 96/30343 PCT/US96/04019 102 mmol) in dimethylformamide (10 mL) was cooled to 0°C under nitrogen. Sodium hydride (0.427 g, 10.6 mmol, 60% dispersion in oil) was added, followed by 1,1'-sulfonyldiimidazole (0.704 g, 3.56 mol).
The reaction was warmed to 20°C for lh, cooled to 0°C and quenched with water. Dimethylformamide was distilled in vacuo, and the residue partitioned between ethyl acetate and water. The organic phase was washed with saturated brine and dried over magnesium sulfate. The crude product was chromatographed on silica gel with 70% ethyl acetate in hexane, followed by 5% methanol in chloroform. The title compound was obtained as the major product, FAB ms 352. A lesser amount of 1-[(1-butoxycarbonylaziridinyl)methyl]-2(S)-butyl-4- (1-naphthoyl)piperazine was also isolated.
Step B: 1-(2(R)-Amino-3-(3-benzylthio)propyl)-2(S)-butyl-4-(1naphthoyl)piperazine ditrifluoroacetate 1-[(1-Aziridinyl)methyl]-2(S)-butyl-4-(1naphthoyl)piperazine (0.050 g, 0.142 mmol) was refluxed for 18h with benzyl mercaptan (0.100 mL, 0.852 mmol) and triethylamine (0.200 mL) in methanol (4 mL). The crude product was first chromatographed on silica gel with 3% methanol in chloroform, and then purified by preparative HPLC (85% to 10% solvent The title compound was obtained after lyophilization. FAB ms 476.
Anal. Calc. for C29H37N30S 2.6 CF3CO2H .0.3 H20. C, 52.83; H, 5.21; N, 5.40. Found: C, 52.78; H, 5.17; N, 5.66.
EXAMPLE 14 1-(2(R)-Amino-3-[3-(4-nitrobenzylthio)propyl]))-2(S)-butyl-4-(1naphthoyl)piperazine ditrifluoroacetate A solution ofl-[(1-butoxycarbonylaziridinyl)methyl]-2(S)butyl-4-(1-naphthoyl)piperazine (0.050 g, 0.111 mmol) in methanol (4 mL) was reluxed with p-nitrobenzylthioacetate (0.070 g, 0.333 mmol) and triethylamine (0.200 mL) for 2h. The crude product was chromatographed on silica gel with 3% methanol in chloroform. The WO 96/30343 PCT/US96/04019 103 purified product was treated with 33% trifluoroacetic acid in methylene chloride for 20 min. The solvents were evaporated and the product purified by preparative HPLC (85%-10% solvent The title compound was obtained after lyophilization. FAB ms 529.
Anal. Calc. for C29H36N403 2 CF3CO2H -0.08 H20. C, 51.94; H, 5.23; N, 7.34. Found. C, 51.87; H, 5.06; N, 7.47.
EXAMPLE 2(S)-Butyl- 1- [(4-imidazolyl)ethyl]-4-(1-naphthoyl)piperazine dihydrochloride Step A: N-Methyl-N-methoxy-2-(1-triphenylmethyl-1 H-imidazol-4ylDacetamide To a solution of 4-imidazoleacetic acid (1.04g, 6.40 mmol) and triphenylmethyl bromide (2.48 g, 7.68 mmol) in dimethylformamide (40 ml) was added triethylamine (4.46 ml, 32 mmol) and the suspension allowed to stir for 18 hours at room temperature. After this time, the mixture was treated with 3-hydroxy- 1,2,3-benzotriazin-4(3)-one (HOOBT) (1.31g, 8 mmol), N, 0dimethylhydroxyamine hydrochloride (1.56g, 16 mmol) and 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (1.53 g, 8 mmol) and stirred for 24 hours at room temperature. After this time, sat. aq. sodium bicarbonate (50 ml) and water (50 ml) were added and the mixture was extracted with ethyl acetate 2 x 100 ml).
The combined extracts were washed with sat. aq. NaHCO3 (100 ml) and then brine (50 ml) and the solvent evaporated in vacuo. The residue was suspended in ether (20 ml) and the white solid filtered to give the title compound as a white solid.
1NMR(CD30D, 300 MHz) 8 7.37(10H, 7.16(6H, 6.84(1H, s), 3.73(2H, 3.68(3H, s) and 3.18(3H, s)ppm.
WO 96/30343 PCT/US96/04019 104 Step B: 2- (1-triphenylmethyl-1 H-imidazol-4-yl)acetaldehyde To a solution of the product from Step A (300 mg, 0.73 mmol) in freshly distilled THF (15 ml) cooled to -40 0 C over dry ice/acetone was added lithium aluminum hydride (33.2 mg, 0.874 mmol). The resulting suspension was allowed to warm to +5 0 C and then maintained at 0°C for 30 min. After this time, the reaction mixture was recooled to -40 0 C and quenched sequentially with water (33 gl), NaOH (33 gl) and water (100 gl). The resulting suspension was stirred for 30 min, filtered and the solvent removed in vacuo. The residue was dissolved in methylene chloride (5 ml) and washed with aq. citric acid (5 ml) and then water (5ml). The organic layer was dried(MgS04) and the solvent evaporated in vacuo to give the title compound.
1 HNMR (CDC13, 300 MHz) 8 9.79(1H, t, J=3Hz), 7.44(1H, 7.4- 7.1(15H, 6.76(1H, s) and 3.63(2H, d, J=3Hz)ppm.
Step C: 2(S)-Butyl-1-[(4-imidazolyl)ethyl]-4-(1naphthoyl)piperazine ditrifluoroacetate To a solution of the product from Step B (89 mg, 0.263 mmol) and 3(S)-butyl-l-naphthoylpiperazine hydrochloride (62.6 mg, 0.188 mmol) in 1,2-dichloroethane (4 ml) was added 3A molecular sieves (400 mg) and sodium triacetoxyborohydride (200 mg, 0.94 mmol). This mixture was stirred at room temperature for 4 days. After this time, filtered the mixture through sintered glass. The filtrate was diluted with methylene chloride (50 ml) and washed with water (25 ml).
The solvent was evaporated in vacuo and the residue was purified by flash chromatography eluting with 2-5% methanol/methylene chloride to provide the trityl protected title compound as an oil. This oil was dissolved in methylene chloride (2 ml) and trifluoroacetic acid (1 ml) and treated with triethylsilane (2 drops) to give a colorless solution.
This solution was stirred at room temperature for 3 hours and then the solvent was evaporated in vacuo. The resulting residue was dissolved in water (20 ml) and washed with hexanes (20 ml). The aqueous layer was lyophilized to give the title compound.
WO 96/30343 PCTIUS96/04019 105 1 HNMR (CD30D, 300 MHz) 8 8.83(1H, 8.08-7.75(3H, 7.67- 7.49(4H, 7.45(1H, 4.5-3.8(2H, 3.65-2.95(9H, 1.3(4H, m) and 2.2-0.2(5H, m)ppm.
Anal. calc'd for C24H30N40 3.45 TFA 0.75H20: C, 46.54; H, 4.42; N, 7.03. Found: C, 46.54; H, 4.41; N, 7.35.
FAB HRMS exact mass calc'd for C23H31N40 391.249787 found 391.249028 EXAMPLE 16 2(S)-Butyl-l-[(4-imidazolyl)methyl]-4-(1-naphthoyl)piperazine ditrifluoroacetate To a solution of the product from Step C (102 mg, 0.30 mmol) and 3(S)-butyl-1-naphthoylpiperazine hydrochloride (62.6 mg, 0.188 mmol) in 1,2-dichloroethane (5 ml) was added sodium triacetoxyborohydride (200 mg, 0.94 mmol) and triethylamine to pH and stirred at room temp. for 18 hours. After this time, the mixture was filtered. The filtrate was concentrated in vacuo and dissolved in ethyl acetate (25 ml) and washed with sat. aq. NaHCO3 ml) and then brine (10 ml). The solvent was evaporated in vacuo and the residue was purified by flash chromatography eluting with 3-8% methanol/methylene chloride to provide the trityl protected title compound. This oil was dissolved in methylene chloride (4 ml) and trifluoroacetic acid (2 ml) and treated with triethylsilane until the yellow color disappeared to give a colorless solution. Stirring continued at room temp. for 10 min. and the solvent evaporated in vacuo. The resulting white solid was partially dissolved in water (7 ml) and filtered. The filtrate was purified by Prep HPLC using a Nova Prep 5000 Semi Preparative HPLC system and a Waters PrepPak cartridge (47 X 300mm, C18, 15 im, 100A) eluting with 5 acetonitrile/water 0.1% TFA) at 100 ml/min Chromatography A to give the title compound after lyophilization 1 HNMR (DMSO-d6, 400 MHz, 150 0 C) 8 8.53(1H, 7.94(2H, m), 7.79(1H, 7.53(3H, 7.41(1H, 7.40(1H, 4.12(1H, d, WO 96/30343 PCTIUS96/04019 106 J=4.8Hz), 3.95(1H, d, J=4.8Hz), 3.70(1H, 3.63(1H, 3.48(1H, s), 3.40(1H, 3.01(1H, 2.82(1H, 2.74(1H, 1.70(1H, m), 1.49(1H, 1.18(2H, 1.08(2H, s) and 0.77(3H, t, Anal. calc'd for C23H29N40 2 TFA 0.70H20: C, 52.55; H, 5.13; N, 9.08. Found: C, 52.54; H, 5.11; N, 9.35.
FAB MS mass calc'd for C23H30N40 377 found 377.
EXAMPLE 17 2(S)-Butyl- 1- [(1-naphth-2-ylmethyl)-1 H-imidazol-5-yl)acetyl]-4-(1naphthoyl)piperazine dihydrochloride Step A: Preparation of 1H-Imidazole-4- acetic acid methyl ester hydrochloride To a solution of 1H-imidazole-4-acetic acid hydrochloride (4.00g, 24.6 mmol) in methanol (100 ml) was bubbled hydrogen chloride gas until saturated. This solution was allowed to stand for 18h at room temperature and the solvent evaporated in vacuo to give the title compound as a white solid.
1 H NMR(CDC13, 400 MHz) 8 8.85(1H, s),7.45(1H, 3.89(2H, s) and 3.75(3H, s) ppm.
Step B: Preparation of 1-(Triphenylmethyl)-1H-imidazol-4-ylacetic acid methyl ester To a suspension of the product from Step A (7.48g, 42.4 mmol) in methylene chloride (200ml) was added triethylamine (17.7 ml, 127 mmol) and triphenylmethyl bromide(16.4g, 50.8 mmol) and stirred for 72h. After this time, the reaction mixture was washed with sat. aq. NaHCO3 (100 ml) and water 100 ml). The organic layer was evaporated in vacuo and the residue was purified by flash chromatography( 30-100% ethyl acetate in hexanes gradient elution) to provide the title compound as a white solid. 1 H NMR(CDC13, 400 MHz) 8 7.35(1H, 7.31(9H, 7.22(6H, 6.76(1H, 3.68(3H, s) and 3.60(2H, s) ppm.
WO 96/30343 PCT/US96/04019 107 Step C: Preparation of 2- [1-(Naphth-2-ylmethyl)-1H-imidazol-5yl)]acetic acid methyl ester To a solution of the product of Step B (4.36g, 11.4 mmol) in acetonitrile (70 ml) was added 2-(bromomethyl)naphthalene and heated to 55 0 C for 4h. After this time, the reaction was cooled to room temperature and the resulting white precipitate was collected by filtration. The filtrate was concentrated to 30 ml and heated to 55°C for 18h. After this time, the reaction was cooled to room teperature and filtered the resulting white precipitate collected by filtration. The filtrate was concentrated to 10 ml volume and heated to 55 0 C for lh.
After this time, the reaction was again cooled to room temperature and diluted with ethyl acetate (25 ml). The resulting precipitate was collected by filtration and combined with the previous 2 precipitates in methanol (100 ml) and heated to reflux for 30m. After this time, the solvent was removed in vacuo and the resulting residue was partioned between methylene chloride(200 ml) and sodium bicarbonate (100 ml).
The organic layer was evaporated in vacuo to dryness and the residue was purified by flash chromatography methanol/methylene chloride gradient) to provide the title compound as an off white solid 1 HNMR (CDC13, 400 MHz) 8 7.82(2H, 7.75(1H, 7.70(1H, s), 7.49(3H, 7.20(1H, d, J=8.4Hz), 7.06(1H, 5.32(2H, 3.57(3H, s) and 3.49(2H, s) ppm.
Step D: Preparation of 2-[1-(Naphth-2-ylmethyl)-lH-imidazol-5yllacetic acid hydrochloride 2- [1 -(Naphth-2-ylmethyl)-1 H-imidazol-5-yl]acetic acid methyl ester (0.92g, 3.28mmol was dissolved in 2.5N hydrochloric acid 50ml and heated to 55 0 C for 3h. After this time, the solution was concentrated to dryness in vacuo to give the title compound as a white solid.
1 HNMR (CD30D, 400 MHz) 8 8.92(1H, s),7.94(1H, d, J=8.6Hz), 7.88(2H, 7.83(1H, 7.54(3H, 7.43(1H, d, J=14Hz), 5.60(2H, s) amd 3.82(2H, s) ppm.
WO 96/30343 PCTIUS96/04019 108- Step E: Preparation of 2(S)-Butyl-l-[(1-(naphth-2-ylmethyl)-lHimidazol-5-yl)acetyl]-4-(1-naphthoyl)piperazine dihydrochloride To a solution of the product from Step D (100 mg, 0.330mmol), 3(S)-butyl-1-naphthoylpiperazine hydrochloride (100 mg, 0.300 mmol) and 3-hydroxy-1,2,3-benzotriazin-4(3H)-one
(HOOBT)
(54 mg, 0.33mmol) in dimethylformamide (2 ml) was added 1-(3dimethylaminopropyl)- 3 -ethylcarbodiimide hydrochloride (EDC) (63mg, 0.33 mmol) and triethylamine (161ul, 1.16mmol) and the resulting suspension stirred for 18 hours. After this time, sat. aq.
NaHCO3 (7 ml) was added and the resulting precipitate filtered. The solid was redissolved in methylene chloride and washed with water ml) and brine (20 ml). The solvent was evaporated in vacuo and the residue purified by Preparative HPLC (Chromatography A to give after lyophillization the title compound.
1 HNMR (CDC13, 400 MHz) 8 8.98(1H, 8.03-7.27(15H, 5.69- 5.50(2H, 4.79-4.34(2H, 4.15-2.50(7H, 1.8-0.2(9H, m)ppm.
Anal. calc'd for C35H35N402 HCl 0.65H20: C, 67.30; H, 6.16; N, 8.97. Found: C, 67.25; H, 6.16; N, 9.15.
FAB HRMS exact mass calc'd for C35H36N402 545.291652 found 545.292050.
EXAMPLE 18 2(S)-Butyl- 1 -[(1-naphth-2-ylmethyl)-1H-imidazol-5-yl)ethyl]-4-( 1naphthoyl)piperazine ditrifluoroacetate Step A: Preparation of N-Methyl-N-methoxy-2-[1-(naphth-2ylmethyl- 1H-imidazol-5-vl)1acetamide To a solution of 2-[1-(naphth-2-ylmethyl)-lH-imidazol-5yl]acetic acid hydrochloride (0.819 mg, 2.70 mmol) in dimethylformamide (15 ml) was added sequentially N, 0dimethylhydroxylamine hydrochloride (293 mg, 3.0 mmol 3- WO 96/30343 PCT/US96/04019 109 hydroxy-1,2,3-benzotriazin-4(3H)-one (HOOBT) (489 mg, 3.0 mmol), 1-(3-dimethylaminopropyl)- 3 -ethylcarbodiimide hydrochloride
(EDC)
(575 mg, 3.0 mmol) and triethylamine (1.67 ml, 12.0 mmol). This mixture was stirred at room temperature for 18h. After this time, sat.
aq. NaHCO3 (30ml) and water (30ml) were added and the mixture was extracted with methylene chloride 2 x 50ml The combined organic extracts were washed with brine (50 ml) and the solvent evaporated in vacuo. The residue was purified by flash chromatography eluting with 2-4% methanol/methylene chloride gradient to provide the title compound as an oil.
1 HNMR (CDC13, 400 MHz) 8 7.80(2H, 7.74(1H, 7.56(1H, s), 7.47(3H, 7.22(1H, d, J=8.6Hz), 6.97(1H, 5.37(2H, 3.58(2H, 3.51(3H, s) and 3.12(3H, s)ppm.
Step B: Preparation of 2-[1-(Naphth-2-ylmethyl)(1H-imidazol-5yl)lacetaldehyde To a suspension of lithium aluminum hydride (40.8mg, 1.07mmol) in tetrahydrofuran (5ml) cooled to -45 0 C over a dry ice/acetone bath was added a solution of the product from Step A (243 mg, 0.895 mmol) in tetrahydrofuran (5 ml) via canula at such a rate to maintain temperature the temperature at After the addition was complete, the solution was allowed to warm to +5°C and then recooled to -35 0 C. To this solution was added a solution of potassium bisulfate (272 mg) in water (1 ml). This mixture was stirred for 30 min at room temperature and filtered through celite. The celite pad was washed with ethyl acetate (25 ml). The combined filtrates were washed with sat.
sodium bicarbonate (10 ml) and then water (10ml). The organic layer was dried over magnesium sulfate, filtered and evaporated to give the title compound as a clear oil.
1 HNMR (CDC13, 400 MHz) 8 9.50(1H, t, 2Hz), 7.85-7.70(3H, m), 7.64(1H, 7.53-7.40(3H, 7.16(1H, d, J=12Hz), 7.06(1H, s), 5.20(2H, s) and 3.53(2H, m)ppm.
WO 96/30343 PCT/US96/04019 110- Step C: Preparation of 2(S)-Butyl-l-[(1-naphth-2-ylmethyl)-lHimidazol-5-yl)ethyl]-4-( 1 -naphthoyl)piperazine ditrifluoroacetate To a solution of the product from Step B (58.4 mg, 0.232 mmol) and 3(S)-butyl-l-naphthoylpiperazine hydrochloride (96.5 mg, 0.279 mmol) in 1,2-dichloroethane (10ml) and dimethylformamide was added 3A molecular sieves (250mg) and sodium triacetoxyborohydride (236.5 mg, 1.12 mmol). This mixture was stirred at room temperature for 18 h. After this time, the mixture was filtered. The filtrate was diluted with methylene chloride (100ml) and washed with sat sodium bicarbonate (50ml). The organic layer was dried(MgSO4), filtered and evaporated in vacuo. The residue was purified first by flash chromatography eluting with 2-5% methanol methylene chloride and then by Prep HPLC (Chromatography A) to provide the title compound.
1H NMR(CD30D, 400 MHz) 8 9.04(1H, 8.17-7.30(15H, m), 5.65(2H, 4.6-2.2(11H, m) and 1.6-0.2(9H, m)ppm.
FAB HRMS exact mass calc'd for C35H39N40 531.312387 found 531.313011.
EXAMPLE 19 1-(2(R)-Amino-3-hydroypropyl)-2(S)-butyl-4-(1-naphthoyl)piperazine bis trifluoracetate salt Step A: N-Boc-O-Benzylserine-(N'-Methoxy) methyl amide N-Boc-O-Benzylserine (Bachem; 5.0g, 16.9 mmol) and HOBT (2.29g, 16.9 mmol) were dissolved in dry DMF (100 mL) under argon. To this solution was added N,O-dimethylhydroxyl amine hydrochloride (1.98 g, 20.3 mmol) and then, at 0°C, EDC hydrochloride (3.56 g, 18.6 mmol). 4-Methylmorpholine was added to bring the pH to -7 (4.5 mL) and the mixture was stirred at room temperature for 3h. The solution was diluted with EtoAc and poured into 0.5N HC1. After extraction with EtoAc (twice), the organic layers WO 96/30343 PCTIUS96/04019 111 were washed with water then brine, dried (MgS04) and evaporated in vacuo to give a pale yellow oil. Column chromatograph (silica gel; hexanel/EtoAc 2:1) gave the title compound as an oil Rf (silica; hexare/EtoAc 1:1) 0.45.
Step B: N-Boc-O-Benzyl-serine aldehyde The amide from Step A (5.7 g, 16.9 mmol) in dry ether mL) was added dropwise to a suspension of LAH (0.705 g, 18.5 mmol) in 80 mL of ether at -50 0 C. After the addition was complete, the solution was stirred at 0°C for 45 min. then cooled back to -50 0 C and a solution of KHSO4 (4 g in 11 mL H20) was added slowly. This mixture was then stirred at room temperature for 1 h, filtered through celite, washed successively with 10% citric acid solution, saturated NaHCO3 solution and brine, dried (MgSO4) and evaporated to give an oil which was used as such in the next step. Rf (silica; hexane/EtoAc 2:1) 0.58.
Step C: 1-(2(R)-N-Boc-Amino-3-benzyloxy propyl)-2(S)-butyl-4- (1-naphythoyl) piperazine A solution of the piperazine hydrochloride from Example 1, Step E (1.7 g, 574 mmol) in CH2C12 (25 mL) was adjusted to pH 6 using Et3N then freshly ground and activated 4 A sieves were added followed by sodium triacetoxyborohydride (4.85 g, 22.9 mmol). The aldehyde from Step B (2.08g, 747 mmol) dissolved in 20 mL CH2C12 was added dropwise at 0°C over 20 min. then the mixture was sitrred at room temperature for 16 h. After this time, the mixture was filtered through celite, diluted with EtoAc and washed successively with KHSO4, solution, NaHCO3 solution and then brine. The dried (MgS04) solution was evaporated in vacuo to give a pale yellow oil which was subjected to column chromatography (silica gel; hexane/EtOAc 1:1) to give the title compound as a foam. Rf (silica; hexane/EtoAc 2:1) 0.15.
WO 96/30343 PCT/US96/04019 112- Step D: 1-(2(R)-N-Boc-Amino-3-hydroxy propyl)-2-(S)-butyl-4- (1-naphythoyl) piperazine The benzyl ether from Step C (700 mg, 1.25 mmol) was dissolved in 20 mL MeOH with 150 gL of acetic acid and then Pd(OH)2 on carbon (500 mg) was added and the mixture hydrogenated at 50 psi for 16 hr. After filtration through celite, the solvent was removed and the residue was chromatographed on silica gel (EtoAc/hexane 1:1 then 5% MeOH/EtoAc) to give the title compound as an oil.
Step E: 1-(2(R)-Amino-3-hydroxy propyl)-2(S)-butyl-4-(1naphythoyl)piperazine bis trifluoroacetate salt A solution of the N-Boc amine from Step D (140 mg) in mL EtoAc was treated with HC1 (gas) until saturated. After 5 min, the solution was purged with argon then the solvent was removed to give a solid which was purified by preparative HPLC (C-18 column; H20/CH3CN with 0.1% TGA; gradient). The aqueous solution was frozen and lyophilized to give the title compound as a hygroscopic powder. FAB mass spectrum m/z 370 Analysis calculated for C22H32N302-2.35 TFA C, 50.31; H, 5.27; N, 6.59 Found: C, 50.28; H, 5.49; N, 6.70 EXAMPLE 1-(2(R)-Amino-4-hydroxybutyl)-2(S)-butyl-4-(1 -naphthoyl)piperazine bishydrochloride salt Following the procedure of Example 19, Steps A to E but using N-Boc-O-benzyl homoserine (Bachem) as starting material, the title compound was obtained as the bis hydrochloride salt. FAB Mass spectrum, m/z 384 Analysis calculated for C23H33N302*1.5 HC1 C, 54.04; H, 7.20; N, 8.22 Found: C, 53.95; H, 7.23; N, 8.50 WO 96/30343 PCTIUS96/04019 113- EXAMPLE 21 1-(2-Amino-3-(2-benzyloxyphenyl)propyl)-2(S)-butyl-4-(1naphthoyl)piperazine bistrifluoroacetate salt Step A: D.L-N-Boc-ortho-tyrosine methyl ester The title compound was prepared as a crystalline solid from D,L-orthotyrosine (Sigma) in two steps ((Boc)20/K2CO3 in followed by diazomethane in EtOAc).
Step B: 3-(2-Hydroxyphenyl)-2-(N-Boc-Amino)propanol To a solution of the ester from Step A (1.34 g, 4.54 mmol) in THF (20 mL) at 0°C was added LAH (400 mg, 10.5 mmol) in portions. After 4 hs at room temperatrue, 0.4 mL H20 was added dropwise followed by 0.4 mL IN NaOH and then 1.2 mL H20. The slurry was stirred for 1 h, filtered through celite rinsing with THF and the solvent was removed chromatography of the residue (silica gel; hexane/EtoAc 1:1) gave the title compound as a solid. Rf (silica; hexane/EtoAc 1:1) 0.45.
Step C: 3-(2-Benzyloxyphenyl)-2-(N-Boc-amino)propanol A mixture of the alcohol from Step B (280 mg, 1.05 mmol) benzyl bromide (150 gL, 1.26 mmol) and Cs2CO3 (513 mg, 1.57 mmol) in DMF (10 mL) was stirred at room temperature under argon for 16 h. The mixture was poured into H20, extracted twice with EtOAc, washed with water then brine, dried (MgSO4) and evaporated to give an oil. Purification by chromatography (silica gel; hexane/EtoAc 2:1) gave the title compound as an oil. Rf (silica; hexane/EtoAc 2:1) 0.36.
Step D: 3-(2-Benzyloxyphenyl)-2-(N-Boc-amino)propanol To a solution of the alcohol from Step C (280 mg, 0.78 mmol) in 3 mL DMSO, 3 mL CH2C12 and 0.55 mL Et3N at room temperature under argon was added pyridine S03 complex (500 mg, WO 96/30343 PCT/US96/04019 114 3.14 mmol) and the mixture stirred for lh. The solution was poured into saturated NaHCO3 solution, extracted twice with EtoAc, washed with water then brine, dried (MgSO4) and concentrated in vacuo. The title compound was thus obtained as an oil and was used as such in the following step. Rf (silica; hexane/EtoAc 4:1) 0.41.
Step E: 1-(2-N-Boc-Amino-3-(2-benzyloxyphenyl)propyl)-2(S)butyl-4-(1-naphthoyl)piperazine The aldehyde from Step D and the piperazine hydrochloride from Example 1, Step E were coupled via reductive alkyltion using the procedure described for Example 19, Step C.
Purification by column chromatgraphy (silica gel; hexane/EtoAc 3:2) gave the title compound as a 1:1 mixture of diastereomers. Rf (silica; hexane/EtOAc 1:1) 0.51 and 0.45.
Step F: 1-(2-Amino-3-(2-benzyloxyphenyl)propyl)-2(S)-butyl-4- (1-naphthovl)piperazine bis trifluoroacetate salt A solution of the N-Boc amine from Step E (70 mg) in EtOAc (15 mL) was treated with HCI until saturated. After min., the solution was purged with argon and then the solvent removed to yield a solid. Purification by preparative HPLC (C-18 column, H20/CH3CN with 0.1% TFA; gradient) afforded (after lyophilization) the title compound as a powder. FAB mass spectrum, m/z 536 Analysis calculated for C35H41N302*2.2 TFA-0.35 C, 59.68; H, 5.58; N, 5.30 Found: C, 59.70; H, 5.60; N, 5.56 WO 96/30343 PCTIUS96/04019 115- EXAMPLE 22 1-(2-Amino-3-(2-hydroxyphenyl)propyl)-2(S)-butyl-4-(1naphthoyl)piperazine bis trifluoroacetate salt, diastereomer A Step A: 1-(2-N-Boc-Amino-3-(2-hydroxyphenyl)propyl)-2(S)butyl-4-(1 -naphthoyl)piperazine A mixture of 1-(2-N-Boc-Amino-3-(2-benzyloxyphenyl)propyl)-2(S)-butyl-4-(1-naphthoyl)piperazine (from Example 19, Step E; 290 mg, 0.5 mmol), acetic acid (60 gL, 1.0 mmol) and Pd(OH)2 on carbon (100 mg) in MeOH (20 mL) was hydrogenated at 67 psi for 5 h. The solution was filtered through celite and the solvent evaporated to give an oil which showed 2 well resolved spots on silica tic. Column chromatography (silica gel; hexane:EtoAc 1:1) gave: a) diastereomer A of the title compound RF (silica; hexane/EtoAc 1:1) 0.49.
b) diastereomer B of the title compound RF (silica; hexane/EtoAc 1:1) 0.35.
Step B: 1-(2-Amino-3-(2-hydroxyphenyl)propyl)-2(S)-butyl-4-(1naphthoyl)piperazine bis trifluoroacetate salt, diastereomer
A
The N-Boc amine, diastereomer A from Step A, was deprotected using HC1 (gas) in EtoAc. Removal of the solvent followed by preparative HPLC (C-18-column; H20/CH3CN with 0.1% TFA; gradient) gave (after lyophilization) the title compound as a powder.
FAB mass spectrum, m/z 446 Analysis calculated for C28H35N302*2 TFA C, 57.05; H, 5.54; N, 6.24 Found: C, 57.08; H, 5.64; N, 6.32 EXAMPLE 23 1-[3-(4-imidazolyl)propyl]-2(S)-butyl-4-(1-naphthoyl)piperazine bis trifluoroacetate salt WO 96/30343 PCT/US96/04019 116- Step A: Ethyl 3-( 4 -imidazolvl)propionate The title compound was prepared from urocanic acid (Aldrich) in 2 steps using standard chemical procedures (esterification using HC1 in EtOH followed by hydrogenation with 10% Pd-C in EtOH).
1H NMR (CDC13): 8 1.23 (3H, 2.65 (2H, 2.94 (2H, 4.15 (2H, 6.81 (1H, 7.56 (1H, s).
Step B: 3-(4-imidazolyl) propanol To a solution of the ester from Step A (120 g, 71.4 mmol) in dry THF (230 mL) at 0°C was added LAH (2.99 g, 78.6 mmol) portionwise over 30 min. The mixture was stirred for 2 h at room temperatrue then cooled back to 0 C and H20 (4.2 mL) was added (care!) dropwise. This was followed by the dropwise addition of 10.6 mL of IN NaOH then the resulting slurry was stirred at room temperature for 1 h. After filtration through celite washing with EtOAc, the solvent was removed to give the title compound as a clear oil (8.16 g).
IH NMR (CD30D): 8 1.84 (2H, pentet), 2.68 (2H, 3.58 (2H, 6.88 (1H, 7.80 (1H, s).
Step C: 3-(4-N-BOC-imidazolvl)propanol The imidazole from Step B (166 mg, 1.32 mmol), (302 mg, 1.38 mmol) and K2CO3 (190 mg, 1.38 mmol) were stirred in THF (10 mL) for 2 h. After filtration, the solvent was removed in vacuo to give the desired compound as an oil. Rf (silica; MeOH/CHCl3) 0.17. This was used as such in the next step.
Step D: 1-[3-(4-imidazolyl)propyl]-2(S)-butyl-4-(1-naphthoyl)piperazine bis trifluoroacetate salt The alcohol from Step C (-1.32 mmol) was dissolved in 4 mL DMSO, 4 mL CH2C12 and 0.92 mL Et3N and then pyridine S03 complex (600 mg, 5.28 mmol) was added in portions. After 3 h, the WO 96/30343 PCTIUS96/04019 117mixture was poured into EtOAc, extracted with saturated NaHCO3 solution then brine, dried and evaporated to afford the corresponding aldehyde which was used without further purification.
This aldehyde was coupled with the piperazine from Example 1, Step E by reductive alkylation following the procedure described for Example 19, Step C and the product was obtained by column chromatography (silica gel; 5% MeOH/CHC13). This product was dissolved in 10 mL EtOAc saturated with HCI (gas). The solvent was removed and the residue purified by preparative HPLC (C-18; H20/CH3CN with 0.1% TFA; gradient). Lyophilization of the frozen aqueous solution gave the title compound as a hygroscopic powder.
FAB mass spectrum, m/z 405 Analysis calculated for C25H32N40*2.35 TFA 0.4 C, 52.48; H, 5.21; N, 8.24 Found: C, 52.45; H, 5.22; N, 8.27 EXAMPLE 24 2(S)-n-Butyl-4-(1-naphthoyl)-l-[i-(1-naphthylmethyl)imidazol-5ylmethyll-piperazine ditrifluoroacetic acid salt The title compound was prepared from (3-triphenylmethylimidazolyl)methyl]-4-(1-naphthoyl)piperazine (0.124 g, 0.200 mmol) and 1-bromomethylnaphthalene (0.046 g, 0.21 mmol) according to the procedure described in Example 4. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 30%-75% acetonitrile/0.1% TFA; 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms 517. Anal. Calc. for C34H36N40 0.05 H20 2.0 TFA: C, 60.55; H, 5.22; N, 7.43. Found: C, 60.48; H, 5.12; N, 7.42.
WO 96/30343 PCT/US96/04019 118 EXAMPLE 2(S)-n-Butyl-4-(1-naphthoyl)-1- [1-(2-naphthylmethyl)imidazol-5ylmethyll-piperazine ditrifluoroacetic acid salt The title compound was prepared from 2(S)-n-butyl-1-[5- (3-triphenylmethylimidazolyl)methyl]-4-(1-naphthoyl)piperazine (0.124 g, 0.200 mmol) and 2-bromomethylnaphthalene (0.046 g, 0.21 mmol) according to the procedure described in Example 4. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 30%-75% acetonitrile/0.1% TFA; 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms 517. Anal. Calc. for C34H36N40 1.7 H20 2.0 TFA: C, 58.87; H, 5.38; N, 7.23. Found: C, 58.90; H, 4.93; N, 7.13.
EXAMPLE 26 2(S)-n-Butyl-1-[1-(4-cyanobenzyl)imidazol-5-ylmethyl]-4-(1naphthoyl)piperazine ditrifluoroacetic acid salt The title compound was prepared from 2(S)-n-butyl-1-[5- (3-triphenylmethylimidazolyl)methyl]-4-(1-naphthoyl)piperazine (0.124 g, 0.200 mmol) and 4-cyanobenzylbromide (0.041 g, 0.21 mmol) according to the procedure described in Example 4. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 25%-65% acetonitrile/0.1% TFA; 35% 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms 492. Anal. Calc. for C31H33N50 0.35 H20 2.0 TFA: C, 57.91; H, 4.96; N, 9.65. Found: C, 57.93; H, 4.91; N, 9.55.
EXAMPLE 27 2(S)-n-Butyl-l-[1-(4-methoxybenzyl)imidazol-5-ylmethyl]-4-(1naphthoyl)piperazine ditrifluoroacetic acid salt The title compound was prepared from (3-triphenylmethylimidazolyl)methyl]-4-(1-naphthoyl)piperazine (0.124 WO 96/30343 PCTIUS96/04019 119g, 0.200 mmol) and 4-methyoxybenzylchloride (0.041 mL, 0.21 mmol) according to the procedure described in Example 4, with the addition of potassium iodide (100 mg) to the reaction mixture. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 25%-65% acetonitrile/0.1% TFA; 75%-35% 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms (m+1) 497. Anal. Calc. for C31H36N402 1.7 H20 2.0 TFA: C, 53.40; H, 5.30; N, 7.12. Found: C, 53.37; H, 4.78; N, 7.00.
EXAMPLE 28 2(S)-n-Butyl-l-[1-(3-methyl-2-butenyl)imidazol-5-ylmethyl]-4-(1naphthoyl)piperazine ditrifluoroacetic acid salt The title compound was prepared from (3-triphenylmethylimidazolyl)methyl]-4-(1-naphthoyl)piperazine (0.124 g, 0.200 mmol) and 4-bromo-2-methyl-2-butene (0.024 mL, 0.21 mmol) according to the procedure described in Example 4. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 5%-95% acetonitrile/0.1% TFA; 95%-5% 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms (m+1) 445. Anal. Calc. for C28H36N40 1.8 H20 2.0 TFA: C, 54.51; H, 5.95; N, 7.95. Found: C, 54.54; H, 5.39; N, 7.73.
EXAMPLE 29 2(S)-n-Butyl-1- [1-(4-fluorobenzyl)imidazol-5-ylmethyl]-4-(1naphthoyl)piperazine ditrifluoroacetic acid salt The title compound was prepared from (3-triphenylmethylimidazolyl)methyl]-4-(1-naphthoyl)piperazine (0.124 g, 0.200 mmol) and 4-fluorobenzylbromide (0.026 mL, 0.21 mmol) according to the procedure described in Example 4. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 25%-65% acetonitrile/0.1% TFA; 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms WO 96/30343 PCTIUS96/04019 120 485. Anal. Calc. for C30H33FN40 3.0 H20* 2.0 TFA: C, 53.26; H, 5.39; N, 7.31. Found: C, 53.21; H, 4.56; N, 7.08.
EXAMPLE 2(S)-n-Butyl-1- [1-(4-chlorobenzyl)imidazol-5-ylmethyl]-4-( 1naphthoyl)piperazine ditrifluoroacetic acid salt The title compound was prepared from (3-triphenylmethylimidazolyl)methyl]-4-( 1 -naphthoyl)piperazine (0.124 g, 0.200 mmol) and 4-chlorobenzylchloride (0.034 mg, 0.21 mmol) according to the procedure described in Example 4, with the addition of sodium iodide (100 mg) to the reaction mixture. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 25%-65% acetonitrile/0.1% TFA; 75%-35% 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms (m+1) 501. Anal. Calc. for C30H33C1N40 4.8 H20 2.0 TFA: C, 50.07; H, 5.51; N, 6.87. Found: C, 50.10; H, 4.25; N, 6.48.
EXAMPLE 31 1-[1-(4-Bromobenzyl)imidazol-5-ylmethyl]-2(S)-n-butyl-4-( 1naphthoyl)piperazine ditrifluoroacetic acid salt The title compound was prepared from (3-triphenylmethylimidazolyl)methyl]-4-(1-naphthoyl)piperazine (0.124 g, 0.200 mmol) and 4-bromobenzylbromide (0.053 mg, 0.21 mmol) according to the procedure described in Example 4, with the addition of sodium iodide (100 mg) to the reaction mixture. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 30%-65% acetonitrile/0.1% TFA; 70%-35% 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms (m+1) 545. Anal. Calc. for C30H33BrN40 1.7 H20 2.0 TFA: C, 50.78; H, 4.81; N, 6.97. Found: C, 50.81; H, 4.39; N, 6.88.
WO 96/30343 PCTIUS96/04019 121 EXAMPLE 32 2(S)-n-Butyl-4-(1-naphthoyl)-l-[1-( 4 vlmethyll-piperazine ditrifluoroacetic acid salt The title compound was prepared from 3 -triphenylmethylimidazolyl)methyl]-4-(1-naphthoyl)piperazine (0.124 g, 0.200 mmol) and 4 -trifluoromethylbenzylbromide (0.053 mg, 0.21 mmol) according to the procedure described in Example 4. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 30%-65% acetonitrile/0.1% TFA; 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms 535. Anal. Calc. for C30H33BrN40 2.0 TFA: C, 55.12; H, 4.63; N, 7.35. Found: C, 57.46; H, 4.98; N, 7.84.
EXAMPLE 33 2(S)-n-Butyl-1-[1-( 4 -methylbenzyl)imidazol-5-ylmethyl]-4-( 1naphthovD-piperazine ditrifluoroacetic acid salt The title compound was prepared from 3 -triphenylmethylimidazolyl)methyl]-4-( 1 -naphthoyl)piperazine (0.124 g, 0.200 mmol) and 4 -methylbenzylbromide (0.029 mL, 0.21 mmol) according to the procedure described in Example 4, with the addition of sodium iodide (100 mg) to the reaction mixture. The title compound was obtained after purification by reverse phase preparative
HPLC
(gradient elution with 30%-65% acetonitrile/0.1% TFA; 70%-35% 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms (m+1) 481. Anal. Calc. for C31H36N40 2.6 H20 2.0 TFA: C, 55.64; H, 5.76; N, 7.42. Found: C, 55.61; H, 5.09; N, 7.43.
WO 96(30343 PCT/US96I04019 122 EXAMPLE 34 2(S)-n-Butyl-1- [1 3 -methylbenzyl)imidazol-5-ylmethyl] 1naphthovl)-pip~erazine ditrifluoroacetic acid salt The title compound was prepared from 2(S)-n-butyl- 1- (3-triphenylmethylimidazolyl)methyl..4.( 1-naphthoyl)piperazine (0.124 g, 0.200 mmol) and 3-methylbenzylbromide (0.029 m.L, 0.21 mmol) according to the procedure described in Example 4. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 25 %-65 acetonitrile/O. 1 TFA; 75 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms 481. Anal. Calc. for C31H36N40 2.0 TFA: C, 67.26; H, 6.92; N, 10.12. Found: C, 69.60; H, 6.98; N, 10.51.
EXAMPLE 4 -Phenylbenzyl)imidazol-5-ylmethyly2(S)-n-.butyl4( 1naphthovl)-piperazine ditrifluoroacetic acid salt The title compound was prepared from (3-triphenylmethylimidazolyl)methyl] 1-naphthoyl)piperazine (0.124 g, 0.200 minol) and 4-phenylbenzylbromide (0.029 mL, 0.21 mmol) according to the procedure described in Example 4. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 30%-65% acetonitrile/0. 1% TFA; 35% 0.1 aqueous TFA over 50 min.) and lyophilization. FAB ms 543. Anal. Calc. for C36H38N40 4.95 H20. 2.0 TFA: C, 55.87; H, 5.85; N, 6.52. Found: C, 55.55; H, 4.58; N, 6.23.
EXAMPLE 36 2(S)-n-Butyl-4-( 1 -naphthoyl)- 1I-[1 piperazine ditrifluoroacetic acid salt The title compound was prepared from 2(S)-n-butyl-1-[5- (3-triphenylmethylimidazolyl)methyl]-4.( 1-naphthoyl)piperazine (0.124 WO 96/30343 PCT/US96/04019 123 g, 0.200 mmol) and 2-phenylethylbromide (0.029 mL, 0.21 mmol) according to the procedure described in Example 4, except with the addition of sodium iodide (120 mg) and refluxing for 12 h. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 30%-65% acetonitrile/0.1% TFA; 0.1% aqueous TFA over 50 min.) and lyophilization. FAB ms 481. Anal. Calc. for C36H38N40 4.20 H20 2.0 TFA: C, 53.60; H, 5.96; N, 7.14. Fouid: C, 53.54; H, 4.86; N, 6.86.
EXAMPLE 37 2(S)-n-Butyl-4-(1-naphthoyl)-l-[1-(4-trifluoromethoxy)imidazol-5ylmethyllpiperazine ditrifluoroacetic acid salt The title compound was prepared from 2(S)-n-butyl-1-[5- (3-triphenylmethylimidazolyl)methyl]-4-(1-naphthoyl)piperazine (0.124 g, 0.200 mmol) and 4 -trifluoromethoxybenzylbromide (0.032 mL, 0.21 mmol) according to the procedure described in Example 4, except with the addition of sodium iodide (120 mg) and refluxing for 12 h. The title compound was obtained after purification by reverse phase preparative HPLC (gradient elution with 35%-70% acetonitrile/0.1% TFA; 65%-30% 0.1% aqueous TFA over 50 min.) and lyophilization.
FAB ms 551. Anal. Calc. for C31H33F3N402 4.00 H20 TFA: C, 49.42; H, 5.09; N, 6.59. Found: C, 48.95; H, 4.06; N, 6.26.
EXAMPLE 38 Preparation of 1- [1-(4-cyanobenzyl)-1H-imidazol-5-yl]acetyl butyl-4-(1-naphthoyvpiperazine trifluoroacetate Step A: Preparation of 1H-Imidazole-4- acetic acid methyl ester hydrochloride.
A solution of 1H-imidazole-4-acetic acid hydrochloride (4.00g, 24.6 mmol) in methanol (100 ml) was saturated with gaseous hydrogen chloride. The resulting solution was allowed to stand at room WO 96/30343 PCT/US96/04019 124temperature (RT) for 18hr. The solvent was evaporated in vacuo to afford the title compound as a white solid.
IH NMR(CDCl3, 400 MHz) 5 8.85(1H, 7.45(1H, 3.89(2H, s) and 3.75(3H, s) ppm.
Step B: Preparation of 1-(Triphenylmethyl)-1H-imidazol-4-ylacetic acid methyl ester.
To a solution of the product from Step A (24.85g, 0.141 mol) in dimethyl formamide (DMF) (115ml) was added triethylamine (57.2 ml, 0.412mol) and triphenylmethyl bromide(55.3g, 0.171mol) and the suspension was stirred for 24hr. After this time, the reaction mixture was diluted with ethyl acetate (EtOAc) (1 L) and water (350 ml). The organic phase was washed with sat. aq. NaHCO3 (350 ml), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography (SiO2, 0-100% ethyl acetate in hexanes; gradient elution) to provide the title compound as a white solid.
1 H NMR (CDC13, 400 MHz) 8 7.35(1H, 7.31(9H, 7.22(6H, m), 6.76(1H, 3.68(3H, s) and 3.60(2H, s) ppm.
Step C: Preparation of 4 acid methyl ester.
To a solution of the product from Step B (8.00g, 20.9mmol) in acetonitrile (70 ml) was added bromo-p-toluonitrile (4.10g, 20.92 mmol) and heated at 55°C for 3 hr. After this time, the reaction was cooled to room temperature and the resulting imidazolium salt (white precipitate) was collected by filtration. The filtrate was heated at 55 0 C for 18hr. The reaction mixture was cooled to room temperature and evaporated in vacuo. To the residue was added EtOAc (70 ml) and the resulting white precipitate collected by filtration. The precipitated imidazolium salts were combined, suspended in methanol (100 ml) and heated to reflux for 30min. After this time, the solvent was removed in vacuo, the resulting residue was suspended in EtOAc and the solid isolated by filtration and washed (EtOAc). The WO 96/30343 PCT/US96/04019 125 solid was treated with sat aq NaHCO3 (300ml) and CH2C12 (300ml) and stirred at room temperature for 2 hr. The organic layer was separated, dried (MgS04) and evaporated in vacuo to afford the title compound as a white solid 1 HNMR(CDCl3, 400 MHz) 5 7.65(1H, d, J=8Hz), 7.53(1H, 7.15(1H, d, J=8Hz), 7.04(1H, 5.24(2H, 3.62(3H, s) and 3.45(2H, s) ppm.
Step D: Preparation of 1-(4-cyanobenzyl)- acid A solution of [1 -(4-cyanobenzyl)- acid methyl ester (4.44g, 17.4mmol in THF (100ml) and 1 M lithium hydoxide (17.4 ml, 17.4 mmol) was stirred at RT for 18 hr. 1 M HCI (17.4 ml) was added and the THF was removed by evaporation in vacuo. The aqueous solution was lyophilised to afford the title compound containing lithium chloride as a white solid.
IH NMR(CD30D, 400 MHz) 8 8.22(1H, 7.74(1H, d, J=8.4Hz), 7.36(1H, d, J=8.4Hz), 7.15(1H, 5.43(2H, s) and 3.49(2H, s) ppm.
Step E: Preparation of [1-(4-cyanobenzyl)-1H-imidazol-5yl]acetyl 2 (S)-n-butyl-4-(1-naphthoyl)piperazine trifluoroacetate To a solution of the acid from step D (100 mg, 0.35 mmol), the amine hydrochloride salt from example step (117 mg, 0.35mmol), HOOBT (58 mg, 0.35 mmol), and triethylamine (0.123ml, 0.88 mmol) in DMF (2ml) was added EDC (75 mg, 0.38mmol). The reaction was stirred at room temperature for 16hrs, diluted with EtOAc and the organic layer washed with sat. aq NaHCO3 brine dried (Na2SO4). and evaporated in vacuo. The residue was purified by preparative HPLC (C-18; 95:5 to 5:95 water:CH3CN containing 0.1% trifluoroacetic acid; gradient elution). Lyophilisation of the collected fractions afforded the title compound as a white solid.
1 H NMR(CD30D, 400 MHz) 6 9.00-8.90(1H, 8.05-7.94(2H,m), 7.94-7.40(10H,m), 5.60-5.40(2H,m), 5.00-2.80(9H,m), 1.90- 1.15(4H,m) and 1.05-0.40(5H, m)ppm.
WO 96/30343 PCT/US96/04019 126 Anal. calc'd for C32H33N50 2 1.40 TFA; 0.55H20: C, 60.65; H, 5.19; N, 10.16. Found: C, 60.66; H, 5.17; N, 10.06.
EXAMPLE 39 2 3 -dimethylphenyl)-4-(4-imidazolylmethyl)piperazin- 2-one ditrifluoroacetic acid salt Step A: N-Methoxy-N-methyl 2 (S)-(tert-butoxycarbonylamino)hexanamide 2 (S)-(tert-Butoxycarbonylamino)hexanoic acid (24.6 g, 0.106 mol), N,O-dimethylhydroxylamine hydrochloride (15.5 g, 0.15 mol), EDC hydrochloride 22.3 g, 0.117 mol) and HOBT (14.3 g, 0.106 mol) were stirred in dry, degassed DMF (300 mL) at 20 0 C under nitrogen. N-Methylmorpholine was added to obtain pH 7. The reaction was stirred overnight, the DMF distilled under high vacuum, and the residue partitioned between ethyl acetate and 2% potassium hydrogen sulfate. The organic phase was washed with saturated sodium bicarbonate, water, and saturated brine, and dried with magnesium sulfate. The solvent was removed in vacuo to give the title compound.
Step B: 2(S)-(tert-Butoxvcarbonvlamino)hexanal A mechanically stirred suspension of lithium aluminum hydride (5.00 g, 0.131 mol) in ether (250 mL) was cooled to -45 0
C
under nitrogen. A solution of the product from Step A (28.3 g, 0.103 mol) in ether (125 mL) was added, maintaining the temperature below 0 C. When the addition was complete, the reaction was warmed to then recooled to -45 0 C. A solution of potassium hydrogen sulfate (27.3 g, 0.200 mol) in water was slowly added, maintaining the temperature below -5 0 C. After quenching, the reaction was stirred at room temperature for lh. The mixture was filtered through Celite, the ether evaporated, and the remainder partitioned between ethyl acetate and 2% potassium hydrogen sulfate. After washing with saturated WO 96/30343 PCT/US96/04019 127 brine, drying over magnesium sulfate and solvent removal, the title compound was obtained.
Step C: N-( 2 3 -Dimethylphenyl)-2(S)-(tert-butoxycarbonylamino)hexanamine 2,3-Dimethylaniline (8.32 mL, 68.3 mmol) was dissolved in dichloroethane under nitrogen. Acetic acid was added to obtain pH and sodium triacetoxyborohydride (17.2 g, 80.8 mmol) and crushed molecular sieves (4 g) were added. A solution of the product from Step B (13.3 g, 62.1 mmol) in dichloroethane (80 mL) was added slowly dropwise at 20 0 C. The reaction was stirred overnight, then quenched with saturated sodium bicarbonate solution. The aqueous layer was removed, the organic phase washed with saturated brine and dried over magnesium sulfate. Crystallization from hexane gave the title compound.
Step D: 4 -tert-Butoxycarbonyl-5(S)-n-butyl- 1-(2,3dimethylphenyl)piperazin-2-one A solution of the product from Step C (8.50 g, 26.5 mmol) in ethyl acetate (250 mL) was vigorously stirred at 0°C with saturated sodium bicarbonate (150 mL). Chloroacetyl chloride (2.33 mL, 29.1 mmol) was added, and the reaction stirred at 0°C for 1h. The layers were separated, and the ethyl acetate phase was washed with saturated brine, and dried over magnesium sulfate. The crude product was dissolved in DMF (300 mL) and cooled to 0°C under nitrogen. Sodium hydride (1.79 g, 60% dispersion in oil, 44.9 mmol) was added portionwise to maintain moderate hydrogen evolution. After 30 min, an additional amount of sodium hydride was added (0.8 The reaction was stirred another 30 min, then quenched with saturated ammonium chloride. The DMF was distilled in vacuo, and the residue partitioned between ethyl acetate and water. The organic phase was washed with water, saturated brine, and dried over magnesium sulfate.
The crude product was chromatographed on silica gel with 20-30% ethyl acetate in hexane to obtain the title compound.
WO 96/30343 PCTIUS96/04019 128 Step E: 5(S)-n-Butyl- 1-(2,3-dimethylphenyl)-4-[4-(1triphenylmethylimidazolyl)methyllpiperazin-2-one A solution of the product from Step D (0.570 g, 1.58 mmol) in ethyl acetate (50 mL) was cooled to -15°C under nitrogen.
HCI gas was bubbled through for 15 min, and the reaction solution warmed to 0°C for 2h. The solvent was removed in vacuo, and the resulting solid was dissolved in dichloroethane (20 mL). Sodium triacetoxyborohydride (0.502 g, 2.37 mmol) and 1-triphenylmethyl-4imidazolyl carboxaldehyde (0.534 g, 1.58 mmol) was added. The reaction was stirred overnight at 20'C then poured into saturated sodium bicarbonate solution. The organic phase was washed with saturated brine and dried over magnesium sulfate. Silica gel chromatography using 4% methanol in dichloromethane as eluant yielded the title compound.
Step F: 5(S)-n-Butyl-1-(2,3-dimethylphenyl)-4-(4imidazolylmethyl)piperazin-2-one ditrifluoroacetic acid salt To a solution of the compound from Step E (0.233 g, 0.40 mmol) in dichloromethane (6 mL) was added triethylsilane (0.254 mL) and trifluoroacetic acid (2 mL) were added, and the reaction stirred at for 2h. The volatiles were removed in vacuo, and the residue partitioned between hexane and water-methanol. The aqueous phase was injected onto a preparative HPLC column and purified with a mixed gradient of 15%-60% acetonitrile/0.1% TFA; 85%-40% 0.1% aqueous TFA over 50 min. The title compound was isolated after lyophilization.
FAB ms 341. Anal. Calc. for C20H28N40 2.0 TFA: C, 50.80; H, 5.15; N, 9.87. Found: C, 51.31; H, 5.41; N, 10.11.
WO 96/30343 PCTIUS96/04019 129 EXAMPLE 5(S)-n-Butyl-4- 4 -cyanobenzyl)imidazol-5-ylmethyl]-1 dimethylphenvl)piperazin-2-one ditrifluoroacetic acid salt 4-Cyanobenzylbromide (0.043 g, 0.22 mmol) was added at 0 C to a solution of 5(S)-n-butyl-l-( 2 ,3-dimethylphenyl)-4-[4-(1triphenylmethylimidazolyl)methyl]piperazin-2-one (0.120 g, 0.21 mmol) from Example 39, Step E, in acetonitrile (10 mL). After 48 h, the solvent was removed in vacuo, and the crude product dissolved in dichloromethane (6 mL). Triethylsilane (0.13 mL) and trifluoroacetic acid (2 mL) were added, and the reaction stirred at 20 0 C for 2h. The volatiles were removed in vacuo, and the residue partitioned between hexane and water-methanol. The aqueous phase was injected onto a reverse phase preparative HPLC column and purified with a mixed gradient of 30%-60% acetonitrile/0.1% TFA; 70%-40% 0.1% aqueous TFA over 50 min. The title compound was isolated after lyophilization from water-acetonitrile solution. FAB ms 456. Anal. Calc. for C28H33N50 0.7 H20 2.0 TFA: C, 55.28; H, 5.13; N, 10.07. Found: C, 55.27; H, 5.20; N, 10.41.
EXAMPLE 41 4 -Cyanobenzyl)imidazol-5-ylmethyl]-1 -(2,3-dimethylphenyl)- 2 -methoxvethyl)piperazin-2-one ditrifluoroacetic acid salt Step A: N-Methoxy-N-methyl 4 -benzyloxy-2(S)-(tertbutoxycarbonvlamino)butanamide 4 -Benzyloxy- 2 (S)-(tert-butoxycarbonylamino)butanoic acid (1.00 g, 3.23 mmol) was converted to the title compound following the procedure described in Example 39, Step A, using EDC HCI (0.680 g, 3.55 mmol). HOBT (0.436 g, 3.23 mmol) and N,Odimethylhydroxylamine hydrochloride (0.473 g, 4.85 mmol) in DMF mL) at pH 7. After workup, the title compound was obtained as a clear gum.
WO 96/30343 PCT/US96/04019 130 Step B: 4-(1-Benzyloxyethyl)-2(S)-(tert-butoxycarbonylamino) butanal The title compound was obtained by lithium aluminum hydride reduction of the product of Step A using the procedure described in Example 39, Step B.
Step C: N-( 2 3 -Dimethylphenyl)-4-( 2 -benzyloxyethyl)-2-(S)-(tertbutoxvcarbonylamino)butanamine The title compound was prepared from the product of Step C according to the procedure described in Example 39, Step B, using 2 ,3-dimethylaniline (0.505 mL, 4.14 mmol), sodium triacetoxyborohydride (1.20 g, 5.65 mmol) and crushed molecular sieves (1 g) at pH 5 in dichloroethane (20 mL). The title compound was obtained after purification on silica gel, eluting with 15% ethyl acetate in hexane.
Step D: 2 -Benzyloxyethyl)-4-tert-butoxycarbonyl 1-(2,3dimethylphenyl)piperazin-2-one The title compound was prepared from the product of Step C according to the procedure described in Example 39, Step D, using chloroacetyl chloride (0.21 mL, 2.57 mmol) in 60 mL 1:1 ethyl acetate:saturated sodium bicarbonate, followed by reaction of the crude product with sodium hydride (0.373 g, 60% dispersion in oil, 9.32 mmol) in DMF (30 mL). After workup, the crude product was chromatographed on silica gel with 30% ethyl acetate in hexane to obtain the title compound.
Step E: 4 -tert-Butoxycarbonyl- 1-(2,3-dimethylphenyl)-5(S)-(2hydroxvethyl)piperazin-2-one The product from Step D was dissolved in methanol mL) and 10% Pd/C was added (0.160 The reaction was shaken under 60 psi hydrogen overnight. The catalyst was removed by filtration, and the solvent evaporated to give the title compound.
WO 96/30343 PCT/US96/04019 131 Step F: 4 -tert-Butoxycarbonyl- 1-( 2 ,3-dimethylphenyl)-5(S)-(2methoxyethyl)piperazin-2-one The product from Step E (0.241 g, 0.688 mmol) was dissolved in DMF (10 mL) containing methyl iodide (0.21 mL, 3.44 mmol) and the stirred solution cooled to 0°C under nitrogen. Sodium hydride (0.070 g, 60% dispersion in oil, 1.72 mmol) was added and the reaction stirred for lh. The reaction was quenched with water, and the DMF removed under vacuum. The residue was partitioned between ethyl acetate and water, and the organic phase washed with saturated brine and dried over magnesium sulfate. The crude product was chromatographed on silica gel with 40% ethyl acetate in hexane to give the title compound.
Step G: 1-(2,3-Dimethylphenyl)-5(S)-(2-methoxyethyl)-4-[4-(1triphenvlmethylimidazolvl)methyllpiperazin-2-one The product from Step F (0.113 g, 0.312 mmol) was converted to the title compound according to the procedure described in Example 39, Step E, except using 30% trifluoroacetic acid in dichloromethane (10 mL) for 1 h for the initial deprotection. The volatiles were removed in vacuo, and the residue dissolved in dichloroethane. Triethylamine was added to obtain pH 5. Sodium triacetoxyborohydride (0.100 g, 0.468 mmol) and 1-triphenylmethyl-4imidazolylcarboxaldehyde (0.1164 g, 0.343 mmol) was added. The reaction was stirred overnight at 20 0 C then poured into saturated sodium bicarbonate solution. The organic phase was washed with saturated brine and dried over magnesium sulfate. Silica gel chromatography using 5% methanol in chloroform as eluant yielded the title compound.
WO 96/30343 PCTIUS96/04019 132 Step H: 4 -Cyanobenzyl)imidazol-5-ylmethyl]-1-(2,3- 2 -methoxyethyl)piperazin-2-one ditrifluoroacetic acid salt The product from Step G (0.182 g, 0.312 mmol) was converted to the title compound according to the procedure described in Example 40, using 4-cyanobenzylbromide (0.061 g, 0.312 mmol) in acetonitrile (10 mL), followed by reaction of the crude imidazolium salt with triethylsilane (0.13 mL) and trifluoroacetic acid (2 mL) in dichloromethane (6 mL). Purification was accomplished by reverse phase preparative HPLC with a mixed gradient of 0%-70% acetonitrile/0.1% TFA; 100%-30% 0.1% aqueous TFA over 60 min.
The title compound was isolated after lyophilization from water. FAB ms 458. Anal. Calc. for C27H31N502 0.35 H20 2.0 TFA: C, 53.81; H, 4.91; N, 10.21. Found: C, 53.83; H, 4.95; N, 10.29.
EXAMPLE 42 Preparation of (S)-l-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5imidazolylmethyl]-5-[2-(methanesulfonyl)ethyl]-2-piperazinone dihydrochloride Step A: Preparation of 1-triphenylmethyl-4-(hydroxymethyl)imidazole To a solution of 4-(hydroxymethyl)imidazole hydrochloride (35.0 g, 260 mmol) in 250 mL of dry DMF at room temperature was added triethylamine (90.6 mL, 650 mmol). A white solid precipitated from the solution. Chlorotriphenylmethane (76.1 g, 273 mmol) in 500 mL of DMF was added dropwise. The reaction mixture was stirred for 20 hours, poured over ice, filtered, and washed with ice water. The resulting product was slurried with cold dioxane, filtered, and dried in vacuo to provide the titled product as a white solid which was sufficiently pure for use in the next step.
WO 96/30343 PCTIUS96/04019 133 Step B: Preparation of 1-triphenylmethyl-4-(acetoxymethyl)imidazole Alcohol from Step A (260 mmol, prepared above) was suspended in 500 mL of pyridine. Acetic anhydride (74 mL, 780 mmol) was added dropwise, and the reaction was stirred for 48 hours during which it became homogeneous. The solution was poured into 2 L of EtOAc, washed with water (3 x 1 5% aq. HCI soln. (2 x 1 L), sat. aq. NaHCO3, and brine, then dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude product. The acetate was isolated as a white powder which was sufficiently pure for use in the next reaction.
Step C: Preparation of 1-( 4 imidazole hydrobromide A solution of the product from Step B (85.8 g, 225 mmol) and a-bromo-p-tolunitrile (50.1 g, 232 mmol) in 500 mL of EtOAc was stirred at 60 °C for 20 hours, during which a pale yellow precipitate formed. The reaction was cooled to room temperature and filtered to provide the solid imidazolium bromide salt. The filtrate was concentrated in vacuo to a volume 200 mL, reheated at 60 °C for two hours, cooled to room temperature, and filtered again. The filtrate was concentrated in vacuo to a volume 100 mL, reheated at 60 °C for another two hours, cooled to room temperature, and concentrated in vacuo to provide a pale yellow solid. All of the solid material was combined, dissolved in 500 mL of methanol, and warmed to 60 'C.
After two hours, the solution was reconcentrated in vacuo to provide a white solid which was triturated with hexane to remove soluble materials. Removal of residual solvents in vacuo provided the titled product hydrobromide as a white solid which was used in the next step without further purification.
WO 96/30343 PCT/US96/04019 134 Step D: Preparation of 1-(4-cyanobenzyl)-5-(hydroxymethyl)imidazole To a solution of the acetate from Step C (50.4 g, 150 mmol) in 1.5 L of 3:1 THF/water at 0 °C was added lithium hydroxide monohydrate (18.9 g, 450 mmol). After one hour, the reaction was concentrated in vacuo, diluted with EtOAc (3 and washed with water, sat. aq. NaHCO3 and brine. The solution was then dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude product as a pale yellow fluffy solid which was sufficiently pure for use in the next step without further purification.
Step E: Preparation of 1-(4-cyanobenzyl)-5imidazolecarboxaldehyde To a solution of the alcohol from Step D (21.5 g, 101 mmol) in 500 mL of DMSO at room temperature was added triethylamine (56 mL, 402 mmol), then SO03-pyridine complex (40.5 g, 254 mmol). After 45 minutes, the reaction was poured into 2.5 L of EtOAc, washed with water (4 x 1 L) and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the aldehyde as a white powder which was sufficiently pure for use in a subsequent step (Step L) without further purification.
Step F: Preparation of (S)-2-(tert-butoxycarbonylamino)-Nmethoxy-N-methyl-4-(methyvlthio)butanamide L-N-Boc-methionine (30.0 g, 0.120 mol), N,Odimethylhydroxylamine hydrochloride (14.1 g, 0.144 mol), EDC hydrochloride (27.7 g, 0.144 mol) and HOBT (19.5 g, 0.144 mol) were stirred in dry DMF (300 mL) at 20 0 C under nitrogen. More N, 0dimethylhydroxylamine hydrochloride (2.3 g, 23 mmol) was added to obtain pH 7-8. The reaction was stirred overnight, the DMF distilled to half the original volume under high vacuum, and the residue partitioned between ethyl acetate and sat. NaHCO3 soln. The organic phase was washed with saturated sodium bicarbonate, water, 10% citric acid, and WO 96/30343 PCTIUS96/04019 135 brine, and dried with sodium sulfate. The solvent was removed in vacuo to give the title compound.
Step G: Preparation of (S)-2-(tert-butoxycarbonylamino)-4- (methylthio)butanal A suspension of lithium aluminum hydride (5.02 g, 0.132 mol) in ether (500 mL) was stirred at room temperature for one hour.
The solution was cooled to -50 °C under nitrogen, and a solution of the product from Step F (39.8 g, ca. 0.120 mol) in ether (200 mL) was added over 30 min, maintaining the temperature below -40 When the addition was complete, the reaction was warmed to 5°C, then recooled to -45°C. Analysis by tlc revealed incomplete reaction. The solution was rewarmed to 5 stirred for 30 minutes, then cooled to A solution of potassium hydrogen sulfate (72 g, 0.529 mol) in 200 mL water was slowly added, maintaining the temperature below The mixture was warmed to 5 filtered through Celite, and concentrated in vacuo to provide the title aldehyde.
Step H: Preparation of (S)-2-(tert-butoxycarbonylamino)-N-(3chlorophenyl)-4-(methylthio)butanamine To a solution of 3-chloroaniline (10.3 mL, 97.4 mmol), the product from Step G (23.9 g, 97.4 mmol), and acetic acid (27.8 mL, 487 mmol) in dichloroethane (250 mL) under nitrogen was added sodium triacetoxyborohydride (41.3 g, 195 mmol). The reaction was stirred overnight, then quenched with saturated sodium bicarbonate solution. The solution was diluted with CHC13, and the organic phase was washed with water, 10% citric acid and brine. The solution was dried over sodium sulfate and concentrated in vacuo to provide the crude product (34.8 g) which was chromatographed on silica gel with 20% ethyl acetate in hexane to obtain the title compound.
WO 96/30343 PCTIUS96/04019 136- Step I: Preparation of (S)-4-(tert-butoxycarbonyl)-1-(3chlorophenyl)-5-r2-(methylthio)ethyllpiperazin-2-one A solution of the product from Step H (22.0 g, 63.8 mmol) in ethyl acetate (150 mL) was vigorously stirred at 0°C with saturated sodium bicarbonate (150 mL). Chloroacetyl chloride (5.6 mL, 70.2 mmol) was added dropwise, and the reaction stirred at 0°C for 2h. The layers were separated, and the ethyl acetate phase was washed with citric acid and saturated brine, and dried over sodium sulfate. After concentration in vacuo, the resulting crude product (27.6 g) was dissolved in DMF (300 mL) and cooled to 0°C under argon. Cesium carbonate (63.9 g, 196 mmol) was added, and the reaction was stirred for two days, allowing it to warm to room temperature. Another portion of cesium carbonate (10 g, 30 mmol) was added, and the reaction was stirred for 16 hours. The DMF was distilled in vacuo, and the residue partitioned between ethyl acetate and water. The organic phase was washed with saturated brine, and dried over sodium sulfate.
The crude product was chromatographed on silica gel with 20-25% ethyl acetate in hexane to obtain the title compound.
Step J: Preparation of (S)-4-(tert-butoxycarbonyl)-l-(3- 2 -(methanesulfonyl)ethyllpiperazin-2-one A solution of the product from Step I (14.2 g, 37 mmol) in methanol (300 mL) was cooled to 0 and a solution of magnesium monoperoxyphthalate (54.9 g, 111 mmol) in 210 mL MeOH was added over 20 minutes. The ice bath was removed, and the solution was allowed to warm to room temperature. After 45 minutes, the reaction was concentrated in vacuo to half the original volume, then quenched by the addition of 2N Na2S203 soln. The solution was poured into EtOAc and sat NaHCO3 solution, and the organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude sulfone. This material was chromatographed on silica gel with 60-100% ethyl acetate in hexane to obtain the titled compound.
WO 96/30343 PCTIUS96/04019 137 Step K: Preparation of (S)-1-(3-chlorophenyl)-5-[2- (methanesulfonyl)ethyllpiperazin-2-one Through a solution of Boc-protected piperazinone from Step J (1.39 g, 3.33 mmol) in 30 mL of EtOAc at 0 °C was bubbled anhydrous HC1 gas. The saturated solution was stirred for 35 minutes, then concentrated in vacuo to provide the hydrochloride salt as a white powder. This material was suspended in EtOAc and treated with dilute aqueous NaHCO3 solution. The aqueous phase was extracted with EtOAc, and the combined organic mixture was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. The resulting amine was reconcentrated from toluene to provide the titled material suitable for use in the next step.
Step L: Preparation of (3-chlorophenyl)-4- cyanobenzyl)-5-imidazolylmethyl]-5-[2-(methanesulfonyl)ethyl] -2-piperazinone dihydrochloride To a solution of the amine from Step K (898 mg, 2.83 mmol) and imidazole carboxaldehyde from Step E (897 mg, 4.25 mmol) in 15 mL of 1,2-dichloroethane was added sodium triacetoxyborohydride (1.21 g, 5.7 mmol). The reaction was stirred for 23 hours, then quenched at 0 °C with sat. NaHCO3 solution. The solution was poured into CHC13, and the aqueous layer was backextracted with CHC13. The combined organics were washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. The resulting product was purified by silica gel chromatography (95:5:0.5-90:10:0 EtOAc:MeOH:NH4Cl), and the resultant product was taken up in EtOAc/methanol and treated with 2.1 equivalents of 1 M HC1/ether solution. After concentrated in vacuo, the product dihydrochloride was isolated as a white powder.
WO 96/30343 PCT/US96/04019 138 EXAMPLE 43 Preparation of (S)-1-(3-chlorophenyl)-4- [1-(4-cyanobenzyl)-5imidazolylmethyl]-5-[2-(ethanesulfonyl)ethyl]-2-piperazinone dihydrochloride Step A: Preparation of (S)-N-(tert-butoxycarbonyl)homoserine lactone To a solution of (S)-homoserine lactone hydrochloride (11.0 g, 79.9 mmol) and di-tert-butylpyrocarbonate (19.2 g, 88.0 mmol) in 160 mL of dichloromethane at 0 °C was added diisopropylethylamine (13.9 mL, 79.9 mmol) over 3 min. The solution was allowed to warm to room temperature. After 3 hours, another portion of di-tert-butylpyrocarbonate (1.75 g, 8.0 mmol) and diisopropylethylamine (0.70 mL, 4.0 mmol) were added, and the mixture was stirred for an additional 2.5 hours. The solution was washed with 10% citric acid, sat. NaHCO3, and brine, dried (Na2SO4), filtered, and concentrated in vacuo. The resulting material was purified by silica gel chromatography (50% EtOAc/hexane) to provide pure titled compound.
Step B: Preparation of (S)-N-(tert-butoxycarbonyl)homoserine lactol To a solution of the lactone from Step A (7.0 g, 35 mmol) in 175 mL of THF at -78 °C was added diisobutylaluminum hydride (72.0 mL, 1M in THF, 72 mmol) dropwise, while maintaining the reaction temperature below -72 After 3 hours, another portion of diisobutylaluminum hydride (10.0 mL, 10 mmol) was added, followed by another after 1 hour (20.0 mL, 20 mmol). After an additional hour, the reaction was quenched with EtOAc at -78 followed by sat. Na- K-tartrate soln., then warmed to room temperature. The solution was poured into EtOAc, washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. The resulting material was purified by silica gel chromatography (50% EtOAc/hexane) to give the titled lactol.
WO 96/30343 PCT/US96/04019 139 Step C: Preparation of (S)-3-(tert-butoxycarbonylamino)-N-(3chlorophenyl)-4-hydroxy-1 -butanamine To a solution of lactol from Step B (4.49 g, 22.2 mmol) and 3-chloroaniline (2.58 mL. 24.4 mmol) in 50 mL of dichloromethane at room temperature was added acetic acid (1.27 mL.
22.2 mmol). After 10 min, sodium triacetoxyborohydride (6.59 g, 31.1 mmol) was added, and the solution was stirred for 1.5 hours. The reaction was quenched with sat. aq. NaHCO3, diluted with CH2C12, and the layers were separated. The organic material was dried (Na2SO4), filtered, and concentrated in vacuo to provide a solid which was purified by silica gel chromatography (EtOAc/hexane) to give the titled amine.
Step D: Preparation of (S)-N-[2-(tert-butoxycarbonylamino)-4hydroxybutyll- 2 -chloro-N-(3-chlorophenyl)acetamide The aniline derivative from Step C (5.29 g, 16.9 mmol) was dissolved in 60 mL of EtOAc and 60 mL of sat. NaHCO3 soln., then cooled to 0 With vigorous stirring, chloroacetyl chloride (1.48 mL. 18.5 mmol) was added dropwise. After 2 hours, the reaction was diluted with water and EtOAc, and the organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled chloroacetamide, which was used without further purification.
Step E: Preparation of (S)-4-(tert-butoxycarbonyl)-1-(3chlorophenyl)-5-(2-hydroxvethyl)piperazin-2-one To a solution of the chloroacetamide from Step D (6.32 g, 16.1 mmol) in 80 mL of DMF at 0 °C was added cesium carbonate (15.8 g, 48.3 mmol). The solution was stirred until tlc analysis indicated consumption of the starting material (ca. 5 hours). The solution was poured into EtOAc, washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude product. This material was purified by silica gel chromatography WO 96/30343 PCT/US96/04019 140- (99:1:0-95:5:0.15 CHC13:MeOH:NH40H) to yield the product containing a minor amount of DMF impurity.
Step F: Preparation of (S)-4-(tert-butoxycarbonyl)-l-(3chlorophenyl)-5-[2-(methanesulfonyloxy)ethyl]piperazin-2one To a solution of the alcohol from Step E (3.58 g, 10.1 mmol) in 50 mL of dichloroilethane at 0 °C was added diisopropylethylamine (3.5 mL, 20.2 mmol), followed by methanesulfonyl chloride (0.936 mL, 12.1 mmol). The solution was stirred for 45 minutes, then quenched with 10% citric acid. The solution was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude product which was used in the next step without further purification.
Step G: Preparation of (S)-4-(tert-butoxycarbonyl)-1-(3r2-(ethylthio)ethyllpiperazin-2-one To a solution of the mesylate from Step F (3.6 g, 8.3 mmol) in 100 mL of DMF at 0 °C was added sodium ethanethiolate (1.4 g, 16.6 mmol). After 2 hours, the reaction was poured into EtOAc, washed with sat. NaHCO3 and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude product which was used in the next step without further purification.
Step H: Preparation of (S)-4-(tert-butoxycarbonyl)-l-(3chlorophenyl)-5-[2-(ethanesulfonyl)ethyllpiperazin-2-one To solution of the product from Step G (3.12 g, 7.82 mmol) in methanol (50 mL) was added a solution of magnesium monoperoxyphthalate (11.6 g, 23.5 mmol) in 50 mL MeOH at room temperature. After 45 minutes, the reaction was quenched by the addition of 2N Na2S203 soln. The solution was poured into EtOAc and sat NaHCO3 solution, and the organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the WO 96/30343 PCT/US96/04019 141 crude sulfone. This material was chromatographed on silica gel with 2% methanol in chloroform to obtain the titled compound.
Step I: Preparation of (S)-l-(3-chlorophenyl)-5-[2- (ethanesulfonvl)ethyllpiperazin-2-one Through a solution of the Boc-protected piperazinone from Step H (1.75 g, 4.06 mmol) in 20 mL of EtOAc at 0 °C was bubbled anhydrous HC1 gas. The saturated solution was stirred for 30 minutes, then concentrated in vacuo to provide the hydrochloride of title compound as a white powder. This material was suspended in EtOAc and treated with dilute aqueous NaHCO3 solution. The aqueous phase was extracted with EtOAc, and the combined organic mixture was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo.
The resulting titled amine was reconcentrated from toluene to provide the title compound suitable for use in the next step.
Step J: Preparation of (S)-l-(3-chlorophenyl)-4-[1-(4cyanobenzyl)-5-imidazolylmethyl]-5-[2- (ethanesulfonyl)ethyll-2-piperazinone dihydrochloride To a solution of the amine from Step I (480 mg, 1.45 mmol), imidazole carboxaldehyde from Step E of Example 42 (460 mg, 2.2 mmol), and acetic acid (0.415 mL, 7.25 mmol) in 10 mL of 1,2dichloroethane was added sodium triacetoxyborohydride (615 mg, 2.9 mmol). The reaction was stirred for 18 hours, then quenched at 0 °C with sat. NaHCO3 solution. The solution was poured into CH2C12, and the organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. The resulting product was purified by silica gel chromatography MeOH:CHCl3), to give the desired product and less polar boron complex. The latter compound was taken up in dichloromethane (1 mL) and benzene (5 mL), treated with npropylamine (1 mL) for 18 hours, and concentrated in vacuo. The residue was purified by silica gel chromatography MeOH:CHCl3), combined with the former batch, taken up in EtOAc/methanol, and treated with 2.1 equivalents of 1 M HC1/ether WO 96/30343 PCTIUS96/04019 142 solution. After concentrated in vacuo, the product dihydrochloride was isolated as a white powder.
EXAMPLE 44 Preparation of (S)-l-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5- 2 -(ethanesulfonyl)methyl]-2-piperazinone dihydrochloride Step A: Preparation of (S)-2-(tert-butoxycarbonylamino)-N-(3chlorophenvl)-3-[(triphenyvlmethyl)thio-1 -propanamine To a solution of 3-chloroaniline (0.709 mL. 6.70 mmol) in mL of dichloromethane at room temperature was added 1.2 g of crushed 4A molecular sieves. Sodium triacetoxyborohydride (3.55 g, 16.7 mmol) was added, followed by dropwise addition of Nmethylmorpholine to achieve a pH of 6.5. L-S-Trityl-N-Boc-cysteinal (3.15 g, 7.04 mmol) (prepared according to S.L. Graham et al. J. Med.
Chem., (1994) Vol. 37, 725-732) was added, and the solution was stirred for 48 hours. The reaction was quenched with sat. aq. NaHCO3, diluted with EtOAc, and the layers were separated. The organic material was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide an oil which was purified by silica gel chromatography (15% EtOAc/hexane) to give the title amine.
Step B: Preparation of (S)-N-[2-(tert-butoxycarbonylamino)-3- ((triphenylmethyl)thio)propyl]-2-chloro-N-(3chlorophenyl)acetamide The aniline derivative from Step A (2.77 g, 4.95 mmol) was dissolved in 73 mL of EtOAc and 73 mL of sat. NaHCO3 soln., then cooled to 0 With vigorous stirring, chloroacetyl chloride (0.533 mL. 6.69 mmol) was added dropwise. After 3 hours, the reaction was diluted with water and EtOAc, and the organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo WO 96/30343 PCTIUS96/04019 143to provide crude titled chloroacetamide which was used without further purification.
Step C: Preparation of 4 -(tert-butoxycarbonyl)-l-(3chlorophenyl)-5- [S-(triphenylmethyl)thiomethyl]piperazin- 2-one To a solution of chloroacetamide from Step B (3.29 g crude, theoretically 4.95 mmol) in 53 mL of DMF at 0 °C was added cesium carbonate (4.84 g, 14.85 mmol). The solution was stirred for 48 hours, allowing it to warm to room temperature. The solution was poured into EtOAc, washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude product as an oil. This material was purified by silica gel chromatography EtOAc/hexane) to yield the product as a white solid.
Step D: Preparation of 4 -(tert-butoxycarbonyl)-1-(3chlorophenyl)-5-(thiomethyl)piperazin-2-one A solution of piperazinone from Step C (625 mg, 1.04 mmol) in degassed EtOAc (38 mL) and EtOH (12 mL) was warmed to 30 A solution of AgNO3 (177 mg, 1.04 mmol) and pyridine (0.084 mL, 1.04 mmol) in 8 mL of EtOH was added, and the solution was heated to reflux. After 45 minutes, the reaction was concentrated in vacuo, then redissolved in 26 mL of degassed EtOAc. Through this solution was bubbled H2S gas for 2.5 minutes, then activated charcoal was added after 4 minutes. The material was filtered through celite and rinsed with degassed EtOAc, concentrated in vacuo, then reconcentrated from degassed CH2C12 to provide the crude product which was used without further purification.
Step E: Preparation of (S)-4-(tert-butoxycarbonyl)-l-(3- [(ethyvlthio)methvllpiperazin-2-one A solution of the thiol from Step D (ca. 1.04 mmol) in 3 mL of THF was added via cannula to a suspension of NaH (51.4 mg, disp. in mineral oil, 1.28 mmol) in 2 mL THF at 0 After WO 96/30343 PCT/US96/04019 144minutes, iodoethane was added (0.079 mL, 0.988 mmol), and the solution was stirred for 1.5 hours. The reaction was poured into EtOAc, washed with sat. NaHCO3 and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude product. This material was purified by silica gel chromatography (1 MeOH/CH2Cl2) to yield the titled product.
Step F: Preparation of (S)-4-(tert-butoxycarbonyl)- 1-(3- [(ethanesulfonyl)methyllpiperazin-2-one To a solution of the sulfide from Step E (217 mg, 0.563 mmol) in 3 mL of MeOH at 0 °C was added a solution of magnesium monoperoxyphthalate (835 mg, 1.69 mmol) in 2 mL MeOH. The reaction was stirred overnight, allowing it to warm to room temperature. The solution was cooled to 0 quenched by the addition of 4 mL 2N Na2S203 soln., then concentrated in vacuo. The residue was partitioned between EtOAc and sat NaHCO3 solution, and the organic layer was washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude sulfone as a white waxy solid.
Step G: Preparation of (S)-1-(3-chlorophenyl)-4-[1-(4cyanobenzyl)-5-imidazolylmethyl]-5-[2- (ethanesulfonyl)methyll-2-piperazinone dihydrochloride To a solution of the Boc-protected piperazinone from Step F (224 mg, 0.538 mmol) in 5 mL of dichloromethane at 0 °C was added mL of trifluoroacetic acid (TFA). After 45 minutes, the reaction was concentrated in vacuo, then azeotroped with benzene to remove the excess TFA. The residue was taken up in 4 mL of 1,2-dichloroethane and cooled to 0 To this solution was added 4A powdered molecular sieves (340 mg), followed by sodium triacetoxyborohydride (285 mg, 1.34 mmol) and several drops of triethylamine to achieve pH 6. The imidazole carboxaldehyde from Step E of Example 42 (125 mg, 0.592 mmol) was added, and the reaction was stirred at 0 After 2 days, the reaction was poured into EtOAc, washed with dilute aq. NaHCO3, WO 96/30343 PCT/US96/04019 145 and brine, dried (Na2SO4), filtered, and concentrated in vacuo. The crude product was taken up in methanol and injected onto a preparative HPLC column and purified with a mixed gradient of 15%-50% acetonitrile/0.1% TFA; 85%-50% 0.1% aqueous TFA over 60 minutes.
After concentration in vacuo, the resultant product was partitioned between dichloromethane and aq. NaHCO3 soln., and the aqueous phase was extracted with CH2C12. The organic solution was washed with brine, dried (Na2SO4), filtered, and concentrated to dryness to provide the product free base, which was taken up in CH2C12 and treated with 2.1 equivalents of 1 M HCl/ether solution. After concentrated in vacuo, the product dihydrochloride was isolated as a white powder.
EXAMPLE Preparation of (S)-1-(3-chlorophenyl)-4- [1-(4-cyanobenzyl)-5imidazolylmethyl]-5-[N-ethyl-2-acetamido]-2-piperazinone dihydrochloride Step A: Preparation of (S)-4-(tert-butoxycarbonyl)-1-(3chlorophenvl)-5- r2-(oxo)ethyllpiperazin-2-one To a solution of oxalyl chloride (0.608 mL, 6.97 mmol) in dichloromethane (40 mL) at -78 °C was added DMSO (0.990 mL, 13.9 mmol) over 2-3 minutes. The solution was stirred for 10 minutes, then a solution of the alcohol from Step E of Example 43 (2.06 g, 5.81 mmol) in 10 mL of dichloromethane was added over 5 minutes, keeping the reaction temperature below -70 The reaction was stirred for minutes, then triethylamine (2.43 mL) was added, and the reaction was stirred at -78 °C for 5 minutes, then allowed to warm to room temperature. After 45 minutes, the solution was poured into dichloromethane, and washed with sat. NH4Cl soln., 10% citric acid soln., water, and brine. The solution was dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled aldehyde.
WO 96/30343 PCTIUS96/04019 146 Step B: Preparation of (carboxymethyl)- 1-(3-chlorophenyl)piperazin-2-one To a solution of the aldehyde from Step A (1.52 g, 4.31 mmol) in 2-methyl-2-propanol (50 mL) and 2-methyl-2-butene (10 mL) at room temperature was added a solution of sodium chlorite (585 mg, 5.17 mmol) and sodium dihydrogenphosphate (595 mg, 4.31 mmol) in mL of water. The reaction turned yellow, then slowly faded to light pink over 45 minutes. The solution was poured into EtOAc, and washed with sat. sodium bisulfite soln. The aqueous layer was acidified to pH 3 with 2.75 M KHSO4 soln., and extracted several times with EtOAc. The combined organic extracts were dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled carboxylic acid.
Step C: Preparation of (S)-4-(tert-butoxycarbonyl)-5-[N-ethyl-2acetamidol-1 -(3-chlorophenyl)piperazin-2-one The product from Step B (200 mg, 0.56 mmol), ethylamine hydrochloride (114 mg, 1.4 mmol), EDC hydrochloride (140 mg, 0.73 mmol) and HOBT hydrate (113 m g, 0.84 mmol) were stirred in dry DMF (3 mL) at 0°C under nitrogen. After one hour, the solution was warmed to room temperature, and stirred overnight. The DMF was removed in vacuo, and the residue was partitioned between ethyl acetate and water. The organic phase was washed with 10% citric acid, saturated sodium bicarbonate, water, and brine, and dried with sodium sulfate. The solvent was removed in vacuo to give the title compound.
Step D: Preparation of (S)-1-(3-chlorophenyl)-4-[1-(4cyanobenzyl)-5-imidazolylmethyl]-5-[N-ethyl-2-acetamido]- 2-piperazinone dihydrochloride The titled product was prepared from the product of Step C (184 mg, 0.47 mmol) in analogy to Example 42, Steps K and L. The product was isolated as a white solid.
WO 96/30343 PCT/US96/04019 147 EXAMPLE 46 Preparation of (±)-5-(2-butynyl)-l-(3-chlorophenyl)-4-[1-(4cyanobenzyl)-5-imidazolylmethyll-2-piperazinone dihydrochloride Step A: Preparation of 1-(methanesulfonvl)-2-butyne To a solution of 2-butynol (10.0 mL, 134 mmol) in 200 mL of dichloromethane at 0 °C was added methanesulfonyl chloride (23.4 g, 134 mmol), followed by dropwise addition of diisopropylethylamine (30 mL, 174 mmol). After 1.5 hours, the solution was poured into 0.5 N KHSO4 soln, and the organic layer was washed with brine. The solution was dried over Na2SO4, filtered, and concentrated in vacuo to provide the titled product.
Step B: Preparation of (±)-ethyl 2-[(phenylmethyl)imino]-4hexynoate To a solution of glycine ethyl ester hydrochloride (10.11 g, 72.4 mmol) in 200 mL of dichloromethane was added benzaldehyde (7.36 mL, 72.4 mmol), triethylamine (20.0 mL, 143 mmol), and magnesium sulfate The solution was stirred at room temperature for 16 hours, filtered through a glass frit, and concentrated in vacuo.
The residue was partitioned between ether and water, and the organic layer was washed with brine. The solution was dried over Na2SO4, filtered, and concentrated in vacuo to provide a pale yellow oil. A portion of this oil (9.90 g, 51.8 mmol) was dissolved in 200 mL of THF and cooled to -78 °C under nitrogen atmosphere. A solution of potassium tert-butoxide in THF (51.8 mL of 1 M, 51.8 mmol) was added dropwise to produce a bright red solution. After 20 minutes, a solution of the mesylate from Step A (8.05 g, 54,4 mmol) in 20 mL of THF was added dropwise via cannula, and the solution was allowed to warm to room temperature. After 2 hours, the reaction was poured into EtOAc and washed with sat. NaHCO3 soln. and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled product.
WO 96/30343 PCTIUS96/04019 148 Step C: Preparation of (±)-ethyl 2-[(tert-butoxycarbonyl)amino]-4hexvnoate A solution of the product from Step B (ca. 51.8 mmol) was stirred at room temperature in 5% aqueous HC1 solution (100 mL).
After 12 hours, the solution was concentrated in vacuo to give an orange oil. This product was taken up in 50 mL of THF and sat.
NaHCO3 soln. was added (50 mL), followed by di-tertbutylpyrocarbonate (11.3 g, 51.8 mmol) at room temperature. After 6 hours, the reaction was poured into EtOAc and washed with sat.
NaHCO3 soln. and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled product.
Step D: Preparation of (±)-2-[(tert-butoxycarbonyl)amino]-4hexvnoic acid To a solution of the product from Step C (ca. 51.8 mmol) in THF (100 mL) and water (20 mL) was added at 0 °C a solution of lithium hydroxide monohydrate (6.5 g, 155 mmol). The solution was stirred for 1 hour at 0 then warmed to room temperature. After 48 hours, the solution was concentrated in vacuo. The aqueous mixture was extracted with EtOAc, acidified at 0 °C with 10% aq. HCI soln., then extracted with three portions of dichloromethane. The combined dichloromethane extracts were dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled product as an orange oil.
Step E: Preparation of (±)-2-(tert-butoxycarbonylamino)-Nmethoxy-N-methyl-4-hexvnamide The product from Step D (10.58 g, 46.6 mmol), N,Odimethylhydroxylamine hydrochloride (9.09 g, 93.2 mmol), HOBT a 30 hydrate (9.44 g, 69.9 mmol) and triethylamine (13.0 mL, 93.2 mmol) were stirred in dry DMF (150 mL) at 0°C under nitrogen. EDC hydrochloride (11.5 g, 60.6 mmol) was added, and the reaction was stirred for 3 hours. The solution was partitioned between 2:1 ethyl acetate:hexane and water, washed with water, 10% aq. HC1, sat.
WO 96/30343 PCTIUS96/04019 149 NaHCO3 soln and brine, then dried with sodium sulfate. The solvent was removed in vacuo to give the title compound as an orange oil Step F: Preparation of 2 -(tert-butoxycarbonylamino)-4-hexvnal A suspension of lithium aluminum hydride (1.56 g, 41.1 mmol) in ether (150 mL) was stirred at room temperature for minutes. The solution was cooled to -55 °C under nitrogen, and a solution of the product from Step E (11.10 g, 41.1 mmol) in ether (150 mL) was added over 15 min, maintaining the temperature below -50 °C.
When the addition was complete, the reaction was warmed to 5 then recooled to -40 A solution of potassium hydrogen sulfate (21.8 g) in 25 mL water was slowly added, maintaining the temperature below The mixture was warmed to room temperature and stirred for one hour, filtered through Celite, and concentrated in vacuo to provide the title aldehyde.
Step G: Preparation of 2 -(tert-butoxycarbonylamino)-N-(3chlorophenyl)-4-butynamine To a 0 °C solution of 3-chloroaniline (4.33 mL, 40.9 mmol), the product from Step F (ca. 41 mmol), and crushed 4 A molecular sieves (10 g) in dichloroethane (100 mL) under nitrogen was added sodium triacetoxyborohydride (12.9 g, 61.5 mmol). The reaction was stirred for one hour, then warmed to room temperature. After 3 hours, the solution was poured into EtOAc and washed with water, sat.
NaHCO3 soln. and brine. The solution was dried over sodium sulfate and concentrated in vacuo to provide the crude product.
Step H: Preparation of (±)-N-[2-(tert-butoxycarbonylamino)-4hexynyll-2-chloro-N-(3-chlorophenyl)acetamide A solution of the product from Step G (1.68 g, 5.22 mmol) and triethylamine (1.20 mL, 8.61 mmol) in 15 mL of CH2C12 was cooled to 0 Chloroacetyl chloride (0.457 mL, 5.74 mmol) was added dropwise, and the reaction was maintained at 0 °C with stirring.
After 30 minutes, another portion of chloroacetyl chloride (0.20 mL) WO 96/30343 PCT/US96/04019 150 and triethylamine (0.5 mL) was added dropwise. After 30 min, the reaction was poured into EtOAc and washed with 10% aq. HC1, sat. aq.
NaHCO3 soln., and brine. The solution was dried (Na2SO4), filtered, and concentrated in vacuo to provide a brown oil This material was purified by silica gel chromatography (20-35% EtOAc/hexane) to yield the titled product.
Step I: Preparation of 4 -(tert-butoxycarbonyl)-5-(2-butynyl)- 1-(3-chlorophenyl)-2-piperazinone To a solution of the chloroacetamide from Step H (1.68 g, 4.23 mmol) in 15 mL of dry DMF at 0 °C was added Cs2CO3 (3.08 g, 9.48 mmol). The solution was stirred for 30 minutes, then allowed to warm to room temperature. After 14 hours, the reaction was poured into 50% EtOAc/hexane, washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the crude product. This material was purified by silica gel chromatography (20-40% EtOAc/hexane) to yield the titled product.
Step J: Preparation of (±)-5-(2-butynyl)-1-(3-chlorophenyl)-4-[1- (4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone dihydrochloride To a solution of the Boc-protected piperazinone from Step I (1.03 g, 2.85 mmol) in 7 mL of dichloromethane at 0 °C was added 4 mL of trifluoroacetic acid (TFA). After 4 hours, the reaction was warmed to room temperature, and stirred an additional 6 hours. The solution was concentrated in vacuo, then azeotroped with benzene to remove the excess TFA. A portion of the residue (255 mg, 0.678 mmol) was taken up in 6 mL of 1,2-dichloroethane and cooled to 0 °C.
To this solution was added 4A powdered molecular sieves (600 mg), A 30 followed by sodium triacetoxyborohydride (214 mg, 1.02 mmol). The imidazole carboxaldehyde from Step E of Example 42 (186 mg, 0.881 mmol) was added, and the reaction was stirred at 0 After 24 hours, the reaction was poured into EtOAc, washed with dilute aq. NaHCO3, and brine, dried (Na2SO4), filtered, and concentrated in vacuo. This WO 96/30343 PCTIUS96/04019 151 material was purified by silica gel chromatography MeOH:CH2Cl2) to yield a white foam which was taken up in CH2C12 and treated with 2.1 equivalents of 1 M HCl/ether solution. After concentrated in vacuo, the product dihydrochloride was isolated as a white powder.
EXAMPLE 47 Preparation of 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)imidazolylmethyll-2-piperazinone dihydrochloride Step A: Preparation of N-(3-chlorophenyl)ethylenediamine hydrochloride To a solution of 3-chloroaniline (30.0 mL, 284 mmol) in 500 mL of dichloromethane at 0 °C was added dropwise a solution of 4 N HCI in 1,4-dioxane (80 mL, 320 mmol HC1). The solution was warmed to room temperature, then concentrated to dryness in vacuo to provide a white powder. A mixture of this powder with 2oxazolidinone (24.6 g, 282 mmol) was heated under nitrogen atmosphere at 160 °C for 10 hours, during which the solids melted, and gas evolution was observed. The reaction was allowed to cool, forming the crude diamine hydrochloride salt as a pale brown solid.
Step B: Preparation of N-(tert-butoxycarbonyl)-N'-(3chlorophenyl)ethylenediamine The amine hydrochloride from Step A (ca. 282 mmol, crude material prepared above) was taken up in 500 mL of THF and 500 mL of sat. aq. NaHCO3 soln., cooled to 0 oC, and di-tertbutylpyrocarbonate (61.6 g, 282 mmol) was added. After 30 h, the reaction was poured into EtOAc, washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled carbamate as a brown oil which was used in the next step without further purification.
WO 96/30343 PCT/US96/04019 152 Step C: Preparation of N-[2-(tert-butoxycarbamoyl)ethyl]-N-(3chlorophenvl)-2-chloroacetamide A solution of the product from Step B (77 g, ca. 282 mmol) and triethylamine (67 mL, 480 mmol) in 500 mL of CH2C12 was cooled to 0 Chloroacetyl chloride (25.5 mL, 320 mmol) was added dropwise, and the reaction was maintained at 0 °C with stirring. After 3 h, another portion of chloroacetyl chloride (3.0 mL) was added dropwise. After 30 min, the reaction was poured into EtOAc (2 L) and washed with water, sat. aq. NH4Cl soln, sat. aq. NaHCO3 soln., and brine. The solution was dried (Na2SO4), filtered, and concentrated in vacuo to provide the chloroacetamide as a brown oil which was used in the next step without further purification.
Step D: Preparation of 4-(tert-butoxycarbonyl)-1-(3-chlorophenyl)- 2-piperazinone To a solution of the chloroacetamide from Step C (ca. 282 mmol) in 700 mL of dry DMF was added K2CO3 (88 g, 0.64 mol).
The solution was heated in an oil bath at 70-75 'C for 20 hours, cooled to room temperature, and concentrated in vacuo to remove ca. 500 mL of DMF. The remaining material was poured into 33% EtOAc/hexane, washed with water and brine, dried (Na2SO4), filtered, and concentrated in vacuo to provide the product as a brown oil. This material was purified by silica gel chromatography (25-50% EtOAc/hexane) to yield pure product, along with a sample of product (ca. 65% pure by HPLC) containing a less polar impurity.
Step E: Preparation of 1-(3-chlorophenyl)-2-piperazinone Through a solution of Boc-protected piperazinone from Step D (17.19 g, 55.4 mmol) in 500 mL of EtOAc at -78 °C was bubbled anhydrous HCI gas. The saturated solution was warmed to 0 and stirred for 12 hours. Nitrogen gas was bubbled through the reaction to remove excess HC1, and the mixture was warmed to room temperature. The solution was concentrated in vacuo to provide the hydrochloride as a white powder. This material was taken up in 300 WO 96/30343 PCT/US96/04019 153 mL of CH2C12 and treated with dilute aqueous NaHCO3 solution. The aqueous phase was extracted with CH2C12 (8 x 300 mL) until tic analysis indicated complete extraction. The combined organic mixture was dried (Na2SO4), filtered, and concentrated in vacuo to provide the titled free amine as a pale brown oil.
Step: Preparation of 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5imidazolylmethyll-2-piperazinone dihydrochloride To a solution of the amine from Step E (55.4 mmol, prepared above) in 200 mL of 1,2-dichloroethane at 0 °C was added 4A powdered molecular sieves (10 followed by sodium triacetoxyborohydride (17.7 g, 83.3 mmol). The imidazole carboxaldehyde from Step E of Example 42 (11.9 g, 56.4 mmol) was added, and the reaction was stirred at 0 oC. After 26 hours, the reaction was poured into EtOAc, washed with dilute aq. NaHCO3, and the aqueous layer was back-extracted with EtOAc. The combined organics were washed with brine, dried (Na2SO4), filtered, and concentrated in vacuo. The resulting product was taken up in 500 mL of 5:1 benzene:CH2Cl2, and propylamine (20 mL) was added. The mixture was stirred for 12 hours, then concentrated in vacuo to afford a pale yellow foam. This material was purified by silica gel chromatography MeOH/CH2Cl2), and the resultant white foam was taken up in CH2C12 and treated with 2.1 equivalents of 1 M HCl/ether solution.
After concentrated in vacuo, the product dihydrochloride was isolated as a white powder.
EXAMPLE 48 5(S)-Butyl-4- [1 -(4-cyanobenzyl)-2-methyl-5-imidazolylmethyl]- 1- (2,3dimethylphenvl)-piperazin-2-one dihydrochloride WO 96/30343 PCT/US96/04019 154 Step A: 4 4 -Bromo-5-hydroxymethyl-2-methylimidazole was prepared according to the procedure described by S. P. Watson, Synthetic Communications, 22, 2971-2977 (1992). A solution of 4bromo-5-hydroxymethyl-2-methylimidazole (4.18 g, 21.9 mmol) was refluxed with manganese dioxide (16.1 g) in 1:1 methylene chloride:dioxane (200 mL) for 16 h. The cooled reaction was filtered through celite and concentrated to yield the title compound as a pale yellow solid. IH NMR (CDC1 3 300 MHz) 8 9.57 (1H, 2.52 (3H, s).
Step B: 4-Bromo- 1-(4-cyanobenzyl)-2-methylimidazole-5carboxaldehyde 4-Cyanobenzylbromide (1.05 g, 5.39 mmol) was added to a solution of 4 -bromo-2-methylimidazole-5-carboxaldehyde (1.02 g, 5.39 mmol) in dimethylacetamide (15 mL). The solution was cooled to 0 C and powdered potassium carbonate (0.745 g, 5.39 mmol) added.
The reaction was stirred at -10 0 C for 2 h, and a further 4 h at The reaction was diluted with water and extracted with ethyl acetate.
The organic phase was washed with water, saturated brine, and dried over magnesium sulfate. Solvent evaporation yielded a white solid. 'H NMR (CDC1 3 400 MHz) 8 9.68 (1H, 7.64 (2H, d, J=7 Hz) 7.15 (2H, d, J=7Hz) 5.59 (2H, 2.40 (3H, s).
Step C: 1-( 4 A solution of 4-bromo-l-(4-cyanobenzyl)-2- (1.33 g, 4.37 mmol) and imidazole (0.600 g, 8.74 mmol) in 1:1 ethyl acetate-alcohol (150 mL) was stirred with 10% palladium on carbon (0.020 g) under 1 atm hydrogen. After 2 h, the reaction was filtered through celite and concentated to give the title compound as a white solid. 1 H NMR (DMSO-d 6 400 MHz) 8 9.62 (1 H, 7.90 (1H, 7.81 (2H, d, J=8 Hz), 7.20 (2H, d, J=8 Hz), 5.64 (2H, 2.33 (3H, s).
WO 96/30343 PCTIUS96/04019 155 Step D: 5(S)-Butyl-4- [1-(4-cyanobenzyl)-2-methyl-5imidazolylmethyl]- 1-( 2 3 -dimethylphenyl)piperazin-2-one dihydrochloride Sodium triacetoxyborohydride (0.265 g, 1.25 mmol) was added to a solution of 1-(4-cyanobenzyl)-2-methylimidazole-5carboxaldehyde (0.190 g, 0.843 mmol), 5(S)-butyl-l-(2,3dimethylphenyl)piperazin-2-one hydrochloride (0.250 g, 0.843 mmol), N-methylmorpholine (0.093 mL, 0.843 mmol) in dichloroethane mL), according to the procedure described in Example 39, Step E. The title compound was purified by preparative HPLC using a gradient of to 45% Solvent A. The free base was isolated and converted to dihydrochloride salt. The title compound was obtained as a white solid.
FAB ms: 470 Anal. Calc for C 2 9
H
35
N
5 0 2 HC1 1.45 H 2 0, C, 61.25; H, 7.07; N,12.32. Found: C, 61.56; H, 6.99; N, 11.32.
EXAMPLE 49 2 4 -Cyanophenyl)-2-propyl)-5-imidazolylmethyl]-1-(3- 2 -methylsulfonylethyl)piperazin-2-one dihydrochloride Step A: 4-(tert-Butyldimethylsilyloxymethyl)- 1triphenylmethylimidazole tert-Butyldimethylsilylchloride (2.83 g, 18.76 mmol) was added to a suspension of 4-hydroxymethyl-1 -triphenylmethylimidazole (5.80 g, 17.05 mmol) in DMF (200 mL) containing imidazole (3.48 g, 51.1 mmol). After 15 min, a clear colorless solution was obtained which was stirred at room temperature. When reaction was complete, the DMF was removed in vacuo and the residue patitioned between ethyl acetate and water. The organic phase was washed with water, saturated brine, and dried over magnesium sulfate. The title compound was obtained as a clear gum.
WO 96/30343 PCT/US96/04019 156 Step B: 5-tert-Butyldimethylsilyloxymethyl- 1-(4cyanobenzvylimidazole A solution of 4-(tert-butyldimethylsilyloxymethyl)-1triphenylmethylimidazole (4.66 g, 10.26 mmol) and 1-bromomethyl-4cyanobenzene (2.01 g, 10.26 mmol) in acetonitrile (50 mL) was refluxed 4 h. The reaction was cooled, acetonitrile removed in vacuo, and the residue dissolved in methanol (30 mL). This solution was refluxed for 2h, cooled and methanol evaporated. The residue was partitioned between ethyl acetate and saturated sodium bicarbonate. The crude product was chromatographed on silica with 3% methanol in chloroform. The title compound was obtained as a white solid.
Step C: 5-tert-Butoxydimethylsilyloxymethyl-1- cyanophenyl)-2-propyl)]imidazole A solution of 5-tert-butyldimethylsilyloxymethyl-1 cyanobenzyl)imidazole (1.005 g, 3.07 mmol) in THF (25 mL) under nitrogen was cooled to -78 0 C. A solution of lithium hexamethyldisilazide (4.61 mL, 1 M in THF) was added and the reaction stirred at -78°C for 1 h, then warmed to -60 0 C over 30 min. The reaction was cooled to -78 0 C, methyl iodide added (0.287 mL, 4.61 mmol), and stirring continued at -78 0 C for an additional 2 h, before warming to 0°C over 2 h. After 30 min, the reaction was cooled to -78 0 C, and lithium hexamethyldisilazide (4.61 mL, 1 M in THF) added.
After 1 h, methyl iodide was added (0.287 mL, 4.61 mmol) and the reaction allowed to warm to room temperature overnight. The reaction was quenched with water, extracted with ethyl acetate, and the organic phase washed with saturated brine. The crude product was chromatographed on silica gel with 6:4 ethyl acetate: methylene chloride. The title compound was obtained as a golden oil. 1 H NMR (CDC13, 400 MHz) 6 7.78 (1H, 7.61 (2H, d, J=8Hz), 7.15 (2H, d, J=8Hz), 7.02, (1H, 4.00 (2H, 1.99 (6H, 0.79 (9H, -0.74 (6H, s).
WO 96/30343 PCT/US96/04019 157 Step D: 1-[ 2 -(4-Cyanophenyl)-2-propyl)]-5-hydroxymethylimidazole Tetra-N-butylammonium fluoride (2.99 mL, IM in THF) was added to a solution of 5-tert-butoxydimethylsilyloxymethyl-1-[2-(4cyanophenyl)-2-propyl)]imidazole (0.750 g, 2.72 mmol) in THF mL). After 2 h at room temperature, the reaction was poured into ethyl acetate and extracted with saturated sodium bicarbonate solution. The organic phase was extracted with saturated brine, and dried over magnesium sulfate. The crude product was chromatographed on silica gel with 3% methanol in ethyl acetate. The title compound was obtained as a semi-solid. IH NMR (CDC1 3 400 MHz) 6 7.77 (1H, 7.62 (2H, d, J=8Hz), 7.19 (2H, d, J=8Hz), 7.02, (1H, 4.01 (2H, 2.57 (1H, br 2.01 (6H, s).
Step E: 1-[ 2 4 carboxaldehyde A solution of 1-[ 2 4 hydroxymethylimidazole (0.450 g, 1.87 mmol) was refluxed in dioxane (20 mL) with manganese dioxide (1.62 g, 18.7 mmol) for 5h. The reaction was cooled, filtered through celite and concentrated. The crude product was purified by chromatography on silica gel; the title compound was isolated as a semi-solid. 1 H NMR (CDC13, 400 MHz) 6 9.37 (1H, 8.11 (1H, 7.92 (1H, 7.58 (2H, d, J=8Hz), 7.15 (2H, d, J=8Hz), 2.01 (6H, s).
Step F: 1 4 -Cyanophenyl)-2-propyl)-5-imidazolylmethyl]-1 (3-chlorophenyl)-5(S)-(2-methylsulfonylethyl)piperazin-2one dihydrochloride The title compound was prepared according to the procedure described in Example 39, Step E, except using 1-(3chlorophenyl)-5(S)-(2-methylsulfonylethyl)piperazin-2-one hydrochloride (0.297 g, 0.84 mmol), 1-[2-(4-cyanophenyl)-2- (0.200 g, 0.84 mmol), N- WO 96/30343 PCT/US96/04019 158methylmorpholine (0.092 mL, 0.84 mmol) and sodium triacetoxyborohydride (0.267 g, 1.26 mmol). The crude product was purified by preparative HPLC with an 80 to 58% Solvent A gradient.
The pure fractions were combined and converted to the hydrochloride salt, yielding the title compound. FAB ms: 540 Anal. Calc for
C
27
H
30 C1N 5 03S 2 HC1 .3 H 2 0, C, 48.62; H, 5.74; N,10.50. Found: C, 48.62; H, 5.73; N, 9.89.
EXAMPLE 5(S)-n-Butyl-4-[ 4 -cyanobenzyl)-5-imidazolylmethyl]-1-(2methylphenyl)piperazin-2-one dihydrochloride Step A: N-(2-Methylphenyl)-2(S)-(tert-butoxycarbonylamino)hexanamine The title compound was prepared according to the procedure described in Example 39, Step C, except using o-toluidine (0.32 mL, 3.00 mmol), 2 (S)-(tert-butoxycarbonylamino)hexanal (0.538, 2.50 mmol), sodium triacetoxyborohydride (0.795 g, 3.75 mmol) in dichloroethane (10 mL) The crude product was purified by column chromatography to yield the title compound.
Step B: 4-tert-Butoxycarbonyl-5(S)-n-butyl-1-(2methylphenvDpiperazin-2-one The title compound was prepared essentially according to the procedure described in Example 39, Step D, except using N-(2methylphenyl)-2(S)-(tert-butoxycarbonylamino)hexanamine (0.506 g, 1.65 mmol), chloroacetyl chloride (0.158 mL, 1.98 mmol) in ethyl acetate-saturated sodium bicarbonate at 0°C. The crude product thus obtained was dissolved in DMF (15 mL), cooled to 0°C under nitrogen, and treated with cesium carbonate (1.61 g, 4.95 mmol). The reaction was stirred at 0°C for 2h, and at room temperature for 2h. The reaction was quenched with saturated ammonium chloride, and WO 96/30343 PCTIUS96/04019 159 extracted with ethyl acetate. The extracts were dried and evaporated to give the title compound.
Step C: 5(S)-n-Butyl-4-[ 1-(4-cyanobenzyl)-5imidazolylmethyl] -1 2 -methylphenyl)piperazin-2-one dihydrochloride The product from Step B (0.534 g, 1.50 mmol) was deprotected with trifluoroacetic acid (4 mL) in methylene chloride mL). The title compound was prepared according to the procedure described in Example 39, Step E, except using 5(S)-n-butyl-l-(2methylphenyl)piperazin-2-one ditrifluoroacetic acid salt, 1-(4- (0.317 g, 1.50 mmol), and sodium triacetoxyborohydride (0.477 g, 2.25 mmol) in dichloroethane (15 mL). The crude product was injected onto a preparative HPLC column and purified with a mixed gradient of acetonitrile/0.1 TFA and 0.1% aqueous TFA. The pure fractions were combined and converted to the HCI salt. The title compound was obtained as a white solid. FAB ms 442. Anal. Calc. for C27H31N50 2.5 HC1 2.05 H20: C, 56.95; H, 6.66; N, 12.30. Found: C, 56.93; H, 5.75; N, 11.55.
EXAMPLE 51 4- [1-(4-Cyanobenzyl)-5-imidazolylmethyl]-5(S)-(2-fluoroethyl)- 1-(3chlorophenyl)vpiperazin-2-one dihydrochloride Step A: 4-tert-Butoxycarbonyl- 1-(3-chlorophenyl)-5(S)-(2fluoroethyl)-DiDerazin-2-one 4-tert-Butoxycarbonyl- 1-(3-chlorophenyl)-5(S)-(2methylsulfonyloxyethyl)- piperazin-2-one (0.433 g, 1.00 mmol) and tert-butylammonium fluoride (3.0 mL, IM in THF) were stirred at room temperature in acetonitrile (5 mL) for 72 h. The reaction was quenched with saturated sodium bicarbonate and extracted with ethyl WO 96/30343 PCT/US96/04019 160 acetate. The organic extracts were dried, concentrated and purified by column chromatography using 20% ethyl acetate in hexane. The title compound was obtained as a thick oil.
Step B: 4-[1-(4-Cyanobenzyl)-5-imidazolylmethyl]-5(S)-(2fluoroethyl)- 1 -(3-chlorophenyl)piperazin-2-one dihydrochloride 4-tert-Butoxycarbonyl- 1-(3-chlorophenyl)-5(S)-(2fluoroethyl)-piperazin-2-one (0.191 g, 0.54 mmol) was deprotected with trifluoroacetic acid (4 mL) in methylene chloride (10 mL). The title compound was prepared according to the procedure described in Example 39, Step E, except using 1-(3-chlorophenyl)-5(S)-(2fluoroethyl)piperazin-2-one ditrifluoroacetic acid salt, 1-(4cyanobenzylimidazole)-5-carboxaldehyde (0.114 g, 0.54 mmol), and sodium triacetoxyborohydride (0.172 g, 2.25 mmol) in dichloroethane mL). The crude product was injected onto a preparative HPLC column and purified with a mixed gradient of acetonitrile/0.1% TFA and 0.1% aqueous TFA. The pure fractions were combined and converted to the HC1 salt. The title compound was obtained as a white solid. FAB ms 452. Anal. Calc. for C24H23C1FN50 2. HC1 1.7 H20: C, 51.90; H, 5.15; N, 12.61. Found: C, 52.22; H, 5.10; N, 12.22.
EXAMPLE 52 4-[3-(4-Cyanobenzyl)pyridin-4-yl]-1-(3-chlorophenyl)-5(S)-(2methylsulfonylethyl)-piperazin-2-one Step A: 3-(4-Cvanobenzyl)pyridin-4-carboxylic acid methyl ester A solution of 4-cyanobenzyl bromide (625 mg, 3.27 mmol) in dry THF (4mL) was added slowly over -3 min. to a suspension of activated Zn (dust; 250 mg) in dry THF (2 mL) at 00 under an argon atmosphere.
WO 96/30343 PCT/US96/04019 161 The ice-bath was removed and the slurry was stirred at room temperature for a further 30 min. Then 3-bromopyridin-4carboxylic acid methyl ester (540 mg. 2.5 mmol) followed by dichlorobis(triphenylphosphine)nickel (II) (50 mg). The resultant reddish-brown mixture was stirred for 3h at -40-450c. The mixture was cooled and distributed between EtOAc (100 ml) and 5% aqueous citric acid (50 mL). The organic layer was washed with H 2 0 (2X50 mL), dried with Na 2
SO
4 After evaporation of the solvent the residue was purified on silica gel, eluting with 35% EtOAc in hexane to give 420 mg as a clear gum. FAB ms 253.
Step B: 3-(4-Cyanobenzvl)-4-(hydroxymethyl)pyridine The title compound was obtained by sodium borohydride (300 mg) reduction of the ester from Step A (415 mg) in methanol mL) at room temperature. After stirring for 4 h the solution was evaporated and the product was purified on silica gel, eluting with 2% methanol in chloroform to give the title compound. FAB ms (M+1) 225.
Step C: 3-(4-Cyanobenzyl)-4-pyridinal The title compound was obtained by activated manganese dioxide (1.0g) oxidation of the alcohol from Step B (240 mg, 1.07 mmol) in dioxane (10 mL) at reflux for 30 min. Filtration and evaporation of the solvent provided title compound, mp 80-83oC.
Step D: 4-[3-(4-Cyanobenzyl)pyridine-4-yl]-1-(3-chlorophenyl)- (2-methylsulfonvlethyl)-piperazin-2-one.
This compound was prepared essentially by the same methods as described in Example 39, Step E, except that the imidazolyl carboxaldehyde was replaced by an equal amount of product from Step C (vide supra) and the piperazinone was replaced by an equal amount of 1-(3-chlorophenyl)-5(S)-(2-methylsulfonylethyl)-piperazin-2-one, there was obtained the title compound. FAB ms 523. Anal. Calc. for WO 96/30343 PCTIUS96/04019 162
C
27
H
27 C1N 4 0 3 S-0.15 CHC1 3 60.28; H, 5.06; N, 10.36 Found: C, 60.37; H, 5.03; N, 10.64.
EXAMPLE 53 4-[5-(4-Cyanobenzyl)-l-imidazolylethyl]-l-(3-chlorophenyl)piperazin- 2-one.
Step A: 1-Trityl-4-(4-cyanobenzvl)-imidazole.
To a suspension of activated zinc dust (3.57g, 54.98mmol) in THF (50ml)was added dibromoethane (0.315ml, 3.60mmol) and the reaction stirred under argon at 20 0 C. The suspension was cooled to 0 C and a-bromo-p-tolunitrile (9.33g, 47.6mmol) in THF (100ml) was added dropwise over a period of 10 min. The reaction was then allowed to stir at 20'C for 6hr and bis(triphenylphosphine)Nickel II chloride (2.4g, 3.64mmol) and 5-iodotrityl imidazole (15.95g, 36.6mmol) was added in one portion.The resulting mixture was stirred 16hr at and then quenched by addition of saturated NH4Cl solution (100ml) and the mixture stirred for 2 hours. Saturated NaHCO3 solution was added to give a pH of 8 and the solution was extracted with EtOAc 2x250ml), dried MgSO4 and the solvent evaporated in vacuo. The residue was chromatographed (Si02, 0-20% EtOAc/CH2Cl2 to afford the title compound as a white solid.
IH NMR 8 CDC13 (7.54 (2H,d, J=7.9Hz), 7.38(1H,s), 7.36-7.29 (11H,m), 7.15-7.09(6H,m), 6.58(1H,s), and 3.93(2H,s)ppm.
Step B: 1-Methyl acetyl-5-(4-cyanobenzyl)-imidazole.
To a solution of 1-trityl-4-(4-cyanobenzyl)-imidazole (3.01 g, 6.91 mmol) in acetonitrile (50ml) was added methyl bromoacetate (0.687ml, 7.26mmol) and the mixture heated at 55°C for 16 hours, and then the solvent was evaporated in vacuo. The solids were triturated with EtOAc, collected by filtration and dissolved in methanol This suspension was heated at refux for 20min, cooled and evaporated WO 96/30343 PCTIUS96I04O19 163 to dryness. The residue was triturated with EtOAc and the title compound was obtained as a white solid by filtration 1 H NMR 8 CDC13 (7.61 (2H,d, J=7.9Hz), 7.53(1H,s), 7.27(2H,d,J=7.9Hz), 6.89(1H,s), 4.47(2H,s), 3.98(2H,s) and 3.66(3H,s)ppm.
Step C: 1 -Hvdroxvethyl-5- 4 -cvanobenzvl)-imidazole.
A solution of 1-methyl acetyl-5-(4-cyanobenzyl)-imidazole 113 g, 0.472 mmol) in methanol (2m1) at 0 0 C was treated with sodium borohydride (80.7mg, 2. 1 mmol). After 1 hour the reaction was quenched by addition of saturated NH4Cl solution (2m1). Saturated NaHCO3 was added and the mixture extracted with ethyl acetate (3x25m1), dried MgSO4 and evaporated in vacuo. The title compound was isolated by chromatography (Si02, 10%MeOH in CH2C12) as a white solid. 1 H NMR 8 CDCl3(7.61 (2H,d, J=7.9Hz), 7.55(1H,s), 7.27(2H,d,J=7.9Hz), 6.83(1H,s), 4.05(2H,s), 3.87(2H,t, J=5. 1Hz) and 3.74(2H,t, J=5. lHz)ppm.
Step D: 2 anobenzyl)-imidazolvl)ethyl methanesulfonate A solution of 1 -hydroxyethyl-5-(4-cyanobenzyl)-imidazole (0.532 g, 2.34 mmol) in methylene chloride (70m1) at 0 0 C was treated with Hunigs base (0.489m1, 2.8 immol) and methane sulfonyl chloride (0.219m1, 2.8lmmol). After 2 hour the reaction was quenched by addition of saturated NaHCO3 solution (50mi) and the mixture extracted with methylene chloride (50ml), dried MgSO4 and the solvent evaporated in vacuo. The title compound was used without furthur purification. 1 H NMR 8 CDCI3(7.62 (2H,d, J=7.9Hz), 7.54(1H,s), 7.29(2H,d,J=7.9Hz), 6.87(1H,s), 4.25(2H,t), 4. 10-4.0O(4H,m), 3.74(2H,t, J=5.lHz) and 2.90(3H,s)ppm.
Step E: 4- [5-(4-Cyanobenzyl)-l1-imidazolylethyl]-l1-(3chlorop~henyl)pip~erazin-2-one.
WO 96/30343 PCTIUS96/04019 164 A solution of 2 4 -cyanobenzyl)-imidazolyl)ethyl methanesulfonate (24 mg, 0.079 mmol) in DMF (0.2ml) was added to 3- (chlorophenyl)piperazin-2-one( 17.7mg, 0.084mmol), sodium iodide 0.336mmol) and Hunigs base (0,0146ml, 0.084mmol). The mixture was stirred at 55 0 C for 12 hours, and the solvent evaporated in vacuo. The residue was purified by preparative tlc eluting with saturated ammonia/acetonitrile to afford the title compound.
1 H NMR 5 CDCl3(7.61 (2H,d, J=8.4Hz), 7.56(1H,s), 7.35-7.20 (7H,m), 7.16(1H,d, J=8Hz), 6.85(1H,s), 4.03(2H,s),, 3.83(2H,t, 3.61(2H,t, J=5.4Hz), 3.27(2H,s), 2.68(2H,t, J=5.4Hz) and 2.57(2H,t, EXAMPLE 54 In vitro inhibition of ras farnesyl transferase Assays of farnesyl-protein transferase. Partially purified bovine FPTase and Ras peptides (Ras-CVLS, Ras-CVIM and Ras-CAIL) were prepared as described by Schaber et al., J. Biol. Chem. 265:14701- 14704 (1990), Pompliano, et al., Biochemistry 31:3800 (1992) and Gibbs et al., PNAS U.S.A. 86:6630-6634 (1989), respectively. Bovine FPTase was assayed in a volume of 100 gl containing 100 mM N-(2hydroxy ethyl) piperazine-N'-(2-ethane sulfonic acid) (HEPES), pH 7.4, mM MgCl2, 5 mM dithiothreitol (DTT), 100 mM 3 H]-farnesyl diphosphate 3 H]-FPP; 740 CBq/mmol, New England Nuclear), 650 nM Ras-CVLS and 10 gg/ml FPTase at 31 0 C for 60 min. Reactions were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in ethanol. Precipitates were collected onto filter-mats using a TomTec Mach II cell harvestor, washed with 100% ethanol, dried and counted in an LKB (3-plate counter. The assay was linear with respect to both substrates, FPTase levels and time; less than 10% of the 3 H]-FPP was utilized during the reaction period. Purified compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the assay. Percentage inhibition is measured by the amount of incorporation of radioactivity in the presence of the test compound WO 96/30343 PCTIUS96/04019 165 when compared to the amount of incorporation in the absence of the test compound.
Human FPTase was prepared as described by Omer et al., Biochemistry 32:5167-5176 (1993). Human FPTase activity was assayed as described above with the exception that 0.1 (w/v) polyethylene glycol 20,000, 10 JIM ZnC1 2 and 100 nM Ras-CVIM were added to the reaction mixture. Reactions were performed for 30 min., stopped with 100 gl of 30% trichloroacetic acid (TCA) in ethanol and processed as described above for the bovine enzyme.
The compounds of the instant invention described in the above Examples and in the Tables hereinafter were tested for inhibitory activity against human FPTase by the assay described above and were found to have IC50 of 50 gM.
EXAMPLE In vivo ras farnesylation assay The cell line used in this assay is a v-ras line derived from either Ratl or NIH3T3 cells, which expressed viral Ha-ras p21. The assay is performed essentially as described in DeClue, J.E. et al., Cancer Research 51:712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound (final concentration of solvent, methanol or dimethyl sulfoxide, is After 4 hours at 37 0 C, the cells are labelled in 3 ml methionine-free DMEM supplemeted with 10% regular DMEM, 2% fetal bovine serum and 400 mCi[ 3 5S]methionine (1000 Ci/mmol). After an additional 20 hours, the cells are lysed in 1 ml lysis buffer NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/1mM DTT/10 mg/ml aprotinen/2 mg/ml leupeptin/2 mg/ml mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min. Aliquots of lysates containing equal numbers of acid-precipitable counts are bought to 1 ml with IP buffer (lysis buffer lacking DTT) and immunoprecipitated with the ras-specific monoclonal antibody Y13-259 (Furth, M.E. et al., J. Virol. 43:294-304, (1982)). Following a 2 hour antibody incubation at 4°C, 200 ml of a WO 96/30343 PCTIUS96/04019 166 suspension of protein A-Sepharose coated with rabbit anti rat IgG is added for 45 min. The immunoprecipitates are washed four times with IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1% Triton X- 100.0.5% deoxycholate/0.1%/SDS/0.1 M NaCI) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and autoradiographed. The intensities of the bands corresponding to farnesylated and nonfarnesylated ras proteins are compared to determine the percent inhibition of farnesyl transfer to protein.
EXAMPLE 56 In vivo growth inhibition assay To determine the biological consequences of FPTase inhibition, the effect of the compounds of the instant invention on the anchorage-independent growth of Ratl cells transformed with either a v-ras, v-raf, or v-mos oncogene is tested. Cells transformed by v-Raf and v-Mos maybe included in the analysis to evaluate the specificity of instant compounds for Ras-induced cell transformation.
Rat 1 cells transformed with either v-ras, v-raf, or v-mos are seeded at a density of 1 x 104 cells per plate (35 mm in diameter) in a 0.3% top agarose layer in medium A (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum) over a bottom agarose layer Both layers contain 0.1% methanol or an appropriate concentration of the instant compound (dissolved in methanol at 1000 times the final concentration used in the assay). The cells are fed twice weekly with 0.5 ml of medium A containing 0.1% methanol or the concentration of the instant compound.
Photomicrographs are taken 16 days after the cultures are seeded and comparisons are made.
WO 96/30343 PCTfUS96/04019 167 EXAMPLE 57 Tables 1-18 show other compounds of the instant invention that were prepared by the procedures described in Examples 1-53.
These compounds are meant to be illustrative and are not meant to be limiting. In Table 2, the stereochemistry of the amino-containing carbon atom is as indicated (R or S) or, if unknown, the two separated stereoisomers are delineated by an or designation.
WO 96/30343 PCTfUS96/04019 168 Table 1 FAB ms (m+1) Formula Analysis (Calc, Found) 0H 3 0
H
2 F -&CH 2 C H 2 0H 2 526 506 494 490 0 33
H
39
N
3 0S-2.3 TFAO0.9 H 2 0 0, 56.16; H, 5.40; N, 7.22.
0, 56.12; H, 5.37; N, 7.39.
C
30
H
39
N
3
O
2 S-2.55 TFAO0.55 H 2 0 0, 53.19; H, 5.46; N, 5.36.
0, 53.17; H, 5.46; N, 5.60.
0 29
H
36
N
3 0S-2.25 TFAO0.35 H 2 0 C, 53.19; H, 5.18; N, 5.55.
C, 53.16; H, 5.18; N, 5.68.
C
30
H
3 qN 3 0S-2 TEA 0.9 H 2 0 C, 55.64; H, 5.88; N, 5.73.
0, 55.57; H, 5.81; N, 5.83.
512
C
29
H
35
F
2
N
3 0S-2.4 TFAO0.6 H 2 0 C, 50.99; H, 4.89; N, 5.28.
0, 50.98; H, 4.86; N, 5.56.
WO 96/30343 PTU9/41 PCTIUS96/04019 169 Table 2 y 4 0
NN
2
H
2
N~
FAB mass amine spectrum stereo. X Y- 1) Analysis (calcd.. found) A n-Bu 2-O(CH2)13CH3 642.5 C42H63N302*2.55HC1 C, 68.46; H, 8.97; N, 5.70.
C, 68.40; H, 8.70; N, 5.61.
B n-Bu 2-O(CH2)13CH3 642.6 C42H63N302*2.65HC1 C, 68.63; H, 8.99; N, 5.72.
C, 68.66; H, 8.90; N, 5.70.
A n-Bu 2-O(CH2)1 1CH3 614.4 C40H59N302.2.8HCl C, 67.09; H, 8.70; N, 5.87.
C, 67.03; H, 8.66; N, 5.76.
B n-Bu 2-0(CH2)1 1CH3 614.4 C40H59N302.2.85HC100.05H20 C, 66.84; H, 8.69; N, 5.85.
C, 67.20; H, 8.70; N, 5.45.
WO 96/30343 PCTIUS96/04019 170 FAIB mass amine Sti-.ri-.n X spectrum A n] I C- (NXo. LSL' u d A n-Bu 2-O(CH2)9CH3 586.5 C38H55N302e3HC100.25hexane C, 66.18; H, 8.65; N, 5.86.
C, 66.14; H, 8.44; N, 5.50.
B n-Bu 2-O(CH2)9CH3 586.5 C38H55N3O2-3HC100.l5hexane C, 65.97; H, 8.55; N, 5.93.
C, 66.04; H, 8.41; N, 5.57.
A n-Bu 2-O(CH2)7CH3 558 C36H5 1N302-2. 1HC1*0.65H2 C, 66.73; H, 8.47; N, 6.49.
C, 66.74; H, 8.46; N, 6.52.
C36H5j1N302*2. 1 HC1*0.65H20 C, 66.82; H, 8.42; N, 6.49.
C, 66.85; H, 8.43; N, 6.52.
B n-Bu 2-O(CH2)7CH3 558 A n-Bu 2-O(CH2)3Ph B n-Bu 2-O(CH2)3Ph 564 C37H45N302-2HCI1.05H20 C, 67.78; H, 7.55; N, 6.41.
C, 67.78; H, 7.52; N, 6.26.
564 C37H45N302-2HCI11.05H20 C, 67.78; H, 7.55; N, 6.41.
C, 67.78; H, 7.44; N, 6.33.
536 C35H41N302.3.55HC1 C, 63.19; H, 6.75; N, 6.32.
C, 63.12; H, 6.61; N, 6.47.
536 C35H41N302-3.S5HC1.0.4H20 C, 62.52; H, 6.80; N, 6.25.
C, 62.14; H, 6.69; N, 6.65.
A n-Bu 3-OCH2Ph B n-Bu 3-OCH2Ph WO 96/30343 PCTfUS96/04019 171 FAB mass amine stereo.
spectrum x y (CM+ 1) Analvsis (calcd found) Ana1v~i~ (calcd fonndi A n-Bu 3-0(CH2)13CH3 642 C42H63N3 02.2 .4HC1 C, 69.15; H, 9.04; N, 5.76.
C, 69.08; H, 9.08; N, 5.73.
C42H63N302.2.35HC100.25H 2 0 C, 69.15; H, 9.04; N, 5.76.
C, 69.08; H, 9.08; N, 5.73.
B n-Bu 3-O(CH2)13CH3 R n-Bu 4-O(CH2)13CH3 542.5 642 C42H63N3022.2HCO 1H20 C, 68.14; H, 9.15; N, 5.68.
C, 68.13; H, 9.03; N, 5.68.
642 C42H63N302-2.8HC1 C, 67.79; H, 8.91; N, 5.65.
C, 67.77; H, 9.80; N, 5.64.
S n-Bu 4-0(CH2)13CH3 S n-Bu 4-OCH2Ph C35H4lN302*2. 15HC1*1H20 C, 66.49; H, 7.20; N, 6.65.
C, 66.48; H, 7.15; N, 6.62.
C38H55N302 1 .5HC1'O.3H20 C, 66.88; H, 8.58; N, 6.16.
C, 66.82; H, 8.64; N, 6.15.
RIS H 2-0(CH2)13CH3 586 WO 96/30343 WO 9630343PCTIUS96104019 172 Table 3 FAB mass spectrum Y (M+1) Analysis (calcd.. found) 3-SO2Me 3-OCF3 506 512.23 C27H3 1N503S*3.O HCl*O. 10 C, 52.61; H, 5.59; N, 11.36.
C, 52.63; H, 5.41; N, 10.72.
C27H28N502F3-2.30 HCl*0.50 C, 53.66; H, 5.22; N, 11.59.
C, 53.73; H, 5.23; N, 10.86.
WO 96/30343 PCTJS96/04019 173 Table 4 NC
N
0
N
FAB mass spectrum y Ilitti 1
UJU
Ann]l~wc o; tlI A f- L a %,CL Ull I CH20CH2Ph CF3 574 C32H30N502F 3 1 .4OHC1*0.301120 C, 61.02; H, 5.12; N, 11. 12.
C, 61.01; H, 5.10; N, 10.78.
CH2SO2Et CF3 560 C27H28N503F 3
S
.3 .2OHCIl.O C, 47.86; H, 4.67; N, 10.34.
C, 47.89; H, 4.49; N, 9.92.
CH2SO2Ph CF3 608 C3 1H28N503F3S-2.1OHCl CH2SO2Me 512 C, 54.42; H, 4.43; N, 10.24.
C, 54.43; H, 4.42; N, 9.98.
C25H26N503C1S *2.OHCl*0.25CHC13*0.25H 2 0 C, 48.97; H, 4.68; N, 11.31.
C, 48.95; H, 4.64; N, 11.51.
WO 96/30343 PCTIUS96/0j4019 174- Table 4 (continued) NC-0-
N
N
FAB mass spectrum Y (M+1) Analysis (calcd., found) CH2SO2Et 526 C26H28N503C1S-2HCl.0.25CHC1 3 C, 50.14; H, 4.85; N, 11.14.
C, 50.20; H, 4.91; N, 10.93.
CONH[Me CF3 511 C26H25N602F 3 1 .9OHCI1. 70H20 C, 51.20; H, 5.01; N, 13.78.
C, 51.17; H, 4.99; N, 13.36.
CONHEt CF3 525 C27H27N602F 3 *1 .6OHCl*0. I10H20 C, 55.54; H, 4.97; N, 14.39.
C, 55.57; H, 4.87; N, 15.28.
CH2SO2Ph 574 C3OH28N5O3ClS*2HC1*0.30H 2 0 C, 55.23; H, 4.73; N, 10.73.
C, 55.25; H, 4.57; N, 10.61.
WO 96/30343 PTU9/41 PCTIUS96/04019 175 Table 4 (continued) NC -0
Y
N N 0
N
FAB mass spectrum Y (M+1) Analvsis (calcd fournd) CONHMe CONHEt 477 C25H25N602C*2HC1 1O5CHCl3*0.85H20 C, 52.24; H, 5.03; N, 14.56.
C, 52.21; H, 5.07; N, 14.98.
491 C26H27N602C1.2HCl.O.25CHC1 3 C, 53.10; H, 4.97; N, 14.15 C, 53.32; H, 5.21; N, 13.77.
CONHc-Pr 503 C27H27N602C1.2HCl.O.40CHC1 3 C, 52.77; H, 4.75; N, 13.47.
C, 53.01; H, 4.99; N, 13.32.
CONHc-Pr CF3 537 C28H27N602F 3 -2.45HC1*0.55dioxane C, 5 3.8 1; H, 5.06; N, 12.47.
C, 53.76; H, 5.09; N, 12.44.
WO 96/30343 WO 9630343PCTIUS96/04019 176 Table 4 (continued) NC -N Nd
N-
FAB mass spectrum x Y (M+1) NHCOMe 477 Analysis (calcd.. found) C25H25N602C1 *2HCl*0.6OCHCl 3 *2.0H 2 0 C, 46.76; H, 4.84; N, 12.78.
C, 46.79; H, 4.46; N, 12.37.
CONMe2 CF3 525 C27H27N602F3*2.OHC1'0. I10H20 C, 54.12; H, 4.91; N, 14.02.
C, 54.10; H, 4.96; N, 13.79.
SO2Et 512 C25H26N5O3ClS.2.OHCl-..1 C, 51.18; H, 4.84; N, 11.94.
C, 51.24; H, 5.19; N, 11. CH2SMe 480 C25H26N5OCLS 15CHC13*0.05H 2 0 C, 52.83; H, 4.98; N, 12.25.
C, 52.82; H, 5.36; N, 11.85.
WO 96/30343 WO 9630343PCTIUS96/04019 177 Table 4 (continued) NC N NN6
N
FAB mass spectrum Y (M4-1 Anayj 1vicz(-'21cc ft'nil W± C=-CMe 458 C26H24N50C*2.OHC1*. .0H20 C, 56.89; H, 5.14; N, 12.76.
C, 56.99; H, 5.20; N, 12.42.
WO 96/30343 WO 9630343PCTIUS96/04019 178 Table FAB mass spectrum Y 1) Analysis (calcd. found~ Analvsis (calcd. found) CH2CH2 386 C23H23N50 1 .4OHC1*0.40H 2 0 C, 62.29; H, 5.73; N, 15.79.
C, 26.26; H, 5.71; N, 15.43.
400 C23H2jN50 2 *2.6HC 1 .70H20 CH2CO C, 52.71; H, 5.19; N, 13.36.
C, 52.82; H, 5.21; N, 13.04.
CH2 372 C22H2 1N502.OHC*2.6OH 2
O
C, 53.80; H, 5.79; N, 14.26.
C, 52.86; H, 5.98; N, 13.92.
CH2 3-Cl 406 C22H2oN5OCl*2.5OHCl*0.90H 2 0 C, 51.48; H, 4.77; N, 13.65.
C, 51.55; H, 4.75; N, 13.34.
WO 96/30343 PCTIUS96/04019 179 Table 5 (continued)
NC
7 X-N X-
N--
(N\
FAB mass spectrum Analysis (calcd.. found) y
(M+D
NHS02 NHSO2 C2l1H2oN60 3 S 1 .OHC1*2.60H 2 0 C, 48.53; H, 5.08; N, 16.17 C, 48.60; H, 5.19; N, 15.80.
CH2CH2CO 3-Cl 448 C24H22N50 2 C1* 1.OHC1. 1 CH2 2,3-Cl 2 440 C, 57.17; H, 5.04; N, 13.89.
C, 57.22; H, 4.94; N, 13.47.
C22Hl19N5OCI2r2.OHCl.0.60H 2 0 C, 50.42; H, 4.27; N, 13.36.
C, 5 0.5 1; H, 4.5 6; N, 12.18.
CH2 2-Br 450 C22H20N5OBr2.OHCOO.30H 2 0 C, 49.98; H, 4.31; N, 13.25.
C, 49.94; H, 4.47; N, 12.53.
WO 96/30343 PCTIUS96/04019 180 Table 5 (continued) N~ X-N N FAB mass spectrum Ain I I A f- A 4a 3 t- (A UV I Uj
CH
2 3-CF 3 440 C23H20N50F 3 .1 .7OHCl*.40H 2 0 C, 54.40; H, 4.47; N, 13.79.
C, 54.45; H, 4.49; N, 13.82.
4-Cl C22H20N50C1..5OHCl*.80H 2 0 C, 55.71; H, 4.91; N, 14.77.
C, 55.8 1; H, 4.94; N, 14.11.
CH2 CH2CO 3-Cl C23H20N50 2 CI1. 4OHCl* 1.1 C, 54.73; H, 4.71; N, 13.87.
C, 54.80; H, 4.73; N, 13.46.
CH2 3-F C22H2oN50F.2HCl 90.35CHC13*0.95H 2 0 C, 51.50; H, 4.69; N, 13.44.
C, 51.56; H, 4.73; N, 13.30.
WO 96/30343 PCTIUS96/04019 181 Table 5 (continued) NC-&-\NX-N
NO
0
N
FAB mass spectrum Alnnl t I A 4 A V~ aM~1 ai~i )1 UILI I CH2 3-Br C22H2oN5OBr 1 .4OHClol1.30H20 C, 50.35; H, 4.61; N, 13.34.
C, 50.36; H, 4.63; N, 12.84.
WO 96/30343 WO 9630343PCTIUS96/04019 182 Table 6 FAB mass spectrum An21v~i~ (c~1cd fniinch 1) Analysis (i-nlr(i fn"nih 4-CN CH2 5-CH2CH2CO 554 C27H28N50 4 C1S* 1.30HC1. 20H20 C, 52.05; H, 5.13; N, 11.24.
C, 52.09; H, 5.15; N, 10.95.
3-CN CR2 5-CH2 512 C25H26N50 3
CS*
2.OHC*O. 1OCHCl3*0.60H20 C, 49.61; H, 4.86; N, 11.52.
C, 49.63; H, 5.01; N, 11.14.
2-CN CH2 5-CH2 512 C25H26N50 3 C1S *2HC1*0.35H20 C, 50.79; H, 4.89; N, 11.84.
C, 50.82; H, 5.29; N, 11.90.
4-CN CH 2 4-CH 2 CH2CO 554 C27H28N504C1S *2 .OHCl*0.5OCHC13*0.60H 2 0 C, 47.36; H, 4.58; N, 10.04.
C, 47.35; H, 4.60; N, 9.66.
WO 96/30343 WO 9630343PCT/US96/04019 183 Table 6 (continued) MeO 2
S,
FAB mass spectrum X Y Z 1) Analysis (calcd.. found) 4-CN (CH2)2 4-CH2CH2CO C28H30N504C1S *1 .OHCl*.4OCHCl3*.95H20 C, 50.96; H, 5.01; N, 10.46.
C, 50.91; H, 5.02; N, 10.13.
WO 96/30343 WO 9630343PCTIUS96/04019 184 Table 7 NC -a
\I
Y CI N N\ 0 FAB mass spectrum x y 1) Analysis (calcd., found) 4-Me CH2CH2SO2Me 526 C26H28N503C1S *2HC1*O. 35CHC13*O. 85H20 C, 48.24; H, 4.92; N, 10.67.
C, 48.25; H, 4.93; N, 10.36.
4-Me 420 C23H22N50C1*2.OHCl.0.90H 2 0 C, 54.27; H, 5.11; N, 13.76.
C, 54.21; H, 5.37; N, 12.97.
420 C23H22N50C*3 .2OHCl*0. 1 0H20 C, 51.31; H, 4.76; N, 13.01.
C, 51.30; H, 4.74; N, 12.87.
2-Me I WO 96/30343 WO 9630343PCTIUS96/04019 185 TABLE 8
NC'
N-CN
NN
Formula
Y
3-CF 3 3-CH 3 FAB ms (m+1) 496 442 Analysis Found
C
27
H
28
F
3
N
5 0 -2 HCI 1.55 H 2
C
C, 54.36; H, 5.59; N, 11.74 C, 54.40; H, 5.29; N, 11.26
C
27
H
31
N
5 0 -2 HCl C, 63.01; H, 6.47; N, 13.61 C, 63.45; H, 6.71; N, 13.53
C
30
H
35
N
5 0 -5.2 HCl 0. 1 H 2
C
C, 53.66; H, 6.06; N, 10.43 C, 53.62; H, 5.30; N, 9.35 2,3-(CH 2 4 482 3-OCH 3 458
C
27
H
3 1
N
5 0 2 -2 HCl C, 61.13; H, 6.27; N, 13.20 C, 62.43; H, 6.53; N, 13.24 WO 96/30343 PCTIUS96/04019 186 TABLE 8-(continued) n-C 4
H
9 NC' N N 0
N
FBms (m+1) 3-Cl 2-CH 3 ,3-Cl 463 477 Formula AnalsisCaic AnalsisFound
C
26
H
28
CIN
5 0 -2 HCl 0.75 H 2
C
C, 56.94; H, 5.79; N, 12.77 C, 56.92; H, 5.59; N, 12.30
C
27
H
30 C1N 5 0 2 -2 HCl 3.1 H 2 0 C, 53.62; H, 6.37; N, C, 53.44; H, 5.37; N, 11.58 10.76 428 C 26
H
29
N
5 0 3.9 HCl 2 H 2 0 C, 51.63; H, 6.51; N, 11.58 C, 51.59; H, 5.10; N, 10.35 IWO 96/30343 PTU9/41 PCTfUS96/04019 187 TABLE 8 (continued) n-0 4
H
9 0 FAB ms (m+1) Formula AnalsisCalc AnalsisFound
C
26
H
28
FN
5 0 -2 HCI 2.55 H 2
C
C, 55.87; H, 6.22; N, 12.53 C, 55.83; H, 5.84; N, 11.71 3-F 446 WO 96/30343 PTU9/41 PCT/US96/04019 188 TABLE 9
-CF
3
NN
NC-O N 0
N
Formula FAB ms (m+1) Analysis Caic Found
CH
2
CH
2
OCH
2
CF
3 566 C 27
H
25
F
6
N
5 0 2 -2 HCl 0.67 H 2 0 C, 49.85; H, 4.39; N, 10.77 C, 49.86; H, 4.26; N, 10.33
OCH
2
CH
2 524 C 28
H
28
F
3
N
5 0 2 2 HCl C, 56.38; H, 5.07; N, 11.74 C, 56.21; H, 5.27; N, 11.46
CH
2
CH
2
N
3 509 C 25
H
23
F
3
N
8 0 2 -2 HCl 2.35 H 2 0 C, 48.14; H, 4.80; N, 17.96 C, 48.79; H, 4.38; N, 16.99
C
27
H
27
F
3
N
6 0 2 -2 HCl 0.7 H 2 0 C, 53.16; H, 5.02; N, 13.78 C, 53.30; H, 5.07; N, 13.39
CH
2
CH
2
NHCOCH
3 525
CH
2
CH
2
NHCOC
2
H
5 539 C 28 H1 29
F
3
N
6 0 2 -2 HCl 3.66 H 2 0 C, 52.43; H, 5.39; N, 13.10 C, 52.44; H, 5.20; N, 12.48 WO 96/30343 PTU9/41 PCTfUS96/04019 189 TABLE 9 (continued) N
CF
3 NC 0 FAB ms (m+1) Formula Analysis Caic Found
CH
2
CH
2
SO
2
CH(CH
3 2 574 C 28
H
30
F
3
N
5 0 3 S -2 HCl 1.35 H 2 C, 50.13; H, 5.21; N, 10.44 C, 50. 10; H, 4.88; N, 10.08
CH
2
CH
2
SCH(CH
3 2 542 C 28
H
30
F
3
N
5 0S ,2 HCl 0.75 H 2 0 C, 53.55; H, 5.38; N, C, 53.57; H, 5.33; N, 11.51 11.04
CH
2
CH
2 S (O)CH(CH 3 2 558 C 28
H
30
F
3
N
5 0 2 S -2 HCl 0.7 H 2 0 C, 52.29; H, 5.23; N, 10.89 C, 52.27; H, 5.08; N, 10.35 WO 96/30343 PCTIUS96/04019 190 TABLE n-0 4
H
9 OH 3
OH
3 R-N N6 0
R
0 2 N C H 2 FBms (m+1) Formula Analysis Caic Found 462 C 26 H1 3
IN
5 0 3 -2 CF 2
CO
2 H -2.8 H 2
C
C, 48.69; H, 5.26; N, C, 48.70; H, 4.42; N, 9.46 9.12
NCCH
NC(N
OH
3
C
29
H
35
N
5 0 -2 HCl 0.3 CH 2 C1 2 470 0.6
C
6
HI
4 C, 63.76; H, 7.48; N, 11.30 C, 64.77; H, 7.07; N, 11.26 431
C
27
H
34
N
4 0 .2 HC1
NJ
445 C, 64.4 1; H, 7.2 1; N, 11. 13 C, 66.35; H, 7.28; N, 11.25
C
28
H
36
N
4 0 2 HC1 1.3 H 2 0 C, 62.17; H, 7.56; N, 10.36 C, 62.15; H, 7.09; N, 9.83
C
29
H
35
N
5 0'2HCl 3.05 H 2 0 470 C, 58.30; H, 6.28; N, 10.90 548, 550 C 29
H
34 BrN 5 O .2 HC1 0. 1 H 2 0 C, 55.89; H, 5.85; N, 11.24 C, 55.91; H, 5.96; N, 10.73 IWO 96130343 PCTIUS96/04019 191 TABLE 11I
H
3 0- So 2 R-N
N-
0 Formula Y FAB ms Cl Analysis Foand ci 511 C 26
H
27 C1N 4 0 3
S
2HCl -2.85
H
2 0 C, 49.16; H, 5.5 1; N, 8.82 C, 49.17; H, 4.74; N, 8.87
NC
NC
F 496 Ci 527
C
25
H
26
FN
5 0 3
S
2HCI 1.65
H
2 0 C, 50.20; H, 5.27; N, 11.71 C, 50.19; H, 4.90; N, 11.44
C
26
H
28 C1N 5 0 3
S
2 HCP 0.55
H
2 0
OH
3
OH
2 HN N-O\ O &N CI C, 51.29; H, 5.15; N, 11.50 C, 51.32; H, 5.39; N, 11.31 530 C 26
H
32 C1N 5 0 3
S
3HCI *0.6 HCl C, 48.02; H, 5.61; N, 10.77 C, 48.30; H, 5.91; N, 9.78 WO 96/30343 PCTIUS96/04019 192 TABLE 12
H
3 0- S0
CI
R-N N0 0 FABmr (m+1) 545 Formula
IS
AnalsisCaic AnalsisFound
C
26
H
30 C1N 5 0 4
S
2 HCl 0.75
H
2 0 C, 49.53; H, 5.36; N, 11. 11 C, 49.56; H, 5.58; N, 10.65
C
28
H
29 C1N 5 0 3
S
2HCI C, 53.90; H, 5.01; N, 11.22 C, 54.06; H, 5.78; N, 10.67 552 H OH 2
N
N
OH
2 HN N-C C N 0 396
C
1 7
H
20 C1N 4 0 3
S
2HCI .7 H 2 0 C, 42.41; H, 4.90; N, 11.64 C, 42.98; H, 5.49; N, 11.06 544
C
26
H
30 C1N 5 0 4
S
2 HCl 0.75
H
2 0 C, 49.5 1; H, 5.3 6; N, 11. 11 C, 49.74; H, 5.66; N, 10. 11 WO 96/30343 PCTIUS96/04019 193 TABLE 12 (continued) R-N NN 0 0I Formula FAB ms (m+1) AnalsisCaic AnalsisFound
OH
2 524 C 27
H
27 C1N 4 0 3 S -0.55 CHC1 3 C, 58.67; H, 4.92; N, 10.03 C, 5 8.7 1; H, 4.94; N, 9.95 523 C 28
H
28 C1N 3 0 3 S -0.1 CHCl: 0.2
CH
3 0H C, 62.89; H, 5.39; N, 7.78 C, 62.87; H, 5.37; N, 7.84 ON WO096/30343 PCTIUS96/04019 194 TABLE 13
H
3 0- so 2 ft-N
N--
FA0 m Formula
OH
2 Ph"
N
563 Anlyi Caic AnalsisFound
C
30
H
31
CIN
4 0 3
S
2HCI 1.8
H
2 0 53.90; H, 5.52; N, 8.38 53.90; H, 5.38; N, 7.82
NC'
NC
540 512
C
27
H
30
CIN
5 0 3
S
2HCl 1.35
H
2 0 C, 50.88; H, 5.49; N, 10.99 C, 51.37; H, 5.51; N, 10.20
C
25
H
26 C1N 5 0 3
S
2 HC1 0.3 H 2 0 50.86; H, 4.88; N, 51.06; H, 5.33; N, 11.86 10.87
CH
2 HN NH 415
OH
2 HN N-S -a C
C
28
H
27 C1N 4 0 3
S
3 3HC -4 H 2 0 C, 36.25; H, 6.42; N, 9.39 C, 3 8.12; H, 5.9 1; N, 7.41
C
25
H
30 C1N 5 0 5
S
2 2HCl'-0.85
H
2 0 C, 44.93; H, 5.08; N, 10.48 C, 44.96; H, 5.08; N, 9.96 580 IWO 96/30343 PCTJUS96/04019 195 TABLE 14 FAB ms (m+1) Formula Analysis Caic Found
C
19
H
1 9 C1N 4 0 2HClO- .5 H 2 0 355 C, 52.25; H, 5.08; N, C, 52.3 1; H, 5.14; N, 12.83 12.23
CH
2
CH
2
CH
2
F
452 C 24
H
23 C1FN 5 0 2HCI 1.70
H
2 0 C, 51.90; H, 5.15; N, 12.61 C, 52.22; H, 5. 10; N, 12.22 r'
HN,.
H 448
C
24
H
22 C1N 5 0 2 1 HC1 0.30 CHC1 3 -0.85
H
2 0 C, 54.50; H, 4.71; N, 13.08 C, 54.5 1; H, 4.69; N, 12.87
NC
I WO 96/30343 WO 9630343PCTUS96/04019 196 TABLE R-N
-O
0 Formula
R
OH
2
O-NN
NC
OH
2
NC
FAB ms (m+1) AnalsisCaic AnalsisFound
C
26
H
27
N
5 0 2 HCl 0. 15 2,3-(CH 2 4 426 C, 62.3 1; H, 5.89; N, 13.97 C, 62.38; H, 6.18; N, 13.27 2-CR 3 3-Cl 420 C 23
H
22
CIN
5 0 2HCI 1.01H20 C, 54.08; H, 5.13; N, 13.71 C, 54.57; H, 5.77; N, 12.92 3-Cl 420
C
22
H
18 C1N 5 0 2 .2 HCl -0.5
H
2 0 C, 56.78; H, 4.33; N, 15.05 C, 56.79; H, 4.69; N, 13.47
NC
WO 96/30343 WO 9630343PCT/US96/04019 197 TABLE 16 n-C 4H.
R-N N- Formula FAB ms (m+1) AnalsisCaic AnalsisFound
;H
2
CH
2 506 C 32
H
35
N
5 0 -3.2 CF 3
CO
2
H
2.65
H
2 0 C, 54.14; H, 5.75; N, 9.15 C, 54.15; H, 5.74; N, 9.18
NC-
484 C 29
H
33
N
5 0 2 -4 HCl 3 H 2 0 C, 51.03; H, 6.35; N, 10.26 C, 51.02; H, 5.66; N, 9.67 506 C 32
H
35
N
5 0 -2 HCl 1.7 H 2
C
C, 63.09; H, 6.68; N, 10.26 C, 51.02; H, 5.66; N, 9.67 I WO 96/30343 WO 9630343PCTIUS96/04019 198 Table 17 R-N Formula
R
K'N-CH
2
CH
2 N b FAB ms (m+1) AnalsisCaic AnalsisFound
OH
2 347 C 21
H
22
N
4 0 -0.2 CHC1 3 0.4 CH 3 0H C, 67.7 1; H, 6.26; N, 14.62 C, 67.7 1; H, 6.26; N, 14.53 358 C 23
H
23
N
3 0 -0.55 CHC1 3 C, 66.85; H, 5.61; N, 9.93 C, 66.87; H, 5.70; N, 10.03 WO 96/30343 WO 9630343PCTIUS96/04019 199 Table 18 FAB mass spectrum 1 Analysis (calcd.. found) MeMe Me 0
NC
7 N N-
N
CI
N
NC 0 406 C29H33N502* 1.OHCl* 0.25CHC13*0.70H20 C, 62.45; H, 6.39; N, 12.45.
C, 62.45; H, 6.46; N, 12.37.
C22H20N50C1-2.6OHCl C, 53.97; H, 4.78; N, 14.30 C, 5 3.97; H, 5.2 1; N, 13. C26H28N50 3 C1S*2.OHCl 1 .20H20 C, 50.32; H, 5.26; N, 11.28 C, 50.31; H, 5.31; N, 10.72.
MeO 2
S
NC NN
N
526 I WO 96/30343 WO 9630343PCTUS96/04O19 200 Table 18 (continued) FAB mass spectrum fM+D Analysis (calcd., found) 420 C23H22N50C*2.OHCl'2. 1 0H20 C, 52.06; H, 5.36; N, 13.20 C, 51.99; H, 5.36; N, 12.57.
Claims (5)
1. A compound which inhibits famesyl-protein transferase of the formula A: R 8 r R 9 )q R 2 R 3 V A'(CR 2 )nA 2 (CR a 2 )n W b2p Y t X Y R 4 R A wherein: Ia lb 10 10 Rla and R are independently selected from: hydrogen, -N(R R C(O)NR or unsubstituted or substituted C 1 -C 6 alkyl wherein the substituent on the substituted CF-C 6 alkyl is selected from unsubstituted or substituted phenyl, -N(R R 0- and 1 10 S:R C(O)NR 2 0 0 R 6 R R 6 R is selected from: H, 0 0 and an unsubstituted or 10 substituted group, the group selected from C_g alkyl, C2- 8 alkenyl and C2- 8 alkynyl; wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C1- 4 alkyl, 6 b) (CH2)pOR c) (CH 2 )PNR R halogen, 2) C 3 -6 cycloalkyl, 6 3) OR 6a 6 6a 4) SR S(O)R a, SOR [I:\DAYLIB\iba393945d.doc:SSD 202 -NR 6 R 7 R 6 6) -N R 7 0 R 6 7) -N N 7 R 7 a 0 8) -0o NR 6 R 7 0 0 09) -0 OR 6 0 NR)R 0 6 R 7 1 0 *0 4 0 R6 000 0 1) F;0 2 or 6 R R4adRar yrgn 2 3 4 an an0w@fRRRadR r pinlyatce t h aecro tm R 6 n aaeidpnetysletdfo :hdoeusbtttdo susiue *0 lyusbsiue rsbtttday ndusbtttdo usiue 00lo lk l [I :DAYLIB\ibaJ393945d .doc:SSO R is selected from: unsubstituted or substituted CF 1 C 6 alkl, unsubstituted or suibstituted aryl and unsubstituted or substituted cycloalkyl; R S s independently selected from: a) hydrogen, aryl, heterocycle, C -C 1 cycloalkyl, C,-C 6 alkenyL. C,)_C 6 ayn, 00 6 Ikyy perfluoroalkyl, F, Cl, Br, R 1 1SOmR1 C(O)NR" (R R i CN, N0 2 R 10C(O)-, R 10OC(O)-, N 3 -N(R I. or R IIOC(O)NR 10-, and c) C 1 FC6 alkyl unsubstituted or substituted by aryl. cyanophenyl. heterocycle, C -C cvcloalkyl, C,6- alkenvh. alkynyt, pertluoroalkyl. F, C1. Br. R'0O-, 10 10 10 1( or R OC(O)NH-:, R is selected from: hydrogen and methyl;, is independently selected from hydrgen alkyl an alyl ezlan rl 1 2 A and A are independently, selected from: a bond. -CH=CH-. 1 10 1 I) OV, NR 0, -N(R -S(O)XN(R or S(O)n: V' is phenyl; W is a heterocycle selected from imidazolinyl, imidazolyl, oxazolyl. pyrazolvl. pyrrolidinyl. thiazolyl and pyridyl; 2U X is Y is unsubstituted or substituted phenyl or unsubstituted or substituted naphthyl, wherein the substituted phenyl or substituted naphthyl is substituted with one or more of: 1) C 1 4 alkyl, unsubstituted or substituted with: a) C 1 4 alkoxy, R7, c) C 3 6 cycloalkyl, d) aryl or heterocycle, e) HO. f) or g) -C(O)NRR, 2) aryl or heterocycle, [I:\DAYLIB\Iiba393945d.doc:SSD 204 3) halogen, 6 4) OR~ 6 7 NR R 6) CN, 7) NO 2 8) CF 3 6a 9) -S(O)mR 6 7 -C(O)NR R or 11) C 3 -C 6 cycloalkyl; mn is 0, 1 or 2; n is 0.1, 2, 3or 4; p is 0. 1, 2, 3 or4; q qis Ilor 2; r is 0 to 5, provided that r is 0 when V is hydrogen: S is 0Gori1; too t tis 0Oor1; and u is 4 or too or an optical isomer or pharmaceutically acceptable salt thereof. to.2. A compound which inhibits farnesyl-protein transferase of the formula B: \r 2RUG a 2 C Ra2) W (CRlb 2 7 N, R 3 R 4 B wherein: R la and R ib are independently selected from: hydrogen, N(R to)2, RoC(O)NR or unsubstituted or substituted C 1 -C 6 alkyl wherein the substituent on the substituted C 1 -C 6 alkyl is selected from unsubstituted or substituted phenyl, -N(R O)2, RI 0- and R 10C(O)NR 1 [I:\DAYLIB\Iiba]393945d.doc:SSD R 6 R 7 R6 R 2is selected from: H, 0 0 and an unsubstituted or substituted group, the group selected from alkyl, C 28 alkenyl and C 2 alkynyl; wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C 4 alkyl, 6 b) (CH 2 )POR c) (CH 2 )PNR R, d) halogen, 2) C 3 6 cycloalkyl, 6 o .103.) OR 6a 6. 6a SR S(O)R, S02R
6. -NR 6 7 7 0 7) N~ NR Ra 0 [1A:DAYLIB\iba]393945d.doc:SSD 206 8) -O NR 6 R 7 0 9) -0 OR 6 0 "Y NR 6 R 7 0 11) -S0 2 -NR 6 R 7 12) R 6 rR 0 14) O 6 0 N 3 or 16) F or R"is selected from: hydrogen and C-C6 alkyl R and R are hydrogen; *2 3 4 5 and any two of R R R and R are optionally attached to the same carbon atom; 6 7 7a R R and R are independently selected from: hydrogen, unsubstituted or substituted C 1 -C 6 alkyl, unsubstituted or substituted aryl and unsubstituted or substituted cycloalkyl; R 6ais selected from: unsubstituted or substituted CFC 6 alkyl, unsubstituted or substituted aryl and unsubstituted or substituted cycloalkyl; R 8is independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -C 10 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, 1110 perfluoroalkyl, F, Cl, Br, R0-, R R 0 OC(0)NR (R o) 2 NC(0)-, 10 10 10 10 11 10 R 2 N-C(NR CN, NO 2 R R N 3 -N(R or R OC(0)NR and [I:\DAYLIB\iba393945d.doc:SSD c) cl-c 6 alkyl unsubstituted or substituted by aryl, cyanophienyl, heterocycle, -cycVloalkyl, C- 6 alkenyl. C 2 -C alkynyl, peril uo roalkyl1, F, CL. Br. R 0-, I 0 10 I)100 1K R (R 2 RI CN. R R N 3 or R OC(O)NH-:- R 9 is selected from: hydrogen and methyl:, Ris independently selected fromn hydrogen. C,-C( 6 alkyl. benzyl and aryl: R is independently selected from C 1 -C 6 alkyl and aryl: 12 .A anid A are independently selected from: a bond. -C-C 10 1I -C(0)NR NR 0. -N(R -N(R or S0111 (i is 0i: V is hn is is a heterocvcle selected from imidazolinyl. inaidazolyl7. oxazolyl. pyrazolyl. pyrrolidinyl. thiazolvlI and pyridvl: X is 7 is a unsubstituted or substituted group selected from aryl. heteroaryl. arv lmethyl. hieteroarvimethyh. aryILulfonyl. hieteroarvILslfonyl. wherein the substituted ffoup is substituted with one or more of the following: 1) akvl. unsubstituted orsubstituted wi th: a) C 1 4 alkoxy. 6 7 b) NR R, C 3 6 cycloalkyt, d) aryl or heterocycle, e) HO. 6a f) or g-C(O)NR R 2) aryl or heterocycle, 3) halogen, 6 4) OR' 627 NR R CN, 7) NO 2 8) CFE 3 [I:\DAYLIB\iba393945d.doc:SSD 6a 9) -S(0)mR 67 -C(0)NR R or 11) C 3 -C 6 cycloalkyl; m is 0, 1 or 2; nis 0, 1,2, 3 or 4; p is 0, 1, 2, 3 or 4; q is 1 or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0 or 1; t is 1: and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof. 3. A compound which inhibits farnesyl-protein transferase of the formula C: V A(CR A 2 (CR la 2 (CR 1 -Z unsubstituted or substituted -C 6 alkyl wherein the substituent on the substituted CF-C 6 S.alkyl is selected from unsubstituted or substituted phenyl, -N(R R 0 and R i selected from: H, 0 0hydrogen, and an unsubstituted or substituted group, the group selected from C 1 8 alkyl, C 2 8 alkenyl and C 2 8 alkynyl; wherein the substituted group is substituted with one or more of substituted C-C 1)alky aryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkyl, 6 b) (CH 2 pOR c) (CH 2 )pNR 6 R d) halogen, [I:\DAYLIB\fiba]393945d.doc:SSD 209 2) C 3 6 cycloalkyl, 6 3) OR 6. 6. 6a 4) SR S(O)R S02R -NR 6 R 7 6) -N R 7 0 R 6 7) -N N 7 7 a 0 8) RR 0 -o0 OR 6 NR 6 R 7 R 6 12) 14N S- 2 -R 6 a 13) R 0 14) OR 0 N 3 o r 16) F; or [1:\DAYLIB\Iiba]393945d.doc:SSD 210 R 3 is selected from: hydrogen and C I-C 6 alkyl; R 4 and W 5 are hydrogen; 2 3 4 and any two of R R R and R are optionally attached to the same carbon atom: 6 7 7a R .R and R are independently selected from: hydrogen. unsubstituted or 3substituted C -C 6 alkyt, unsubstituted or substituted aryl and unsubstituted or substituted CNC loalkyl: RP0 is selected from: unSUbstituted or substituted C-C 6 alkyl. unsubstituted or stibsti tited aryl and unsubstituted or substituted cycl1oalkyl-, R is independently selected from: 0a) hydrogen. K) aryl. heterocycle, C, cvcloalkNyl. 6 alkenvl. C,-CO alkvnN'l. perfluoroaikyi. F Cl. Br. R R P. C(O)NR (R *1w 10 1I 1O 1 P N-C(NR CN. NO, P. R N 3 -N(R R. OC(O)NR and C 1 -C6cx alkyl unsubstituted orsubstituted by ar. 16npent eercce C Cloalkyl, C,-C 0 alkenvl. alkvnyl. perfluoroalkyl. F. Cl. Br. R 0-. R H 1 R 10C(O)NH-. I R 10N-C(NR I- CN. R I )C R. N11 -N(R ),or R OC(O)NH-- P is selected from: hydrogen and methyl; :R is independently selected from hydrogen. C Il-C6 alkyl, benzyl and aryl; .R 0 P. is independently selected from CI-C6 alklan rl. ccA and A are independently selected from: a bond, -CH=CH-. 1) 10 11() I10 -C(O)NR 0, -N(R S(O) 2 N(R -N(R)SO- or (n, G isO0: V is phenyl; W is a heterocycle selected from imidazolinyl. imidazolyl, oxazolyl, pyrazolyl. pvrrolidinyl. thiazoly I and pyridyl; X is 7, is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl. heteroarylmethyl, arylsulfonyl, heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: 1) C4 alkyl, unsubstituted or substituted with: a) C 1 4 alkoxy, [I ADAYLI B\Iiba]393945d. doc:SS D 6 7 b) NRR, c) C 3 6 cycloalkyl, d) aryl or heterocycle, e) HO, 6a f) or 6 7 g) -C(O)NR R aryl or heterocycle, halogen, 6 OR~ 6 7 NR R CN. NO,, CE7 3 6a 6 7 -C(O)NR R. or C 3 -C 6 cycloalkyl; 9A 9 9 9* .9 9
9. *9 9 9. 9* 9* 9 9 9 9* 9 9 9 999 9 99 99 9. 99 9 .9. 9 9
99.. 9 9*99 9 9* 99 10) 11) MIS 0.l1or2I n is 0. 1, 2, 3or 4; p is 0, 1,2,3or 4; 20 q is Ilor 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 1; t is 0Oor1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof. 4. The compound according to Claim 1 of the formula A: (R 8 )r (R9 RR V Al(CR a 2 2 (CRla 2n- I (CR 2 )p N y/j NP A wherein: R la is independently selected from: hydrogen or C 1 -C 6 alkyl; [IA:DAYLI B\iba393945d. doc: SSD lb R is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R -N(R )2 or C 2 -C 6 alkenyl, c) unsubstituted or substituted C,-C 6 alkyl wherein the substitutent on the substituted Ci-C 6 alkyl is selected from unsubstituted or substituted aryl, heterocycle, cycloalkyl, alkenyl, R O- and -N(R )2; R is selected from H and CH 3 4 R and R are hydrogen; NR 6 R 7 R is H: 0 or CI, alkyl, unbranched or branched. unsubstituted or 10 substituted with one or more of: 1) aryl. 2) heterocycle, S OR, 6a 6a 4) SR ,SO 2 R ,or 5) NR 6 R 7 O 2 3 4 and any two fR,R and R are optionally attached to the same carbon atom; S6 7 7a R, R and R are independently selected from: H; C,_ 4 alkyl, C3- 6 cycloalkyl, aryl, heterocycle, unsubstituted or substituted with: a) CI- 4 alkoxy, b) halogen, or c) aryl or heterocycle; 6a R is selected from: C 1- 4 alkyl or C 3 -6 cycloalkyl, unsubstituted or substituted with: a) C,- 4 alkoxy, b) halogen, or c) aryl or heterocycle; R is independently selected from: a) hydrogen, [I :DAYLiB\Iiba]393945d.doc:SSD a a. a a a. a a. a a a a. a a a a a a a a.. a a a a a. a b) C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 perfluoroalkyl, F, Cl, Rto0, R1 0 C(O)NRI, CN, NO 21(R 0 )2N-C(NR 0 RIC(O), R]OC(O), NR0)2 or R 11OC(O)NR and c) C 1 -C 6 alkyl substituted by CI-C 6 perfluoroalkyl, R 100-, R toC(O)NR o-, 10 10 10 10 10 110 (R )XN-C(NR R RI -N(R or R OC(O)NR' 0 R 9is selected from: hydrogen and methyl; R 10is independently selected from hydrogen, C 1 -C 6 alkyl, benzyl and aryl; R1 is independently selected from C -C 6 alkyl and aryl; 1 2 10 II0 A and A are independently selected from: a bond, -C(O)NR NR 0, -N(R -S(a 10)-and SO,- V is phenyl; W is a heterocycle selected from imidazolinyl, imidazolyl. oxazolyl, pyrazolyl, pyrrolidinyl, thiazolyl and pyridyl; X is -CH 2 5 Y is phenyl or naphthyl, unsubstituted or substituted with one or more of: a) C 14 al kyl, b) C 1 4 alkoxy, c) halogen, or 6 7 d) NR R; 20 m is 0, 1 or 2; n is 0, 1, 2,3 or 4; p is 0,1, 2, 3or 4; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0or1; and t is 1 or an optical isomer or pharmaceutically acceptable salt thereof. The compound according to Claim 2 of the formula B: [I :DAYLiB\Iiba]393945d.doc:SSIJ (R )r (R9" R 2 G V Al(CR 2),A 2 (CRl 2 11 (CRl2)p\,K R 3 R 4 B wherein: R lais independently selected from: hydrogen or C 1 -C 6 alky]; R Ibis independently selected from: a) hydrogen, b) aryl, heterocycle, cvcloalkyl, RI -N(R or C 2 -C 6 alkenyl, C) unsubstituted or substituted C 1 -C 6 alkvl wherein the substitutent on the :0substituted C 1 -C 6 alkyl is selected from unsubstituted or substituted aryl. heterocycle, 1. 00 cloalkyl, alkenyl, R 0- and R is selected from H and CH 3 0 4 R is hydrogen; NR 6 R 7 is H; 0 or C,- 5 alkyl, unbranched or branched, unsubstituted or substituted with one or more of: 0 1 aryl, 15 2) heterocycle, 3) OR, 6a 6a 4) SR S0 2 R ,or NR 6 R 7 0 and any two of R 2, R 3, R 4 and R 5are optionally attached to the same carbon atom; R R 7and R 7aare independently selected from: H; C 1-4 alkyl, C3 -6 cycloalkyl, aryl, heterocycle, Linsubstituted or substituted with: a) C,- 4 alkoxy, b) halogen, or c) aryl or heterocycle; 6a R is selected from: [i:\DAYLI8\Iiba]393945d .doc:SSD C 4 alkyl or C 3 6 cycloalkyl, unsubstituted or substituted with: a) C 4 a]lkoxy, b) halogen, or c) aryl or heterocycle; R 8is independently selected from: a) hydrogen, b) C-C 6 alkyl, C-C 6 alkenyl, C,,-C 6 alkynyl, C-C perfluoroalkyl. F, Cl, b) 10 C 20 6 0 10 10 01 R 100-, R 10C(O)NRI CN, N02, (R 10) 2 N-C(NR R 10C(O)-, RI -N(R O)2' or I 1 R OC(O)NR -,and 0 c) Cl-C 6 alkyl substituted by C 1 -C 6 perfluoroalkyL, RI R 10C(O)NR (0 10-(N R 10 R -N(R or R OC(O)NR~- R is selected from: hydrogen and methyl; R is independently selected from hydrogen, CFC alkyl, benzyl and aryl; :R 1 is independently selected from C 1 -C 6 alkyl and aryl; and A are independently selected from: a bond, -C(0)NR NR 0, 101 10 -N(R and -N(R G Gis 0; V. V is phenyl; W is a heterocycle selected from imidazolinyl, imidazolyl, oxazolyl, pyrazolyl, S 20 pyrrolidinyl, thiazolyl and pyridyl; Xis -CH 2 Z is mono- or bicyclic aryl, mono- or bicyclic heteroaryl, mono- or bicyclic arylmethyl, mono- or bicyclic heteroarylmethyl. mono- or bicyclic arylsulfonyl, mono- or bicyclic heteroarylsulfonyl, unsubstituted or substituted with one or two of the following: 1) C 14 alkyl, unsubstituted or substituted with: a) C 1 4 alkoxy, 6 7 b) NRR c) C 3 6 cycloalkyl, d) aryl or heterocycle, e) HO, 6 f0 -S(O) 1 nR or 6 7 g) -C(O)NR R [I:\DAYLIB\Iiba]393945d.doc:SSD 2) aryl or heterocycle, 3) halogen, 6 4) OR, 6 7 NR R 6) CN, 7) NO 2 8) CE 3 6 9) -S(O)n R 6 7 -C(O)NR R ,or 1011) C3 6 cycloalkyl; m is 0. 1 or 2, n is 0. 1.2. or 4. .pis 0. 1,2 or 4, r is 0 to 5, provided that r is 0 when V is hydrogen: sis 0Oorl1; t is 1, and ulis 4 or :or pharmaceutically acceptable salt thereof. A compound which inhibits farnesyl -protein transferase which is: 20 1- -Amino (2 -naphthylmethylamino)prop -I -vl)-2(S)-butyl-4-( I naphthovl)piperazine 2(S)-Butyl- 1 1 -(2-naphthylmethvl)] -4,5 -dihvdroimidazol methvl-4-(l naphthoyl)piperazine 1- 1-Benzylimidazol)methyl]-2(S)-butyl-4-( 1-naphthoyl)piperazine 1- {5-fl -(4-Nitrobenzyl)imidazolyl]methyl }-2(S)-butyl-4-( 1-naphthoyl)piperazine 2(R)-Butyl- 1 -(4-imidazolyl)-4-methyl-4-( 1 -naphthoyl)piperazine 2 (S)-Butyl-4-( 1 -naphthoyl)- 1 -pyridylmethyl)piperazine 1 2 (S)-Butyl-(2(R)-(4-nitrobenzyl)amino-3 -hydroxypropyl)..{.(1. naphthoyl)piperazine 2 (S)-Benzyl- I -imidazolyl-4-methyl-4-( 1 -naphthoyl)piperazine 1 -(2(R)-Amino-3 -benzylthio)propyl)-2 (S)-butyl-4-( 1 -naphthoyl)-piperazine 1 -(2(R)-Amino-3 -(4-nitrobenzylthio)propyl]))-2(S)-butyl-4-( 1 -naphthoyl)piperazine 2(S)-Butyl- 1 -[(4-imidazolyl)ethyl] 1 -naphthoyl)piperazine 2(S)-Butyl- 1 -[(4-imidazolyl)methyl] 1 -naphthoyl)piperazine [1:\DAYLIB\Iiba]393945ddoc: SSD 2(S)-Butyl- 1 -naphth-2-ylmethyl)- 1 H-imidazol-5-yl)ethyl]-4-( 1- naphithoyl)piperazine 1 -Amino- 3 -benzyloxyphenyl)propy)>2 (S)-butyl 4-(1 -naphthoyl)piperazine 1 -Amino -3 2 -hydroxyphenylI)propyly2 (S)-butylA I -naphthoyl)piperazine 1- [3 4 -Jmidazolyl)propyl]-2(S)-bLutyl-4( 1 -naphthoyl)piperazine 2(S)-n-Butyl-4-( 1-naphthoyl)- -naphthvlmethyl)imidazol.5-ylmethylj piperazine 2( S)-n-Butyl-4-( 1 -naphthovl)- 1-[l 2 -naphthvlrnetlhyl)irnidazol.5 -ylmethyll- piperazine 0 2 (S)-n-BLutyl- 1- [1 4 -cyanobenzyl)irnidazol-5-vlmethvl]-4-( I -naphthovl)piperazine 2 (S)-n-Butyl- 1-[l 4 -rnethioxybenzvlimidazol15-yimethivl]-4-( 1- naphthoyl )piperazine i 2 (S )-n-Butvl- 1-[l -methvl-2-butenvl)imidazol.5 -yvlmethvl]-4-(l naphthoyl)piperazine I S 2(S)-n-Butvl- I -fl-( 4 -fluorobenzvl)imidazol-5-ylmethvly4.( 1 -naphtliovl)piperazine 2(S)-n-Butvl- 1 -(4-chlorobenzvl)imidazol-5 -vimethyl 1 -naphthovl)piperazine 1-fl 4 -Bromobenzyl)imidazol.5 -ylmethvl]-2(S)-n-butvl-4-( 1-raphthoyl)piperazine I-fl 4 -Bromobenzvl)imidazol- 5-ylmethy 1] 2 (S)-n-butyl -naphthoyl)piperazine 2(S)-n-Butyl-4-( 1 -naphthoyl)- I1-[lI 4 -trifl uorom ethyl benzyl)imidazolS ylrnethyll-piperazine 2(S)-n-Butyl- 1-[Il-( 4 -methylbenzyl)imidazol-5 -ylmethyl]-4-( 1-naphthoyl)- piperazine 2(S)-n-Butyl- 1-fl-(3 -methylbenzyl)imidazol-5-ylmethyly4-( 1-naphthoyl)- piperazine 1-fl 4 -Phenybenzy)imidazo5 ylmethy] 2(S-n-butyl.4-(I -naphthoyl)-piperazine 2 utyl-4-( 1 -naphthoyl)- 1 -fl 2 -phenylethyl)imidazol-5Sylmethyl] p iperazine 2 (S)-n-Butyl-4-( 1 -naphthoyl)- 1 -fl 4 ylmethyllpiperazine (S)-n-Butyl- 1l-( 2 3 -dimethylphenyl) -imidazo lylmethl)y1piperazin2-one 5 (S)-n-Butyl-4- [1 4 -cyanobenzyl)imidazol-5 ylmethyl] 1 -(2,3 dimethylphenyl)piperazin-2-one 4-f 4 -Cyanobenzyl)imidazol-5 -ylmethyl] 1 -dimethylphenyl)-5 methoxyethyl)piperazin-2 -one (S)-i1 -Chlorophenyl)-4-f I -(4-cyanobenzyl)-5 -imidazolylmethyl] -5-f[2- (methanesulfonyl)ethyl] 2 -piperazinone [I :\DAYLiB\Iiba]393945d.docSSD (S 1 -(3'-Chlorophenyl)-4-j1 -(4-cyanobenzyl)-5-imidazoiylmethyl]-5-[2- (e Ih aneSuL fo ny )ethylI] -2-piperazinone I -(3)-Chlorophenyl)-4-[ 1-(4-cyanobenzyl)-5-imidazolylmethyl]-5-[2- (ethancs u fonvl)methyli -2-piperazinone (S I )-Chioropheny [1-(4-cyanobenzvl)-5-imidazo lvlmethlyl]-5 -[jjN-ethyl-2- acetamnido 1-2 -piperazi none 1 -(3)-chlorophenvl)-4-[ 1-(4-cvanobenzvl)-5-imidazolv lmethvl]-2- ni perazinione I -(3-ChIlorophenyt)-4-[1-(4-cvaniobenzyIl)-5 -imiiciazolvlmethvI]-'2-piperazinone S )-Butx'1-4-[ I-(4-cyanobenzvt-2-methv1)-5-imidazolylm-iethy1]- 1 I imethiyI li envl'j-piperazin- -one 4-1 l-('--(4-C\vanoplhen-v1)-2-propyl)-5 -iidazoINv ii-ethl-]- 1 3-chlorophenyl)-5( S)- -meWtl suitfonylethNvI)piperazin-2)-onie 0: -S)-n-BLItvl 1-(4-cvanoben-zvl )-5-imidazolvlmi-ethvl]- 1 0: 11CLIIN phen, I)piperazin-2-one l -(4-CNvariobenzyl)-5 imidazolvlImethvlj1-5(S)-( 2-fltioroethv1)- c 1 I ho ro phenvyl)piperazin-2-o ne 4-1 S-(4-C yanoberizvl)pyridin-4-yl1--(-c liorophen y1) II CO 111hV ISLtfonyiethyl)-piperazmn-'-one 4-[5-(4-Cvanobenzvl)- I-irnidazolylethvl]- 1-(3)-chlorophenvl)piperazin-2-onie OF LI pharmaceutically acceptable salt or optical isomer thereof. 7. A compound which inhibits farnecsyl-protein transferase which is: Soso 0 so0 [I:\DAYLIB\Iiba393945d.doc:SSD 219 Table 1 CH 3 O H 2 *1* 0* 4* F H 2 C CH 2 C H 2 OH 2 TABLE 2 stereo. X Y R n-Bu 2-O(CH29 13 CH 3 S n-flu 2-O(CH 2 1 3 CH 3 R n-flu 2-O(C-19 11 CH 3 S n-flu 2-O(CH29 1 ,CH 3 R n-flu 2-O(CH29 9 CH 3 H 2 N [I:\DAYLIB\Iiba]393945d.doc:SSD S R S R S R n-Bu n-Bu n-Bu n-flu n-flu n-Bu 2-O(CI-1299CH 3 2-O(CH2)7CH 3 2-O(CH2 7 C- 3 2-O(CH 2 3 Ph 2-O(CH 2 3 Ph 3-OCH2Ph TABLE 2 (continued) 2 H 2 N' 0 ~0 0 C stereo. X Y 0 S n-flu 3-OCH 2 Ph R n-flu 3)-O(CH 2 1 CH- S n-flu 3)-O(CH 2 1 3 CH 3 R n-Bu 4-O(CH 2 1 3 CH 3 S n-flu 4-O(CH29 13 CH 3 15sS n-flu 4-OCH 2 Ph R/S 1- 2-O(CH 2 13 CH 3 TABLE 3 Me NC N 0/ 0 N 3-SO 2 Me 3)-OCF 3 [I:\DAYLIB\Iiba]393945d .doc:SSD TABLE 4 NC N~ NN N x Y CH,,OCH2Ph CF 3 CH 2 SO 2 Et CF., CH,,SO 2 Ph CF 3 CJ-LSO 2 Me CL *CH 2 SOEt Cl CONHMe CF, i CONHEt CF,. CH~SO2,Ph *CONHMe Cl CONHEt Cl :CONI-c-Pr CI 1 5 CONHc-Pr CF, TABLE 4 -continued) x y .:NC N N N X 0 N x y NHCOMe Cl CONMe 2 CF 3 SO 2 Et Cl CH 2 SMe Cl ()C=-CMe Cl [I:\DAYLIB\Iiba]393945d.doc:SSD TABLE X-N N 0 0* S. S S *5 S S 5 *5S* S S S S S S *5*S S .55. S S. 5 I x CH 2 CH 2 CR, CH? CHR) CH, CaI, 0 CH, CH, CH, Y H H -_Cl 2, 3-Cl. 2-Br 3)-CF. 4-Cl 3)-F 3-Br TABLE 6 Me0 2 S N 15 X Y Z 3-CN CR 2 -C 2 2-CN CH 2 5-CH 2 TABLE 7 NC N NN X'N X 4-Me CH 2 CH 2 SO 2 M 4-Me H 2-Me H [I:\DAYLI B\Iiba]393945d. doc: SSD 223 TABLE 8 a a S. S S S *SS S .5.5 S S S S a a S a S *555 S a S S S *5 S S. S Y 3-CF 3 .3-CH- 4 -3-Cl 2-CH 3 ,3-Cl H [I:\DAYLIB\Iiba]393945d. doc: SS D 224 TABLE 9 R CF 3 NC N N R CH-&H, OCHCF 3 OCH 1 CH,, old *CHCH2NCCH3 o-j CH 2 CHSNHC 2 a....CH 2 CHSCH(CH 3 )2 [1:\DAYLIB\Iiba]393945d.doc:SSD 225 TABLE n-C 4 H 9 OH 3 OH 3 R-N N 0 R 0 2 N N CH 2 OH 2 NCN NC H 2 NC a a **H 2 *Z a. N NC B a N [I :\DAYLIB\Iiba]393945d.doc:SSD 226 TABLE 11I R Y cI F S. 50 SO S. S C. 0. S 0 C C. S S S 0 C 0* C C S OCS *SC. 0 C C S C. C C CC OH 2 NCN CH 3 OH 2 NCN N TABLE 12 OH 3 OH2 H 2 N [I:\DAYLIB\Iiba]393945d.doc:SSD ON TABLE 13 H 3 C-S0 2 R-N N-- 0 R a a a a a a a a .a a a a a. a. .a. .a.a a .aaa a a. a a. a a a OH 2 NCCN [I :\DAYLIB\Iiba]393945d.doc:SSD 228 TABLE 14 Rl R7- CH 2 NCN CHCH,,F 9 9 S. a a. a a a a a a a a a. S *Sa* a. S a .9 a. a .Sa S a a a. a a a S. S TABLE R-N N-0 0 R CH 2 NC OH 2 NCN Y 2,3-(C11 9 1) 4 2-CH 3 3-Cl [[:\DAYLIB\Iiba]393945d .doc:SSD 229 TABLE 16 n-C 4 Hq R-N N 0 R z CH 2 CH 2 Nx NC N NC 00 *N CH 2 N [I:\OAYLIB\Iiba]393945d.doc:SSD 230 TABLE 18 (-S IV' NC-0 N a a a. a a a a. a a a a. a a. S a a a. S a a a a a a a a a a a a a. a a a a a a. a. a or a pharmaceutically acceptable salt or optical isomer thereof. 8. The compound according to Claim 6 which is: 1-(4-nitrobenzyl)]imidazolylmethvlI 1 -naphthoyl)piperazine 0 0 2 N N N N or a pharmaceutically acceptable salt thereof. 9. The compound according to Claim 6 which is: 1-[5-(l1 -Benzylimidazol)methyl]-2 (S)-butyl-4-( 1 -naphthoyl)piperazine 0 N \-jN N or a pharmaceutically acceptable salt or optical isomer thereof. The compound according to Claim 6 which is: [I:\DAYLIB\Iiba]393945d.doc:SSD 9. 99 9 9 99 9 9. 99 S 99 9 99 99 9 99 9. 9 9 9 9 .9 9 9 9 9 999 9 9999 99 .9 9*99 9 99 9 999 9 9 9999 9999 9 9 99 9 4 #9 9 231 I -(2(R)-Amino-3 -benzylthio)propyl)-2(S)-butyl-4-( 1 -naphthoyl)piperazine -~NH 2 0 S K N N or a pharmaceutically acceptable salt or optical isomer thereof 11. The compound according to Claim 6 which is: 1 -(2(R)-Amino-3 -(4-nirrobenzylthio)propyll)-2(S)-butyl-4-( 1- naphthovl)piperazine 0 2 N -N NH0 S -K N \jN or a pharmaceutically acceptable salt or optical isomer thereof. 12. The compound according to Claim 6 which is: 2(S)-n-Butyl- 1 -(4-cyanobenzyl)imidazol-5-ylmethyl]-4-( I -naphthovl)piperazine 0 NC N N N J or a pharmaceutically acceptable salt or optical isomer thereof. 13. The compound according to Claim 6 which is: 2(S)-n-Butyl-l1-[1 -(4-cyanobenzyl)imidazol-5-ylmethyl]-4-(2,3 -one [I:\DAYLIB\iba393945ddoc:SSD 232 H 3 C OH 3 NC -0 \N N N N or a pharmaceutically acceptable salt or optical isomer thereof. 14. The compound according to Claim 6 which is: 2(S)-n-Butyl- 1-ri 4 -chlorobenzyl)imidazol-5-ylmethyl]1A( 1 -naphthoyl)piperazine 0~ *0 I N N N 0 *3 CH* N N~ N or a pharmaceutically acceptable salt or optical isomer thereof. The compound according to Claim 6 which is: 1(S-ri-4-C 4--4yanobenzao- yl--mthyly3methylphcn 15 methoyetyl)piperazin-2 -one [I:\DAYLIB\Iiba]393945d.doc:SSD OH 3 H 3 C NC N N N0 N or a pharmaceUtically acceptable salt or optical isomner thereof. I S. The compound according to Claim 6 which is: (S 1 -(3)-Clhlorophenyl)-4-[ 1-(4-cvanobenzvl )-5-imidazolylmeth-vl 1-5-19 (iinetlaiestifonvlI)ethvl]-2-piperazinonc o/s H 3 *2S NC N a OF a p harmaceutic ally acceptable salt or optical isomer thereof. *19. The Compound according to Claim 6 which is: 3-Chlorophenvl)-4-[11-(4-cyainobenizvl)-5-imidazolylmethvil]-5-[2- u (ethianesulfonvl )ethvl]- 2 '-piperazinone ,CH 2 CH3 C. 0 2 S Cl NC N N- N Ir 0 N or a phiarm aceutic ally acceptable salt or optical isomer thereof. The compound according to Claim 6 which is: I -(3)-Chiloropheniyl)-4-[ 1-(4-cyanobenizyl)-5-imidazotylmethivl]-5-[2- 1 (ethaniestulfonyl)n-ethyll -2-piperazinone [I\ADAYL IB\Iiba]393945d. doc: SS D CH 3 SO 2 CI NC N or a pharmaceutically acceptable salt or optical isomer thereof. 21. The compound according to Claim 6 which is: 1-(3-Chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolyl-methyl]-2-piperazinone CI NC N N N or a pharmaceutically acceptable salt or optical isomer thereof. 22. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 1. 23. A pharmaceutical composition comprising a pharmaceutical carrier, and 10 dispersed therein, a therapeutically effective amount of a compound of Claim 2. 24. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of Claim 3. 25. A pharmaceutical composition comprising a pharmaceutical carrier, and :0 dispersed therein, a therapeutically effective amount of a compound of Claim 6. 26. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula A: (R 8 )r /R 9 )q R 2 R 3 V Al(CRla 2 )nA 2 (CRla 2 )n W (CR1 2 )pX N\ N R 4 R A wherein: R nand Rlb are independently selected from: [1A\IAYLIB\Iiba]393945d.doc:SSD 235 a) hydrogen, b) aryl, heterocycle, C 3 -C 10 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, R'O-, R' 0 -N(R' 0 or R"lOC(O)NR'o c) unsubstituted or substituted CI-C 6 alkyl wherein the substitutent on the substituted C 1 -C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 -CI 0 cvcloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, R' 0 R! R 10 C(O)NR' 0 (R' 0 2 CN, (R 1 2 N-C(NR' 0 R 10 R' 0 N 3 -N(R' 0 and R' 'OC(O)-NR R 2 and R 3 are independently selected from: H; unsubstituted or substituted C 1 8 alkyl, unsubstituted or substituted C-) 8 alkenyl, unsubstituted or substituted alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocyclec, Y R 6 R 7 o -eR 0 0 wherein the substituted group is substituted with one or more of: :1 1) aryl or heterocycle, unsubstituted or Substituted with: a) CI- 4 alkyl. b) (CH 2 1 ,OR 6 .c (CH)pNR R d) halogen, e) CN, 2) C 3 6 cycloalkyl, 3) OR 6 4) SR 6a, S(O)R 6 a S0 2 R 6 a, 5) -NR R 7 6) 0 7) -N NR 7 R 7 a 0 [I:\DAYLIB\Iiba]393945d.doc:SSD 236 8) -0 NR 6 R 7 Y 0 9) -O OR 6 0 rNR 6 R 7 0 11) -S0 2 -NR 6 R 7 12) N~S0 2 R 6 a R 0 0 R6 15) N3 1or
169. o 0* Aweei n V of th cab nao si9pinlyrpae yam it eetdfo :0 O *92 3 Rn n w RRR and R are otoal attached to the same Cctmadar obie of r o atom;, heen n R 6: R and R are independently selected from and 4 alyCH6 3 ;olk eercce Rb,) and or 7 ~aeidpnetyslce rm ;C 4 akl ylak heterocycle, c) halogen, d) HO, e) YR 0 f) -SO 2 R' 1 or g) N(R 10 2 or [l:\DAYLIB\iba393945d.doc:SSD R( and R 7 may be joined in a ring; R' and R may be joined in a ring; RNI is selected from: CI- 4 alkyl, C 3 -6 cycloalkyl, heterocycle, aryl, unsubstituted or Substituted with: aI) C1-4 aikoxy, b) aryl or h eterocycle, 0) halog~en. dI) HO,0 e) R 0 f) -S0 2 R 1 or H 2 R' Is independently selected from: a) hydrogen. h) arvi. heterocycle. C 3 -CIO cycloalkyl. C 2 alkenivi. C2-C6' alkynyl. periluoroalkyl, 0 I Br. R R" 3 'C(O)NR' 0 R u 2 CN, NO,. R N 3 1 2 or R' 'OC(O)NR'( and C -C 1 alkyl Unsubstituted or substituted by aryl, cyanophen\'l. heterocvele, C 3 -C 10 :cvcloalkyl. C-1-C6, alkenyl. C_)C alkynyl, perfluoroalkyl. F. CL. Br. R'O R R'OC(O)NH-. (R Rt'A 2 CN, R' 0 N. R 1 11 0C(0)NH-: i~R is selected from: a) hydrogen, CI-C 6 alkenyl, C 2 -C 6 alkynyl. pefurakl RI (C(O)NR" (R O) 2 R 2 N-C(NR CN, R' 1 N 3 N(R' 1 or R' 'OC(O)NR" 3 and 53 c) alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, WOO0-, I R' 0 C(O)NR' (R" 1 2 CN, R' 0 R"O 9 N 3 NR(),or R It0C(O)NR' 0 R 1 ('is independently selected from hydrogen. C I-C 6 alkyl, benzyl and aryl: R'is independently selected from C -C 6 alkyl and aryl; A' and A are independently selected from: a bond, -CH CH-, -C(O)NR 1 0 NR 111 0, -S(O) 2 2 or SO,, [I;\DAYLIB\iba]393945d.doc:SSD V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) Ci-C 20 alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from 0, S, and N, and e) C 2 -C 20 alkenyl, provided that V is not hydrogen if A' is S(O)m and V is not hydrogen if A' is a bond, n is 0 and A 2 is S(O)m; W is a heterocycle; X is -CH 2 or Y is unsubstituted or substituted aryl or unsubstituted or substituted heterocycle, wherein the substituted aryl or substituted heterocycle is substituted with one or more of: 1) Ci- 4 alkyl, unsubstituted or substituted with: a) C1- 4 alkoxy, b) NRR 7 c) C 3 -6 cycloalkyl, d) aryl or heterocycle. e) HO, f) -S(O),mR or g) -C(O)NR 6 R 7 2) aryl or heterocycle. 3) halogen. 4) OR 6 *6 7 5 5) NR 6 R 7 6) CN. 7) NO2, 8) CF 3 9) -S(O)mR 6 *7 20 10) or o 11) C 3 -C 6 cycloalkyl; m is 0, 1 or 2; n is 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q is 1 or 2; r is 0 to 5, provided that r is 0 when V is hydrogen; s is 0 or 1; t is 0 or 1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof. 27. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula B: (R 8 )r (R 9 )q R 2 G V Al(CRa 2 )nA 2 (CRa 2 n -W (CRlb 2 )p N N-Z R 3 R 4 B wherein: [I:\DAYLIB\Iiba393945d.doc:SSD b R1 and R Ib are independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -CI 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, R' 0 0-, R 1 1 R' 0 C(O)NR 1 0 CN(R' 0 2 R' 0 2 N-C(NR' 0 CN, N0 2 R' 0 R' 0 -N(R 1 0 2 or R''OC(O)NR' 0 c) unsubstituted or substituted CI-C 6 alkyl wherein the substitutent on the substituted C 1 -C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 -CIO cycloalkyl, C 2 )-C 6 alkenyl, C 2 -C 6 alkynyl, R'00-, R'('C(O)NR' 0 (R 10 2 NC(O)-, R 10 2 N-C(NR' 0 CN, R' 0 R' 0 N 3 -N(R 1 2 and R 1 'OC(O>-NR' 0 R 2 and R 3 are independently selected from: unsubstituted or substituted CI-x alkyl. unsubstituted or substituted C-) 8 alkenyl, unsubstituted or substituted C 2 8 alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, R 6 R 7 R 6 or .0 0 wherein the substituted group is substituted with one or more of: 1 I 1) aryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkyl, b) (CH 2 ,)pOR 6 c) (CH 2 )pNR 6 d) halogen, e) CN, 2) C 3 6 cycloalkyl, 1~ 6 a 6a, 6am~ *4 SRx S2 -NR 6 R 7 R 6 R 6 0 [I:\DAYLIB\Iiba]393945ddoc:SSD 8) -0 NR 6 R 7 0 9) -0 OR 6 0 "Y NR 6 R 7 0 11) -SO -NR 6 R 7 12) -N-SO 2 -Ra :.13)R6 :.:14)6 0 N 3 or 16) F; or a a R 2 and R 3 are attached to the same C atom and are combined to form (CH 2 wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, and -N(COR' 0 R is selected from H and CH 3 and any two of R 2 R 3 and R 4 are optionally attached to the same carbon atom; R 6, R 7and R 7aare independently selected from: H; C 1 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) C 1 4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) R1 f) S0 2 R 1 1 ,or [IAD\AYUIB\1ba393945d.doc:SSD or [ZI anid R 7 may be joined in a ringZ R 7and R 7 a may be j oined in a ring; IS selected fromn: C1-4 alkyl, C 3 -6 cycloalkyl, heterocycle, aryl, unsUbstituted or suibstituted with: a) CI-4 alkoxy. h) arvi1 or heterocycle. c) lialot~en. di) 110. e) R 11 0 f) -SOR' or R' is independently selected from: hydrogen. b) arvi. heterocycle. C 3 -CIO cvcloalkvl,. C&-C6 alkenvI. C?-C6, alkynyl, perfluoroalkyl. F C L Br. R'U R 1 R' 11 (R' 0 R'( 1 2N-C(NR 1 (iN. NO?, N 3 -N(R 1 or R' 'OC(0)NR 1 K* and C) Cl-C), alkyl unsubstituted or substituted by aryl. cyanophenvl, heterocycle. C 3 ,-C 1 QCvclalkyl, C 2 '-C 6 alkenyl. C_2-C6 alkynvl. perfluoroaikNl. F. Cl. Br. R' (R 0) 2 R" 2 CN, R' 0 R' 11 N 3 2 or R1 P OC(0)NH-; P. is selected from: a) hydrogen. b) alkenyl, alkynyl, peril uoro alkvl F. Cl. Br, R' 0 R''S(0> 1 R' 0 2 N-C(NR' 0 CN, NO%. R' 0 R' 0 N 3 -N(R" t 2 or R3 P.OC(0)NR 1 1 and C) C 1 -C 6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R' 11 O-, R 1 0 C(0)NR'K, (R' 0 2 R' 0 2 (iN, R' 0 R' 0 N 3 N(R or R"'OC(0)NR' 0 Rio is independently selected from hydrogen, C I-C6, alkyl. benzvl and aryl; R. is independently selected from C 1 -C 6 alkyl and aryl; A' and A? are independently selected from: a bond, -CH=CH-, -C(0)NR K- 0, -S(0) 2 -N(R 1 0 )S(0) 2 orS(), [I:\DAYLIB\Iiba393945d.doc:SSD o is or 0-, is selected from: a) hydrogen, b) heterocycle. c) arvi. d) Cl-C 20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0, S, and N, and e) C 2 -C 2 alkenyl. providedthat V is not hydrogen if A' is and V is not hvdro,)en ifAisabn.ns0 and A 2 is W is a heterocycle; X is or Z is a unsubstituted or substituted group selected fromn aryi, he teroarvi. aryimethyl. heteroarvrnLmetvl. arvlsulfonivl. hereroaryisulfonvl. wherein the substituted aroun is substituted with one or more of the following: C, aikvi. '[usiue r usiue I-h: a) alkoxv. ID) NR"R c; \oaK. d) aCor here-ocvlCic. c) 4 or L,-CO) R~ )arvl- or heterocvclh2'. S~ halooen, 6* C" 7) NO* 1 CF-OR_ 9) _Sa.'R, 7 10 C()NRRo 11 C3C cvcloalk<J is 0.1o ,s0 ,2 r4 ,1 sIo :ri o5 rvddta 2* 0,Ae Vashdo :si rIt s0o :adui or an opia ismro-hraetclyacpalatteef 28. (A CehdfrihbiigfreC.roentasea hc opie 7)insern toamma n edteef hrpuiclyefciv.muto phraeuia copsto opiigapamcuialcriraddsesdteen thrpuial efetvamuto omon ftefruaC [l:\DAYLI B\iba]393945d. doc: SSID (R 8 )r 2 R 3 V Al(CRla 2)A 2 (CRla 2) (CRlb 2 )p K"N -N -z wherein: Ri "and Ri b are independently selected from: a) hydrogen, b) aryl, heterocycle. C 3 -C 10 cycloalkyl. C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, R1 0 0-, R' 0 C(O)NR' 0 (R' 0 R" 0 2 N-C(NR 1 0 CN. NO 2 R 10 R' 0 0C(O)-, N 3 -N(R 10 2 or R' 1 I0C(O)NR 0 c) unsubstituted or substituted C 1 -C 6 alkyl wherein the substitutent on the substituted CI-C(, alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 -CI 0 cycloalkyl, C 2 -C 6 alkenyl. C 2 -C 6 alkynyh, RWO-, R' 0 C(O)NR' 0 (R' 0 R 2 ,N-C(N CN, R' 0 R -N(R 1 0 2 n 1 CO-R 1 R 2and R 3 are independently selected from: H; unsubstituted or substituted Cl- 8 alkyl, *unsubstituted or substituted C 2 8 alkenyl, unsubstituted or substituted C 2 8 alkynyl, *unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, N R 6 R R or 0 0 wherein the substituted group is substituted with one or more of: aryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkyl, b) (CH 2 )pOR 6 C) 6 (CH,)pNR d) halogen, e) CN, 2) C 3 6 cycloalkyl, 3) OR 6 6a 6a 6a 4) SR S(O)R S0 2 R [I:\DAYLIB\Iiba]393945d.doc:SSD -NR 6 R 7 R 6 6) R7 0 7) NR7R7 0 8) -0o NR 6 R 7 0 0 O6 0 6. R 6 0 and -S0 2 -NR 6 R 7 R 4 i.slce rmHadC 3 anan w fR n aeotoal.atce.otesaecro tm [i:\DAYLIB\Iiba393945d.doc:SSD R 6 R 7 and R 7 are independently selected from: H; C 1 4 alkyl, C3-6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) CI- 4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) Y R 0 f) -S0 2 R 11 or g) N(R 10 2 or R 6 adR 7 may be j oined in a ring; R) R' and R 7 a may be joined in a ring; 6, I S selected from: C 1 4 alkyl. C 3 6 cycloalkvl. heterocycle. aryl. unsubstituted or substituted with: a) C- 4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) Re 0 f) S0 2 R 1 or g) N(R 0 2 R 8 isindependently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -CIO cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl, Br. R' 0 R 11 R 10 C(O)NROL, (R' 0 2 R 10 2 N-C(NR 10 CN, NO 2 R 10 R' 0 -N(R' 0 2 or R 1 'OC(O)NR' 0 and C) CI-C 6 alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C 3 -CI 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl, Br, R' 0 R' 1 S(O)m-, R' 0 C(O)NH-, (R' 0 2 R' 0 2 N-C(NR' 0 CN, R' 0 N 3 -N(R' 0 2 or R' 0 0C(O)NH-; R 9 is selected from: a) hydrogen, [I:\DAYLIB\Iiba]393945d.doc:SSo b) C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl, Br, R' 'S(O) 1 R' 0 C(O)NR' 0 (R' 0 2 R 10 2 CN, NO,, R' 0 R' 0 NR 2,or and 0) CI-C 6 alkyl unsubstituted or substituted by perfluoroalkyl, F, Cl, Br, R' 0 0-, R' 0 C(O)NR' 0 (R' 0 2 R' 0 2 CN, R' 0 R' 'OC(O)NR 1 0 i neednl eetdfo yrgn IC lybny n rl R 11is independently selected fromC hydroge nd C alyl, ezlan rl Al and A 2are independently selected from: a bond, -CH=CH-, -CC, 0 NR' 0 0, -N(R' 0 -S(O) 2 N(R' 0 -N(R' 0 )S(O) 2 or *GisO0; is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatomn selected from 0, S. and N, and e) C,-C-,o alkenyl. provided that V is not hydrogen if Al is and V is not hydrogen if A' is a bond. n is 0 and A 2 is S(O)m; W is a heterocycle; X is -CH 2 or Z is a unsubstituted or substituted group selected from aryl, heteroaryl, arylmethyl, 20 heteroarylmethyl, arylsulfonyl, heteroarylsulfonyl, wherein the substituted group is substituted with one or more of the following: 1) C- 4 alkyl, unsubstituted or substituted with: a) C,. 4 alkoxy, b) NR R 7 ,c C 3 6 cycloalkyl, aryl or heterocycle, e) HO, f) -S(O)mR~a or g) -C(O)NR R 7 2) aryl or heterocycle, 3) halogen, 4) OR 6 NR 6 R 7 6) CN, 7) NO 2 8) C17 3 -C(O)NR R 7 or 11) C 3 -C 6 cycloalkyl; mnis 0, 1 or 2; n isO0, 1, 2, 3 or 4; p isO0, 1, 2, 3 or 4; q is I or 2; r is 0 to 5, provided that r is 0Owhen Vis hydrogen; sis; t iso0or1; and uis 4or [I :DAYLIB\Iiba393945d.doc:SSD or an optical isomer or pharmaceutically acceptable salt thereof. 29. A method for inhibiting farnesyl-protein transferase which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 30. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula A: (R 8 )r (R 9 )q R 2 R 3 V Al(CRa 2 )nA 2 (CRla 2 )n W (CR 1 b N2)p R 4 R* A 10 wherein: R l and Rib are independently selected from: S a) hydrogen, b) aryl, heterocycle, C 3 -C 10 cycloalkyl., C 2 -C 6 alkenyl, C2-C 6 alkynyl, Ri'O-, R"S(0)m RIC(O)NRio-, CN, NO2, (R 1 0 )2N-C(NRio)-, RI o 15 N 3 -N(R' 0 2 or R"'OC(O)NRo-, c) unsubstituted or substituted Ci-C 6 alkyl wherein the substitutent on the substituted Ci-C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 -C 10 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, R 1 0O-, R' 1 Ri'C(O)NR 10 (R'I) 2 CN, (R' 0 2 N-C(NRI 0 RiOC(O)-, N 3 2 and R 1 OC(O)-NR I 0 20 R and R 3 are independently selected from: H; unsubstituted or substituted Ci-8 alkyl, unsubstituted or substituted C 2 8 alkenyl, unsubstituted or substituted C 2 -8 alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, R6R7 O R6 O 0 wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkyl, b) (CH 2 )pOR 6 c) (CH 2 )pNR 6 R 7 d) halogen, e) CN, 2) C3- 6 cycloalkyl, 3) OR 6 4) SR 6a S(O)R 6 a SO 2 R 6 a, [I:\DAYLIB\Iiba393945d.doc:SSD 248 -NR 6 R 7 R 6 6) R7 0 R 6 7) 1 7 -N YNR Ra 0 8) -oyNR 6 R 7 0 9) -0 OR 6 0 0* 0 -S2NR 6 R 7 *6a 000. 9..6 0 14) -S0 2 -R 6 R *440 N3 or 16 F; o R 2 n 3aeatce otesaeCao n r obndtofr CA hri n ftecro tm sotonlyrpae yamit elce rm ,S0 ,-CO an 12) O 'O- R 13) r idpnety eetdfomHadC3 an an.w fR2,R3,R n r pioal tahdt h aecro tm [I:\OAYLIB\Iiba]393945d.doc:SSD R 6 R 7 and R 7 are independently selected from: H; CI- 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) CI-4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) "Y R 0 f)0R1 or g) N(R' 0 2 or R 6 and R 7 may be joined in a ring,; 0 R' and R 7a may be joined in a ring; R, R 6 is selected from: CI. 4 alkyl. C3-6 cycloalkyl, heterocycle, aryl, unsubstituted or substituted with: a) C- 4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) 9940 f) -S0 2 R 1 1 or g) N(R 0)2; R 8 isindependently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -CI 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl1, Br, R' 0 R 11 R 10 C(O)NR 10 (R' 0 2 R' 0 2 N-C(NR' 0 CN, NO 2 R 10 R' 0 -N(R 10 2 or R' 1 0C(O)NR 0 and C) CI-C 6 alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C 3 -C 10 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl, Br, R' 0 R 11 S(O)m-, *1 0 C(O)NH-, (R 1 0 R 1 N-C(NR 1 0 CN, R 1 0 R' 0 -N(R' 0 2 or *R1 0 0C(O)NH-; R 9 is selected from: a) hydrogen, b) C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl, Br, R 1 0 O0, R 11 R 10 C(O)NR'K, (R 10 2 R1 0 2 CN, NO 2 R' 0 [I :DAYLIB\Iiba]393945d.doc:SSD N 3 -N(R' 0 or R 11 OC(O)NR and c) CI-C 6 alkyl unsubstituted or substituted by perilutoroalkyl. F, Cl, Br, R' (R' 0 R')2N- CN, R' 0 R 10 N 3 -N(R' 0 X, or R' 'OC(O)NR 0- R')is independently selected from hydrogen, C I-C 6 alkyl, benzyl and aryl; R' 'is independently selected from C,-C 6 alkyl and aryl; I 1 and A2 are idependently selected from: a bond. -CH=CH-, 0, -S(O)2N(R' -N(R"u)S(Oy2-, orS(), V is selected from: a) hydrogen, b) heterocycle. c) aryl, d) C 1 -C 20 o alkyl wherein from 0 to 4 carbon atoms are replaced with a heteroatom selected from 0, S. and N. and e) C 2 ,-C 20 o Iu alkenyl. provided that V is not hydrogen if A' is and V is not hydrogen if A' is a bond. n1 is 0 an-d A- is :*ot is a hetcrocycle: X Is -CI or *I Li nsubstituted or substituted arvl or unsubstituted or substituted heteroevecle. wherein the Substituted aryl or substituted heterocycle is substituted with one or more of: 7* C I C 1 4 al kvl. unsubstituted or substituted with: a) C 1 4 alkoxy. b) NR 6 R'.c C 3 -6 c-,vcloallk-yl, di) arvi or heterocycle, e) HO, f) 6 or g) -C (O)NR0R 2) arvi or heterocycle, 2 3)halolaen. 4) oQj). t* 0' 6) CN. :96 7) NO?, 2S 8) CF 3 -C(O)NR 6 or 11) cycloalkyl; ii is 0. 1 or 2 n I s 0, 1, 2, 3 or 4; p is 0, 1, 2, 3 or 4; q is I or 2; r is 0 to 5, provided that r is so0 when V is hydrogen; s isO0 or 1; t is 0 or 1; and u is 4 or or an optical isomer or pharmaceutically acceptable salt thereof. 31. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of' a composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula B: [1A:DAYLIB\iba]393945d.doc: SSE (R 8 )r 2 V Al(CRla 2)A2(CRla) W t-(RbPK B R 3 R wherein: Rla and R Ib are independently selected from: a) hydrogen, aryl, heterocycle. C 3 -CI 0 ccoakl C 2 -C 6 aleyC 2 -C 6 alkvnyl, R1 0 0-, RIOC(O)NRO, CN(R' 0 ),NC(Oy- RIO2N-C(NRIOy- CN. NO,,R(CO- R' 0 -N(R 10 or RIIOC(O)NRO. cc cec) unsubstituted or substituted CI-C 6 alkyl wherein the substitutent on the substituted o C 1 -C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 -CI 0 cylakl C2C alkenyl, Lr2-C6 aikynyl, R'00-, R 'SOm-, R'C-(J)1NR-, (Rfk)2INLC()-, R CN, R' 0 R' 0 N 3 -N(R' 0 2 and R' R 2 and R 3 are independently selected from: H; unsubstituted or substituted CI..s alkyl, *n u si u e or su si u e 28 ak n l nSsi u e r s b tt t d C -S ak n l unsubstituted or substitutedC 2 akyl, unsubstituted or substituted heteaokynle, R 6 7 or R 15 0 0 wherein the substituted group is substituted with one or more of: S1) aryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkyl, b) (CH 2 )pOR 6 C) (CH 2 )pNR d) halogen, e) CN, 2) C 3 6 cycloalkyl, 4) SR a, S(O)R a, S0 2 R 6 [i:\DAYLIB\iba393945ddoc:SSD -NR 6 R 7 R 6 6) -Ny R 7 0 7) 1 -N YNR 7 R 7 a 0 8) -0 NR 6 R 7 0 9) -0 OR 6 *N R 0 7 6* 12) N0-R 67 14) -r 2 OR 6 R F; o 14) OR 6 OR)- anR n w and R 4 are otoal attached to the same catmanrrbcmiedt o atom; 11 hren n [I :\AYLjB\1ba393945ddoc:SSD R 6 R 7 and R 7 are independently selected from: H; C 1 4 alkyl, C3- 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) C 1 .4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) R 11 0 f) S0 2 R 1 1 or g)N(R' 0 2 or :99R 6 and R 7 may be j oined in a ring; 10 R 7and R 7, may be joined in a ring; I :R iS selected from: C 1 4 alkyl, C 3 -6 cycloalkyl. heterocycle. aryt, unsubstituted or ~9 substituted with: a) C 1 4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, 0 -SO 2 R'1 or R8 is independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -CI 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl1, Br, R' 0 R 11 R' 0 C(O)NR 10 (R 1 0 2 R 10 2 N-C(NR' 0 CN, NO 2 R' 0 R' 0 N 3 -N(R 1 0 2 or R''OC(O)NR 1 0 and C) CI-C 6 alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C 3 -CI 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl, Br, R R' R 10 C(O)NH-, (R 10 2 R' 0 2 N-C(NR 10 CN, R 1 0 R 1 0 N 3 -N(R' 0 2 or R' 0 0C(O)NH-; R 9 isselected from: a) hydrogen, [I :\DAYLIB\iba393945d.doc: SSD b) alkenyl. alkynyl, perfluoroalkyl, F, Cl, Br, R' 0 R' R' 0 R 1 %,N-C(NR 10 CN, NO, N 3 or 'OC(O)NR 1 and C) C 1 -C 6 alkvl unsubstituted or substituted by perfiucroalkyl, F, Cl. Br, RuJ)C(O)NR()-, (R' 1 2 CN, R 11 N 3 N( R 1 'is independently selected from hydrogen, C I-C 6 alkyl, benzyl and aryl, R' is independently selected from C I-C 6 alkyl and arvi; .and A-are independently selected from: a bond, -CH=CH-. -C(O)NR K- NR 0. -S(O) 2 -N(R 1 2 or SO,, Li Is IH, or 0: V is selected from: a) hydrogTen. b) heterocycle, c) arvi. d) CI-C2) alkyl wherein fromn 0 to 4 *carbon atoms are replaced with a a heteroatorn selected from 0. S. and N. aind e) al1kenvi. i provided that V is not hydrogen if A' is and V is not hydrouen if A' is a bond, n is 0 and -A is \\is a lieteroeN dc: N~ is or ru eetdfo rh eeorl rleh X is a unsubstituted or sbttd gruseetdfo ayl tray.aymth. lieteroarylmethyl. arvlsulfonyl, heteroarvisulfonyl, xwherefi the substituted gYroup is SLIbstituted with one or more of the l'ollowing,: LI Cj_ 4 alkyl. unsubstituted or Substituted with: a) C 1 4 alkoxy, b) NR~R 7 C) C-3-6 cycloalkyl. d) arvA or heterocycle. e) HO, f) or g) -C(O)NR R', 2arvl or heterocycle, 3) halogen. 4) OR'- NR 6R- 6) CN. 7) NO,~. 3) 8) CFs: 1 0) -C(O)NR 6 or 11I) C 3 -C 6 cycloalkyl; mnis 0. 1 or 2; n isO0, 1, 2, 3 or 4; p isO0, 1, 2, 3 or 4; q is I or 2; r isO0 to 5, provided that r is 0Owhen Vis hydrogen; sis or tiso0or1; and uis 4or (I :DAYLIB\iba]393945d.doc:SSD or an optical isomer or pharmaceutically acceptable salt thereof. 32. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula C: (1 9 )2 V Al(CR a 2 )nA 2 (CR a 2 )n -W (CRlb 2 )px, N\ N-Z t x V t s wvherein: R and R 1"are independently selected from: a) hydrogen, 0 b) aryl, heterocycle, C 3 -CIO cycloalkyl. C 2 -C 6 alkenyl, C 2 -C 6 alkynyl. R' 0 0-, R' 0 C(O)NR' 0 (R' 0 2 R 10 2 N-C(NR 10 CN, NO 2 R' 1 CO- R1 0 CO- N 3 -N(R' 0 2 or R"'OC(O)NR 0 c) unsubstituted or substituted C I-C 6 alkyl wherein the substitutent on the substituted CI-C6, alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 -C 10 15 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, R 10 R' 0 C(O)NR' 0 (Rl 0 R 2 N-C(NR' 0 CN, R 10 R 1 0 N 3 N( 1 ),and R''OC(O)-NR 1 o o R and R' are independently selected from: H; unsubstituted or substituted C 1-8 alkyl, :unsubstituted or substituted C 2 8 alkenyl, unsubstituted or substituted C 2 8 alkynyl, *unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, R 6 R 7 R 6 11--e ~or 0 0 wherein the substituted group is substituted with one or more of:- 1) aryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkyl, b) (CH 2 c) (CH- 2 )pNR 6 d) halogen, e) CN, 2) C 3 6 cycloalkyl, OR', 4) SR 6 S(O)R a, S0 2 R~a [I :DAYLIB\iba]393945d.doc:SSD -NR 6 R 7 R 6 6) R7 0 7) 1I 7 -N Y<NR Ra 0 8) -0o NR 6 R 7 0 NR 6 R 7 6. R6a 12) 11N 1-3 2 -Ra 13)R6 14) OR 6 0 N 3 or 16) F o r R 2 and R 3 are attached to the same C atom and are combined to form (CH 2 1 wherein one of the carbon atoms is optionally replaced by a moiety selected from: 0, and -N(C0R 1 0 R 4 isselected from H and CH 3 and any two of R 2 R 3 and R 4 are optionally attached to the same carbon atom; [IADAYL IB\Iiba]393945d. doc: SS D R 6 R 7 and Ra are independently selected from: H; C 1 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) C 1 4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) R 0 p -S0 2 R 1 1 or g) N(R' 0 2 or 6~ and R 7 may be joined in a ring- R' Rand Ra may be joined in a ring; R' is selected from: C 1 4 alkyl. C 3 6 cycloalkvl. heterocycle, arvI. unsubstituted or substituted with: a)C 1 4 alkoxy, b) aryl or heterocycle. c) halogen. d) HO, e) R 0 R" or g) N(R' 0 2 R8 is independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -CI 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl1, Br, R 1 0 R 1 1 R' 0 C(O)NR 1 L, (R 10 R' 0 2 N-C(NR 1 0 CN, NO 2 R' 0 R' 0 -N(R 10 2 or R 11 0C(O)NR' 0 and C) CI-C 6 alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C 3 -CIO cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl, Br, R' 0 R"S(O)m-, R' 0 C(O)NH-, (R' 0 2 R 10 2 N-C(NR 10 CN, R' 0 R' 0 N 3 -N(R 1 0 2 or R' 0 0C(O)NH-; R 9 isselected from: a) hydrogen, [I:\DAYLIB\Iiba393945d.doc:SSD b) C?-C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, CI. Br, R' 0 (R' 0 R' 1 ,N-C(NR' 0 CN, NO,, R' 0 N 3 N R().or R 1 OC(O)NR 10 and C) CI-C6, alkyl unsubstituted or substituted by peril Loroalkyl, F, Cl, Br, RI 0-, N(R"')2.or R''OC(O)NR h)- is independently selected from hydrogen. C 1 -C 6 alkyl, benzvl and aryl,: R IIis independently selected from C 1 -C 6 alkyl and aryl, A I and .Aare independently selected from: a bond. -CH=CII-. 0. -N(R 1 -S(O) 2 N(R' 0 -N(R 11 2 or G i S 0: V Is selected1 from: a) hyvdrogen. b) heterocvcle. c) arN I, d) C 1 aikvl w"herein 1'orn 0 to 4 carboni atomls are replaced with a a heteroatom selected from 0. S. and N. and e) 0 prov'ided that V is not hvdrog2en if A' is and V is not h\ drogyen if A' is a bond, n is 0 anld A- is WV is a heterocycle: e-eX is or L is a LnsuLbstituted or substituted group selected from aryl, heteroaryl. arylmetbyl, *~li uhte roary liethyl. arvisulfonyl. heteroarylsulfonyl, wherein the substituted group is *too substituted wilth one or more of the following: 1 CI-4 alkvl, unsubstituted or substituted with: a) CI- 4 alkoxy. b) NR C) C. 3 -6 cycloalkyl. 6, 6 5: d) aryl or heterocycle. e) HO, 1) or g) -C(O)NR R 7 2) aryl or heterocycle. )halogen. 4) OR 6 7) NR6 R 7 6) CN, 7) NO). 3) 8) CF 3 1 0) -C(0)NR 6 or 11) C's-C 6 cycloalkyl; in isO0, 1 or 2; 13 isO0, 1, 2, 3 or 4; p isO0, 1, 2, 3 or 4; q is 1 or 2; r isO0 to 5. provided that r is s~0 when V is hydrogen; s is t isO0 or 1; and u is 4 or [I:\DAYLI B\Iiba]393945d .doc: SS D or an optical isomer or pharmaceutically acceptable salt thereof. 33. A method for treating cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of Claim 34. A method for treating or preventing a disease selected from neurofibromin benign proliferative disorder, blindness related to retinal vascularization, infections from hepatitis delta and related viruses, restenosis and polycystic kidney disease, which comprises administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of the formula B: r (R 9 )q R 2 G V Al(CRla 2 )nA 2 (CRla 2 W (CR 1 2) N-Z R 3 R 4 0 B wherein: R and R are independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -Clo cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, R° 0 O-, 15 RoC(O)NR 1 CN(R'°) 2 RIO 2 N-C(NRi 0 CN. NO2, RoOC(O)- N 3 -N(RI O 2 or R 1 OC(O)NRl o c) unsubstituted or substituted Ci-C 6 alkyl wherein the substitutent on the substituted C-C 6 alkyl is selected from unsubstituted or substituted aryl, heterocyclic, C 3 -C 10 cycloalkyl, C 2 -C6( alkenyl, C 2 -C 6 alkynyl, R RioC(O)NRo-, (RI") 2 NC(0)-, R'I 2 N-C(NRo)-, CN, RI°OC(O)-, N 3 -N(RI 0 2 and R"O 1 C(O)-NRo-; R 2 and R 3 are independently selected from: H; unsubstituted or substituted Ci- 8 alkyl, unsubstituted or substituted C2- 8 alkenyl, unsubstituted or substituted C2- 8 alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heterocycle, R 6 Ror 7 R6 0 0 wherein the substituted group is substituted with one or more of: 1) aryl or heterocycle, unsubstituted or substituted with: a) C 1 4 alkyl, b) (CH 2 )pOR 6 c) (CH 2 )pNR 6 R 7 d) halogen, e) CN, 2) C 3 -6 cycloalkyl, 3) OR 6 [I:\DAYLIB\Iiba393945d.doc:SSD 4) SR~a S(O)R 6 S0 2 R~a -NR 6 R 7 6) -N R 7 0 R 6 7) -N NR 7 R 7 a 0 8) -0 NR 6 R 7 0 9) -o OR 6 3 7* 99 0 RI 6 6 R 0 14) -S0 2 -R 6 R 16Ii) F1 o 14) -NCROR 6 an an w f and R 4 are otoal attached to the same catmanrrbcmiedt o atom; 1 heen n [I:\DAYLIB\Iiba]393945d.doc:SSD 261 R 6 R 7 and R 7 are independently selected from: H; CI- 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with: a) C 1 4 alkoxy, b) aryl or heterocycle, c) halogen, d) HO, e) R 0 f) -S0 2 R 1 or g) N(RI 1 2 Or R an R' may be joined in a ring; R' and R 7 may be joined in a ring; R 6 a is selected from: CI- 4 alkyl, C 3 6 cycloalkyl, heterocycle, aryl. unsubstituted or S substituted with: C 1 4 al koxy, b) aryl or heterocycle, c) halogen, d) HO, e)R 0 f) -S0 2 R 1 or N(R 10 2 R8 is independently selected from: a) hydrogen, b) aryl, heterocycle, C 3 -CI 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl1, Br, R' 0 R 11 S(O)mn-, R 10 C(O)NR 1 L, (R' 0 2 R' 0 2 N-C(NR 1 0 CN, NO 2 R 10 R' 0 -N(R' 0 2 or R' 1 0C(O)NR 0 and C) CI-C 6 alkyl unsubstituted or substituted by aryl, cyanophenyl, heterocycle, C 3 -CI 0 cycloalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, perfluoroalkyl, F, Cl, Br, R' 0 R' 0 C(O)NH-, (R' 0 2 R 10 2 N-C(NR' 0 CN, R' 0 R' 0 -N(R' 0 2 or R' 0 0C(O)NH-; R 9 isselected from: a) hydrogen, [I:\DAYLIB\Iiba]393945d.doc:SSD b) alkenyl, alkynyl, perfluoroalkyl, F, Cl, Br, R'OO-, R 1 'OC(O)NR)- (RIO) 2 R 1 %,N-C(NR' 0 CN, NO, R' 0 R' 0 N 3 U or R'1'OC(O)NR' and C) CI-C 6 alkyl unsubstituted or substituted by peril uoroalky 1. F, Cl, Br. WO~O-, 3Ri (R' 0 2 R' 0 CN, R' 0 N 3 N~Z().or R''OC(O)NR' 0 R i s Independently selected from hydrogen. C I-C 6 alkyl. benizvl and arvi; R 1 is independently selected from CI-C 6 alkyl and aryl. ,!and A 2 are independently selected from: a bond. -ClI=CH-. -C(O)NR' 0 N R 10 0, -N(R 1 -S(O>2N(R' 0 or (Iis H, or 0:, V IS slct~ed from: a) hydrogen. b) heterocycle. c) aryi. d) C alkvl wherein lroni 0 to 4 carbon atoms are replaced with a a heteroatom selected from 0. S. and N. and e) C2-C 20 poided that V is not hydrogen if A' is and V is not hydrogen if A' is a bond. ii is 0 :Ilc :And is \\is a heterocycle: X is or is a Unsubstituted or substituted group selected from aryl, heteroaryL. arylmethvl. a2a eteroarN lrnethyl. arylsulfonyL. heteroarylsulfoni.l wherein the substituted group is *...Substituted with one or more of the following: I I) Ci 1 4 alkyl. unsubstituted or substituted with: a) C 1 -4 alkoxy, b) NR 6 c) C 3 -6 cycloalkyl, ch arvi or heterocycle, e) HO. f) or g) -C(O)NR' R 2ar-l or heterocycle, Q 3) hialogeni. 4) OR"~ NR6R" 6) CN. 7) NO%. 8) CF 3 -C(O)NR 6 or 11) C 3 -C 6 cycloalkyl; in isO 0, or 2; n iso0, 1, 2,3 or 4; p isO0, 1, 2,3 or 4; q is I or 2; r isO0 to 5, provided that r is 3 5 0Owhen Vis hydrogen; sis 0or 1; tis 0or 1; and uis 4or [I:\DAYL1B\iba393945ddoc:SSD or an optical isomer or pharmaceutically acceptable salt thereof. The use of a compound of the formula A as defined in claim 26 above, for the manufacture of a medicament for inhibiting farnesyl-protein transferase. 36. The use of a compound of the formula B as defined in claim 27 above, for the manufacture of a medicament for inhibiting farnesyl-protein transferase. 37. The use of a compound of the formula C as defined in claim 28 above, for the manufacture of a medicament for inhibiting farnesyl-protein transferase. 38. A compound of the formula A as defined in claim 26 above, when used for inhibiting farnesyl-protein transferase. 39. A compound of the formula B as defined in claim 27 above, when used for inhibiting farnesyl-protein transferase. A compound of the formula C as defined in claim 28 above, when used for inhibiting farnesyl-protein transferase. 41. The use of a compound of any one of claims 1-21 for the manufacture of a 5 medicament for inhibiting farnesyl-protein transferase. 42. A compound of any one of claims 1-21 when used for inhibiting farnesyl-protein transferase 43. A composition of any one of claims 22 to 25 when used for inhibiting S farnesyl-protein transferase. 20 44. The use of a compound of the formula A as defined in claim 30 above, for l. the manufacture of a medicament for the treatment of cancer. 45. The use of a compound of the formula B as defined in claim 31 above for the manufacture of a medicament for the treatment of cancer. 46. The use of a compound of the formula C as defined in claim 32 above, for the manufacture of a medicament for the treatment of cancer. 47. A compound of the formula A as defined in claim 30 above, when used for the treatment of cancer. 48. A compound of the formula B as defined in claim 31 above, when used the manufacture of a medicament for the treatment of cancer. 49. A compound of the formula C as defined in claim 32 above, when used the manufacture of a medicament for the treatment of cancer. The use of a compound of any one of claims 1-21 for the manufacture of a medicament for the treatment of cancer. 51. A compound of any one of claims 1-21 or a composition of any one of claims 22-25 when used for the treatment of cancer. [I:\DAYLIB\Iiba]393945d.doc:SS0 52. The use of a compound of the formula B as defined in claim 34 above, for the manulfacture of a medicament for the treatment or prevention of a disease selected from neurofibromin benign proliferative disorder. blindness related to retinal vascularisation, infections from hepatitis delta and related viruses. restenosis and poly cystic kidney disease. 53. A compound of the formula B as defined in claim 34 above, when used in the treatment or prevention of a disease selected from neurofibromin benign proliferative disorder, blindness related to retinal vascularisation. infections from hepatitis delta and reiated viruses. restenosis and poly cystic kidney disease. 54. The use of a compound of any one of claims I to 21 for the manufacture of a i medicament for treating or preventing a disease selected from neurofibromin benign proliferative disorder. blindness related to retinal vascularization. infections from hepatitis deita and related viruses, restenosis and polycystic kidney disease. 5. A compound of any one of claims I to 21 or a composition of any one of Claims 22 to 25 when used for treating or preventing a disease selected from neurofibromin a benign proliferative disorder. blindness related to retinal vascularization. infections from o hepatitis delta and related viruses. restenosis and polycystic kidney disease. 1 57. A compound which inhibits farnesyl-protein transferase substantiall\ as hereinbefore described with reference to any one of the Examples. S..Dated 16 July, 1999 Merck Co., Inc. o a "o Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON [I :DAY LI B\Iiba]393945d. doc: SS D
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41282995A | 1995-03-29 | 1995-03-29 | |
| US08/412829 | 1995-03-29 | ||
| US47069095A | 1995-06-06 | 1995-06-06 | |
| US08/470690 | 1995-06-06 | ||
| US08/600728 | 1996-03-01 | ||
| US08/600,728 US5856326A (en) | 1995-03-29 | 1996-03-01 | Inhibitors of farnesyl-protein transferase |
| PCT/US1996/004019 WO1996030343A1 (en) | 1995-03-29 | 1996-03-25 | Inhibitors of farnesyl-protein transferase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5322396A AU5322396A (en) | 1996-10-16 |
| AU710672B2 true AU710672B2 (en) | 1999-09-23 |
Family
ID=27410959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU53223/96A Ceased AU710672B2 (en) | 1995-03-29 | 1996-03-25 | Inhibitors of farnesyl-protein transferase |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0820445A1 (en) |
| JP (1) | JP3043815B2 (en) |
| CN (1) | CN1195340A (en) |
| AR (1) | AR002726A1 (en) |
| AU (1) | AU710672B2 (en) |
| BG (1) | BG101973A (en) |
| BR (1) | BR9607953A (en) |
| CA (1) | CA2216707A1 (en) |
| CZ (1) | CZ306297A3 (en) |
| EE (1) | EE9700314A (en) |
| HR (1) | HRP960143A2 (en) |
| HU (1) | HUP9801883A3 (en) |
| IL (1) | IL117580A0 (en) |
| IS (1) | IS4568A (en) |
| MX (1) | MX9707459A (en) |
| NO (1) | NO974457L (en) |
| NZ (1) | NZ305254A (en) |
| PL (1) | PL322549A1 (en) |
| SK (1) | SK129297A3 (en) |
| TR (1) | TR199701056T1 (en) |
| WO (1) | WO1996030343A1 (en) |
Families Citing this family (177)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| GB9516709D0 (en) * | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
| US6083949A (en) * | 1995-10-06 | 2000-07-04 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| GB9602166D0 (en) | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6313127B1 (en) | 1996-02-02 | 2001-11-06 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
| WO1997036591A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1997036877A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5919785A (en) * | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6080870A (en) * | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| US5780488A (en) * | 1996-04-03 | 1998-07-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP0959883A4 (en) * | 1996-04-03 | 2001-05-09 | Merck & Co Inc | FARNESYLE PROTEIN TRANSFERASE INHIBITORS |
| US5925651A (en) * | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5885995A (en) * | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5852010A (en) * | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2250192A1 (en) * | 1996-04-03 | 1997-10-09 | Chrisopher J. Dinsmore | Inhibitors of farnesyl-protein transferase |
| US5780492A (en) * | 1996-04-03 | 1998-07-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5859012A (en) * | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6063930A (en) * | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| US5869682A (en) * | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5939557A (en) * | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5874452A (en) * | 1996-04-03 | 1999-02-23 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
| US6001835A (en) * | 1996-04-03 | 1999-12-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5891889A (en) * | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2250232A1 (en) * | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
| EP0944388A4 (en) * | 1996-04-03 | 2001-08-16 | Merck & Co Inc | FARNESYL PROTEIN TRANSFERASE INHIBITORS |
| US5922883A (en) * | 1996-04-03 | 1999-07-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2000507579A (en) * | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | Farnesyl-protein transferase inhibitor |
| US5883105A (en) * | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5965578A (en) * | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CN1228087A (en) * | 1996-08-14 | 1999-09-08 | 曾尼卡有限公司 | Substituted pyrimidine derivatives and their pharmaceutical uses |
| UA56197C2 (en) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Heterocyclic derivatives |
| CA2276081A1 (en) * | 1996-12-30 | 1998-07-09 | Lekhanh O. Tran | Inhibitors of farnesyl-protein transferase |
| JP2001511798A (en) | 1997-02-13 | 2001-08-14 | ゼネカ・リミテッド | Heterocyclic compounds useful as oxide-squalene cyclase inhibitors |
| DE69815509T2 (en) | 1997-02-13 | 2004-05-13 | Astrazeneca Ab | HETEROCYCLIC COMPOUNDS THAT APPLY AS OXIDO-SQUALEN-CYCLASE INHIBITORS |
| US5972942A (en) * | 1997-03-27 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6060038A (en) * | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
| GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
| WO1999010525A1 (en) * | 1997-08-27 | 1999-03-04 | Merck & Co., Inc. | A method of treating cancer |
| US6103487A (en) * | 1997-08-27 | 2000-08-15 | Merck & Co., Inc. | Method of treating cancer |
| US6387903B1 (en) | 1997-08-27 | 2002-05-14 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO1999041242A1 (en) * | 1998-02-13 | 1999-08-19 | Rhone-Poulenc Rorer S.A. | Di-substituted naphthyl derivatives, preparation thereof, pharmaceutical compositions containing them |
| FR2774985A1 (en) * | 1998-02-13 | 1999-08-20 | Rhone Poulenc Rorer Sa | New naphthyl carbonyl or sulfonyl oxopiperazine farnesyl transferase inhibitors, used as antiproliferative agents, e.g. for treating cancer |
| AU5086499A (en) * | 1998-07-01 | 2000-01-24 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
| GB9902989D0 (en) | 1999-02-11 | 1999-03-31 | Zeneca Ltd | Heterocyclic derivatives |
| AU3386600A (en) * | 1999-03-03 | 2000-09-21 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| EP1165013A4 (en) * | 1999-03-03 | 2002-08-07 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASE INHIBITORS |
| EP1158983A4 (en) * | 1999-03-03 | 2003-05-21 | Merck & Co Inc | PRENYL PROTEIN TRANSFERASES INHIBITORS |
| JP2002540072A (en) * | 1999-03-03 | 2002-11-26 | メルク エンド カムパニー インコーポレーテッド | Inhibitors of prenyl protein transferase |
| US6211182B1 (en) * | 1999-03-08 | 2001-04-03 | Schering Corporation | Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms |
| US6458935B1 (en) | 1999-06-23 | 2002-10-01 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| FR2819512B1 (en) * | 2001-01-18 | 2003-02-21 | Servier Lab | NOVEL CYCLO [D] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2819510B1 (en) * | 2001-01-18 | 2003-10-31 | Servier Lab | NOVEL CYCLO [C] AZEPANE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| FR2819509B1 (en) | 2001-01-18 | 2004-04-16 | Servier Lab | NOVEL CYCLOHEPTENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| ES2382814T3 (en) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment |
| TWI387592B (en) | 2005-08-30 | 2013-03-01 | Novartis Ag | Substituted benzimidazoles and methods of their use as inhibitors of kinases associated with tumorigenesis |
| EP1940786B1 (en) | 2005-09-16 | 2010-08-18 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CA2649288C (en) | 2006-04-19 | 2015-11-24 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
| US8173629B2 (en) | 2006-09-22 | 2012-05-08 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| EA200900811A1 (en) * | 2006-12-18 | 2009-12-30 | Новартис Аг | IMIDAZOLES AS ANALYSTERONSYNTASE INHIBITORS |
| JP4611444B2 (en) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | Amide substituted indazoles as poly (ADP-ribose) polymerase (PARP) inhibitors |
| CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| AU2008254425A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| KR20150036210A (en) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| CN103553945B (en) | 2007-10-05 | 2015-01-07 | 奥克塞拉有限公司 | Alkoxy compounds for disease treatment |
| EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| CA2758071C (en) | 2009-04-06 | 2018-01-09 | Agios Pharmaceuticals, Inc. | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use |
| AR076794A1 (en) | 2009-05-22 | 2011-07-06 | Incyte Corp | DERIVATIVES OF N- (HETERO) ARIL-PIRROLIDINA DE PIRAZOL-4-IL-PIRROLO [2,3-D] PIRIMIDINES AND PIRROL-3-IL-PIRROLO [2,3-D] PYRIMIDINS AS INHIBITORS OF THE JANUS KINASE AND COMPOSITIONS PHARMACEUTICS THAT CONTAIN THEM |
| SI2432472T1 (en) | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)octane- or heptane-nitrile as jak inhibitors |
| US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| TWI598337B (en) | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
| JP5860398B2 (en) | 2009-07-02 | 2016-02-16 | アキュセラ インコーポレイテッド | Pharmacology of visual cycle modulators |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| PE20121172A1 (en) | 2009-10-14 | 2012-09-05 | Merck Sharp & Dohme | PIPERIDINS SUBSTITUTED WITH ACTIVITY IN HDM2 |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011090738A2 (en) | 2009-12-29 | 2011-07-28 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| US8987275B2 (en) | 2010-03-16 | 2015-03-24 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
| PE20130216A1 (en) | 2010-05-21 | 2013-02-27 | Incyte Corp | TOPICAL FORMULATION FOR A JAK INHIBITOR |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP3330377A1 (en) | 2010-08-02 | 2018-06-06 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
| US9029341B2 (en) | 2010-08-17 | 2015-05-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| PE20140146A1 (en) | 2010-11-19 | 2014-02-06 | Incyte Corp | PYRROLOPYRIDINE DERIVATIVES AND PYRROLOPYRIMIDINE SUBSTITUTED WITH CYCLOBUTYL AS JAK INHIBITORS |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| WO2012083246A1 (en) | 2010-12-17 | 2012-06-21 | Agios Pharmaceuticals, Inc. | Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| ES2569712T3 (en) | 2010-12-21 | 2016-05-12 | Agios Pharmaceuticals, Inc. | PKM2 bicyclic activators |
| TWI549947B (en) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
| AU2012245971A1 (en) | 2011-04-21 | 2013-10-17 | Piramal Enterprises Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| CN103608016A (en) | 2011-05-03 | 2014-02-26 | 安吉奥斯医药品有限公司 | Pyruvate kinase activators for use in therapy |
| SMT202400081T1 (en) | 2011-05-03 | 2024-03-13 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| CN102827170A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Active treatment compositions and use method thereof |
| CN102827073A (en) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
| CN103797010B (en) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | As the azetidinyl phenyl of JAK inhibitor, pyridyl or pyrazinyl carboxamides derivatives |
| TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
| UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| US9382239B2 (en) | 2011-11-17 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-Jun-N-terminal kinase (JNK) |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
| TW201406761A (en) | 2012-05-18 | 2014-02-16 | Incyte Corp | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| RU2660429C2 (en) | 2012-09-28 | 2018-07-06 | Мерк Шарп И Доум Корп. | Novel compounds that are erk inhibitors |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| USRE48175E1 (en) | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| RS56680B1 (en) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Compositions and methods for treating cancer |
| KR102196882B1 (en) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| RS62867B1 (en) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Processes and intermediates for making a jak inhibitor |
| ES2753386T3 (en) | 2013-03-13 | 2020-04-08 | Forma Therapeutics Inc | 2-Hydroxy-1- {4 - [(4-phenyl) phenyl] carbonyl} piperazin-1-yl} ethane-1-one derivatives and related compounds as fatty acid synthase inhibitors (FASN) for the treatment of cancer |
| CN105593215B (en) | 2013-07-11 | 2019-01-15 | 安吉奥斯医药品有限公司 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutant inhibitors for the treatment of cancer |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015010297A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| SMT202000315T1 (en) | 2013-08-07 | 2020-07-08 | Incyte Corp | Sustained release dosage forms for a jak1 inhibitor |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| NZ723859A (en) | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
| DK3209655T3 (en) | 2014-10-24 | 2020-09-28 | Landos Biopharma Inc | Lanthionine Synthesis C-like 2-based Therapeutica |
| JP6854762B2 (en) | 2014-12-23 | 2021-04-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Inhibitor of cyclin-dependent kinase 7 (CDK7) |
| USRE50776E1 (en) | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| CA2989111C (en) | 2015-06-11 | 2023-10-03 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| AU2016319125B2 (en) | 2015-09-09 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| FI3362065T3 (en) | 2015-10-15 | 2024-06-19 | Servier Lab | Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia |
| KR102699521B1 (en) | 2015-10-15 | 2024-08-26 | 르 라보레또레 쎄르비에르 | Combination therapy for the treatment of malignant tumors |
| JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
| EP3525785B1 (en) | 2016-10-12 | 2025-08-27 | Merck Sharp & Dohme LLC | Kdm5 inhibitors |
| KR102702926B1 (en) | 2017-04-13 | 2024-09-06 | 사이로파 비.브이. | Anti-SIRP alpha antibody |
| IL283725B2 (en) | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Preparations and methods for increasing the efficiency of heart metabolism |
| EP3706747B1 (en) | 2017-11-08 | 2025-09-03 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
| CN110294713B (en) * | 2018-03-22 | 2022-08-02 | 西华大学 | A kind of preparation method of imidazole methylamine derivatives |
| SMT202400306T1 (en) | 2018-03-30 | 2024-09-16 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| EP3810132A4 (en) | 2018-06-25 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | TAIRE KINA INHIBITORS AND THEIR USES |
| US12173026B2 (en) | 2018-08-07 | 2024-12-24 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| US12552826B2 (en) | 2018-08-07 | 2026-02-17 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
| EP3866794B1 (en) | 2018-10-17 | 2024-12-04 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| US12281126B2 (en) | 2018-12-28 | 2025-04-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| EP3976101A4 (en) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | METHOD OF TREATMENT OF FIBROSIS USING COMPOUNDS TO PROMOTE GLUCOSE OXIDATION |
| BR112022012015A2 (en) | 2019-12-17 | 2022-08-30 | Merck Sharp & Dohme Llc | PRMT5 INHIBITORS |
| US12441730B2 (en) | 2019-12-17 | 2025-10-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| KR20230026522A (en) | 2019-12-20 | 2023-02-24 | 란도스 바이오파마, 인크. | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same |
| US12234578B2 (en) | 2020-01-29 | 2025-02-25 | Wisconsin Alumni Research Foundation | Tannin composite fibers |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| EP4673747A1 (en) | 2023-03-02 | 2026-01-07 | CARCIMUN BIOTECH GmbH | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
| WO2026027944A1 (en) | 2024-07-30 | 2026-02-05 | Sairopa B.V. | Anti-sirp alpha antibody formulations and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1056055B (en) * | 1974-03-01 | 1982-01-30 | Malesci Sas Inst Farmaco Bilog | Substd 1-alkyl 4-phenylpiperazines - with anti-hypertensive, vasodilating, alpha-inhibiting, anti-histamine and anti-bradykinin activity |
| US4371737A (en) * | 1981-05-04 | 1983-02-01 | Merrell Dow Pharmaceuticals Inc. | 5-Aminomethyl-2,3-dihydro-2-oxo-1H-imidazole-4-carboxylic acid derivatives |
| US5182141A (en) | 1990-02-13 | 1993-01-26 | Co-Ex-Tec Industries | Bilaminate polymer coated metal strip and method for manufacture thereof |
| US5159083A (en) * | 1990-12-28 | 1992-10-27 | Neurogen Corporation | Certain aminomethyl phenylimidazole derivatives; a class of dopamine receptor subtype specific ligands |
| WO1995000497A1 (en) * | 1993-06-18 | 1995-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5478934A (en) * | 1994-11-23 | 1995-12-26 | Yuan; Jun | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands |
-
1996
- 1996-03-20 IL IL11758096A patent/IL117580A0/en unknown
- 1996-03-25 MX MX9707459A patent/MX9707459A/en unknown
- 1996-03-25 JP JP8529559A patent/JP3043815B2/en not_active Expired - Fee Related
- 1996-03-25 WO PCT/US1996/004019 patent/WO1996030343A1/en not_active Ceased
- 1996-03-25 NZ NZ305254A patent/NZ305254A/en unknown
- 1996-03-25 CA CA002216707A patent/CA2216707A1/en not_active Abandoned
- 1996-03-25 HU HU9801883A patent/HUP9801883A3/en unknown
- 1996-03-25 SK SK1292-97A patent/SK129297A3/en unknown
- 1996-03-25 EE EE9700314A patent/EE9700314A/en unknown
- 1996-03-25 EP EP96909851A patent/EP0820445A1/en not_active Withdrawn
- 1996-03-25 TR TR97/01056T patent/TR199701056T1/en unknown
- 1996-03-25 AU AU53223/96A patent/AU710672B2/en not_active Ceased
- 1996-03-25 CZ CZ973062A patent/CZ306297A3/en unknown
- 1996-03-25 CN CN96194206A patent/CN1195340A/en active Pending
- 1996-03-25 BR BR9607953A patent/BR9607953A/en not_active IP Right Cessation
- 1996-03-25 PL PL96322549A patent/PL322549A1/en unknown
- 1996-03-27 HR HR08/600,728A patent/HRP960143A2/en not_active Application Discontinuation
- 1996-03-27 AR ARP960101942A patent/AR002726A1/en unknown
-
1997
- 1997-09-24 IS IS4568A patent/IS4568A/en unknown
- 1997-09-26 NO NO974457A patent/NO974457L/en unknown
- 1997-10-15 BG BG101973A patent/BG101973A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10511098A (en) | 1998-10-27 |
| MX9707459A (en) | 1997-12-31 |
| EP0820445A1 (en) | 1998-01-28 |
| IL117580A0 (en) | 1996-07-23 |
| CZ306297A3 (en) | 1998-03-18 |
| HUP9801883A2 (en) | 1999-06-28 |
| IS4568A (en) | 1997-09-24 |
| JP3043815B2 (en) | 2000-05-22 |
| EE9700314A (en) | 1998-06-15 |
| NZ305254A (en) | 1999-03-29 |
| CA2216707A1 (en) | 1996-10-03 |
| AR002726A1 (en) | 1998-04-29 |
| SK129297A3 (en) | 1998-05-06 |
| AU5322396A (en) | 1996-10-16 |
| PL322549A1 (en) | 1998-02-02 |
| BG101973A (en) | 1998-05-29 |
| CN1195340A (en) | 1998-10-07 |
| NO974457L (en) | 1997-11-28 |
| HUP9801883A3 (en) | 2000-09-28 |
| NO974457D0 (en) | 1997-09-26 |
| HRP960143A2 (en) | 1998-04-30 |
| WO1996030343A1 (en) | 1996-10-03 |
| TR199701056T1 (en) | 1998-02-21 |
| BR9607953A (en) | 1998-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU710672B2 (en) | Inhibitors of farnesyl-protein transferase | |
| US5856326A (en) | Inhibitors of farnesyl-protein transferase | |
| AU716338B2 (en) | Inhibitors of farnesyl-protein transferase | |
| US5756528A (en) | Inhibitors of farnesyl-protein transferase | |
| US5919785A (en) | Inhibitors of farnesyl-protein transferase | |
| US5869682A (en) | Inhibitors of farnesyl-protein transferase | |
| AU715603B2 (en) | Inhibitors of farnesyl-protein transferase | |
| US5885995A (en) | Inhibitors of farnesyl-protein transferase | |
| AU707139B2 (en) | Inhibitors of farnesyl-protein transferase | |
| AU715667B2 (en) | Inhibitors of farnesyl-protein transferase | |
| US5780492A (en) | Inhibitors of farnesyl-protein transferase | |
| WO1997036605A1 (en) | Inhibitors of farnesyl-protein transferase | |
| AU717298B2 (en) | Inhibitors of farnesyl-protein transferase | |
| AU706495B2 (en) | Inhibitors of farnesyl-protein transferase | |
| WO1997036892A1 (en) | Inhibitors of farnesyl-protein transferase | |
| US5627202A (en) | Inhibitors of farnesyl-protein transferase | |
| EP0935464A1 (en) | Inhibitors of farnesyl-protein transferase | |
| AU707347B2 (en) | Inhibitors of farnesyl-protein transferase | |
| US5972942A (en) | Inhibitors of farnesyl-protein transferase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |